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Abstract
Scoping systematic review of treatments for eczema
Helen Nankervis, Kim S Thomas, Finola M Delamere,
Sébastien Barbarot, Natasha K Rogers and Hywel C Williams*
Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK
*Corresponding author hywel.williams@nottingham.ac.uk
Background: Eczema is a very common chronic inflammatory skin condition.
Objectives: To update the National Institute for Health Research (NIHR) Health Technology Assessment
(HTA) systematic review of treatments for atopic eczema, published in 2000, and to inform health-care
professionals, commissioners and patients about key treatment developments and research gaps.
Data sources: Electronic databases including MEDLINE, EMBASE, Cochrane Central Register of Controlled
Trials, Cochrane Skin Group Specialised Register, Latin American and Caribbean Health Sciences Literature
(LILACS), Allied and Complementary Medicine Database (AMED) and Cumulative Index to Nursing and
Allied Health Literature (CINAHL) were searched from the end of 2000 to 31 August 2013. Retrieved
articles were used to identify further randomised controlled trials (RCTs).
Review methods: Studies were filtered according to inclusion criteria and agreed by consensus in cases of
uncertainty. Abstracts were excluded and non-English-language papers were screened by international
colleagues and data were extracted. Only RCTs of treatments for eczema were included, as other forms of
evidence are associated with higher risks of bias. Inclusion criteria for studies included availability of data
relevant to the therapeutic management of eczema; mention of randomisation; comparison of two or
more treatments; and prospective data collection. Participants of all ages were included. Eczema diagnosis
was determined by a clinician or according to published diagnostic criteria. The risk of bias was assessed
using the Cochrane Collaboration risk-of-bias tool. We used a standardised approach to summarising the
data and the assessment of risk of bias and we made a clear distinction between what the studies found
and our own interpretation of study findings.
Results: Of 7198 references screened, 287 new trials were identified spanning 92 treatments. Trial
reporting was generally poor (randomisation method: 2% high, 36% low, 62% unclear risk of bias;
allocation concealment: 3% high, 15% low, 82% unclear risk of bias; blinding of the intervention: 15%
high, 28% low, 57% unclear risk of bias). Only 22 (8%) trials were considered to be at low risk of bias
for all three criteria. There was reasonable evidence of benefit for the topical medications tacrolimus,
pimecrolimus and various corticosteroids (with tacrolimus superior to pimecrolimus and corticosteroids) for
both treatment and flare prevention; oral ciclosporin; oral azathioprine; narrow band ultraviolet B (UVB)
light; Atopiclair™ and education. There was reasonable evidence to suggest no clinically useful benefit for
twice-daily compared with once-daily topical corticosteroids; corticosteroids containing antibiotics for
non-infected eczema; probiotics; evening primrose and borage oil; ion-exchange water softeners; protease
inhibitor SRD441 (Serentis Ltd); furfuryl palmitate in emollient; cipamfylline cream; and Mycobacterium
vaccae vaccine. Additional research evidence is needed for emollients, bath additives, antibacterials,
specialist clothing and complementary and alternative therapies. There was no RCT evidence for topical
corticosteroid dilution, impregnated bandages, soap avoidance, bathing frequency or allergy testing.
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Limitations: The large scope of the review coupled with the heterogeneity of outcomes precluded formal
meta-analyses. Our conclusions are still limited by a profusion of small, poorly reported studies.
Conclusions: Although the evidence base of RCTs has increased considerably since the last NIHR HTA
systematic review, the field is still severely hampered by poor design and reporting problems including
failure to register trials and declare primary outcomes, small sample size, short follow-up duration and
poor reporting of risk of bias. Key areas for further research identified by the review include the optimum
use of emollients, bathing frequency, wash products, allergy testing and antiseptic treatments. Perhaps the
greatest benefit identified is the use of twice weekly anti-inflammatory treatment to maintain disease
remission. More studies need to be conducted in a primary care setting where most people with eczema
are seen in the UK. Future studies need to use the same core set of outcomes that capture patient
symptoms, clinical signs, quality of life and the chronic nature of the disease.
Funding: The National Institute for Health Research Programme Grants for Applied Research programme.
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Glossary
Abstracted Pulling out essential information from published trial reports.
Allocation Assignment to a treatment group.
Atopy Predisposition to mount an excessive immune response.
Balneotherapy Salt bathing.
Bias Factors that may alter the outcome of a study.
Blind When treatment allocation is unknown by the people taking part and the researchers conducting
the trial. A trial can be double blind (whereby neither participants nor investigators know the treatment
allocation) or single blind (whereby only one of these knows the treatment allocation).
Calcineurin inhibitors Non-steroidal treatments that block a chemical that activates inflammation.
Dermatoses Skin conditions.
Emollient Non-cosmetic moisturisers that are designed to prevent and treat dry skin.
Erythema Redness of the skin.
Excoriations Destruction or removal of skin from scratching.
Folliculitis Infection of the hair follicles.
Genotype Genetic make-up of a person.
Impetigo Contagious skin infection.
Intention-to-treat analysis An assessment of participants according to their initial treatment assigned
regardless of other factors (such as whether they dropped out or switched treatments).
Intertriginous regions When areas of skin come into contact with each other, for example between
the toes.
Lysate Contents of cells.
Meta-analysis The statistical combination of results from two or more separate studies.
Nares Nostrils.
Nasopharyngitis Common cold.
Pityriasis alba Dry white patches.
Pruritus Itching.
Pulsed treatment Burst of continuous treatment with periods of no treatment in between.
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Pyrexia Fever.
Random sequence generation Ensuring that there is an equal probability of being assigned to a control
or a treatment group according to a predefined list.
Randomised controlled trial A way to compare treatments – participants are randomly assigned to
receive either the treatment being assessed or an alternative treatment, which may be a placebo or
no treatment.
GLOSSARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxxiv
List of abbreviations
AAD American Academy of Dermatology
ADASI Atopic Dermatitis Area and
Severity Index
AMED Allied and Complementary
Medicine Database
CDLQI Children’s Dermatology Life
Quality Index
CI confidence interval
CINAHL Cumulative Index to Nursing and
Allied Health Literature
DHA docosahexaenoic acid
DLQI Dermatology Life Quality Index
EASI Eczema Area and Severity Index
EFA essential fatty acid
EPA eicosapentaenoic acid
GLA gamma-linolenic acid
GP general practitioner
GREAT Global Resource of EczemA Trials
HOME Harmonising Outcome Measures
for Eczema
HTA Health Technology Assessment
IDLQI Infant Dermatology Life Quality
Index
IGA Investigator’s Global Assessment
IgE immunoglobulin E
IQR interquartile range
LILACS Latin American and Caribbean
Health Sciences
MRSA methicillin-resistant
Staphylococcus aureus
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
PGA Physician Global Assessment
POEM Patient-Oriented Eczema Measure
PUVA psoralen plus ultraviolet A
RAST radioallergosorbent test
RCT randomised controlled trial
SASSAD Six Area, Six Sign Atopic Dermatitis
SCORAD Severity Scoring of Atopic
Dermatitis
SD standard deviation
SED standard erythemal dose
SIGN Scottish Intercollegiate Guidelines
Network
TIS Three-Item Severity
VAS visual analogue scale
w/w weight by weight
DOI: 10.3310/pgfar04070 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 7
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nankervis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxxv

Plain English summary
Eczema is an itchy red rash caused by genetic and environmental factors.
This review summarises randomised controlled trials of eczema treatments published since 2000. We
aimed to find, organise and comment on this evidence to help clinicians and patients make informed
choices about eczema treatments, as well as identify areas for further research. The review included
287 new trials, covering 92 treatments, the majority of which were not clearly reported, making it difficult
to judge their quality.
There was reasonable evidence of benefit for topical corticosteroids, tacrolimus, pimecrolimus, education,
ultraviolet light therapy, Atopiclair™ (Graceway Pharmaceuticals), ciclosporin and azathioprine tablets.
Studies to date suggest no benefit for twice-daily compared with once-daily topical corticosteroids, topical
corticosteroids containing antibiotics, montelukast, probiotics, evening primrose oil and borage oil and
ion-exchange water softeners.
Insufficient research exists for different emollient regimes, wet wraps, antiseptic bath additives, antifungal
creams, antihistamines, specialised clothing, e-health management, dietary interventions, Chinese
herbal treatment, complementary and alternative treatments, psychological therapies, salt baths, tablet
treatments (steroids, methotrexate, mycophenolate mofetil), biologics or injected treatments
(immunoglobulin, desensitisation therapy).
We did not find any trials that evaluated dilution of topical corticosteroids, impregnated bandages,
soap avoidance or routine allergy testing.
Almost as many trials were published in the last 14 years as in the previous 50 years. Although there
are still problems with trial design and reporting, the evidence presented here provides information for
clinicians, patients and careers. We recommend that patients are included in the prioritisation and design
of future eczema trials.
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Scientific summary
Background
Eczema, also known as ‘atopic eczema’ or ‘atopic dermatitis’, is a chronic, itchy, inflammatory skin
condition. Eczema affects around 20% of UK children and 5% of adults, and its prevalence is increasing.
Eczema is a complex disease caused by a combination of genetic and environmental influences.
Objectives
This review aimed to scope and summarise current randomised controlled trials (RCTs) of eczema to inform
evidence-based clinical practice and to identify possible research gaps for the future. The review is an
update of a previous similar review published in 2000 by the National Institute for Health Research (NIHR)
Health Technology Assessment (HTA) programme. The new information in this update places current
treatment options in the context of best-quality evidence. This review was conducted as part of a NIHR
Programme Grant for Applied Research award (RP-PG-0407-10177), details of which are found in a
companion report.
Methods
Only RCTs of treatments for eczema were included, as other forms of evidence are associated with higher
risks of bias. Inclusion criteria for studies included availability of data relevant to the therapeutic
management of eczema; mention of randomisation; comparison of two or more treatments; and
prospective data collection. Participants of all ages were included. Eczema diagnosis was determined by a
clinician or according to published diagnostic criteria. The risk of bias was assessed using the Cochrane
Collaboration risk-of-bias tool. We used a standardised approach to summarising the data and the
assessment of risk of bias and we made a clear distinction between what the studies found and our own
interpretation of study findings.
Outcomes
The main outcomes for this review were change in patient-rated symptoms; global severity as rated by
patients or physicians; change in composite rating scales (both named and un-named); quality of life;
and adverse events.
The following electronic databases were searched from the end of 2000 to 31 August 2013: MEDLINE;
EMBASE; the Cochrane Central Register of Controlled Trials and the Cochrane Skin Group Specialised
Trials Register; the Latin American and Caribbean Health Sciences (LILACS) database; the Allied and
Complementary Medicine Database (AMED); and the Cumulative Index to Nursing and Allied Health
Literature (CINAHL). Disease terms for atopic eczema [as a text word and medical subject heading (MeSH)
term if possible] were combined with a search for RCTs. A manual filtering process was undertaken to
assess whether a reference fitted the review’s inclusion criteria. Full papers were scrutinised in cases of
doubt. Excluded studies were identified by one reviewer and checked by a second reviewer in cases
of uncertainty. All papers were catalogued on an EndNote X6 database (Thompson Reuters, CA, USA).
There were no language restrictions; non-English-language papers were screened for eligibility by
international colleagues and data were fully abstracted if eligible.
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Results
Main findings
This review included 287 new trials covering 92 different treatments including topical, systemic,
non-pharmacological, behavioural, complementary and alternative treatments. As with the earlier review,
which included 254 eczema treatment trials, trial reporting was generally poor (randomisation method:
2% high, 36% low and 62% unclear risk of bias; allocation concealment: 3% high, 15% low and
82% unclear risk of bias; blinding of the intervention: 15% high, 28% low, 57% unclear risk of bias).
Only 22 (8%) trials were considered to be at low risk of bias for all three quality criteria.
There was reasonable evidence of benefit to support the following treatment comparisons: superiority of
topical corticosteroids compared with vehicle; superiority of 0.03% and 0.1% topical tacrolimus compared
with mild-potency topical corticosteroids, mainly in children with moderate to severe eczema; superiority
of 0.1% tacrolimus over moderate topical corticosteroids for adults with moderate to severe facial
eczema; superiority of topical pimecrolimus over vehicle, mainly in children with mild to moderate eczema;
superiority of topical tacrolimus compared with pimecrolimus for adults and children with eczema of all
severities; superiority of Atopiclair™ (Graceway Pharmaceuticals) emollient compared with vehicle in
children and adults with mild to moderate eczema; superiority of topical corticosteroids 2 days a week
compared with vehicle for preventing flares, mainly in adults and children with moderate to severe
eczema; superiority of tacrolimus 2 or 3 days a week over vehicle for preventing flares in children and
adults with mild to severe eczema; superiority of pimecrolimus over vehicle for preventing flares, mainly in
children with mild to severe eczema; superiority of narrowband ultraviolet B (UVB) light therapy compared
with placebo (visible light) for adults with moderate to severe eczema; superiority of ciclosporin over
placebo, mainly in adults with severe eczema; superiority of azathioprine over placebo in adults with
moderate to severe eczema; and superiority of educational intervention compared with no educational
intervention, mainly in children with moderate to severe eczema.
There was evidence of no clinically useful benefit for the following: twice daily compared with once daily
topical corticosteroids; topical corticosteroids containing antibiotics for non-infected eczema; protease
inhibitor SRD441 (Serentis Ltd) compared with vehicle in adults with mild to moderate eczema; emollient
with furfuryl palmitate in children with unspecified eczema severity; cipamfylline cream in adults with
eczema on the arms of unspecified severity; Mycobacterium vaccae vaccine in children with moderate to
severe eczema; probiotics for treating established eczema in children whose disease severity was not clearly
described; ion-exchange water softening devices in children with moderate to severe eczema; and dietary
supplements rich in linoleic acid such as evening primrose oil and borage oil in children and adults with
eczema of unspecified severity.
The trial evidence was not clear enough to make recommendations with regard to using emollients to
reduce the severity of eczema and prevent flares or to reduce the need for other eczema treatments;
topical corticosteroids in combination with antibiotics for infected eczema; wet wraps in addition to topical
corticosteroids; antiseptic bath additives; topical antifungals; other topical treatments such as WBI-1001
cream (Welichem Biotech Inc.), topical coal tar, topical vitamin B12 or Vitreoscilla filiformis lysate cream;
oral treatments including antihistamines, prednisolone, methotrexate, montelukast, mycophenolate
mofetil, pimecrolimus and naltrexone; immunotherapy (desensitisation); omalizumab; mepolizumab;
autologous blood therapy; tandospirone citrate; full-spectrum light therapy; excimer laser; intravenous
immunoglobulin; specialised clothing (silk or synthetic fibres with or without antibiotics); environmental
interventions such as house dust mite reduction; staying in a different climate; different approaches to the
organisation of care such as additional visits to the doctor or nurse-led clinics; support groups; e-health
management; dietary interventions such as prebiotics, dietary restrictions and synbiotics; complementary
therapies such as Chinese herbal treatment; hypnotherapy; massage therapy; aromatherapy; acupuncture;
acupressure; other herbal treatments; psychological therapies such as stress reduction techniques and
biofeedback; and balneotherapy (salt baths).
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There was a complete absence of RCT evidence for dilution of topical corticosteroids, impregnated
bandages (zinc paste bandages), soap avoidance, frequency of bathing and the role of routine
patch testing.
Changes in the evidence base since the previous review in 2000
Topical calcineurin inhibitors, educational interventions, oral azathioprine and Atopiclair have entered the
category of ‘reasonable evidence of benefit’ since the previous review in 2000.
Some interventions have now been tested sufficiently to suggest that they are not clinically useful. These
include topical corticosteroids containing antibiotics for eczema that is not overtly infected, probiotics,
ion-exchange water softeners and supplements rich in linoleic acid (e.g. evening primrose oil).
Many dietary, non-pharmacological, complementary and other topical or systemic interventions have been
investigated in small and generally poorly reported trials resulting in inconclusive findings.
Clinical relevance of the new evidence
Patients and setting
Eczema participants included in the published trials are generally skewed towards moderate or severe
disease as most trials recruited participants through secondary care. For some interventions, such as
systemic treatments and light therapy, this may be appropriate. However, for the more commonly used
topical interventions such as emollients, topical corticosteroids and bath products, it is important to
evaluate the interventions in a primary care setting where most patients are cared for.
Trial duration and comparators
There has been some improvement in the length of RCTs, with many trials of topical corticosteroids and
calcineurin inhibitors lasting from 6 months to 1 year. There is still a tendency for pharmaceutical
companies to undertake placebo-controlled studies, which do not give information on how new
treatments compare with existing treatments. For example, topical tacrolimus and pimecrolimus have now
been tested in a total of 30 placebo-controlled studies, the ethics of which is questionable. Encouragingly,
some trials are now using ‘standard care’ as a comparator, making it easier to assess the clinical relevance
of the evidence.
Outcomes
There has been a modest improvement in the number of trials that include participant-reported outcome
measures, although the results were often poorly reported. The move towards using the same core
outcome sets as encouraged by the Harmonising Outcome Measures for Eczema (HOME) initiative
[see www.homeforeczema.org (accessed 11 October 2015)] can only be beneficial for future clinical
interpretation and evidence syntheses.
Limitations of this review
Despite searching the main bibliographic databases (MEDLINE and EMBASE) and several smaller, specialist
databases (CINAHL, AMED and LILACS), it is still possible that we might have missed some RCTs. Masking
the identity of the trial authors from the review team was not practically possible, which may have
introduced bias when summarising qualitative aspects of the results. Given the very wide scope of this
review and heterogeneous nature of participants, interventions and outcomes, it has not been possible to
undertake detailed meta-analysis for single interventions. These will hopefully be conducted within much
narrower intervention-specific Cochrane systematic reviews. As with all systematic reviews, the evidence
presented will become out of date quite rapidly for some topics, and readers are directed to our Global
Resource of EczemA Trials (GREAT) database [see www.greatdatabase.org.uk (accessed 11 October 2015)]
for newly published eczema RCTs.
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Many of the treatments that are lacking in RCT evidence have been studied using uncontrolled designs.
Rare treatment adverse effects reported outside RCTs could also have been missed.
Our classification of treatment options into categories such as ‘evidence of benefit to support’ is not
tantamount to a positive recommendation for widespread use or otherwise, as that is the remit of
guideline developers and depends on factors such as magnitude of benefit, adverse effects and how the
treatment compares with existing active treatments, as well as factors such as availability and cost.
Conclusions
Implications for research
Primary research
Although not unique to eczema, perhaps the biggest priority for future research is to better understand
why researchers across the world continue to conduct small, poorly planned, unregistered and poorly
reported trials. In addition, there is a lack of clinical trials conducted in a primary care setting where most
patients are seen. The research questions being investigated often fail to reflect the most pressing
questions for clinicians and patients.
Our recent James Lind Alliance Priority Setting Partnership, reported in the companion report to this
review, used consensus methodology to identify the most important treatment uncertainties as judged by
patients and clinicians. It is salutary that three treatment areas with no RCT evidence at all are included on
the list of priority topics as identified by patients and health-care professionals.
Of the topics identified, the following areas seem to be most pressing when set in the context of the
updated evidence base from this review:
1. role of allergy testing in the management of eczema
2. use of emollients in the management of eczema
3. washing and bathing – no trials to date have examined frequency of bathing or the role of different
wash products in the management of eczema
4. optimum use of topical corticosteroids – the significant anxiety from parents and some health-care
providers over potential adverse effects, such as skin thinning and systemic absorption, need to be
addressed by observational studies, and head-to-head trials of pimecrolimus or tacrolimus compared
with topical corticosteroids for the prevention of flares are needed
5. systemic therapies for severe eczema in children
6. education for health-care providers (including doctors, nurses and pharmacists) and cost-effective
education programmes for patients and their families.
Some important topics have already been picked up by NIHR funding bodies and large pragmatic trials
are currently under way in the UK evaluating the role of topical and oral antibiotics for the treatment
of infected eczema [ChildRen with Eczema, Antibiotic Management (CREAM) study; UK Clinical
Research Network (UKCRN) ID 11233, silk clothing for the management of moderate to severe eczema
(UKCRN ID 15132) and the role of bath emollients in the management of eczema Bath Additives in
the Treatment of cHildhood Eczema (BATHE); HTA reference number 11/153].
Secondary research
Several Cochrane reviews of eczema, which will provide a more in-depth analysis of specific interventions,
either have been completed or are in progress. Overviews of existing systematic reviews are also needed,
as is the application of mixed-treatment comparisons for understanding more about treatments that have
yet to be compared in head-to-head trials.
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Methodological research
The greatest methodological challenge is in the field of outcome measures. Despite significant progress
from international consensus in identifying the four core outcome domains of symptoms, clinical signs,
quality of life and long-term control outlined in our companion report, there is still work to be done in
identifying and developing appropriate instruments for these domains and for establishing suitable tools
for routine clinical practice.
Implications for health care
The evidence base of RCTs for eczema has accelerated since the last HTA programme systematic review
and many commissioners, guideline developers, health-care professionals and patients can now refer to
this report for a rapid summary of relevant evidence to support everyday decisions in the treatment of
eczema. In addition to the established approach for treating eczema flares with topical corticosteroids,
perhaps the single largest advance in eczema treatment since the last review has been the strong evidence
supporting the value of a proactive approach for maintaining eczema remission through the use of twice
weekly topical corticosteroids, topical tacrolimus or topical pimecrolimus. Educational approaches have also
emerged as a promising intervention that should be tailored to the treatment setting.
Equally important is the understanding that some interventions now have sufficient evidence to suggest
little or no benefit for eczema patients. These include the use of topical corticosteroids containing
antibiotics when used for the management of non-infected eczema, probiotics, ion-exchange water
softeners and supplements rich in linoleic acid (borage oil, evening primrose oil).
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of the
National Institute for Health Research.
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Chapter 1 Background and aims
What is eczema?
Eczema, commonly referred to as ‘atopic eczema’ or ‘atopic dermatitis’, is a chronic inflammatory skin
condition characterised by an itchy red rash. Eczema can affect any part of the body but it typically settles
in the skin creases such as the folds of elbows or behind the knees; the face is commonly involved in
infants and in adults. Eczema lesions vary in appearance from collections of fluid in the skin (vesicles) to
gross thickening of the skin (lichenification) on a background of poorly demarcated redness. Other features
such as crusting, scaling, cracking and swelling of the skin can occur.1 Dry skin that results in impaired
barrier function is also a key feature of eczema. Eczema is associated with other atopic diseases such as
seasonal allergic rhinitis (hay fever) and asthma. Around 30% of people with eczema develop asthma and
35% develop allergic rhinitis.2 Atopic eczema typically starts in early life, with about 80% of cases starting
before the age of 5 years.3
When is eczema ‘atopic’?
Although the word ‘atopic’ is often used when describing eczema, up to two-thirds of people with eczema
do not have measurable levels of circulating allergen-specific immunoglobulin E (IgE) antibodies, which are
a necessary criterion to denote a person as ‘atopic’.4 The relationship between atopy and eczema is
unclear. Atopy is more common in more severe disease in hospital populations than in community
populations and atopy is also more common in affluent than in non-affluent countries. It has been
suggested that the relationship between eczema and atopy might be apparent only because of shared
causes for both conditions.5
The nomenclature for allergy6 has been revised and is now based on the mechanisms that initiate and
mediate allergic reactions. The term ‘atopic eczema’ should be used only when IgE sensitisation has been
confirmed by allergen-specific IgE antibodies in the blood or by a positive skin-prick test to common
allergens such as house dust mite.7 As this review includes cases of eczema based purely on a clinical
diagnosis, the term ‘eczema’ is used throughout to refer to what is more often described as ‘atopic
dermatitis’ or ‘atopic eczema’.
How is eczema defined in clinical studies?
Quite often no definition of eczema is given in clinical studies, which leaves the reader guessing as to what
sort of people were studied. Eczema is a difficult disease to define as the clinical features are highly
variable. This variability can relate to the skin rash morphology (e.g. it can be dry and thickened or
weeping and eroded), location (e.g. it commonly affects the cheeks in infants and skin creases in older
children) and time (it can be bright red one day and apparently gone a couple of days later) (Figure 1).
There is no specific diagnostic test for all people with typical eczema to serve as a reference standard;
diagnosis is therefore a clinical one.
Until the late 1970s at least 12 synonyms for eczema-like conditions were in common usage in the
dermatological literature and it is not certain whether physicians were all referring to the same disease
when using these terms. A major milestone in describing the main clinical features of eczema was the
Hanifin and Rajka diagnostic criteria of 1980.8 These consensus criteria are frequently cited in clinical trial
articles, thereby providing a degree of confidence that researchers are referring to a similar disease.
Scientifically developed refinements of the Hanifin and Rajka diagnostic criteria have been developed by a
UK Working Party9 and these criteria have been validated widely10 and used throughout the world and in
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National Institute for Health and Care Excellence (NICE) guidance. To qualify as a case of eczema,
the person must have an itchy skin condition plus three or more of the following:
l past involvement of the skin creases, such as the bends of elbows or behind the knees
l personal or immediate family history of asthma or hay fever
l tendency towards a generally dry skin
l onset under the age of 2 years (except when aged ≤ 4 years)
l visible flexural dermatitis as defined by a photographic protocol.
Binary or continuous disease?
It is unclear whether eczema is an ‘entity’ in itself or whether it is part of a continuum when considered at
a population level.11 Although it may be appropriate to ask the question, ‘How much atopic eczema does
he/she have?’ as opposed to ‘Does he/she have atopic eczema – yes or no?’, most population and clinical
studies require a categorical cut-off.
Is it all one disease?
It is quite possible that there are distinct subsets of eczema, for example those with filaggrin mutations,12,13
which may lead to more persistent and severe disease. When assessing which treatments are going to be
effective for eczema it is still sensible to consider the clinical disease as one condition. As more evidence
about the different phenotypes of eczema is collected (e.g. those who are definitely atopic with raised
circulating IgE levels to allergens or those with severe disease and associated asthma),11 sensitivity analyses
can be carried out to evaluate whether such subdivisions are useful for predicting treatment response.
The prevalence of atopic eczema
Eczema is a very common problem. The International Study of Asthma and Allergies in Childhood (ISAAC)
has been collecting data using standardised questionnaires combined with physical examinations since
1992 [see http://isaac.auckland.ac.nz/ (accessed 12 December 2015)]. Data from just under half a million
children and adolescents who participated in both phase I (1992–4) and phase III (1999–2004) have shown
that eczema is a truly global problem. The most recent phase revealed that prevalence among 6- to
7-year-olds ranged from 0.9% in Jodhpur, India, to 22.5% in Quito, Ecuador. Among 13- to 14-year-olds
FIGURE 1 Facial eczema. Severe eczema with signs of weeping, crusting and scratching. Image reproduced
with permission.
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the prevalence ranged from 0.2% in Tibet, China, to 24.6% in Barranquilla, Colombia. Prevalence in the
UK for 6- to 7-year-olds was 16% and for 13- to 14-year-olds was 10.6%. ISSAC has shown that eczema
prevalence has increased globally by just under 2%.14 Rising rates of prevalence have been found in many
developing countries, whereas a ‘levelling off’ or decrease in prevalence has been reported for developed
countries. The increased prevalence in developing countries could be for a number of reasons. One review
postulated that the increase in use of soaps, shower gels and other harsh cleaning products, often seen in
countries undergoing rapid development, could contribute towards this rise in prevalence.15 In the UK the
incidence of eczema has been assessed once, through a large primary care database in 2005; it was found
to affect around one in nine people at some point in the year.16
Age
Eczema is more common in childhood, particularly in the first 5 years of life.17 The prognosis of eczema
shows a mixed picture, with one study18 showing a 90% clearance rate for children within 10 years, and
other studies finding the rate to be around 60% by age 16 years. These figures may still not reflect the
true level of eczema clearance, as many people relapse at some point in their life. Eczema prognosis may
differ between the community setting (where the majority of cases are mild) and the hospital setting
(where cases tend to be more severe). One study found that 10% of hospital eczema patients still suffer as
adults. Adults constitute around one-third of all those with eczema in a general practice community.17
Adults also tend to represent a more persistent and severe subset of cases.
Severity distribution
Most cases of childhood eczema are mild. A study from 1998 by Emerson and colleagues19 found that
84% of 1760 children aged 1–5 years from four urban and semi-urban general practices in Nottingham
were mild cases (as defined globally by the examining physician), with 14% of cases in the moderate
category and 2% in the severe category. However, there has been little research regarding the severity
distribution of eczema, even though this would provide useful information for allocating health resources
(as the costs of managing severe eczema are disproportionally large in comparison to the costs of
managing mild eczema).
How does eczema affect people?
Direct morbidity has been estimated in several studies using generic dermatology quality-of-life scales.20,21
Impairment of quality of life has been found to be directly proportional to the severity of eczema.20 It has
been found that atopic eczema usually accounts for the worst scores compared with other dermatological
disease. Specific aspects of a child’s life that are affected by atopic eczema are:
l itch and associated sleep disturbance
l ostracism by other children and parents
l the need for special clothing and bedding
l avoidance of activities such as swimming, which other children can enjoy
l the need for frequent applications of greasy ointments and visits to the doctor.
Family disturbance is also considerable, with sleep loss and the need to take time off work for visits to
health-care professionals.21,22 Eczema in infancy incorporating sleep disruption is associated with an
increased risk of mental health issues at age 10 years.23
Economic costs
In financial terms, the cost of atopic eczema is potentially very large. The costs associated with the
management of eczema are largely indirect, such as workdays lost by parents and travel costs for
heath-care appointments, with much of this expense being met by the family of the person with eczema.
There have been a number of studies in the UK, the Netherlands and the USA that have shown the costs
to vary between country and according to severity.16,24,25
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What causes eczema?
Genetics
There is strong evidence to suggest that genetic factors are important in the predisposition to eczema.
In addition to family studies, twin studies have shown a much higher concordance for monozygotic
(identical) (85%) than for dizygotic (non-identical) (21%) twins.26 Mutations that occur in the filaggrin
(filament-aggregating-protein) gene give rise to a faulty filaggrin protein that results in dry skin
and an increased risk of developing eczema, as well as more severe and persistent disease and
associated asthma.13
Environment
Although genetic factors are probably a very important factor for disease predisposition, there are
numerous general and specific clues that point strongly to the crucial role of the environment in disease
expression.27 The recent, large increases in the prevalence of atopic eczema are difficult to explain purely in
genetic terms.15 It has been shown that atopic eczema is more common in wealthier families.28,29 It is
unclear whether this positive social class gradient is a reflection of indoor allergen exposures or whether it
reflects a whole constellation of other factors associated with ‘development’. The observation that many
cases of atopic eczema improve spontaneously around puberty is also difficult to explain in genetic terms
alone. Recent large birth cohort studies14 have not found any protective effect of elder siblings, conflicting
with earlier studies.30 The original observation that increasing family size was associated with decreased
eczema prevalence led to the ‘hygiene hypothesis’, which proposed that children in larger families were
protected from expressing atopy because of frequent exposure to infections.31 The role of exposure to
microbes and allergens in the environment is still being debated.
Migrant studies also point strongly to the role of environmental factors in eczema development. It has
been shown that 14.9% of black Caribbean children living in London develop atopic eczema (according to
the UK diagnostic criteria) compared with only 5.6% of similar children living in Kingston, Jamaica.25 Other
migrant studies reviewed elsewhere have consistently recorded large differences in ethnic groups migrating
from warmer climates to more prosperous cooler countries.32
Further work has suggested that the tendency to develop eczema could be programmed at birth and could
be related to factors such as maternal tobacco exposure.33 Specific risk factors for eczema expression in the
environment include furry pets; however, there is evidence that these can also have protective effects.34
Allergic factors such as exposure to the house dust mite could be important, but non-allergic factors such
as exposure to nylon clothing, dust or shampoo may also be important.35
Pathophysiology
A number of molecular mechanisms and cell types are thought to be important in atopic eczema and
these are reviewed in detail elsewhere.36 Microscopically, the characteristic appearance of eczema is fluid
between the cells in the epidermis (spongiosis). When severe, this fluid eventually disrupts the adjacent
cells in the epidermis to form small collections of fluid, which are visible to the naked eye as vesicles. In the
chronic phase, atopic eczema is characterised by gross thickening of the epidermis (acanthosis) and a
lymphocytic infiltrate in the dermis. The pathophysiology of atopic eczema may be related to abnormal
gene expression of immune cells as they infiltrate and remain in the mucosal surfaces and skin. There
appears to be a failure to switch off the natural predominance of type 2 helper (Th2) lymphocytes that
normally occurs in infancy, leading to an abnormal response of cytokines (chemical messengers) to a
variety of stimuli. This failure to achieve the normal balance of type 1 helper (Th1) and Th2 cells may be a
result of mutations in the interleukin-18 gene37 or other genes,38 for example those that produce receptors
for the innate immune system. Defects in the composition of the skin barrier leading to dry skin and
enhanced penetration of irritants and allergens are also thought to be critical.39,40
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Does eczema clear with time?
Although the tendency towards a dry and irritable skin is probably lifelong, the majority of children with
atopic eczema appear to ‘grow out’ of their disease, at least to a point at which the condition no longer
requires active medical care. A detailed review of studies that have determined the prognosis of atopic
eczema has been reported elsewhere.3 About 60% of childhood cases are clear or symptom free in early
adolescence, although many such apparently clear cases are likely to recur in adulthood, often as hand
eczema. The strongest and most consistent factors that appear to predict more persistent atopic eczema
are early onset, severe widespread disease in infancy, concomitant asthma, wheezing or hay fever, and a
family history of atopic eczema.33
How is eczema treated in the UK?
In 2007 NICE41 published guidance for the management of atopic eczema in children aged < 12 years.
The Scottish Intercollegiate Guidelines Network (SIGN)42 published guidance for eczema management in
2011 that covers adults and children.
National Institute for Health and Care Excellence guidance
The NICE guidance41 covers diagnosis, assessment and management of eczema and information on
eczema. The evidence was systematically reviewed and opinions from clinicians, researchers and consumers
were used to develop the clinical guidelines.
The guidelines recommend a holistic approach at each consultation, taking into account the severity of the
atopic eczema and the child’s quality of life, including everyday activities, sleep, and psychosocial well-being.
The guidelines give a clear list of the first-line (emollients and topical corticosteroids), second-line (topical
calcineurin inhibitors) and third-line (systematic treatments and phototherapy) treatments based on need
and severity.
The mainstay of treatment for all severities of eczema is emollients. The guidelines emphasise the
importance of using emollients even when the skin is clear. It also recommends allowing the patient a
choice of emollients for washing, bathing and moisturising.
Topical corticosteroids should be tailored to the severity and area of eczema and should be used once or
twice daily for an appropriate length of time. Topical steroids are an important tool for eczema treatment,
although care regarding the duration of treatment, site and age of the person treated was emphasised.
Potent steroids are not recommended for use in children aged < 12 months without specialist
dermatologist supervision.
Oral antihistamines should not be used routinely in the management of atopic eczema in children.
However, if sleep disturbance (for the child or their parents/carers) becomes significant during
an exacerbation of eczema (flare), health-care professionals should offer a 7- to 14-day trial of an
age-appropriate sedating antihistamine (for children aged ≥ 6 months). This treatment can be repeated
during subsequent flares if successful.
Occlusive medicated dressings and dry bandages should not be used to treat infected atopic eczema
in children.
Phototherapy or systemic treatments should be initiated in children with atopic eczema only after
assessment and documentation of the severity of atopic eczema and quality of life.
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Health-care professionals should spend time educating children with atopic eczema and their parents or
carers about atopic eczema and its treatment.
Scottish Intercollegiate Guidelines Network guidance
The SIGN guidance42 covers diagnosis, referral, management and patient education. The evidence for the
SIGN guidelines came from a systematic review of the literature from 2004 to 2009, involving five
bibliographic databases. The analysis of the evidence was conducted by the SIGN committee using
standard forms, with any additional evidence submitted by members of the committee, including key
reviews outside the search period. A review of studies on the issues facing patients was conducted and
presented to the committee.
The guidelines give the following key recommendations:
l Emollients should be given on a continuous basis, even when topical corticosteroids are being used.
l Topical corticosteroids should be applied once a day, and twice-weekly treatment should be considered
when those with moderate to severe eczema have frequent relapses.
l Topical calcineurin inhibitors are recommended for use in children aged ≥ 2 years if topical
corticosteroids are not controlling the eczema or the level of use of topical corticosteroid could lead to
adverse effects.
l Topical antibiotics are not recommended for the treatment of non-infected eczema.
Other recommendations included:
l As a precaution topical calcineurin inhibitors should not be applied to skin that appears
actively infected.
l Patients with non-infected moderate to severe eczema should be advised to cover affected areas with
dry wrap dressings to provide a physical barrier to scratching and improve retention of emollient.
l Swabs of potential Staphylococcus aureus carriage sites (of both the patient and family members)
should be considered in patients with recurrent infection.
l In patients with atypical features, or when there is concern about possible streptococcal infection, skin
swabs of affected areas should be considered.
l Short-term use of sedating antihistamines at night-time should be considered in patients with atopic
eczema when there is debilitating sleep disturbance.
l When an irritant effect is suspected, patients should be advised to avoid biological washing powders,
fabric conditioners and fragranced products such as soaps and shower gels.
l Dietary exclusion is not recommended for management of atopic eczema in patients without confirmed
food allergy.
l When there is suspicion of food allergy in infants or children with atopic eczema, general practitioners
(GPs) should refer to an allergist or paediatrician with a special interest in allergy.
l Exercise caution when using herbal medicines and be wary of any herbal product that is not labelled in
English or does not come with information about safe usage.
The guidelines also detail what information can reasonably be expected by a patient during diagnosis
and treatment.
How is care organised in the UK?
Most children with atopic eczema in the UK are managed by a primary care team, with around 4–10% of
children with atopic eczema referred to a dermatologist for further advice.19
The quality of service provided by secondary care has been audited by the British Association of
Dermatologists. Although most departments provided a high-quality service, some aspects of care, such as
the administration of simple standardised record forms, could be improved.43 The audit found that the
outcomes may not be as good as some doctors believe, with the improvements in quality of life and
numbers of adults returning to work not meeting the working standards.43
BACKGROUND AND AIMS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Adherence (or, more correctly, concordance) seems to be a major cause of apparent treatment failure.
A survey conducted in Nottingham found that most parents worry that topical steroids cause adverse
effects, although many were not able to distinguish between weak and strong ones.44
The National Eczema Society [see www.eczema.org (accessed 12 October 2015)] is the UK’s largest
self-help organisation for people with eczema. It has a well-organised information service and national
network of activities geared to help those with eczema and their families. Sources of alternative care
abound in the community, especially with the increased access to the internet, ranging from the highly
professional to elaborate, expensive diagnostic and therapeutic measures of dubious value.
How are the effects of atopic eczema captured in clinical trials?
Outcome measures used in trials have recently been reviewed.45 Most outcome measures have
incorporated some measure of itch as assessed by a doctor at periodic reviews or patient self-completed
diaries. Other more sophisticated methods of objectively recording itch have been tried.46 Composite
outcome measures are most often used. These usually incorporate measures of extent of atopic eczema
and several physical signs such as redness, scratch marks, thickening of the skin, scaling and dryness. Such
signs are typically mixed with symptoms of sleep loss and itching and variable weighting systems are used.
It has been shown that measuring surface area involvement in atopic eczema is fraught with difficulties,27
which is not surprising considering that eczema is, by definition, ‘poorly defined erythema’. A systematic
review of named outcome measure scales for atopic eczema45 found that, of the 20 named scales in
current use, only three have been validated adequately enough to be recommended for use in clinical
trials: Severity Scoring of Atopic Dermatitis (SCORAD),47 Eczema Area and Severity Index (EASI)48 and the
Patient-Oriented Eczema Measure (POEM).49 Quality-of-life measures specific to dermatology include the
Dermatology Quality of Life Index50–52 and Skindex53,54
Why is a scoping systematic review still needed?
Keeping up to date with the rapidly increasing evidence base for eczema treatment is challenging.
The predecessor to this review by Hoare and colleagues55 gave an overview of the evidence, with an
assessment of quality and the implications for both practice and research. The review was well received
and provided major contributions to eczema guidelines around the world. This updated version of the
review has the same aim of giving a succinct, clinically relevant overview and identifying the major
research gaps.
The treatment landscape has also radically changed in the past decade, with many new treatments now in
routine clinical use and new treatment regimens regularly being advocated. Even though the pace of
eczema research has steadily increased, with more relevant Cochrane and non-Cochrane systematic
reviews being published, there is still considerable uncertainty about the effectiveness of the prevention
and treatment of atopic eczema. This is unsurprising as there are still sizeable ‘holes’ in the web of
up-to-date systematic reviews and identifying randomised controlled trials (RCTs) that fill in these holes has
previously been difficult and time-consuming. Although there have been a good number of systematic
reviews of specific eczema treatments over the past 14 years, many treatments have never been reviewed,
and the scoping nature of this updated systematic review helps to redress this imbalance.
The high disease burden and concerns regarding adverse effects coupled with the profusion of treatments
delivered in different care settings are all reasons why an up-to-date scoping systematic review of atopic
eczema treatments is needed.
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This updated review will also contribute to identifying, prioritising and generating further primary,
secondary and methodological research.
Summary of the problem of atopic eczema
l The terms ‘atopic eczema’ and ‘atopic dermatitis’ are synonymous and when ‘atopy’ has not been
tested for, the term ‘eczema’ should be used.
l The definition of eczema is a clinical one based on itching, redness and involvement of the skin creases.
l About 20% of people seen in hospitals with clinically typical eczema are not ‘atopic’.
l Eczema affects about 15–20% of UK children.
l About 80% of cases in the community are mild.
l Adults make up about one-third of all cases in a given community.
l Eczema accounted for the largest burden of disability life-adjusted years for skin diseases in the 2010
World Health Organization global burden of diseases project.56
l The constant itch and resultant skin damage in eczema can lead to a poor quality of life for people
with eczema and their families.
l The economic costs of eczema are high.
l Genetic and environmental factors are both critical for disease expression.
l Non-allergic factors may be just as important as allergic factors in determining disease expression
and persistence.
l The immune system and skin barrier abnormalities are both important in explaining the pathological
processes of atopic eczema.
l About 60% of children with atopic eczema are apparently clear or free of symptoms by adolescence.
l Early onset, severe disease in childhood and associated asthma/hay fever are predictors of a
worse prognosis.
l Current first-line treatment in the UK includes emollients and topical corticosteroids.
l Second-line treatments include topical calcineurin inhibitors and ultraviolet light.
l Third-line treatments include systemic immunomodulatory treatments such as ciclosporin and azathioprine.
l Most people with eczema are managed by their primary care team.
l Some people with eczema seek alternative treatments, such as complementary therapies.
l An up-to-date systematic review is needed to map out in which areas high-quality research has been
conducted to date, with the aim of resolving some areas of uncertainty and identifying knowledge
gaps to be addressed by further primary and secondary research.
Research questions asked in this review
The remit of this project was to provide a summary of RCTs of eczema with the main aim of providing
useful clinical information for health-care professionals, commissioners and people with eczema and their
families, and also to identify research gaps for further primary, secondary or methodological research. It is
also hoped that the review will be of some use to health-care providers, physicians involved in the care of
people with eczema and also people with eczema and their families by placing current treatments in
context within the current evidence base. The main research questions asked in this review are therefore:
1. What treatment recommendations can be made by summarising the available RCT evidence using
narrative and quantitative methods? The main outputs for this question are detailed summaries of
available RCT evidence for different interventions for atopic eczema along with the review authors’
interpretations of the data based on the quality of that evidence, the magnitude of the treatment effect
and the clinical relevance of the evidence.
2. What therapeutic interventions have the RCTs of atopic eczema covered so far? The main output for
this question is a summary of research gaps for further research, with research commissioners, charities
and researchers as the main target audience.
BACKGROUND AND AIMS
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A question- or data-driven review?
The very broad-ranging scoping nature of this review implies that it cannot be hypothesis driven. Trying to
answer similar questions for each of the 92 or so interventions used for the treatment of atopic eczema
would be impossible in one short report.
This updated review is still unashamedly data driven. It is a review that aims to map out what has been
done in terms of RCTs in atopic eczema to date and to reflect and comment on the coverage of
already-researched areas in relation to questions that are commonly asked by physicians and their patients.
The authors are aware that there is a danger that a data-driven review can serve to amplify and perpetuate
current trends in evaluating minor differences between a profusion of similar pharmacological products.
The authors have mitigated against this inevitable hazard by drawing attention to gaps that have not been
addressed when summarising the reported studies and also by including a section on unanswered
questions in the discussion and conclusions section of this report, based on a recently completed
James Lind Alliance Priority Setting Partnership.57
DOI: 10.3310/pgfar04070 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 7
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nankervis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9

Chapter 2 Methods
General methods structure
This review uses methods developed by the Cochrane Collaboration when possible.58 The review follows
the general structure of and guidance from the National Institute for Health Research (NIHR) reports of
systematic reviews and closely follows the methods used in the NIHR Health Technology Assessment (HTA)
programme report published in 200055 for continuity. This previous HTA report serves as the published
protocol for this review and therefore an additional separate protocol was not published.
Types of studies included in the review
Only RCTs of treatments for eczema were included in the data summaries as other forms of evidence are
associated with higher risks of bias. For a RCT to be included, it needed to be prospective and randomise
participants diagnosed with eczema to two or more groups. In addition, the RCT had to be concerned with
therapeutic issues in relation to the treatment of atopic eczema.
Provocation studies that evaluated cellular or biochemical responses to substances such as histamine were
not included. Studies of possible increased incidence of drug adverse effects in atopic people compared
with non-atopic people were also excluded. Studies also had to include at least one clinical outcome.
Therefore, studies that reported only changes in blood tests or cellular mechanisms were excluded.
Study participants
Studies were included if participants (of any age) had eczema meeting diagnostic criteria (e.g. Hanifin and
Rajka criteria,8 UK Working Party criteria9 or similar) or had been diagnosed by a physician. Terms used to
identify trial participants with definite and possible eczema and those definitely not having eczema are
shown in Table 1. Those studies using terms in the ‘definitely not eczema’ category, such as ‘allergic
contact eczema’, were excluded. Those studies using terms in the ‘possible eczema’ category, such as
‘childhood eczema’, were scrutinised by one of the authors and included only if the description of the
participants clearly indicated eczema (i.e. itching and flexural involvement).
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Main outcome measures
Changes in patient-rated symptoms of eczema such as itching (pruritus) or sleep loss were used when
possible. Global severity, as rated by patients or their physician, was also sought. If these outcomes were
not available, then global changes in composite rating scales using a published named scale (Table 2
provides information on the most commonly used scales) or, when not possible, the authors’ modification
of existing scales or new scales developed within the study were summarised. Quality of life, using any
named scale or, when not possible, the authors’ modification of existing scales, and adverse events were
also included if reported.
Secondary outcome measures
Secondary outcomes measures were changes in individual signs of atopic eczema as assessed by a
physician, for example:
l erythema (redness)
l purulence (pus formation)
l excoriation (scratch marks)
l xerosis (skin dryness)
l scaling
l lichenification (thickening of the skin)
l fissuring (cracks)
l exudation (weeping serum from the skin surface)
l pustules (pus spots)
l papules (spots that protrude from the skin surface)
l vesicles (clear fluid or ‘water blisters’ in the skin)
l crusts (dried serum on the skin surface)
l infiltration/oedema (swelling of the skin)
l induration (a thickened feel to the skin).
TABLE 1 Terms used to identify participants with definite and possible eczema and those definitely not
having eczema
Definite eczemaa Possible eczemab Not eczemac
l Atopic eczema
l Atopic dermatitis
l Besnier’s prurigo
l Neurodermatitis atopica (German)
l Flexural eczema/dermatitis
l Atopic eczema/dermatitis syndrome
l Intrinsic/extrinsic eczema
l Atopiform/non-atopiform eczema
l Periorbital eczema
l Childhood eczema
l Infantile eczema
l ‘Eczema’ unspecified
l Constitutional eczema
l Endogenous eczema
l Chronic eczema
l Neurodermatitis
l Neurodermatis (German)
l Xerotic eczema
l Seborrhoeic eczema
l Contact eczema
l Allergic contact eczema
l Irritant contact eczema
l Discoid/nummular eczema
l Asteatotic eczema
l Varicose/stasis eczema
l Photo-/light-sensitive eczema
l Chronic actinic dermatitis
l Dyshydrotic eczema
l Pompholyx eczema
l Hand eczema
l Frictional lichenoid dermatitis
l Lichen simplex
l Occupational dermatitis
l Prurigo
l Palmoplantar eczema
a Include if study was a RCT.
b Implies that original paper must be obtained and read before a judgement is made by one of the authors to include or
exclude based on additional features such as a good clinical description of atopic eczema with atopy.
c Implies that the authors did not accept this term as representing atopic eczema.
METHODS
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TABLE 2 Details of commonly used composite global severity scales
Name Scale
Usually
assessed
by
Assessment
of symptoms Assessment of signs Extent Comments
SCORAD47 0–103 Physician Pruritus, sleep
disturbance
Erythema, oedema/
induration/papulation,
oozing/crusting/
weeping/exudation,
excoriation,
lichenification, dryness
% body
surface area
Used mostly in Europe.
Recommended for use
in clinical trials in one
systematic review of
outcome measures45
EASI48 0–72 Physician Not assessed Erythema, oedema/
induration/papulation,
excoriation,
lichenification
% body
surface area
Mostly used in America.
Recommended for use
in clinical trials in one
systematic review of
outcome measures45
Six Area, Six Sign
Atopic Dermatitis
(SASSAD)59
0–108 Physician Not assessed Erythema, oozing/
crusting/weeping/
exudation, excoriation,
lichenification,
dryness, cracking/
fissuring
Assessment
at defined
body sites
Measures signs only
and therefore it can
be used when blinded
outcome assessment
by a trained observer
is needed
POEM49 0–28 Patient or
carer
Pruritus, sleep
disturbance
Oozing/crusting/
weeping/exudation,
dryness, cracking/
fissuring, flaking,
bleeding
Not
assessed
Recommended for use
in clinical trials in one
systematic review of
outcome measures45
Atopic Dermatitis
Area and Severity
Index (ADASI)60
0–15 Physician Pruritus Erythema, oedema/
induration/papulation,
oozing/crusting/
weeping/exudation,
lichenification, scaling
% body
surface area
affected
Test–retest reliability
and sensitivity to
change have not been
tested45
Leicester Sign
Score (LSS)61
0–150 Physician None Erythema, excoriation,
lichenification,
dryness, cracking/
fissuring
Assessment
at defined
body sites
Interobserver reliability
and test–retest
reliability have not
been tested45
Investigator’s
Global
Assessment Of
Disease Activity
(IGADA)62
Clear to
very
severe
Physician None Erythema, oedema/
induration/papulation,
oozing/crusting/
weeping/exudation,
excoriation,
lichenification, scaling
Assessment
at defined
body sites
Interobserver reliability
and test–retest
reliability have not
been tested. Adequate
sensitivity to change
has been shown45
Three-Item
Severity (TIS)
score63
0–9 Physician None Erythema, oedema/
induration/papulation,
excoriation
Not
assessed
Adequate construct
validity has been
shown45
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For the original review, the selection of outcome measures was explored in more detail with a focus group
of consumers when developing the review methods. The secondary outcomes were not altered for the
updated review to allow synthesis of the evidence. This work also forms part of a larger body of research
on developing core outcome sets for eczema clinical trials known as the Harmonising Outcome Measures
for Eczema (HOME) initiative (see the following section),57 in which there has been considerable patient
and public involvement.
Dealing with different outcome measures
Eczema outcomes have historically been measured in many different ways. In 2007, a systematic review of
eczema outcomes45 identified 20 different named scales for measuring the severity of eczema and
concluded that only three of these (SCORAD, EASI and POEM) could be recommended for use in clinical
trials on the basis of the available validation studies. The eczema severity outcome measures cover different
signs and symptoms of eczema as well as working out the extent of the eczema in different ways. These
differences often make direct comparison of trial results difficult or impossible. To improve the situation,
the HOME initiative was formed.64,65 This initiative is ongoing and involves and welcomes contributions
from researchers, clinicians, patients and the pharmaceutical industry. The aim of this initiative is to decide
on a set of core outcome measures that should be included in all RCTs. These core outcomes will cover the
agreed domains of signs, symptoms, quality of life and long-term control. The HOME initiative has so far
recommended that the signs and symptoms for eczema be recorded using EASI.66 Trials are not restricted
to the core outcome measures but should always include them to facilitate direct comparisons of the
results of RCTs in the future.
Search strategy
Electronic searching
To retrieve all RCTs on atopic eczema treatments in accordance with the inclusion criteria, a systematic and
mainly electronic search was carried out. The Cochrane Handbook for Systematic Reviews of Interventions58
was used as a template.
The following electronic databases were searched from the end of 2000 up to and including August 2013:
l MEDLINE
l EMBASE with its higher yield of non-English reports
l Cochrane Central Register of Controlled Trials
l The Cochrane Skin Group Specialised Trials Register
l Latin American and Caribbean Health Sciences (LILACS) database
l Allied and Complementary Medicine Database (AMED)
l Cumulative Index to Nursing and Allied Health Literature (CINAHL).
Disease terms for atopic eczema [as a text word and medical subject heading (MeSH) term] are shown in
Appendix 1. Possible trials were identified from each of the six databases as follows:
l MEDLINE (OvidSP) – the Cochrane Collaboration ‘highly sensitive electronic search string’ for RCTs was
used (see Appendix 1). Publications from 2000 to 31 August 2013 were searched and yielded > 4000
references using the disease search terms in Appendix 1.
l EMBASE (OvidSP) – because of the different format of this database an alternative search strategy was
employed (see Appendix 1). Publications from 2000 to 31 August 2013 were searched and yielded
> 2000 references using the same eczema terms as for MEDLINE.
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l Cochrane Central Register of Controlled Trials – The Cochrane Library 2013 was searched for
controlled trials within the Cochrane Central Register of Controlled Trials section by exploding the
disease-specific search terms separated by the Boolean ‘AND’ with the advanced search option.
These included clinical controlled trials (quasi randomisation) and RCTs (randomisation).
l Cochrane Skin Group Specialised Register – this was searched with the disease-specific terms and the
kind help of the Cochrane Skin Group Trials Search Coordinator.
l www.controlled-trials.com was searched for completed and ongoing RCTs using the terms ‘atopic
dermatitis’, ‘atopic eczema’ and ‘eczema’. This meta-register of trials contains the entries from the
following databases:
¢ ISRCTN register (international) – copy of the ISRCTN register
¢ Action Medical Research (UK) – subset of the ISRCTN register
¢ Medical Research Council (UK) – subset of the ISRCTN register
¢ US National Institutes of Health ClinicalTrials.gov register (international) – subset of randomised
trial records.
Handsearching
As there are > 200 specialist dermatology journals and none specific to atopic eczema, separate
handsearching was not carried out for this report. Some trials published in journals not listed in the
bibliographic databases searched, or published within the body of a letter to the editor, might therefore
have been missed. However, specialist dermatology journals are handsearched by the Cochrane Skin
Group and these are included in the Cochrane Skin Group Specialised Register of trials, which was
searched. This includes the results of handsearching the following dermatology journals over varying dates:
Cutis, Acta Dermato-Venereologica Supplementum, Archives of Dermatology, British Journal of
Dermatology, Clinical and Experimental Dermatology, International Journal of Dermatology, Journal of
Investigative Dermatology and Journal of the American Academy of Dermatology.
In addition, conference proceedings of previous symposia such as the Atopic Dermatitis Symposia and all
meeting abstracts for the annual meetings of the Society for Investigative Dermatology, European
Academy of Dermatology and British Association of Dermatologists were handsearched by one of the
authors and the results made available to the Cochrane Skin Group Specialised Register. Furthermore, one
of the authors has been prospectively handsearching five dermatology journals (Clinical Experimental
Dermatology, British Journal of Dermatology, Journal of the American Academy of Dermatology, Journal of
Investigative Dermatology and Paediatric Dermatology) since January 1998 for atopic eczema
treatment trials.
Other trial sources
In addition to checking citations in retrieved RCTs, additional trials were sought by personal contact with
atopic eczema researchers and by writing to 15 pharmaceutical companies with a product (commercially
available or in development) related to atopic eczema treatment.
Filtering
The initial search yielded 7168 references. A manual filtering process was conducted to assess whether
each reference fitted the preliminary labels of ‘trial’ and ‘eczema’.
Not all references had abstracts and therefore studies were included if their title related to an eczema trial,
to avoid premature exclusion. In cases of uncertainty, the full paper was requested and scrutinised by one
of the authors and discussed with a second senior author as necessary. Papers excluded were categorised
by reason for exclusion by one reviewer; this was checked by a second reviewer in cases of uncertainty.
When a trial fitted the inclusion criteria but was found to be published only as an abstract, the trial was
excluded from the review. All papers were catalogued on a specialised referencing database (EndNote X7;
Thomson Reuters, CA, USA).
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Non-English-language studies
Non-English-language studies were screened by international colleagues (see Acknowledgements) and full
data extraction performed for those meeting the inclusion criteria.
Identifying treatments with no randomised controlled trials
A data-driven review can identify only treatments for which some evidence exists and therefore there may
be other treatments that are currently used throughout the world for atopic eczema but which are not
necessarily supported by RCTs.
Data assessment
Papers meeting the inclusion criteria were subject to data extraction with a view to pooling data or
producing a narrative summary. Data extraction forms were developed by one of the authors. Data
extraction was carried out independently by two authors for all included trials. One author checked the
two sets of data extraction for discrepancies and then consulted the original papers to resolve these with
the second data extractor or a third arbitrator when unclear.
Study quality
The methodological quality of each study was assessed using the Cochrane Collaboration risk-of-bias
assessment tool,58 with potential sources of bias evaluated:
l method of generating the randomisation sequence
l concealment of the allocation sequence
l blinding of participants, study personnel and outcome assessments
l other issues including incomplete outcome data and selective outcome reporting and the extent to
which the primary analysis included all participants initially randomised (i.e. an intention-to-
treat analysis).
The method of generation of the randomisation sequence, allocation concealment and blinding have been
consistently shown to predict bias in effect estimates67 and so these have been tabulated throughout the
review to assist readers in making comparisons between studies. When assessing the risk of bias for
blinding, a trial was assessed as low risk if the primary outcome assessor was reported as blinded even if
other parties, such as the participants, were not. When the trials are summarised, standard statements
about the collective risk of bias have been used (Table 3). This allows readers to see which aspects of the
study reporting were deficient for each treatment. Because of the sheer size of this scoping review, the
report authors were not blinded to the identity of the RCT authors when assessing quality or carrying out
data extraction.
Quantitative data synthesis
Pooling of the data did not make sense clinically for any of the interventions and so no pooling of
quantitative data was undertaken.
Methods of presenting results
Summarising the evidence for treatments and harms from 287 RCTs covering at least 92 different
interventions in a way that would be helpful to health-care commissioners, providers and physicians is
challenging. There is always a conflict in such a situation of providing too much information, resulting in
loss of the general picture, or of omitting important details in some specific areas.
Readers are encouraged to read the original studies when doubt occurs over the reported data or the
report authors’ conclusions. One of the report authors has led the development of a database of eczema
RCTs [the Global Resource for EczemA Trials (GREAT) database68] in which information about and links to
the included and excluded studies in this review can be found.
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In many of the studies it would have been impractical to document every outcome and therefore the
report authors have highlighted:
l patient-rated global improvement or itch or sleep loss
l global severity score based on several skin signs, or individual skin sign scores.
In some studies evaluating multiple outcomes, statistically significant post hoc tests were highlighted in the
paper’s conclusions or abstract. The report authors have mitigated against this bias by stating whether
the results were from a post hoc test.
If pre-existing systematic reviews were identified for any of the interventions, these were highlighted at the
beginning of the relevant sections.
Separating trial data from authors’ opinions
The report authors have been careful to make a clear distinction between the facts abstracted from
individual studies and the respective authors’ interpretations of what those results or lack of results mean.
Thus, actual data on efficacy and possible harms have been clearly separated from the authors’ ‘overall
implications for research and practice’ sections. In the comments sections of the risk-of-bias tables, the
report authors have also commented on possible sources of bias.
TABLE 3 Criteria used for discussing the risk of bias in the summaries of treatment chapters (see Chapters 4–13)
Collective risk-of-bias
descriptions for summary
statements Basis for description
Overall low risk of bias Method of generating the randomisation sequence, concealment of the allocation
sequence and blinding were assessed as low risk for all of the trials summarised
Overall unclear risk of bias Method of generating the randomisation sequence, concealment of the allocation
sequence and blinding were assessed as unclear risk for all of the trials summarised
Overall high risk of bias Method of generating the randomisation sequence, concealment of the allocation
sequence and blinding were assessed as high risk for all of the trials summarised
Mostly low risk of bias A clear majority of the method of generating the randomisation sequence,
concealment of the allocation sequence and blinding were assessed as low risk of bias
Mostly unclear risk of bias A clear majority of the method of generating the randomisation sequence, concealment
of the allocation sequence and blinding were assessed as unclear risk of bias
Mostly high risk of bias A clear majority of the method of generating the randomisation sequence,
concealment of the allocation sequence and blinding were assessed as high risk of bias
A mixed risk of bias The assessments were a fairly even distribution of risk of bias for method of generating
the randomisation sequence and concealment of the allocation sequence
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Chapter 3 Results
Included studies
There were 287 RCTs of eczema treatments included in this update review (Table 4) (see Chapters 4–13).
The results from the previous review of RCTs of eczema treatment55 were also included in this review
for every treatment for which new RCTs were reported. When no new RCTs were included from the
updated search, the treatment was not discussed and the reader is directed to the previous review of
eczema treatments.55
TABLE 4 Summary of included treatments
Treatment Page number
Topical corticosteroids and topical immunomodulators 25
Topical corticosteroids compared with placebo 26
Topical corticosteroids compared with active treatments 28
Tacrolimus compared with placebo 30
Tacrolimus compared with active treatments 32
Pimecrolimus compared with placebo 37
Pimecrolimus compared with active treatments 39
Tacrolimus compared with pimecrolimus 42
Topical calcineurin inhibitors used concurrently with topical corticosteroids 44
Topical corticosteroids with occlusive therapy 45
Emollients and other topical treatments 51
Emollients 51
Bath additives 58
Furfuryl palmitate 59
Pill mask 60
Black seed oil 61
Rosmarinic acid 62
Hippophae rhamnoides 62
Shale oil 63
Vitreoscilla filiformis 64
Miltefosine 65
Opiate receptor antagonist 66
Topical vitamin B12 67
WBI-1001 cream (Welichem Biotech Inc.) 68
Carbohydrate-derived fulvic acid 70
Protease inhibitor SRD441 (Serentis Ltd) 71
continued
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TABLE 4 Summary of included treatments (continued )
Treatment Page number
Raffinose 72
Atopiclair™ (Graceway Pharmaceuticals) 73
Farnesol and xylitol 75
Levomenol and heparin 76
Bacterial antigens 77
Camomile extract 78
Camellia oil 79
Cipamphylline cream 80
Lipoxin A4 81
N-acetyl-L-hydroxyproline 82
Nalmefene hydrochloride monohydrate 83
Licochalcone A 84
AR-GG27 85
Antimicrobials including antibiotics, antiseptics and antifungals 89
Antibiotics 90
Fusidic acid 90
Mupirocin 92
Tetracycline 94
Clarithromycin 95
Antiseptics 95
Triclosan 95
Bleach baths 96
Antifungals 98
Ketoconazole 98
Miconazole 99
Itraconazole 100
Antihistamines and mast cell stabilisers 105
Cetirizine 106
Loratidine 107
Fexofenadine 107
Ketotifen and epinastine 108
Chlorpheniramine 110
Topical doxepin 111
Topical sodium chromoglycate 112
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TABLE 4 Summary of included treatments (continued )
Treatment Page number
Dietary interventions 115
Probiotics, prebiotics and synbiotics 116, 122, 123
Borage oil 125
Evening primrose oil 126
Fish oil/soybean oil 126
Docosahexaenoic acid 127
Hempseed oil 128
Vitamin D 129
Hypoallergenic formula 132
Non-pharmacological interventions 137
Specialised clothing 137
Education 142
Support groups 149
Ion-exchange water softener 152
Staying in a different climate 153
House dust mite desensitisation 154
Extra visits to the doctor 155
Vaccines 156
Phototherapy 161
Ultraviolet B 161
Ultraviolet A 162
Ultraviolet A vs. ultraviolet B 164
Phototherapy combined with other treatments 166
Full-spectrum light therapy 168
Excimer laser 168
Systemic immunomodulatory agents 171
Azathioprine 171
Ciclosporin 173
Methotrexate 176
Oral prednisolone 177
Mycophenolate mofetil 178
Montelukast 179
Systemic immunotherapy 182
Mepolizumab 184
Omalizumab 185
Intravenous immunoglobulin 186
Oral pimecrolimus 188
continued
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Excluded studies
Eczema prevention trials have not been included in this review as the body of evidence is substantial.
Prevention of eczema has been covered in 40 systematic reviews69 and one overview of the reviews70
(see Chapter 1), which is itself a component of the eczema prevention work programme of this grant.
The details of the excluded studies are shown in Figure 2. Further details of eczema trials that were
excluded in the final stages as they were reported only as abstracts are provided in Appendix 2. A more
comprehensive archive of the excluded papers can be found in the GREAT database.71
TABLE 4 Summary of included treatments (continued )
Treatment Page number
Complementary therapies 193
St John’s wort 193
Acupuncture 195
Hypnotherapy 197
Chinese herbal medicine 199
Homeopathy 201
Other herbal medicines 202
Japanese traditional medicine 203
Hwangryunhaedoktang 204
Balneotherapy 204
Progressive muscle relaxation 205
Other interventions not covered elsewhere 209
Autologous blood therapy 209
Tandospirone citrate 210
Oral naltrexone 211
RESULTS
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Number of records after 
duplicates removed 
(n = 7068)
Number screened
 (n = 7068)
References excluded (n = 6781)a
• Excluded as they were not trials, n = 4225
• ‘Trial’ references were excluded as they 
   did not concern eczema, n = 1386
• ‘Eczema trial’ references were excluded, 
    n = 1130, for the following reasons: 
    • AD patients in only one arm
    • adherence study
    • case–control study
    • case series
    • cost analysis
    • diagnostic test accuracy
    • eczema not separated from others
    • eczema mentioned as AE
    • healthy volunteers
    • no comparative group
    • no benefit or harms outcomes
    • no randomisation described
    • non-randomised follow-up study
    • not a treatment trial
    • not eczema or unclear if it was eczema
    • not in human participants
    • observational study
    • prevalence study
    • study intervation did not attempt to 
       confer benefit
    • treatment study
    • no results for efficacy and harms given
Databases (n = 7198) Other sources (n = 0)
Number included in 
narrative synthesis 
(n = 287)
Number in quantitative
synthesis 
(n = 0)
FIGURE 2 Flow chart of the filtering process. AD, atopic dermatitis; AE, adverse event. a, Duplicate references that
were removed before being filtered are included in this total.
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Chapter 4 Topical corticosteroids and
topical immunomodulators
Background
Topical corticosteroids have been one of the cornerstones of the treatment of atopic eczema for
> 50 years.
Hydrocortisone was first used as a skin treatment in 1952, when it was found to improve various
dermatoses when applied topically.72 Since then, another 30 or so compounds have been developed,
each in different formulations (e.g. creams, oily creams or ointments) and in combination with other
ingredients such as antibiotics. Topical corticosteroids vary in strength (as measured by their ability to
constrict blood vessels rather than their clinical anti-inflammatory or skin thinning effect) from very mild
[e.g. hydrocortisone acetate (HC45, Reckitt Benckiser Healthcare)] to very strong fluorinated products
[e.g. clobetasol propionate (Dermovate®, GlaxoSmithKline)]. Systemic adverse effects are rare and
include suppression of the hypothalamic–pituitary–adrenal axis, Cushing syndrome and osteoporosis.
Local adverse effects include spread of untreated fungal infection, irreversible striae (stretch marks),
prominent fine blood vessels, contact dermatitis, perioral dermatitis, worsening of acne and mild loss of
pigmentation. The adverse effect that undoubtedly causes the most concern is that of skin thinning.73
More recently, topical calcineurin inhibitors have been developed and are now being used to treat some
dermatoses, including eczema, as an alternative to or in combination with topical corticosteroid treatment.
Topical tacrolimus (Protopic®, Astellas Pharma) was first available in 2001 in the USA to treat moderate to
severe eczema. Pimecrolimus (Elidel®, Meda) was licensed for the treatment of mild to moderate eczema in
the USA in 2002. Both tacrolimus and pimecrolimus selectively inhibit the activation of T cells.74,75 T cells
play a key role in the characteristic inflammation of the skin in eczema. Pimecrolimus has also been trialled
as an oral treatment for eczema, which is discussed later in this review (see Chapter 11). Evidence to date
on the potential harms of topical calcineurin inhibitors has not shown serious adverse effects of skin
thinning or stretch marks as seen with prolonged or inappropriate use of topical corticosteroids. Evidence
that tacrolimus and pimecrolimus may increase the risk of some cancers prompted the US Food and Drug
Administration to issue a ‘black box’ warning.76 Long-term trials to assess the potential harms of these
treatments have now been completed77 and another trial is still ongoing.78
Existing systematic reviews
Since 2000, 15 systematic reviews79–93 and three guidelines41,42,94 have been published on the use of topical
corticosteroids and/or topical calcineurin inhibitors. Two reviews have assessed occlusive therapy.95,96
Scope of this chapter
This chapter covers the following treatments:
1. topical corticosteroids:
¢ compared with placebo
¢ compared with active treatments (except topical immunomodulators)
¢ once-daily compared with twice-daily applications
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2. topical immunomodulators:
¢ tacrolimus
¢ compared with placebo
¢ compared with other active treatments
¢ pimecrolimus
¢ compared with placebo
¢ compared with other active treatments
¢ tacrolimus compared with pimecrolimus
3. topical calcineurin inhibitors combined with topical corticosteroid
4. topical corticosteroids with occlusive therapy.
Topical corticosteroids
Topical corticosteroids compared with placebo
Studies
Thirteen trials were published before 200055 (see Appendix 3).
Fourteen new trials97–110 have been reported since 2000. Fluticasone was compared against placebo in four
of the trials98,106–108 and hydrocortisone butyrate was compared against placebo in two of the trials.101,103
Placebo-controlled trials were reported for fluocinonide,104,110 fluocinolone acetonide,97 triamcinolone
acetonide,100 desonide,99 methylprednisolone aceponate,105 clobetasol propionate109 and betamethasone
17-valerate in combination with fusidic acid.102
Reactive treatment regimens
A reactive treatment regimen, in which the eczema was treated continuously for a set period of time or
until clearance, was used in 10 of the 14 trials.97–104,109,110
Proactive treatment regimens
A proactive treatment regimen was used in four of trials,105–108 which involved an initial period (4 weeks)
of more intensive treatment to stabilise or clear the eczema followed by 16 weeks of treatment for only
2 consecutive or evenly spread days a week.
Assessment of risk of bias for the new studies
There was enough detail about the method of randomisation to allow assessment of the risk of bias in only
six97,102,103,107,108,110 out of 14 trials and all were assessed as being at low risk. There was enough detail about
the method used to generate the allocation sequence to allow assessment of the risk of bias in only one97 out
of the 14 trials and this was assessed as low risk. There was enough detail about blinding to allow assessment
of the risk of bias in five97,103,105,106,109 of the 14 trials and all five were assessed as being at low risk.
Benefits
Reactive treatment regimens
Fairly high proportions of participants using topical corticosteroids compared with placebo successfully
responded to treatment as assessed by the Investigator’s Global Assessment (IGA), ranging from 39% to
75% for topical corticosteroid treatment compared with 11–36.4% for placebo treatment.97–99,101–104,109,110
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Definitions of ‘success’ varied, but the most common was an IGA score of 0 or 1 at the end of treatment,
with two trials also adding that there had to be a ≥ 2 point improvement from baseline as well.99,101,103
The participant global assessment and the pruritus assessments were similar to the IGA for the reactive
treatment regimens.
Proactive treatment regimens
There were fairly large differences in the proportion of participants who did not have a flare of their
eczema during 16 weeks of maintenance treatment (‘keep control’ treatment for 2 consecutive days a
week), which ranged from 27.5% to 87.1% for topical corticosteroid treatment and from 19.4% to
65.8% for placebo.105–107
Harms
Reactive treatment regimens
There was one serious adverse event reported, which was not thought to be related to study treatment,99
and four withdrawals from treatment due to adverse events,98,99 some of which were reported to be
probably or possibly related to treatment.99 One mention of skin changes was reported by a participant on
placebo.100 Mild hypopigmentation was reported for two participants being treated with moderate potency
(class IV, US system) fluocinolone acetonide.97
Proactive treatment regimens
Adverse events were reported in 14–45% of the treatment groups. Two trials105,106 reported that skin
atrophy was not seen; however, one trial108 reported that two participants showed skin changes often
seen before atrophy (telangiectasia). Overall, a small number of adverse events assessed as being related
to the trial medication were reported. One trial107 reported four serious adverse events of erysipelas
(skin infection) and two cases of exacerbation of eczema. One trial106 reported two cases of possible
adrenal suppression.
Overall implications for research and practice
The evidence base for topical corticosteroids used to treat eczema is mature and there is plenty of good
evidence that topical corticosteroids are beneficial and safe if used correctly. Therefore, there is now no
reasonable clinical or ethical justification for comparing a new topical corticosteroid against placebo,
as this will not give any new clinically relevant information. Although the number of trials of topical
corticosteroids compared with placebo has decreased considerably in the last decade, the trials that have
been reported are mostly still plagued by the same lack of methodological detail, with non-existent or
inappropriately short follow-up assessment periods. Most of the money spent on this type of trial in the
last decade amounts to research wastage.111 Trials that compare a new topical corticosteroid against other
active treatment options and seek to answer the question, ‘Which is the best topical corticosteroid and
treatment regimen for my patient?’ are still desperately needed.
Reactive treatment regimens
There is strong evidence that continuous use of eczema treatments will result in a large beneficial effect
compared with placebo. However, without follow-up periods after treatment cessation, trials fail to provide
information regarding the potential ability of an intervention to provide, or continue to provide, beneficial
effects. This is an important question to address in the future.
Proactive treatment regimens
There is strong evidence that, in the short term, ‘getting control’ using 2–3 weeks of continuous treatment
and then ‘keeping control’ with treatment on 2 consecutive or evenly spaced days a week has a large
beneficial effect.
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Topical corticosteroids compared with active treatments
(except topical immunomodulators)
Studies
There were 40 trials of topical corticosteroids compared with other topical corticosteroids and four trials of
topical corticosteroids compared with other active agents reported before 200055 (see Appendix 3).
A total of 12 trials112–122 were reported from 2000 onwards, with two trials reported together in one
report.113 Ten of these trials compared novel topical corticosteroids with standard topical corticosteroids and
one trial118 compared a topical corticosteroid with and without the addition of a penetration-enhancing
drug. One trial122 compared continuous treatment with treatment 4 days a week with clobetasone butyrate
ointment [0.05% weight by weight (w/w)]. This trial report was very short and there were very few details
provided about the trial. Nine of these trials112–117,122 compared treatments exclusively in children and
three trials118–120 did not report the age of the participants. Six of the trials113,116–118,121 had > 100 participants
and six112,114,115,119,120,122 had ≤ 50 participants. The treatment regimens varied, with one trial providing 7 days
of treatment as required over an 18-week period116 one trial providing either twice daily treatment for
8 weeks or twice daily treatment for four consecutive days per week for 8 weeks,122 and the other trials
providing continuous treatment for periods from 2 weeks to 42 days.112–115,117–120
An additional four trials123–126 were reported that compared a new active treatment against a topical
corticosteroid as the ‘standard treatment’ comparator. These are discussed in the chapters in which the
active treatments are discussed. This section does not include trials that compared topical corticosteroids
with topical immunomodulators. These trials are discussed separately in the topical immunomodulators
section later in this chapter.
An additional trial by Sillevis Schmitt and colleagues122 was reported that compared two different
treatment regimens of clobetasone butyrate ointment (0.05%): twice a day every day for 8 weeks and
twice a day for 4 days a week for 8 weeks. Forty children with eczema were randomised. The trial report
was very short and very few details were provided about the trial.
Assessment of risk of bias for the new studies
Table 5 provides the risk-of-bias assessment for the new studies.
TABLE 5 Topical corticosteroids compared with active treatments: risk of bias of the included studies (except
topical immunomodulators)
Trial Sequence generation Allocation concealment Blinding
Other potential
sources of bias
Cato 2001118 Low risk Unclear risk Unclear risk
Kim 2013121 Unclear risk Unclear risk Unclear risk
Kirkup 2003113 Unclear risk Unclear risk Unclear risk
Lebrun-Vignes 2000114 Unclear risk Unclear risk Unclear risk
Prado de Oliveira 2002112 Unclear risk Unclear risk Unclear risk
Ruzicka 2012119 Unclear risk Unclear risk Unclear risk
Schlessinger 2006117 Unclear risk Unclear risk High risk
Sillevis Smitt 2000122 Unclear risk Unclear risk Unclear risk
Thomas 2002116 Low risk Unclear risk Low risk
Trookman 2011120 Unclear risk Low risk Unclear risk Intention-to-treat
method not stated
Wong 2008115 Unclear risk Unclear risk Unclear risk
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Benefits
There was no evidence of any significant differences between the topical corticosteroids being compared
except in two identically designed trials113 assessing fluticasone propionate (0.05%) compared with
hydrocortisone (1%) or hydrocortisone butyrate (0.1%). The participants were experiencing an eczema flare
on entry to the trial. The study treatment was used daily for 2–4 weeks (to bring the flare under control) and
then intermittently to maintain control (for up to 12 weeks). Fluticasone propionate showed a statistically
significant benefit over hydrocortisone and hydrocortisone butyrate. Compared with hydrocortisone
butyrate, fluticasone propionate resulted in a greater percentage of participants being ‘much improved’
after the acute treatment phase; however, for both treatments this was high (84% vs. 98%, respectively).
The trial by Thomas and colleagues116 assessed the differences between short bursts of potent topical
corticosteroids and longer bursts of milder topical corticosteroids. The study evaluated the number of
relapses, number of scratch-free days, severity, number of undisturbed nights and quality of life but no
statistically significant differences were found.
The trial by Cato and colleagues,118 involving the manufacturers of laurocapram, found a greater reduction
in induration, pruritus and erythema as well as global disease improvement when using triamcinolone
acetonide combined with laurocapram than when using triamcinolone acetonide alone or vehicle.
A within-person trial by Wong and colleagues115 compared hydrocortisone (1%) combined with the
antifungal agent miconazole with hydrocortisone (1%) alone in children with active eczema affecting the
knees and elbows. Two dermatologists rated the relief of symptoms from photographs in terms of
which treatment gave a better response or whether there was no difference. The inter-rater variability
between the two outcome assessors’ ratings was high and the scores did not show a significant difference
between the treatments. The participants rated their response to the treatments, with 10 stating that
hydrocortisone in combination with miconazole gave a better response, 15 reporting a better response
with hydrocortisone only and four noticing no difference. No significant difference was found in the
amount of topical corticosteroids used.
The trial by Sillevis Smitt and colleagues122 found a significant improvement in eczema severity for
participants using clobetasone butyrate ointment (0.05%) for just 4 days a week in relation to participants
using the treatment continuously. The difference between the improvement in SCORAD scores in each
group was 6.7 [standard deviation (SD) 3.03; p= 0.03] in favour of the 4 days a week treatment regimen.
The trial by Ruzicka and colleagues119 compared a new mometasone furoate oil-in-water cream containing
33% of water with the mometasone furoate commercially available preparation containing 5% of water in
a 2-week intra-individual study including 20 adults with eczema. They found no significant difference in
disease severity between the groups, assessed using a non-validated score. The new formulation seemed
to be preferred by participants.
The trial by Kim and colleagues121 compared mometasone furoate in a new multi-lamellar emulsion containing
pseudoceramide (aimed at enhancing skin penetration) against methylprednisolone aceponate in a 2-week
intra-individual study including 175 children with moderate to severe eczema. The disease severity improvement
ratio assessed by Physician Global Assessment (PGA) was 82.62 SD± 21.62% in the mometasone furoate in
multi-lamellar emulsion group and 68.32 SD± 24.05% in the methylprednisolone aceponate group
(p≤ 0.0001). Pruritus showed a more significant improvement in the mometasone furoate group than in the
methylprednisolone group (p≤ 0.0001). Sixteen participants were excluded from the analysis.
An industry-funded trial by Trookman and Rizer120 compared desonide hydrogel with desonide ointment in
a 4-week single-blind study including 46 participants. The trial authors did not compare the changes in
severity between the two groups making it impossible to assess the results of the trial. Patient rankings of
absorbability and (lack of) greasiness were significantly higher among patients receiving desonide hydrogel
than among those receiving desonide ointment.
DOI: 10.3310/pgfar04070 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 7
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nankervis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
Harms
No serious adverse events linked to the study treatments were reported. The levels and types of adverse
events possibly or definitely related to treatment varied considerably in these trials. The harms that
are commonly associated with topical corticosteroid use, such as skin thinning, were not reported,
although none of the trials looked at consistent long-term use.
Five trials114,115,119,120,122 reported that there were no adverse events during the trial.
Once-daily compared with twice-daily application
There were three trials published before 200055 (see Appendix 3). No new studies have been published
since 2000.
Overall implications for research and practice
The publication of new trials comparing topical corticosteroids has dramatically slowed in the last 10 years,
possibly because of emerging competitors such as the topical calcineurin inhibitors. The few trials reported,
mostly with manufacturer involvement, still do not seem to directly address the knowledge gaps about
the best choices of topical corticosteroids. There is a small amount of evidence that combining a topical
corticosteroid with a penetration-enhancing chemical shows an increased benefit,118 but the trial was not
clear enough about the methodology used to assess the risk of bias and so this must be treated with
caution until stronger, long-term treatment evidence becomes available. There is some very weak evidence
that pulsed treatment is more effective than continuous treatment.122
As all of the trials comparing an active treatment that is not another topical corticosteroid or topical
immunomodulator use the topical corticosteroid as the ‘standard treatment comparator’, they have been
discussed in the chapters of this report that cover the treatments they have been compared against.
Three of the trials123,124,126 are discussed in Chapter 5; the other is discussed in Chapter 10.125
Topical immunomodulators
There were four trials of topical immunomodulatory treatment published before 200055 (see Appendix 3).
Tacrolimus compared with placebo
Studies
Twelve new trials,127–137 two of which were published together in one report,128 of tacrolimus compared
with placebo have been reported since 2000. The treatment regimens can be divided into reactive regimes
(treatment started when signs and symptoms appear or worsen) and proactive regimes (treatment used
intermittently to prevent the eczema recurring).
Reactive treatment regimens
Eight trials127–132,136 of tacrolimus compared with placebo were reported. Participants in all eight trials were
instructed to apply the treatment twice daily, with treatment durations ranging from 2 to 12 weeks. Treatment
was not continued if the eczema went into ‘remission’ in four127–129 of the eight trials. Five127–129,136 of the trials
were industry sponsored and three130–132 did not report funding sources. The number of participants in the
eight trials ranged from 14 to > 600, with five127–129,131 of the trials having > 200 participants.
Proactive treatment regimens
Tacrolimus was compared against vehicle in four trials.133–135,137 We did not find any comparisons of
proactive treatment with tacrolimus against proactive use of topical corticosteroids. Three of the included
trials were multicentre with sample sizes of around 200–250 participants. Of these three trials, one133 was
conducted in the USA and two134,135 were conducted in Europe. One133 of these trials included children and
adults and gave the treatments three times a week for 40 weeks whereas two trials, one in adults135
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and one in children,134 provided the treatments twice a week for 1 year. All participants in the three trials
were allowed to use non-medicated emollients. A smaller open-label trial137 included 70 children and
adults and compared the use of either tacrolimus or emollient treatment for 1 month (treatment regimen
not reported). After induction of remission using tacrolimus, the participants used their usual emollient
twice a day and their usual topical corticosteroid (up to 10 g per week) for the maintenance phase.
Assessment of the risk of bias for the new studies
Reactive treatment regimens
Sufficient detail about the generation of the allocation sequence was available in two129,130 out of eight trials to
allow an assessment of the risk of bias. Both of these trials were assessed as having a low risk of bias. Sufficient
detail about allocation concealment was not given in any of the trials. Sufficient detail about blinding was
available in two132,136 out of eight trials to allow an assessment of the risk of bias. One of these trials136
was assessed as being at low risk of bias and the other trial132 was assessed as being at high risk of bias.
Proactive treatment regimens
None of the four trials133–135,137 reported sufficient detail about the generation of the allocation sequence,
allocation concealment or blinding to allow an assessment of the risk of bias.
Benefits
Reactive treatment regimens
For continuous treatment of eczema with tacrolimus (until clearance or for a set period of time) there is
evidence of a large reduction of pruritus after 2–4 days when using the treatment twice a day. The
reduced levels of pruritus persisted for the length of treatment. There was also evidence from three of the
trials127–129 of a large reduction in severity compared with placebo, with the proportion of participants with
an IGA of 0 or 1 at the end of treatment ranging from 36.8% to 49.7% for tacrolimus compared
with 6.9–29% for placebo. The improvements in participant-assessed severity were in line with the
improvement in pruritus severity.
Proactive treatment regimens
The data on participants’ dermatology-related quality of life were conflicting in the two trials134,135 that
reported this outcome. One trial134 reported that the treatment groups were comparable for Infant
Dermatology Life Quality Index (IDLQI) and Children’s Dermatology Life Quality Index (CDLQI) scores at the
end of the trial and the other trial135 reported a reduction from 9.3 to 3.6 for the tacrolimus group and
from 9.3 to 6.8 in the placebo group, with lower scores equating to a better quality of life. The difference
in these scores was not compared statistically. Two of the trials reported that 50% of the participants on
tacrolimus compared with 30% on placebo134 and 56.9% of the participants on tacrolimus compared with
29.6% on placebo135 experienced no flares during the year of treatment. Another trial133 reported that
there were significantly more flare-free treatment days using tacrolimus (177 vs. 134; p= 0.003) and a
significantly longer time to first flare [169 days, 95% confidence interval (CI) 113 to 225 days for
tacrolimus treatment vs. 43 days, 95% CI 31 to 113 days for vehicle). One trial137 specifically assessed
recurrence of pruritus by visual analogue scale (VAS). In this trial, the cumulative itch recurrence (defined as
an increase in VAS itch score of > 20 points) was 23.8% (95% CI 10.7% to 52.9%) in the tacrolimus
group and 100% in the emollient group after 1 month.
Harms
Reactive treatment regimens
The most common adverse events were application site stinging or burning and skin irritation. In some
trials this was more common in the placebo group and for others it was more common in the tacrolimus
group. Serious adverse events were not mentioned. Two130,136 of the trials did not report any information
on adverse events.
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Proactive treatment regimens
Pruritus and impetigo were more common in the treatment group than in the placebo group in one134 of
the trials. There was a low level of serious adverse events; of these, two were reported as being related to
tacrolimus (application site infection and eczema herpeticum). In another trial,135 application site pruritus
was fairly common and evenly spread between the tacrolimus treatment group and the placebo
treatment group.
Overall implications for research and practice
As a collection of trials that are likely to have been conducted in a methodologically robust way, it is a
shame that the trial reports did not provide enough detail to make a true assessment of the risk of bias.
A lack of longer-term follow-up assessment after the treatment was stopped also restricts the usefulness
of this evidence.
Reactive treatment regimens
There is strong evidence for short-term treatment with tacrolimus compared with placebo: continuous
treatment with tacrolimus twice a day provides a large beneficial effect by reducing the pruritus and
severity of eczema relatively quickly. What is not clear is how long this beneficial effect continues after
stopping treatment, as the trials did not follow up the participants for more than a few weeks once
treatment had stopped. None of the trials used treatment once daily, which has already been shown to be
as effective as twice-daily treatment for corticosteroids. This is an important question for both people with
eczema and health-care commissioners.
Proactive treatment regimens
There is strong evidence for a short-term beneficial effect from ‘getting control’ and ‘keeping control’ with
tacrolimus compared with placebo.
Tacrolimus compared with active treatments
Studies
Tacrolimus compared with hydrocortisone
Six new trials were reported,138–142 one of which included a single-centre extended trial that was
published separately.143 Four138–140 of the six trials were particularly large, multicentre, multinational,
manufacturer-sponsored trials that compared tacrolimus, often at both the lower 0.03% and stronger
0.1% concentrations, against various different preparations of hydrocortisone, particularly 1%
hydrocortisone acetate (weak potency) or 0.1% hydrocortisone butyrate (moderate potency). Two138,139 of
the six trials involved only children, with treatments being applied every day for 3 weeks; participants were
not followed up for > 2 weeks after the end of treatment. One140 of the four trials in adults was conducted
at a single centre and gave treatment for 7 days to clear the eczema and then participants used the
treatments as needed to treat flares for 6 months, with follow-up for 1 year. Another trial in adults was
very small and had mainly mechanistic goals.142 The other two trials, by Reitamo and colleagues138 and
Caproni and colleagues,141 administered treatment twice a day for 3 weeks; Reitamo and colleagues138
also followed up the participants 2 weeks after the end of treatment.
Tacrolimus compared with other topical corticosteroids
The first ‘acute’ phase of a trial by Breneman and colleagues133 compared twice-daily application of the
topical corticosteroid alclometasone dipropionate ointment (0.05%) with twice-daily tacrolimus ointment
(0.03%) for 4 days.
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Two small crossover trials144,145 compared a moderate-potency topical corticosteroid against tacrolimus
(0.1%). The trial by Gradman and Wolthers145 comparing tacrolimus (0.1%) against mometasone furoate
(0.1%) in 20 children aged 5–12 years was primarily concerned with measuring the effect of the
treatments on short-term growth. The trial by Nivenius and colleagues144 compared tacrolimus (0.1%)
against clobetasol butyrate for eyelid eczema. Twenty-five adult participants (age range 18–70 years) with
moderate eczema (specifically those with eyelid eczema and keratoconjunctivitis) applied the treatments
twice daily for 3 weeks.
Four trials104,146–148 compared potent topical corticosteroids against tacrolimus (0.1%) to treat moderate to
severe eczema. The trial by Bieber and colleagues148 compared a relatively new topical preparation of
methylprednisolone aceponate against tacrolimus (0.1%) twice a day for a minimum of 2 weeks and a
maximum of 3 weeks, with cleared areas treated for an additional 7 days. The 265 children randomised
had moderate to severe eczema and were experiencing an acute flare on entry to the trial. The other two
trials by Doss and colleagues,146,147 both industry funded, compared tacrolimus (0.1%) against fluticasone
propionate (0.005%). The first trial146 involved 568 adults with moderate to severe facial eczema involving
at least 10% of the skin surface area. Treatments were used twice daily for 3 weeks or until clearance.
After this period, participants could stop treatment if the eczema had cleared, use the same treatment
once a day or switch to the other treatment group (with twice-daily applications) and still be blinded.
The second, non-inferiority trial147 compared second-line use of tacrolimus (0.1%) or fluticasone propionate
in 479 children with moderate to severe eczema who had not had an adequate response to previous
topical corticosteroid treatment. A within-person trial by Del Rosso and Conte104 compared once-daily
fluocinonide cream (0.1%) against twice-daily tacrolimus ointment (0.1%) applied to the target sites for
4 weeks; in this trial it was reported that the investigator was blinded and only seven adult participants out
of 30 with various dermatoses had moderate eczema.
One manufacturer-supported trial by Neumann and colleagues149 randomly assigned adults with
moderately severe eczema to tacrolimus (0.1%) or standard treatment with topical corticosteroids and
emollients. There was no standard treatment regimen and participants were observed using their own
treatment patterns. The participants were followed up for 6–20 months.
A trial examining tacrolimus and fusidic acid compared with fluticasone propionate and fusidic acid by
Hung and colleagues150 is discussed in Chapter 6.
Tacrolimus compared with other active comparators
The study by Pacor and colleagues151 compared 3mg/kg of oral ciclosporin once a day with topical
tacrolimus (0.1%) twice a day over 42 days using a ‘double dummy’ technique to achieve blinding.
The 30 participants aged 13–45 years had moderate to severe eczema that had only partially resolved
using topical corticosteroids. No other treatment for eczema was allowed during the study except 10mg of
cetirizine once or twice a day to help with itching.
Assessment of risk of bias for the new studies
Table 6 provides the risk-of-bias assessment for the new studies.
Benefits
Tacrolimus compared with hydrocortisone
Six trials compared tacrolimus against hydrocortisone, two in children139,152 and four in adults.138,140–142
Reitamo and colleagues138,139 compared mild-potency hydrocortisone acetate (1%) against tacrolimus in
two trials in children with moderate to severe eczema. The difference in reduction of severity over 3 weeks
of treatment, assessed using EASI, ranged from 55.2% to 76.7% for tacrolimus and from 36.0% to
47.6% for hydrocortisone acetate (1%).
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The potent topical corticosteroid hydrocortisone butyrate (0.1%) was compared with tacrolimus in
three138,140,142 out of four of the trials in adults. The participants in the two larger trials138,140 had moderate
to severe eczema. These two trials reported conflicting results. One trial by Reitamo and colleagues138
reported that hydrocortisone butyrate gave a greater reduction in severity than tacrolimus (0.03%) and
tacrolimus (0.1%) over 3 weeks of twice-daily continuous use, regardless of clearance. The other trial by
Reitamo and colleagues140 reported a significant benefit in terms of reduction in severity for tacrolimus
after 3 months of treatment (primary outcome) and also after 6 months of treatment ‘as required’ for
flares, after initial continuous treatment for 7 days. An additional publication of the trial data from one
centre in Finland,143 including follow-up of the participants for 1 year, also showed this superior benefit of
tacrolimus at 6 months but not at 1 year. Two trials141,142 by the same team, which were mostly concerned
with biochemical and safety outcomes, compared the mild-potency hydrocortisone (1%) preparation
against tacrolimus in participants with a SCORAD score of > 15. These trials, which each analysed
< 25 participants, had conflicting results. In one of the trials141 tacrolimus was found to be superior to
hydrocortisone for post-treatment reduction in severity measured using SCORAD scores (p= 0.027).
However, in the other trial,142 although the tacrolimus-treated group had a greater reduction in SCORAD
scores, there were no significant differences reported between the groups. The time frame for ‘post
treatment’ was not reported.
TABLE 6 Tacrolimus compared with other active comparators: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Tacrolimus vs. hydrocortisone
Antiga 2011142 Low risk Unclear risk Unclear risk
Caproni 2007141 Unclear risk Unclear risk Unclear risk No intention-to-treat analyses
Reitamo 2002138
(hydrocortisone
butyrate)
Unclear risk Unclear risk Unclear risk Known potential side effects may have
unintentionally unblinded some stakeholders
Reitamo 2002138
(hydrocortisone acetate)
Unclear risk Unclear risk Unclear risk Known potential side effects may have
unintentionally unblinded some stakeholders
Reitamo 2004139 Unclear risk Unclear risk Unclear risk Known potential side effects may have
unintentionally unblinded some stakeholders
Reitamo 2005140
(Mandelin 2010143)
Unclear risk Unclear risk Low risk
Tacrolimus vs. other topical corticosteroids
Bieber 2007148 Unclear risk Unclear risk Unclear risk
Breneman 2008133
(acute phase only)
Unclear risk Unclear risk Unclear risk
Del Rosso 2007104 Unclear risk Unclear risk Unclear risk
Doss 2009146 Unclear risk Unclear risk Low risk
Doss 2010147 Unclear risk Unclear risk Unclear risk Unclear what numbers of participants were
included in each analysis
Gradman 2007145 Low risk Unclear risk Low risk Results very difficult to interpret
Neumann 2008149 Unclear risk Unclear risk Unclear risk
Nivenius 2007144 Unclear risk Unclear risk Unclear risk Unclear whether five out of 25 participants
were included in the analyses
Tacrolimus vs. other active treatments
Pacor 2004151 Unclear risk Unclear risk Low risk
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Tacrolimus compared with other topical corticosteroids
In the trial by Breneman and colleagues,133 4 days of treatment with the low-potency topical corticosteroid
alclometasone dipropionate (0.05%) gave a statistically significant reduction in EASI scores from baseline
compared with treatment with tacrolimus (0.03%) (p= 0.03), a significant reduction in itch score
(alclometasone dipropionate group from 5.9 to 3.2, tacrolimus group from 6.2 to 4.2; p= 0.0009) and a
significant reduction in percentage body surface area affected (p= 0.02). There was no significant
difference in the proportion of participants achieving an IGA of ‘clear’ or ‘almost clear’. Few participants in
the whole population achieved this after the 4 days of treatment. None of these were prespecified
outcome end points for the trial.
For moderately potent topical corticosteroids, Gradman and Wolthers145 found that both treatments
cleared the eczema completely; however, the trial population’s low baseline eczema severity should be
taken into account when considering the impact of this treatment. No between-treatment comparisons
seem to have been made. This trial focused on the growth of the children, with growth impairment being
a previously noted adverse side effect of treatment with topical corticosteroids, and did not find a
significant difference in growth per week between twice-daily tacrolimus (0.1%) treatment and
mometasone furoate (0.1%) treatment in mild to moderate eczema. The trial by Nivenius and colleagues144
reported no significant difference between twice-daily clobetasone butyrate (0.05%) and tacrolimus
(0.1%) treatment for the reduction in eczema score or blepharitis scores over a 3-week period.
The combined eczema and blepharitis score just reached statistical significance, with a difference between
the treatments of –2.39 (95% CI –4.79 to 0.00; p= 0.05).
The study by Bieber and colleagues148 reports that the primary outcome of a static IGA taken at the end
of treatment showed no statistically significant difference between the potent topical corticosteroid
methylprednisolone aceponate and tacrolimus. The secondary outcome of reduction in severity using EASI
scores at 7 and 14 days was significantly better for methylprednisolone aceponate; however, there was
no significant difference between treatments in reduction of severity after 3 weeks. The reduction in itch
was significantly better using methylprednisolone aceponate throughout the 3 weeks; this was also a
secondary outcome.
In the study comparing the use of fluticasone propionate (0.005%) with tacrolimus to treat facial eczema146
there was a significant difference in the primary outcome of response rate (proportion of participants with
a ≥ 60% reduction in modified EASI score from baseline to day 21) in favour of tacrolimus, with 93.3%
compared with 87.8% of participants responding, respectively (p= 0.026). The participant- and also
investigator-assessed facial global response to treatment were both statistically significantly in favour of
tacrolimus treatment [64% vs. 55% of participants (p= 0.014) and 88% vs. 79% of participants (p= 0.043),
respectively], whereas the participant-assessed pruritus scores were not significantly different.
Tacrolimus was reported to be non-inferior to fluticasone propionate (0.005%) for treating all areas
of the body excluding the eyelids in children.147 For the primary outcome of response rate (proportion of
participants with a ≥ 60% reduction in modified EASI score from baseline to day 21) there was a
difference in the full analysis set, in which withdrawals were counted as non-responders with a lower 95%
confidence limit of –11.3%, which was within the predefined limit of 15%.
No significant difference was reported in the reduction of severity or body surface area affected in the trial
by Neumann and colleagues149 comparing tacrolimus against standard topical corticosteroid treatment,
which was prescribed according to individual participant severity. It was reported that treatment usage was
slightly higher in the topical corticosteroids group during the trial.
Tacrolimus compared with other active comparators
In the trial by Pacor and colleagues151 both groups showed large reductions in the severity of eczema at
the end of the trial (day 42) but there were no significant difference between the two treatments, with
tacrolimus resulting in a reduction in mean SCORAD score from 69.0 points at baseline to 7.3 at day 42
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and ciclosporin resulting in a reduction in mean SCORAD score from 73.7 to 8.6 at day 42. The severity of
eczema was significantly reduced using tacrolimus compared with ciclosporin at days 14, 21, 28 and 35
but was not significantly reduced after run-in or 7 days. The trial did specify a particular time point for
assessment of the severity of eczema outcome.
For participant-assessed itching, assessed using a 4-point ordinal scale, there was a statistically significant
difference in favour of tacrolimus on days 7, 14 and 21. This difference never went above –0.65 (95% CI
–0.91 to –0.40).
For participant-assessed sleep loss, also assessed using a 4-point ordinal scale, there was a statistically
significant difference in favour of tacrolimus only on days 7 and 21, with the mean difference on day 7
being the largest at –0.4 (95% CI –0.64 to –0.15). For participant-assessed erythema, also assessed using a
4-point ordinal scale, there was a statistically significant difference in favour of tacrolimus on days 7, 14
and 21.
All of these outcomes showed a statistically significant difference in favour of tacrolimus when the ‘area
under the curve’ was calculated over the whole 42 days.
Harms
Tacrolimus compared with topical corticosteroids
All of the trials reported higher rates of application site burning and often pruritus in the tacrolimus groups
compared with the hydrocortisone groups. In the trials that reported the proportion of participants
experiencing adverse events,146–148 levels were high for both treatments, with around 20% more in the
tacrolimus group experiencing adverse events. This difference was always reported to be because of
the higher level of application site burning and pruritus for tacrolimus treatment.
Tacrolimus compared with other active comparators
In the trial by Pacor and colleagues151 four out of 15 participants from each group reported adverse events.
Those in the tacrolimus group all reported skin burning and those in the ciclosporin group reported gastric
irritation (n= 1) and headache (n= 3). Serum creatinine levels were higher in the tacrolimus group
(70.72–141.44 µmol/l) but not outside normal levels.
Overall implications for research and practice
Tacrolimus compared with topical corticosteroids
The evidence for tacrolimus treatment compared with topical corticosteroids is mixed. The treatment
regimens and treatment comparisons vary in this collection of trials. Some of the trials do not make
clinically relevant treatment comparisons, such as tacrolimus compared with the low-potency topical
corticosteroid hydrocortisone acetate in children with moderate to severe eczema, which is likely to
undertreat those randomised to the topical corticosteroid group.
Tacrolimus compared with other active treatments
The evidence from one small trial151 comparing tacrolimus with ciclosporin in participants with moderate to
severe eczema is not sufficient to determine whether tacrolimus, a topical immunomodulator, is a viable
alternative to ciclosporin, a systemic immunomodulator, which is usually used only for the most severe
cases of eczema.
This trial showed some potential benefit of tacrolimus over ciclosporin over the first month of treatment,
which then disappeared after 1.5 months, the end of treatment. This is not surprising given the long time
to initial response to treatment for ciclosporin and it is a great shame that this trial did not include a longer
follow-up period, ideally ≥ 6 months, to provide a fair comparison. The absolute decreases in the severity
of eczema were likely to have been clinically significant for both treatments, which helps to confirm the
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benefit of both treatments for moderate to severe eczema. In clinical practice, a topical corticosteroid
regimen is nearly always in place when systemic immunomodulators are started to ‘buffer’ this slow
response rate.
More long-term research will be needed before a comparison between the potential harms of these two
treatments can be made. Trials or other study designs such as cohort observational studies looking at
combining tacrolimus and systemic immunomodulators for the most severe cases of eczema should ideally
be carried out as well as longer-term RCTs.
Pimecrolimus compared with placebo
Studies
Reactive treatment regimens
Pimecrolimus was compared against vehicle using a regimen of twice-daily continual treatment until
clearance at the first signs and symptoms of a flare or recurrence of eczema in five trials published since
2000. Four out of the five trials, three in children153–155 and one in adults,156 were large multicentre,
industry-sponsored studies that provided treatment for 6 months or up to a year. The fifth trial was a
much smaller single-centre trial157 conducted in the Czech Republic that lasted a year and did not report
funding or sponsorship details. Use of emollients and rescue topical corticosteroids instead of study
treatment in the event of a flare was allowed in all five trials.
A regimen of continual treatment until eczema clearance or for a set period of time was used in 11
trials.158–168 Participants in all 11 trials were instructed to apply the treatment twice daily for a period
anywhere from 7 days to 26 weeks, with 6 weeks being most common. Treatment was not continued if
the eczema went into ‘remission’ in four158–160,162 of the 11 trials. Nine of the eleven trials158–166 were
industry sponsored or funded and two trials167,168 did not report funding sources. The number of
participants in the 11 trials ranged from 19 to > 500, with eight158–160,162–166 trials having > 150 participants.
Proactive treatment regimens
A proactive treatment regimen that aimed to prevent the recurrence of eczema at sites previously
successfully cleared using a burst of continuous treatment with either topical corticosteroid or topical
immunomodulatory agents was used in two manufacturer-supported trials153,169 reported since 2000.
One of these trials169 randomised 74 participants to twice-daily treatment for 3 weeks on the cleared
eczema sites and worsening eczema sites. The other trial153 used treatment for at least 7 days when
eczema signs and symptoms of eczema were present for 24 weeks.
Assessment of risk of bias for the new studies
Reactive treatment regimens
Sufficient detail about the generation of the allocation sequence was available in nine153–156,158,159,161,164,165
out of 16 reactive treatment trials to allow an assessment of the risk of bias. All of these trials were
assessed as having a low risk of bias. Sufficient detail about blinding was available in five153,156,158,161,168 out
of the 16 trials to allow an assessment of the risk of bias. All of these trials were assessed as having a low
risk of bias. Sufficient detail about concealment of the allocation system was available in one of the trials158
and this trial was assessed as having a low risk of bias.
Proactive treatment regimens
Sufficient detail about blinding was available in one out169 of two proactive treatment trials to allow an
assessment of the risk of bias. This trial was assessed as having a low risk of bias. Sufficient detail about
the method of generating the allocation sequence and the concealment of the allocation sequence was
available in both153,169 proactive treatment trials to allow an assessment of the risk of bias. Both trials were
assessed as having a low risk of bias.
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Benefits
Reactive treatment regimens
For twice-daily continual treatment until clearance at the first signs and symptoms of a flare or recurrence
of eczema, there was a statistically significant reduction (p< 0.003 from day 3 onwards) in pruritus
on a scale of 0–3 (units not reported) for pimecrolimus compared with placebo (reduction of 0.9 for
pimecrolimus compared with an increase of 0.3 for placebo) in one trial.156 A statistically significant
difference in the proportion of participants assessing their eczema as ‘completely or well controlled’ at the
end of the treatment period (62/96 for pimecrolimus vs. 34/96 for placebo) was reported in the same trial.
Participant assessments of pruritus and overall eczema severity were not assessed as outcomes in the other
three trials.153,154,157 All four trials reported a significant difference in the number of participants who had
no flares over 6 months of treatment, ranging from 18.8% to 40.7% of participants on placebo compared
with 44.8–71% of participants on pimecrolimus. Other outcomes assessing flares such as number of flares
or time to first flare showed statistically significant benefits for pimecrolimus. The proportion of participants
who did not use topical corticosteroids over 6 months of treatment was reported in three154,156,157 out of
four of the trials and ranged from 57.4% to 66.7% for the pimecrolimus group and from 15.4% to
31.6% for the placebo group. The trial by Wahn and colleagues155 reported that the proportion of
participants who did not use topical corticosteroid treatment after 1 year was 63.7% and 34.8% for
infants in the pimecrolimus and placebo groups, respectively, and 57.4% and 31.6% for children in the
pimecrolimus and placebo groups, respectively. The mean number of days on topical treatment was also
assessed in all four trials and showed statistically significant differences in favour of pimecrolimus.
For continuous twice-daily treatment of eczema with pimecrolimus until clearance or for a set period of
time, there was evidence of a large treatment effect for pimecrolimus compared with placebo for
reduction of pruritus, which then persisted for the length of treatment.159,162,165 There was also evidence of
large treatment effects compared with placebo for the IGA, with the proportion of participants with an
IGA score of 0 or 1 at the end of treatment ranging from 11% to 74.5% for pimecrolimus compared with
0–51.9% for placebo.159–163,166 Participant-assessed improvement in severity also showed a large treatment
effect in line with the improvement in pruritus severity.163
Proactive treatment regimens
The participant-assessed overall self-assessment score was reported for the severe eczema (IGA ≥ 4)
subgroup in the trial by Zuberbier and colleagues.153 A statistically significant result for itching, loss of
sleep and disease in favour of pimecrolimus was reported but it is not clear how many participants
were included in these assessments. The number of days spent on topical corticosteroid ‘rescue’ treatment
was not significantly different but was statistically significant, with a mean of 10% of the study time
on topical corticosteroids in the pimecrolimus group compared with 19% of the study time on vehicle
(9% difference, 95% CI 14.1% to 3.7%; p= 0.0009). A significant improvement in parents’
eczema-related quality of life was reported for pimecrolimus treatment in the same trial. Participants’
dermatology-related quality of life was reported to be not significantly different. In both proactive treatment
regimen trials153,169 the severity of eczema measured using the EASI score showed a statistically significant
difference in favour of pimecrolimus.
Harms
For both proactive and reactive treatment regimens, most events were mild or moderate and there were
very few serious adverse events or withdrawals because of adverse events. Most of the events consisted of
common symptoms such as nasopharyngitis or headache and were not thought to be related to the trial
treatment. There were a handful of cases of eczema herpeticum or herpes simplex, with more cases in the
treatment groups. Application site burning was reasonably common, although it was not consistently more
common in the treatment or placebo group.
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Overall implications for research and practice
As with topical corticosteroids compared with placebo, thousands of participants have taken part in topical
calcineurin inhibitor compared with placebo trials and the evidence base has matured. There is strong
evidence that using a calcineurin inhibitor confers clinically relevant benefits compared with a placebo.
More trials of tacrolimus or pimecrolimus compared with placebo are not needed.
Although these trials were generally better reported than many in this review, there is still a lack of clear
reporting of the method of allocation concealment. Raised awareness of the importance of a full and clear
description of this aspect of methodology is essential for all trial reports to increase confidence in the
results of trials.
Although the treatment effects appear fairly substantial, it is important to note that the placebo groups
showed reasonable benefits from being in the trials as well. The relative merits of adding in another active
treatment compared with encouraging increased adherence to a patient’s current topical treatments merits
further research.
Randomised controlled trials are not appropriate for detecting rare or slow to develop adverse events and
other research is being conducted to evaluate long-term safety as these treatments have not been in
routine clinical use for very long. It is clear that local application site reactions such as burning or stinging
are common when using pimecrolimus, but the evidence from these trials points to a lack of clarity about
whether these adverse events are being caused by the active treatment, the vehicle or both.
Reactive treatment regimens
For short-term and long-term continuous treatment for a set period of time or until remission there is
strong evidence of a moderate to large beneficial effect of using pimecrolimus compared with placebo.
A significant reduction in pruritus is a major benefit, although it is not clear if this results from the
improvement in eczema severity or is the result of a particular mechanism of action by pimecrolimus. For
long-term treatment of eczema by using treatment twice daily at the first signs and symptoms of eczema
until clearance, large reductions in the number of flares and frequency of use of topical corticosteroids as a
rescue medication are evident. As use of pimecrolimus has been compared with placebo and essentially
involves three treatments for complete control in some people with eczema, it is unclear whether this is of
distinct clinical benefit compared with a similar regimen using topical corticosteroids, which is essentially
very close to current clinical reality.
Proactive treatment regimens
Only two relatively small trials have tested a proactive treatment regimen for pimecrolimus compared with
placebo, although both were of low risk of bias.153,169 For long-term treatment (≥ 6 months) there was
some evidence of benefit from a proactive regimen compared with placebo in one trial for a subgroup of
people whose head and neck eczema was problematic.153 For short-term continuous treatment after
induction of remission, the evidence of benefit is weak but does show a modest treatment effect for mild
or moderate eczema.169
Pimecrolimus compared with active treatments
Studies
Pimecrolimus compared with topical corticosteroids
Two new trials170,171 compared pimecrolimus against betamethasone and one new trial compared
pimecrolimus against triamcinolone acetonide.172 The trial by Luger and colleagues170 compared five
different doses of pimecrolimus against betamethasone 17-valerate and placebo in a within-person
dose-ranging study. In total, 260 adults with at least moderate eczema and 5–30% body surface area
coverage applied treatment twice daily to all affected areas (except on the head and neck) until clearance
for up to 3 weeks. The trial by Jensen and colleagues171 compared twice-daily application of pimecrolimus
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(1%) against betamethasone cream (0.1%). This within-person trial, involving 15 adults with mild to
moderate eczema, compared the treatments on the upper limbs for 3 weeks. A multicentre, multinational
trial by Luger and colleagues172 involving 658 adults with moderate to severe eczema compared
pimecrolimus (1%) against triamcinolone (0.1%) with hydrocortisone acetate (1%) for the face, neck and
intertriginous regions. Treatment was applied twice daily until complete clearing and itching cessation,
after which the treatment was restarted if inflammation occurred, for a period of 12 months.
Pimecrolimus compared with other active comparators
An industry-funded within-person study by Frankel and colleagues173 in the USA compared three times
daily ceramide–hyaluronic acid emollient foam application against twice-daily application of pimecrolimus
cream (1%) over a 4-week period. The trial included 30 participants who had been affected by mild to
moderate eczema for at least 1 year. The treatments were applied to an investigator-selected target area
of eczema. A very small single-blind industry-funded trial by Emer and colleagues174 compared a new
lipid-rich topical medical device cream (applied three times daily) with pimecrolimus cream (applied twice
daily). The trial lasted for 4 weeks and involved 20 participants.
Assessment of risk of bias for the new studies
Table 7 provides the risk-of-bias assessment for the new studies.
Benefits
Pimecrolimus compared with topical corticosteroids
The trial of pimecrolimus compared with triamcinolone acetonide by Luger and colleagues172 was primarily
concerned with long-term safety and tolerability, particularly the rate of infections. Triamcinolone
acetonide and hydrocortisone acetate (for the face, neck and intertriginous areas) treatment was reported
to be significantly more effective at reducing severity, assessed using EASI scores, at all time points
assessed during 1 year. The proportion of participants rated as being moderately clear or better according
to the investigator’s assessment was significantly higher in the topical corticosteroid group at all time
points apart from at 13 months. Topical corticosteroids were not used at all during the trial by 135 out of
328 participants using pimecrolimus. There were no significant differences between the groups in time to
first remission and time to first recurrence.
TABLE 7 Pimecrolimus compared with active treatments: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Pimecrolimus vs. topical corticosteroids
Jensen 2009171 Unclear risk Unclear risk Unclear risk Only 15 participants and so not likely to be
powered to detect any differences in efficacy.
Mostly interested in skin barrier effects
Luger 2001170 Unclear risk Unclear risk Unclear risk
Luger 2004172 Unclear risk Unclear risk Low risk
Pimecrolimus vs. other active comparators
Emer 2011174 Unclear risk Low risk Low risk Single-blind, very small study. Objective
outcome assessors were blinded; however,
participants were not
Frankel 2011173 Unclear risk Unclear risk Low risk Patients and study co-ordinator who
dispensed medication were unblinded and
treatments involved different treatment
regimens. Objective outcome assessors were
blinded
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Another trial by Luger and colleagues170 was a dose-ranging study of pimecrolimus (0.05%, 0.2%, 0.6%
and 1%) compared with the standard topical corticosteroid comparator betamethasone 17-valerate (0.1%)
and also placebo. All of the doses of pimecrolimus were significantly less effective than betamethasone
17-valerate for reduction in EASI score, reduction in pruritus and proportion of participants who assessed
their eczema to be moderately clear or better (> 50% improvement). The most potent concentration of
pimecrolimus, 1%, was still markedly less effective than betamethasone, although this was not formally
statistically compared in the trial report.
A trial by Jensen and colleagues171 mostly concerned with assessing the change in skin structure also
compared pimecrolimus (1%) against betamethasone (0.1%). This trial also did not compare the treatment
groups against each other for severity or pruritus. The graphically presented results show a marked
difference in favour of betamethasone, which peaked at 4 weeks, 1 week after treatment was stopped.
Pimecrolimus compared with other active comparators
In the trial by Frankel and colleagues173 there was not very much difference between the treatment groups in
the severity of eczema using the IGA, with 12 out of 28 participants ‘clear’ and 11 out of 28 ‘almost clear’ by
week 4 in the emollient foam group compared with 10 out of 28 ‘clear’ and 10 out of 28 ‘almost clear’ in
the pimecrolimus group. There was also no difference in the level of improvement from baseline to week 4
(67.9% emollient foam group vs. 63.1% pimecrolimus group). Investigator-assessed severity was mirrored
by participant-assessed severity. It was also reported that there were no significant differences between
treatments over time in symptom scores for erythema, infiltration, excoriation, lichenification and scaling for
the target lesions in both groups, but no absolute values were reported. In the trial by Emer and colleagues174
there were no significant differences between the two groups in disease severity assessed by IGA.
Harms
Pimecrolimus compared with topical corticosteroids
Of the two trials170,171 comparing pimecrolimus with betamethasone, one171 did not report adverse events
and the other170 reported that a few systemic adverse events occurred that were not related to treatment.
Application site reactions were the most common adverse event. There were no adverse events that were
specifically attributed to the trial treatments.
Pimecrolimus compared with other active comparators
Adverse events were monitored during the trial by Frankel and colleagues;173 however, no adverse events
were recorded. It is also reported that were no cutaneous side effects such as irritation or atrophy.
In the trial by Emer and colleagues174 there were also no adverse events reported.
Overall implications for research and practice
Pimecrolimus compared with topical corticosteroids
An accurate assessment of the risk of bias for these trials was almost impossible as the trial reports failed
to describe the method of randomisation, allocation concealment and blinding in enough detail. Sweeping
statements that assume prior knowledge of the trial protocol are common. This must be kept in mind
when assessing the evidence.
All of the trials that compared pimecrolimus against topical corticosteroids had safety and tolerability as
the primary outcomes and so the data on efficacy in these trials, which suggest that topical corticosteroids
such as betamethasone are more effective than pimecrolimus, need to be treated with some caution.
To compound this problem, some of the pimecrolimus trials did not formally compare the two treatment
groups. The evidence base for the efficacy of pimecrolimus compared with topical corticosteroids is still
weak. The evidence from the trials on the potential harms of treatment, except for confirming that
application site burning is common for pimecrolimus, is far from clear.
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Trials of long-term treatment using the minimum amount of treatment needed, and paying more attention to
the outcomes that are most important to those with eczema, are still needed to compare these treatments.
There is still not enough evidence to suggest which topical corticosteroid or topical immunomodulator is most
appropriate in common clinical eczema scenarios. The move to looking at proactive treatment regimens is
welcomed and needs to become more pragmatic still when comparing these treatments.
Pimecrolimus compared with other active comparators
Two very small trials173,174 failed to show any hint of a benefit of a ceramide–hyaluronic acid emollient
foam or a lipid-rich topical medical device cream over pimecrolimus in the 4 weeks of treatment, even for
the participant-subjective outcomes in these single-blind trials. The trials did not report any adverse events
but the small numbers of participants and short treatment duration make it unlikely that adverse events
would be captured effectively. It is not clear whether the participants were allowed to use any other
treatments during the trials, which makes interpretation of the trial results difficult.
Tacrolimus compared with pimecrolimus
Studies
Five new multicentre, manufacturer-sponsored trials, three in children175,176 and two175,177 in adults,
compared tacrolimus with pimecrolimus twice daily. Four175,176 of the trials gave treatment for up to
6 weeks and one177 trial gave treatment for 13 days. One175 of the two trials in adults compared tacrolimus
ointment (0.1%) with pimecrolimus cream (1%) twice a day until 1 week after complete clearance of the
affected area or for 6 weeks in 413 participants with mild to very severe eczema. The other trial177 involved
37 adults and was primarily concerned with pharmacokinetic outcomes. Three trials175,176 involving a total
of 793 children compared tacrolimus (0.03%) against pimecrolimus (1%) for up to 6 weeks. One trial175
recruited only participants with mild eczema, another176 recruited only those with moderate eczema and
the third175 recruited participants with moderate to very severe eczema.
Different regimens of tacrolimus or pimecrolimus
The industry-funded trial by Ruer-Mulard and colleagues178 compared once-daily pimecrolimus (1%) with
twice-daily pimecrolimus (1%) for up to 16 weeks in 268 children aged ≥ 2 years, after inducing remission
in all participants.
The trial by Reitamo and colleagues179 compared twice-daily tacrolimus (0.03%) with once-daily tacrolimus
(0.03%), using a placebo for the once-a-day group for the second application of treatment. The
53 children aged 3–24 months had eczema that required mild-potency topical corticosteroids on entry to
the trial. The trial treatment was applied for 14 days; on the first and last days, only one application of
study treatment was given, applied by the investigator. This trial focused on pharmacokinetics.
A multicentre trial conducted in the USA by Ling and colleagues180 compared pimecrolimus (1%) twice a
day with pimecrolimus (1%) four times a day for 1 week, after which participants could choose to continue
on either treatment for a further 2 weeks. Forty-nine participants were randomised aged ≥ 11 years with
eczema that affected ≥ 30% of the body, a pruritus score of at least 2 out of 3 and an IGA of ≥ 2.
Assessment of risk of bias for the new studies
Table 8 provides the risk-of-bias assessment for the new studies.
Benefits
In the three trials by Paller and colleagues175 the combined analysis of the reduction in severity measured
by EASI score from baseline to the end of treatment was significantly greater in the tacrolimus group than
in the pimecrolimus group (54.1% vs. 34.9%; p< 0.0001). Tacrolimus also achieved a significantly greater
treatment success rate (IGA of disease activity of 0 or 1) of 40% compared with 22% in the pimecrolimus
group at the end of the trial (p= 0.001). A significant difference in participant assessment of itch in favour
of tacrolimus was also reported, although this was not as marked as the improvements in eczema severity.
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The trial by Kempers and colleagues,176 sponsored by the manufacturer of tacrolimus, reported a
statistically significant reduction in pruritus in favour of pimecrolimus whereas the three trials by Paller and
colleagues,175 sponsored by the manufacturer of pimecrolimus, did not report any significant difference
between the groups.
The small pharmacokinetic trial by Draelos and colleagues177 sponsored by the manufacturer of
pimecrolimus did not statistically compare the efficacy results from the trial. The intensity of pruritus in both
of the treatment groups reduced from around half of the participants having mild or moderate pruritus to
three-quarters of the participants having absent or mild pruritus. One out of 18 participants (5.6%) in the
pimecrolimus group and two out of 19 (10.5%) in the tacrolimus group achieved whole-body treatment
success (defined as an IGA of 0 or 1 at the end of treatment). Five out of 18 (27.8%) in the pimecrolimus
group and five out of 19 (26.3%) in the tacrolimus group achieved head and neck area treatment success
(defined as an IGA of 0 or 1 at the end of treatment).
Different regimens of tacrolimus and pimecrolimus
The trial by Reitamo and colleagues179 did not compare or analyse data from the different treatment
groups for the clinician’s global assessment. The decreases from baseline for the three surface area
stratification groups were reported as –66.7, –51.8 and –60.9 for tacrolimus treatment once a day and
–66.7, –75.9 and –59.5 for tacrolimus treatment twice a day.
The multinational trial by Ruer-Mulard and colleagues178 reported that the relapse rate was lower in the
twice-daily pimecrolimus group (9.9%) than in the once-daily pimecrolimus group (14.7%). The time to
relapse was not significantly different. The severity of eczema reduced from 83.2% for participants having
an IGA of 0 or 1 at the start of randomised treatment to 62.1% in the twice-daily pimecrolimus group and
59.5% in the once-daily pimecrolimus group at the end of the trial.
The trial by Ling and colleagues180 found no significant differences in pruritus relief or reduction in severity
between pimecrolimus twice daily and pimecrolimus four times daily at the end of the trial; however, as
the participants had a choice as to the number of times they could use the study treatment after the end
of the first week it is difficult to interpret the results.
TABLE 8 Tacrolimus compared with pimecrolimus: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Tacrolimus vs. pimecrolimus
Draelos 2005177 Unclear risk Unclear risk Low risk
Kempers 2004176 Low risk Low risk Low risk Participants who violated the study protocol
were not included in the final analyses
Paller 2005175
(three trials)
Low risk Low risk Low risk Unclear whether all those who withdrew
were included in the analyses or not
Different regimens of pimecrolimus or tacrolimus
Ling 2005180 Unclear risk Unclear risk Low risk Intention-to-treat population of all
participants randomised used for all analyses
Reitamo 2009179 Unclear risk Unclear risk Unclear risk Not powered for statistical comparisons of
the treatment group as the trial was primarily
concerned with pharmacokinetic profiles of
the treatments
Ruer-Mulard 2009178 Low risk Unclear risk Low risk The sample size was not based on statistical
power calculations
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Harms
The trials by Paller and colleagues175 and the trial by Kempers and colleagues176 all reported that there
were adverse events such as application site burning and pruritus but that there were no differences in the
rate of adverse events between the two treatments.
Different regimens of tacrolimus and pimecrolimus
Both trials comparing once-daily with twice-daily pimecrolimus178,179 reported frequent adverse events such
as nasopharyngitis, cough, pyrexia and minor infections. There were a few treatment-related adverse
events reported in both trials relating to application site burning, pruritus and dermatitis. The trial by
Ruer-Mulard and colleagues178 reported that nasopharyngitis occurred slightly more frequently in the
twice-daily group than in the once-daily group (14.9% vs. 8.2%, respectively) but tests for statistical
significance were not reported.
The trial by Ling and colleagues,180 which compared pimecrolimus twice daily with pimecrolimus four times
daily, reported that there were no serious adverse events; there was one withdrawal as a result of study
treatment (application site burning to 90% of the total body surface). The number of participants
experiencing at least one adverse event was five in the four times a day group and 10 in the twice-daily
group. The number of participants experiencing at least one treatment-related adverse event was three in
the four times a day group and four in the twice-daily group.
Overall implications for research and practice
Although pimecrolimus and tacrolimus have now been compared ‘head to head’ in several trials, it is
important to remember that they are licensed for different ranges of severity of eczema. Pimecrolimus is
not licensed for severe eczema as evidence has shown that it is not as potent as tacrolimus (0.1%).
None of the trials comparing treatment regimens for pimecrolimus and tacrolimus have so far attempted
to address clinically important questions such as the optimal treatment regimen for patients with
moderate eczema.
Trials looking at optimal treatment regimens need to be much longer and use regimens that mirror
pragmatic clinical use with an active ‘standard practice’ comparator treatment.
Topical corticosteroids in combination with topical
calcineurin inhibitors
Studies
One new trial by Meurer and colleagues181 compared a combination of fluticasone propionate (with
hydrocortisone acetate for the face neck and hands) and pimecrolimus with fluticasone propionate with
hydrocortisone acetate and vehicle cream. This multinational trial randomised 376 children aged between
2 and 17 years to treatments applied twice a day for 4 weeks. Those children who were clear or almost
clear after 4 weeks of treatment were observed for a further 12 weeks to assess time to relapse.
Another new within-person multicentre trial by Hebert and colleagues182 compared treatment with
tacrolimus (0.1%) ointment used concurrently with desoximetasone (0.25%) ointment with tacrolimus
ointment used concurrently with the vehicle of desoximetasone, twice daily until clear or for 21 days.
Eighty-two adults with eczema in the target lesions of ≥ 8/15 for total symptom score had their left and
right sides randomised to treatment. There was no follow-up of participants beyond 21 days.
Assessment of risk of bias for the new studies
Table 9 provides the risk-of-bias assessment for the new studies.
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Benefits
The trial by Meurer and colleagues,181 which was primarily concerned with safety, combined pimecrolimus
and fluticasone and compared this treatment with fluticasone only. The trial found no significant
differences between the treatments except for an increased time to relapse in what appeared to be a post
hoc subgroup analysis of only those participants who were ‘clear’ of eczema as assessed by the IGA at the
end of treatment.
In the trial by Hebert and colleagues182 the reduction in participant-assessed pruritus over 21 days was
significantly better in the combined treatment group than with tacrolimus alone (p= 0.006); however,
the scores were not reported and only 69 out of 82 participants were included in the pruritus assessment
because of missed visits. The percentage of participants with a score of 0 (no pruritus) at baseline was
58% for combination treatment and 61% for tacrolimus treatment; this compared with 84% for
combination treatment and 71% for tacrolimus treatment after 3 days. This was reported as statistically
significant in favour of combination treatment (p= 0.04). A difference of 0.3 (95% Cl 0.1 to 0.5) between
the groups in the physician’s global assessment score at day 21 was reported, which was significantly
significant in favour of the combination treatment. For the total symptom score for the target lesions,
the difference between the reduction in scores after 21 days was 0.8 (95% Cl 0.4 to 1.2) in favour of
combination treatment (p= 0.0002).
Harms
The trial by Meurer and colleagues181 found a relatively high rate of infections and infestations (25–30% of
participants) in both treatment groups. Bronchitis was far more common in the pimecrolimus and topical
corticosteroid group (2.7% vs. 0%). The proportion of participants experiencing adverse events suspected
to be related to the study drug was slightly higher on combination treatment (6.3%) than with the topical
corticosteroid-only treatment (4.4%). For adrenal suppression, 54 participants (28.4%) on combination
treatment and 44 participants (24.0%) on the topical corticosteroid-only treatment were suspected cases,
but the majority of patients were confirmed not to be suppressed.
Hebert and colleagues182 reported that five participants withdrew from the trial because of ‘non-compliance’,
‘protocol violation’ or an ‘adverse event’, but the number of participants effected by adverse events and the
nature of the events was not reported.
Overall implications for research and practice
There is not enough convincing evidence that combining topical corticosteroids and topical calcineurin
inhibitors confers any short-term beneficial effects compared with topical corticosteroids alone. One large
trial in children181 and a smaller trial in adults182 based their positive conclusions on the results of post hoc
subgroup analysis or complete case analysis that excluded many participants.
Topical corticosteroids with occlusive therapy
Studies
No trials involving wet wrap bandages for the treatment of eczema were reported before 2000. Five new
trials involving the use of wet wrap bandages were reported after 2000.183–187
TABLE 9 Topical corticosteroids combined with topical calcineurin inhibitors: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Hebert 2006182 Low risk Low risk Low risk
Meurer 2010181 Unclear risk Unclear risk Unclear risk
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A left–right within-person comparison trial by Foelster-Holst and colleagues183 compared prednicarbate
ointment and tubular bandages soaked in warm water and then covered with dry dressings with
prednicarbate ointment alone for 48–72 hours. All of the 24 adults and children had experienced an acute
episode of atopic eczema and also used an emollient.
A single-centre UK trial by Hindley and colleagues184 compared conventional treatment [hydrocortisone
(1%) or stronger steroids] under wet wraps with hydrocortisone (1%) and emollients. Fifty children aged
4–27 months (eligibility was from 3 months to 5 years) with eczema that scored ≥ 15 using SCORAD
scores were randomised to treatment. The children were assessed over a 4-week period but it was not
clear whether they were using the study treatment for the whole 4 weeks.
A four-arm trial conducted in Hong Kong, China, by Pei and colleagues185 compared a one-tenth dilution
of mometasone furoate ointment (0.1%) only for 4 weeks (first group) and the same treatment with wet
wraps under dry wraps for the second 2 out of 4 weeks (second group) with a one-tenth dilution of
fluticasone propionate (0.005%) only for 4 weeks (third group) and the same treatment with wet wraps
under dry wet wraps for the second 2 out of 4 weeks (fourth group). The 40 children randomised were
aged between 1 and 15 years with active eczema with a severity of at least 40–144 using a composite
scale despite being treated with UK class II or stronger topical corticosteroids plus soap substitutes
and emollients.
The single-centre trial by Schnopp and colleagues186 compared mometasone furoate (0.1%) with wet
wraps against the vehicle for mometasone furoate with wet wraps. The wet wraps were applied only to a
test area of eczema twice daily for 5 days, but not at night, and the mometasone furoate was applied
morning and evening. Basic adjuvant treatment was allowed, although there were no details of what was
deemed acceptable. Twenty children aged 2–17 years with exacerbated atopic eczema were randomised
into the trial.
A small pilot trial conducted in the UK by Beattie and Lewis-Jones187 compared treatment with hydrocortisone
and wet wraps with treatment with hydrocortisone without wet wraps. The treatment was applied twice a
day for the first week and once a day for the second week. Participants could use emollients freely as long as
a 20-minute gap between application of the hydrocortisone and application of the emollient was observed.
All participants used emollients only for a third week. The 19 participants were aged ≤ 5 years and had
atopic eczema with > 30% body surface area affected and no clinical evidence of infection.
Assessment of risk of bias for the new studies
Table 10 provides the risk-of-bias assessment for the new studies.
TABLE 10 Topical corticosteroids with occlusive therapy: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Beattie 2004187 Low risk Unclear risk Unclear risk
Foelster-Holst 2006183 Unclear risk Unclear risk High risk Number of withdrawals and numbers
included in the analyses not reported
Hindley 2006184 Unclear risk Unclear risk Low risk 5/28 in the wet wrap group withdrew for
‘non-compliance’ and were not included in
the analyses
Pei 2001185 Unclear risk Unclear risk High risk 13/40 participants withdrew, 10 because of a
> 50% improvement in eczema. Numbers
included in the analyses were not reported
Schnopp 2002186 Unclear risk Unclear risk Unclear risk Number of withdrawals and numbers
included in the analyses not reported
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Benefits
In the trial of prednicarbate ointment and wet wraps by Foelster-Holst and colleagues183 only the local
severity of eczema using SCORAD scores was reported. The prednicarbate and wet wrap group improved
by 4.4 SCORAD points whereas the prednicarbate-only group improved by 3.0 SCORAD points after
48–72 hours. This was reported to be a statistically significant difference (p= 0.011) in favour of
prednicarbate with wet wraps. The baseline local SCORAD score was an average of 12.0 (SD 1.04). The
participants had not been allowed any topical corticosteroid treatment in the 2 days before the treatment.
The trial by Hindley and colleagues184 found no significant difference between conventional treatment with
wet wraps and conventional treatment only after 4 weeks for the primary outcome of severity of eczema
measured by SCORAD. ‘Tolerability’, ‘ease of application’ and ‘efficacy’, each on a 5-point Likert scale,
were stated to be outcomes, but no results were reported.
The trial by Pei and colleagues185 reported the severity of eczema using a composite scale; however, the
groups were not compared against each other. The number of participants analysed for each group
was not reported after the second randomisation. The trial reports that the two groups that used
wet wraps continued to improve compared with baseline whereas the two groups that did not use wet
wraps plateaued.
The trial by Schnopp and colleagues186 measured the severity of eczema using local SCORAD scores.
Over 5 days the severity of eczema decreased from 10.6 to 2.5 in the mometasone group and from 11.1
to 4.0 in the vehicle group. This was a significantly better improvement in severity in the mometasone
furoate and wet wraps group compared with the vehicle and wet wraps group (p< 0.01). The nurses and
carers rated the wet wraps more difficult to use in a questionnaire.
The pilot trial by Beattie and Lewis-Jones187 found that there was a greater mean reduction in Six Area,
Six Sign Atopic Dermatitis (SASSAD) score without wet wraps (8 more SASSAD points than with wet
wraps) after the 2-week treatment period (95% CI for difference –18 to + 2; p= 0.11). For quality of life
measured using the IDLQI, the group without wet wraps had a greater median decrease (5 more IDLQI
points) than the group with wet wraps (95% CI for difference –10 to + 3; p= 0.24). The Dermatitis Family
Impact score showed no significant difference between the treatments.
Harms
Two trials185,186 did not report adverse events, one trial187 reported that two participants withdrew because
of folliculitis and one trial183 reported that there were no withdrawals and no adverse effects. The trial by
Hindley and colleagues184 reported that recruitment was stopped early because of clinically significant
adverse event differences between the treatment groups, although it was not clear what these were. It
was also reported that 5 out of 28 of the participants using the wet wraps needed antibiotic treatment for
infected eczema compared with none in the group not using wet wraps.
Overall implications for research and practice
These five small, short-term and poorly reported trials do not currently provide evidence of a beneficial
effect of combining wet wrap treatment with topical corticosteroid treatment, but this may be because of
their small size and design flaws. The between-group results were not properly compared in one trial,185
making interpretation of the evidence difficult.
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Summary for topical corticosteroids and topical
immunomodulators
Topical corticosteroids compared with placebo
l There were 13 trials reported before 2000 and the trials that did report the magnitude of benefit
suggested a large treatment effect of topical corticosteroids compared with placebo.
l Nine trials reported from 2000 onwards that gave a continuous short- to medium-term course of
treatment provide further evidence of the large beneficial effect of topical corticosteroid treatment
compared with placebo.
l There is evidence from four trials that used an initial 4-week continuous treatment regimen to ‘get
control’ followed by a 16-week period of twice-weekly treatment on consecutive or evenly spaced days
to ‘keep control’ of a large beneficial effect of topical corticosteroids compared with placebo.
Topical corticosteroids compared with active treatments
(except topical immunomodulators)
l There were 40 trials reported before 2000 comparing topical corticosteroids against other topical
corticosteroids. The trial evidence was mixed and it was difficult to provide a summary as none
of the trials compared all of the main topical corticosteroids together. Fluticasone propionate and
mometasone furoate were found to be reasonably equivalent to older topical corticosteroids when
used once daily.
l Eleven new trials reported from 2000 onwards compared a new topical corticosteroid against another
commonly used topical corticosteroid. These trials still do not compare more than two treatments and
only add to the previous mixed results seen before 2000. Of these:
¢ one trial provided some very weak evidence that pulsed treatment is more effective than
continuous treatment with the same topical corticosteroid, which needs further research
¢ one trial provided some evidence that adding a penetration-enhancing chemical to topical
corticosteroid treatment was more beneficial than topical corticosteroid alone
¢ one trial provided some evidence that mometasone furoate in multilamellar emulsion was more
beneficial than methylprednisolone aceponate.
l Four trials reported after 2000 compared a topical corticosteroid against a different active comparator.
All of these trials used the topical corticosteroid as the standard comparator and these trials are
discussed in the relevant sections of this review.
Topical immunomodulators
Tacrolimus compared with placebo
l There were two well-reported trials of tacrolimus compared with vehicle reported before 2000, one in
children and one in adults. These trials provided evidence of a short-term large beneficial effect for
tacrolimus compared with vehicle, regardless of the concentration used.
l Eight trials of tacrolimus compared with placebo given twice daily for 2–12 weeks were reported from
2000 onwards. These trials provided evidence of a benefit for tacrolimus compared with placebo.
l Three large multicentre trials and one small open-label trial of tacrolimus compared with placebo given
after initial treatment to gain control of the eczema provided evidence of a benefit for tacrolimus
compared with placebo for the prevention of flares.
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Tacrolimus compared with other active treatments
l There were no trials of tacrolimus compared with other active treatments reported before 2000.
l There were six new trials of tacrolimus compared with hydrocortisone reported from 2000 onwards.
The two trials of hydrocortisone acetate compared with tacrolimus provide evidence that tacrolimus is
more beneficial for moderate to severe eczema. However, this is not a clinically appropriate comparison
of treatments. The three trials comparing the more potent hydrocortisone butyrate against tacrolimus
gave conflicting results, with the hydrocortisone treatment being more beneficial for continuous
treatment for 3 weeks and tacrolimus being more beneficial when using treatment ‘as required’ for
flares over 6 months after an initial 7-day continuous treatment.
l There were eight trials of tacrolimus compared with other topical corticosteroids comparing different
treatments, regimens and areas of the body. There was some evidence from one trial that tacrolimus
(0.1%) was more beneficial than fluticasone propionate (0.005%) for facial eczema in adults and
evidence from another trial of the non-inferiority of tacrolimus (0.1%) compared with fluticasone
propionate (0.005%) on all areas of the body.
l One trial compared tacrolimus against ciclosporin, which is discussed in Chapter 11.
Pimecrolimus compared with placebo
l There were no trials of pimecrolimus compared with placebo reported before 2000.
l There were four trials of continuous treatment with pimecrolimus compared with placebo at the first
signs and symptoms of a flare or recurrence of eczema until clearance. These trials provide evidence of
a large beneficial effect of pimecrolimus.
l There were 11 trials, mostly with industry involvement, of reactive continuous treatment until eczema
clearance or for a set period of time, which was usually 6 weeks. These fairly well-reported trials
provide evidence of a large beneficial effect of pimecrolimus, particularly for the reduction of pruritus.
l There were two small but well-reported trials of the use of either a proactive 3-week continuous
treatment or ‘as-needed’ bursts of continuous treatment over 6 months after induction of remission.
The short-term (3-week) continuous treatment provided weak evidence of benefit for pimecrolimus
compared with placebo for mild to moderate eczema over 6 months. The long-term (as-needed)
treatment provided evidence of a beneficial effect over 6 months only for a subgroup of those with
problematic head and neck eczema.
Pimecrolimus compared with other active treatments
l There were no trials of pimecrolimus compared with topical corticosteroids reported before 2000.
l The three new trials that compared pimecrolimus against topical corticosteroids had safety and
tolerability as primary outcomes. The mostly methodologically unclear trials provide evidence that the
topical corticosteroids betamethasone 17-valerate and triamcinolone acetonide are more beneficial
than pimecrolimus in adults with moderate to severe eczema.
l One very small trial compared pimecrolimus against an emollient foam over 4 weeks and found no
evidence of a significant difference between the treatments.
l One very small trial reported in 2011, with a high risk of bias for blinding, compared pimecrolimus
against a lipid-rich topical cream and found no evidence of a significant difference between
the treatments.
Tacrolimus compared with pimecrolimus
l There were no trials of pimecrolimus compared with tacrolimus reported before 2000.
l Five trials compared tacrolimus against pimecrolimus. Overall, these trials had a mostly low risk of bias
and provide some evidence of benefit for pimecrolimus treatment compared with tacrolimus treatment.
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Topical calcineurin inhibitors combined with topical corticosteroid
l There were no trials of topical calcineurin inhibitors combined with topical corticosteroids reported
before 2000.
l One large, methodologically unclear trial in children that was primarily concerned with safety did not
provide any evidence of a short-term significant difference in benefit when pimecrolimus and a topical
corticosteroid were combined over 4 weeks of treatment. There was a significant difference in relapse
rates over 12 weeks in favour of the combined treatment from a, probably post hoc, subgroup of all
those clear at the end of treatment.
l One small, methodologically unclear trial in adults provides some weak evidence of benefit for the
combination of tacrolimus (0.1%) and a topical corticosteroid.
Topical corticosteroids with occlusive therapy
l There were no trials involving occlusive therapy in combination with topical corticosteroids reported
before 2000.
l There were five new RCTs reported after 2000 but they were all small, very short term and
methodologically unclear. The results do not provide clear evidence of a significant benefit from the
addition of occlusive therapies to topical corticosteroids.
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Chapter 5 Emollients and other topical treatments
Background
Many topical treatments have been tried in people with eczema. This chapter summarises new RCT
evidence on topical eczema treatments that do not fit into other categories in this review.
Existing systematic reviews
There is one systematic review focusing on emollients by Tarr and Iheanacho.188 The SIGN,42 NICE41 and
American Academy of Dermatology (AAD)94 guidelines have all covered emollients. A review of reducing
pruritus for eczema93 covers emollients, topical doxepin and sodium chromoglycate and a Cochrane
review189 covers evening primrose oil and borage oil for eczema treatment.
Emollients
Studies
Five trials were reported before 2000 that tested emollients for eczema55 (see Appendix 3).
Most of the 15 new trials123,126,190–202 looking at emollients reported after 2000 compared twice-daily
treatment with an emollient (often applied concurrently with topical corticosteroid treatment) with
treatment with topical corticosteroids alone, other emollients or, in one case, no treatment. Most trials had
a treatment length of around 4–6 weeks and none of the trials gave treatment for > 2 months. Nearly all
of the trials included participants with mild to moderate eczema, with only three trials123,126,191 including
participants with severe eczema.
Albolene®
One ‘equivalence’ trial of 60 patients with mild eczema sponsored by the manufacturer of the
over-the-counter emollient Albolene® (DSE Healthcare Solutions) compared Albolene against a prescription
device emollient (MimyX™, Stiefel Laboratories), with concurrent use of topical triamcinolone (0.1%) cream
in both groups, twice daily for 4 weeks.190
Assessment of risk of bias
Table 11 provides the risk-of-bias assessment for the new study.
Benefits
Both the investigators and the participants assessed the severity of eczema using the same 6-point ordinal
scale from ‘none’ to ‘severe’. The author reported that there were no statistically significant differences
between the treatments for eczema severity assessed by either the investigators or the participants.
TABLE 11 Albolene: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Draelos 2009190 Unclear risk Unclear risk Unclear risk No details of a sample size calculation or margin
for the claim of ‘parity’ between treatments
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Harms
It was reported that no adverse events occurred during the trial.
Exomega milk
A 6-week unblinded trial funded by the manufacturers of Exomega milk® (Pierre Fabre Limited) randomised
173 infants with moderate to severe eczema to Exomega milk applied twice daily on non-inflammatory
areas of skin or no equivalent treatment.191 All of the participants were allowed to use topical
corticosteroids during the trial to treat inflammatory lesions. The primary outcome was steroid sparing
(decrease in topical corticosteroid use).
A smaller trial,192 also involving the Pierre Fabre Laboratories, included 76 infants and children aged from
6 months to 2 years with mild to moderate eczema. Participants were randomised to use either Exomega
milk or a cleaning bar (A-Derma®) all over the body, twice a day, for 2 months. All participants were
allowed to use topical corticosteroids during the trial.
Assessment of risk of bias
Table 12 provides the risk-of-bias assessment for the new studies.
Benefits
The study by Grimalt and colleagues191 showed a significant difference between the steroid-sparing effect
of the two treatments after 21 days and 42 days of treatment. After 42 days, the Exomega milk group
had used 8.56 g (SD ± 1.74 g) of a potent topical corticosteroid whereas the control group had used
14.7 g (SD ± 2.08 g), a –41.8% difference (p< 0.05). The consumption of moderate-potency
corticosteroids was not significantly different between the groups. The severity of eczema measured using
SCORAD scores fell in both groups by just over half of the baseline value, from 35.63 to 15.96 in the
emollient group and from 35.96 to 16.45 in the control group, showing no difference between the
groups. Although not prespecified as an outcome, the proportions of participants with dryness (p= 0.015,
percentage of participants with dryness in each group not reported) and moderate to severe dryness
(33% vs. 61.5%; p= 0.007) were reported as significantly lower in the emollient group after 21 days.
Dryness was not significant at 42 days (20.25% vs. 36.36%).
The smaller trial by Giordano-Labadie and colleagues192 found no significant difference between the
groups in the severity of eczema measured using SCORAD scores after 28 or 56 days of treatment.
The authors report a significant reduction in the emollient group and the control group for both xerosis
(–35.9% vs. –68.6%; p= 0.01) and pruritus (–41.6% vs. –65.7%; p= 0.01) after 2 months of treatment,
although these were not prespecified outcomes. There was a significant reduction in quality of life, a
prespecified outcome measured using the CDLQI, after 2 months in the emollient group (from 2.24 to
1.18) compared with the control group (from 1.59 to 1.4; p= 0.01).
TABLE 12 Exomega milk: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Giordano-Labadie 2006192 Unclear risk Unclear risk Unclear risk
Grimalt 2007191 Unclear risk Unclear risk Low risk The intention-to-treat population did not
include seven participants from the
emollient group and four from the control
group because of protocol or inclusion
criteria violations and no follow-up data
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Harms
Grimalt and colleagues191 reported a number of adverse events possibly related to the treatment; three
were mild, three were moderate and two were serious and led to treatment discontinuation. The nature
of these adverse events was not reported. The trial report states that all adverse events resolved
without sequelae.
Giordano-Labadie and colleagues192 did not report any information about adverse events.
Urea and glycerine emollients
Two virtually identical trials by Loden and colleagues,193,194 each lasting for 30 days, compared a glycerine
cream (20%) with its vehicle (with glycerine substituted with water) and a cream containing urea (4%) and
sodium chloride (4%). For the earlier trial193 the treatment was applied only twice a day to a patch of dry
skin identified by the dermatologist. For the second trial194 participants were allowed to use the treatments
as much as necessary and at least once a day. The first trial was primarily concerned with physical markers
of efficacy but also measured skin dryness. The second trial was more concerned with efficacy and
measured both participant- and investigator-assessed skin dryness, as well as participant-assessed degree
of stinging, smarting, itching and dryness/irritation.
A trial by Bissonnette and colleagues195 compared a urea moisturiser (5%) against a urea lotion (10%) but
did not include a control arm. The trial included 100 adults aged > 18 years with mild eczema (SCORAD
score of < 30) and treatments were applied twice daily for 42 days.
A trial by Amichai and Grunwald196 compared the liquid soap Axera™ (Perrigo-Pharma), containing 12%
ammonium lactate and 20% urea, with a commercially available liquid soap for showering over a 3-week
period. No other emollients or soaps were permitted during the trial but participants could continue to use
their current eczema treatments. The study included 36 adults and children aged 3–40 years with mild to
moderate eczema, diagnosed according to the UK Working Party’s criteria.9
Assessment of risk of bias
Table 13 provides the risk-of-bias assessment for the new studies.
Benefits
The trial report by Loden and colleagues193 gives very little detail and the two graphs that present the
data on dryness score appear to show very different baseline scores for the three treatment groups,
with the urea group having a noticeably higher baseline score than the glycerine and placebo groups.
No details are given about the method of randomisation or whether allocation concealment took place
and the difference in baseline values raises doubts about these procedures. Although no detailed data are
presented, the trial report states that after 30 days’ treatment the urea treatment group had a significantly
lower dryness score than the glycerine treatment group (p= 0.021). It is unclear whether this refers to the
difference between the final dryness scores or the difference between the change in dryness scores.
TABLE 13 Urea and glycerine emollients: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Amichai 2009196 Unclear risk Unclear risk Unclear risk
Bissonnette 2010195 Unclear risk Unclear risk Unclear risk
Loden 2001193 Unclear risk Unclear risk Unclear risk
Loden 2002194 Unclear risk Unclear risk Unclear risk
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The second trial by Loden and colleagues194 used a dermatologist-assessed dryness scale, with no
statistically significant differences reported between urea cream and glycerine cream and between
glycerine cream and placebo cream. For participant assessment of dryness at the end of treatment there
was no significant difference between the urea and glycerine groups (89% vs. 85% of participants rating
the dryness as ‘improved’; p= 0.77). The proportion of participants rating the dryness as ‘improved’ was
significantly higher in the glycerine cream group than in the placebo group (89% vs. 69%; p= 0.019).
Again, no detailed data are presented, including any baseline scores or demographics.
The trial by Bissonnette and colleagues195 did not find a statistically significant difference in eczema severity
between the urea cream (5%) and the urea lotion (10%) after 42 days of treatment (19.76% vs. 19.23%
reduction in mean SCORAD scores). The trial report states that the urea cream (5%) had better cosmetic
acceptability than the urea lotion (10%).
Amichai and Grunwald196 reported significant reductions for the urea and ammonium liquid soap (Axera)
compared with the commercially available liquid soap in scaling (urea and ammonium soap: from 1.63 to
0.68, ‘placebo’ soap: from 1.75 to 1.42; p< 0.0001), skin dryness scaling (urea and ammonium soap: from
1.88 to 0.77, ‘placebo’ soap: from 1.83 to 1.25; p< 0.0001), redness (urea and ammonium soap:
from 0.58 to 0.14, ‘placebo’ soap: from 0.62 to 0.53; p= 0.03) and participant-assessed itching (urea and
ammonium soap: from 1.38 to 0.32, ‘placebo’ soap: from 1.83 to 0.92; p< 0.001). The participants rated
the urea and ammonium soap significantly better for its non-sticky texture and for the improvement of
skin smoothness; however, no data were provided for this outcome.
Harms
Information about adverse events was not recorded in the first trial by Loden and colleagues.193
Adverse events that could possibly be related to study treatment were recorded and graded in the second
trial by Loden and colleagues.194 The report states that adverse skin reactions were significantly lower in
the glycerine group than in the urea group, with 10% in the glycerine group experiencing moderate to
severe stinging compared with 24% in the urea group (p< 0.0006).
In the trial by Bissonnette and colleagues,195 22 out of the 100 participants experienced at least one
adverse event. Five adverse events were reported as being possibly related to study treatment and no
participant experienced more than two adverse events. Three participants withdrew from the study
because of adverse events, two in the urea lotion group because of irritant contact dermatitis and pruritus
and one in the urea moisturiser group because of erythema.
In the trial by Amichai and Grunwald196 one participant in the Axera group had a mild transient skin
irritation related to using the soap.
Lipid emollient
One trial by Wiren and colleagues197 conducted in Sweden compared an emollient with 20% lipid content
(Canoderm® cream, ACO Hud) with no treatment until relapse or 6 months. All 55 adults with eczema
who were recruited into the trial initially used the topical corticosteroid betamethasone (0.01%) for
3 weeks to induce remission. Only those participants who had ‘cleared eczema’ according to an
assessment by a dermatologist (n= 44) were then randomised to the maintenance period of emollient or
no treatment. The aim of the trial was to assess whether emollient use prolonged the time spent in
remission from eczema.
Assessment of risk of bias
Table 14 provides the risk-of-bias assessment for the new study.
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Benefits
The median time to first relapse was > 6 months for the emollient group compared with 30 days when
using no treatment. This difference in time to relapse was statistically significant, with a relative risk
reduction of 53% and number needed to treat of 2.8.
Harms
No information about adverse events was reported.
Sunflower oleodistillate emollient
Two industry-sponsored trials123,198 from the same group compared a sunflower oleodistillate
(2%)-containing emollient (Stelatopia®; Mustela DermoPediatrie, Laboratoires Expanscience) with
a topical corticosteroid for 3 weeks.
In the first trial, by Msika and colleagues,123 86 infants and young children aged from 4 months to
48 months with mild to moderate eczema were randomised to five groups. Each group received a treatment
based on a moderate-potency topical corticosteroid (Tridesonit®; CS Dermatologie) (0.05%) once or twice
daily or every other day combined or not with application of the sunflower emollient twice daily for
21 days. Overall, two groups received topical corticosteroids alone and three groups received topical
corticosteroids plus emollient. The second trial, by De Belilovsky and colleagues,198 compared twice-daily
application of Stelatopia with the mild-potency topical corticosteroid hydrocortisone butyro-propionate
cream (1mg/g) in infants and young children aged from 4 months to 4 years with mild to moderate eczema.
Assessment of risk of bias
Table 15 provides the risk-of-bias assessment for the new studies.
Benefits
In the trial by Msika and colleagues,123 the overall comparison of the five groups found no significant
differences in disease severity changes assessed by SCORAD scores or in quality of life (SCORAD scores
were reduced by 58–75% from baseline to 3 weeks in the five groups). There was no difference between
using topical corticosteroids twice daily without sunflower emollient and using topical corticosteroids every
other day plus sunflower emollient twice daily. Because of the similar decrease in eczema severity in these
two groups, the trial authors suggested that using a sunflower oleodistillate-containing emollient produced
a topical steroid-sparing effect of 75%. However, there was no statistical comparison between the topical
corticosteroids once-daily group and the topical corticosteroids plus sunflower oleodistillate-containing
TABLE 15 Sunflower oleodistillate emollient: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
De Belilovsky 2011198 Unclear risk Unclear risk Unclear risk The trial was single blinded
Msika 2008123 High risk Unclear risk Unclear risk The trial report does not state what statistical
cut-off point they have used for claims of
‘significance’. The trial was single blinded
TABLE 14 Lipid emollient: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Wiren 2009197 Unclear risk Unclear risk Unclear risk Primary author employed by ACO Hud, the
makers of the study treatments
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emollient group in the study, which is the most appropriate and real-life situation. Furthermore, there was
also no difference between using topical corticosteroids twice daily alone and using topical corticosteroids
twice daily plus sunflower emollient. Thus, the conclusion could also have been that using sunflower
emollient produced no topical corticosteroid-sparing effect at all in this case.
In the trial by De Belilovsky and colleagues,198 there were also no significant difference between groups in
disease severity changes assessed by SCORAD scores at 3 weeks (change from 37.2 to 11 in the topical
corticosteroid group and from 36.9 to 9.4 in the emollient group) or in quality of life, suggesting that
sunflower emollient could have an anti-inflammatory effect.
Harms
The earlier trial by Msika and colleagues123 did not report any information on adverse events and the later
trial by De Beliovsky and colleagues198 reported that no adverse events occurred.
Emollients containing ceramide
An industry-sponsored multicentre trial by Sugarman and Parish126 compared twice-daily application of a
ceramide-dominant barrier repair formulation (EpiCeram) against the topical corticosteroid fluticasone
propionate (0.05%) (Cutivate™; GlaxoSmithKline) on affected areas in body folds. The trial included
121 infants and children aged from 6 months to 18 years. All of the participants used the emollient lotion
Cetaphil™ (Galderma Laboratories) on unaffected areas of skin.
A trial by Berardesca and colleagues200 compared a lipid mixture containing ceramide-3, cholesterol,
palmitic acid and oleic acid in water-in-oil with nanoparticles with the same lipid mixture in combination
with topical corticosteroids. Out of a trial population of 508 participants, 91 participants had eczema.
All participants applied the treatment once or twice a day until healing had occurred or for a maximum
of 8 weeks.
A trial by Draelos201 compared a ceramide-based emollient against a hyaluronic acid-based foam,
the details of which are discussed later in this chapter.
A within-person trial by Simpson and Dutronc202 compared a body wash and moisturiser containing
ceramide (Restoraderm®; Galderma (UK) Ltd) in addition to standard eczema treatment with standard
eczema treatment alone. The trial included 127 adults and children aged > 3 years with mild to moderate
eczema according to IGA, randomised to emollient treatment twice daily on one side of the body and
no emollient treatment on the other side, for an unreported length of time.
Assessment of risk of bias
Table 16 provides the risk-of-bias assessment for the new studies.
TABLE 16 Emollients containing ceramide: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Berardesca 2001200 Unclear risk Unclear risk Unclear risk
Draelos 2011201 Unclear risk Unclear risk Unclear risk
Simpson 2011202 Unclear risk Unclear risk Unclear risk
Sugarman 2009126 Unclear risk Unclear risk High risk Many participants had recently used
fluticasone propionate before the trial, leading
to it being impossible to blind the trial
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Benefits
The industry-funded trial by Sugarman and colleagues126 did not make it clear whether this was a
superiority or an equivalence trial, although the stated aim of the trial seems to have been to prove
equivalence. Similar improvements in eczema severity (measured by SCORAD score), pruritus and sleep loss
were observed in both groups. The relative reductions in eczema severity, measured using SCORAD score,
were fairly large, with the emollient group decreasing from 37.2 to 18.5 and the fluticasone propionate
group decreasing from 34 to 12 (estimated from a graph). The reductions in pruritus were also fairly large,
with the emollient group decreasing from 6.1 to 2.8 and the fluticasone propionate group decreasing from
5.6 to 2.1 (estimated from a graph). The sleep loss assessments showed a decrease from 4.1 to 1.4 in the
emollient group and from 4.1 to 0.7 in the fluticasone propionate group.
The trial by Berardesca and colleagues200 reported a statistically significant difference in favour of combined
treatment with emollient and topical corticosteroids compared with emollient alone for pruritus after
8 weeks (p= 0.018), overall disease severity after 4 weeks (p= 0.007), dryness and scaling, but no detailed
data are provided.
The trial by Simpson and Dutronc202 found a significant reduction in eczema severity for the ceramide-
containing emollient compared with no emollient after 7 (p= 0.0003) and 15 (p= 0.0043) days while
using standard eczema treatment. This difference was not significant at days 21 and 28. There were no
absolute values reported. The mean change was not explicitly stated but appears to have been no more
than –1.0 in the no treatment group and –1.4 in the ceramide-containing emollient group, as determined
from a graph.
Harms
Berardesca and colleagues200 did not report any information on adverse events. In the trial by Sugarman
and colleagues126 there were no serious adverse events and four participants in the emollient group had a
worsening of eczema that required rescue medication. Simpson and Dutronc202 did not report information
about adverse events.
Hyaluronic acid-based emollient
A within-person trial by Draelos201 compared a hyaluronic acid-based foam emollient (Hyaltopic™; Onset
Therapeutics) against a ceramide-based emollient (EpiCeram) used twice daily for 4 weeks. The participants
used the treatment on either their arms or legs, one limb per treatment, and used randomised barrier
treatment on the rest of each side of their body. The 20 adults randomised had mild to moderate eczema
as assessed by IGA and symmetrically distributed lesions
Assessment of risk of bias
Table 17 provides the risk-of-bias assessment for the new study.
Benefits
There was a significant preference for the hyaluronic acid-based emollient for the aesthetics (‘worked
better, ‘less odour’, ‘rubs into skin easier’, ‘more soothing’) of the treatment. There was no significant
difference for ‘would prefer to keep using’. The treatments were not statistically compared against each
other for severity of eczema or individual signs and symptoms of eczema.
Harms
It was reported that there were no problems with safety for both treatments.
TABLE 17 Hyaluronic acid-based emollient: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Draelos 2011201 Unclear risk Unclear risk Unclear risk
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Overall implications for research and practice
Although it is pleasing to note an increase in the number of emollient trials since the 2000 report,55 the
lack of reporting of methodological detail is disappointing. Some studies have tried to demonstrate sparing
of use of topical corticosteroids, presumably on the rationale that the latter may exhibit side effects such as
skin atrophy if used inappropriately. Although skin atrophy and systemic effects have been associated
with prolonged use of potent topical corticosteroids in the past, these adverse effects are probably rare
nowadays with appropriate use in the context of eczema management. Furthermore, reducing cutaneous
inflammation by using topical corticosteroids is probably a way to improve cutaneous barrier functionality.
None of the studies involving topical corticosteroids to date have shown an increase in skin atrophy caused
by topical corticosteroids. It is important that studies aiming to show topical steroid sparing demonstrate
that such sparing is not achieved at the expense of lack of eczema control. One new study has suggested
that regular emollients used once disease has been controlled by topical corticosteroids may reduce the
frequency of flares and time to next flare, an important finding that needs to be replicated in larger studies
that include those with mild, moderate and severe eczema. Despite a lot of interest in emollients that have
been designed to contain specific ‘barrier repair’ ingredients, there is no clear evidence to date that any of
these more expensive preparations are superior to simple cheaper emollients. There is some evidence,
however, that some emollients such as aqueous cream, which contains sodium lauryl sulfate, may harm
the skin barrier203 and more refined mechanistic studies to identify which emollients are helpful and which
are not are needed before large-scale comparative trials are carried out. Research into the effectiveness of
increasing compliance with regard to the use of emollients, such as allowing patients to choose their own
emollient from a range of consistencies, and how long should be left after applying an emollient before
applying a topical corticosteroid is needed. Emollient application from birth is now being considered as an
intervention to prevent or at least delay the onset of eczema.204
Bath additives
One trial involving an antibacterial bath additive was reported before 200055 (see Appendix 3).
Two new trials on antibacterial bath additives were reported after 2000.205,206
The trial by Huang and colleagues,205 which compared 0.005% bleach baths and mupirocin ointment
intranasally for all family members against bathing without bleach and petroleum (placebo) intranasally for
all family members, is discussed in Chapter 6.
A trial carried out in Japan by Shibagaki and colleagues206 compared a bath additive containing eucalyptus
extract, oat extract and oily moisturising ingredients such as a synthetic pseudoceramide with and without
a derivative of diamide (a chemical oxidant that affects cell signalling). The trial randomised 21 participants
with eczema to use 30ml of the treatment dissolved in 180–200 l of hot water for 5 minutes at least four
times a week for 3–6 weeks. It was not clear what ages the participants were.
Assessment of risk of bias
Table 18 provides the risk-of-bias assessment for the new study.
TABLE 18 Bath additives: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Shibagaki
2005206
Unclear risk Unclear risk Unclear risk Analysis of change in severity of eczema was carried out
on an intention-to-treat basis; however, change in
pruritus was not carried out on an intention-to-treat
basis. Six participants from the diamide group and one
from the group that did not contain diamide withdrew
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Benefits
There was no significant difference between the treatment groups for the investigator assessment of
improvement. A significant difference was reported in the number of participants assessed as having an
improvement in their itching scores (six out seven in the diamide derivative group compared with
two out of seven in the control group). This was a per-protocol analysis that included only 7 out of
13 participants in the diamide derivative group and seven out of eight in the control group. All of the
withdrawn participants were withdrawn because they did not use the treatment four or more times a week.
Harms
There was no information on adverse events included in this report.
Overall implications for research and practice
It is unclear from this small trial206 whether adding a diamide derivative to bath emollients improves
eczema. The study was not powered appropriately to pick up anything but very large changes.
The significant difference in rates of improvement in pruritus reported for the per-protocol population of
14 participants is highly susceptible to attrition bias given the differential dropout rate. Much larger,
pragmatic and long-term trials are needed to evaluate the possible additional benefit of bath emollients in
eczema. It is possible that the emollient effects from adding moisturisers to the bath are minimal compared
with leave-on emollients applied after bathing.188
Furfuryl palmitate
Furfuryl palmitate is an antioxidant compound, which can neutralise (block the activity of) free radicals.
Higher levels of free radicals are associated with cellular damage. There is interest in antioxidant
supplementation for eczema as these compounds may stop the skin cell damage that occurs in
eczematous skin.
Studies
No RCTs on furfuryl palmitate for eczema were reported before 2000.
One new trial was reported after 2000.207 This new trial by Tripodi and colleagues207 compared an
emollient with the antioxidants furfuryl palmitate, superoxide dismutase, 18-beta-glycyrrhetinic acid,
vitamin E and alpha-bisabolol against the same treatment without furfuryl palmitate. The trial randomised
117 children aged 3 months to 14 years with eczema according to the UK Working Party’s criteria9 to
treatment twice a day for 2 weeks, using one fingertip unit for every patch of skin the area of two adult
hands. In total, 109 participants completed the trial, 21 of whom took medications not permitted by the
trial protocol. Participants did not change their lifestyle and diet during the trial. Participants were not
allowed to have used any topical or systemic treatments for eczema for 1 week before randomisation and
during the trial.
Assessment of risk of bias
Table 19 provides the risk-of-bias assessment for the new study.
TABLE 19 Furfuryl palmitate-based emollient: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Tripodi
2009207
Low risk Low risk Low risk Intention-to-treat analyses were used (102/117) but it is not
clear from the report why seven participants who violated
the study protocol were not included in this number as the
trial report stated that they should have been
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Benefits
This trial surprisingly reported that the emollient base without furfuryl palmitate showed better efficacy
than the furfuryl palmitate emollient, with 70% (38/54) of the base emollient group compared with 29%
(14/48) of the furfuryl palmitate group having a ≥ 20% reduction in baseline SCORAD scores at the end of
the 2-week study. The investigator- and participant-assessed efficacy results supported this finding, with
the emollient base cream being significantly more effective than the furfuryl palmitate cream.
Harms
No formal data were provided in the trial report about adverse events. The authors report in the discussion
that some of the participants using the furfuryl palmitate emollient cream reported itching and burning
sensations after application. There was no particular difference in the number of withdrawals from the
trial; however, 14 out of 53 of the participants in the furfuryl palmitate group used other topical or
systemic treatments compared with seven out of 56 in the control group.
Overall implications for research and practice
This methodologically robust trial207 based on a formal sample size calculation clearly shows that the
addition of furfuryl palmitate in an emollient base seems to confer a negative effect for eczema. It is a
credit to the trial authors and journal editors for publishing this negative study, which might save money
from being spent on the further pursuit of this treatment.
Pill mask
Studies
No trials involving pill masks for eczema were reported before 2000.
One new trial was reported after 2000.208 This manufacturer-funded, open, three-arm trial by Palombo and
colleagues208 compared a pill mask containing a chitosan-derived anti-inflammatory compound ATOBIOL,
tocotrienols and hyaluronic acid against a lamellar active emulsion containing ATOBIOL or petroleum
ointment only. Thirty-five children applied the study treatments after using bath oils or used petroleum
ointment only, twice a day for the first 8 days. After this treatment period, all participants used
triamcinolone (0.1%) either once a day or twice a week (the abstract and main text do not agree) and the
lamellar gel only. It is not entirely clear from the trial report exactly what the ‘pill mask’ is in this trial,
except that it is a topical method of delivery for medication.
Assessment of risk of bias
Table 20 provides the risk-of-bias assessment for the new study.
Benefits
Erythema and pruritus, scaling and crusting were assessed on a VAS and both of these scores were also
combined to make the ‘clinical score’. The improvement in clinical score after 4 weeks compared with
baseline was reported as 58% in the pill mask group compared with the petroleum ointment, 82% in the
pill mask group compared with the lamellar gel group and 64% in the petroleum group compared with
the lamellar gel group. The erythema and pruritus, scaling and crusting scores were reported in graphs,
but the scores were not compared between groups.
TABLE 20 Pill mask: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Palombo 2004208 Unclear risk Unclear risk High risk
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Harms
No information about adverse events was reported.
Overall implications for research and practice
The lack of methodological and treatment detail, the low number of participants and the unclear analysis
of the results between groups mean that the potential benefits or harms of this topical pill mask cannot be
adequately assessed from this one trial.208
Black seed oil
The seeds of Nigella sativa, a medicinal herb, are used to make an oil that has been used in traditional
medicine practices in parts of Asia and the Middle East. Pharmacological research has found that
components of the oil have antimicrobial and anti-inflammatory properties.
Studies
There were no RCTs for black seed oil topical treatment before 2000.
One new study was reported after 2000.209 This within-person study involving 20 people with eczema was
conducted by Stern and Bayerl209 in Germany. An ointment containing 15% black seed oil was applied on
one arm and the base treatment was applied on the other arm twice a day for 28 days. The application of
the two treatments was randomised to the participants’ left or right side. No other creams or ointments
were allowed on the arms during the study.
Assessment of risk of bias
Table 21 provides the risk-of-bias assessment for the new study.
Benefits
A modified SCORAD score was used to record the overall severity of eczema; there was only a slight
decrease in severity in both treatment groups, with no significant difference between the groups. The
intensity of pruritus was measured on a VAS; there was hardly any change in either group compared with
baseline and no significant difference between the groups at the end of treatment.
Harms
It was reported that there were no adverse events during the trial.
Overall implications for research and practice
It is likely that many of the participants, and possibly the outcome assessors, in this small trial209 will have
known which treatment they were using. Neither the black seed oil treatment nor the base ointment
changed the severity of eczema or pruritus levels. The smell of the black seed oil was reported as
unacceptable. It seems that the addition of black seed oil to topical eczema treatments is not a good
potential candidate for eczema treatment.
TABLE 21 Black seed oil: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Stern 2002209 Unclear risk Unclear risk High risk Black seed oil had a smell that was disliked by
some participants and so it is likely that blinding
was broken at least for some of the participants
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Rosmarinic acid
Rosmarinic acid is a plant-derived compound. Laboratory research has shown rosmarinic acid to have
antiviral, antibacterial, anti-inflammatory and antioxidant properties. It is found in many culinary herbs such
as peppermint and rosemary.
Studies
No trials on rosmarinic acid for eczema were reported before 2000.
One new trial was reported after 2000.210 This study from Korea by Lee and colleagues210 compared a
cream containing rosmarinic acid (0.3%) against the vehicle cream applied twice daily for 8 weeks in
21 participants. It is not clear whether this was a within-person trial or a parallel-group trial as the trial
report describes the area being treated as ‘half an elbow flexure’.
Assessment of risk of bias
Table 22 provides the risk-of-bias assessment for the new study.
Benefits
After treatment for 8 weeks the severity of eczema decreased from a mean SCORAD score of 7.37 to 3.27
in the rosmarinic acid group and from a mean SCORAD score of 6.49 to 5.63 in the placebo group. The
individual symptom scores for erythema, oedema/papulation, oozing/crusting, lichenification and local
pruritus were all reported to have significantly decreased after 8 weeks of treatment compared with
baseline in the rosmarinic acid group. As no between-group comparisons were reported, it is not known
whether rosmarinic acid showed a beneficial effect in comparison to the vehicle cream; however, nearly all
severity and symptom scores for both groups were almost the same at 8 weeks.
Harms
The trial report states that there were no reactions to rosmarinic acid at 4 or 8 weeks and that no adverse
reactions such as erythema, burning and pruritus were observed.
Overall implications for research and practice
The lack of methodological clarity and appropriate analyses of the results in this trial210 mean that the trial
does not provide any evidence of a beneficial effect of rosmarinic acid.
Hippophae rhamnoides
Hippophae rhamnoides (common sea buckthorn) is a flowering plant native to Europe and Asia.
Compounds derived from H. rhamnoides berries have been shown to have many different properties,
including immunomodulatory and antimicrobial.
Studies
One trial involving H. rhamnoides for eczema was reported before 2000.
One new trial was reported after 2000.211 This trial by Thumm and colleagues,211 conducted in Germany,
included 58 Caucasian participants who were randomised to one of three creams for 28 days:
H. rhamnoides (20%), H. rhamnoides (10%) or Miglyol® (CREMER OLEO) (placebo). The vehicle cream
for all three treatments was based on beeswax, glycerine and paraffin.
TABLE 22 Rosmarinic acid: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Lee 2008210 Unclear risk Unclear risk Unclear risk
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Assessment of risk of bias
Table 23 provides the risk-of-bias assessment for the new study.
Benefits
The severity of eczema significantly improved in all three groups, but the degree of improvement appeared
comparable (improvement of 10.98 points for H. rhamnoides (20%), 9.52 points for H. rhamnoides (10%)
and 13.76 points for Miglyol cream), although this was not statistically analysed. These results were closely
mirrored by the quality-of-life scores as well as participant-assessed signs and symptoms of eczema
(redness, itching, dryness and general skin condition).
Harms
No information was given in the trial report about adverse events.
Overall implications for research and practice
This short-term trial211 did not show any significant benefit of adding H. rhamnoides to an emollient base.
Shale oil
Shale oil is produced when oil shale rocks are heated to a high temperature. The oil can undergo further
processing to form sulfonated shale oil, which comes in dark and pale forms. It has been used topically for
other skin diseases such as acne and psoriasis and some studies have shown it to have anti-inflammatory
and antimicrobial properties.
Studies
No RCTs on shale oil for eczema were reported before 2000.
One new trial was reported after 2000.212 This manufacturer-sponsored trial conducted in Germany by
Korting and colleagues212 compared a cream containing sodium bituminosulfonate (4%) (Ichthosin® cream;
Ichthyol-Gesellschaft) (pale sulfonated shale oil) with the vehicle cream in 99 children aged 0–12 years with
mild to moderate eczema. All participants applied the treatments three times a day for 4 weeks and no
concomitant medications were allowed during the trial. Skincare products were allowed on unaffected skin.
Assessment of risk of bias
Table 24 provides the risk-of-bias assessment for the new study.
TABLE 23 Hippophae rhamnoides: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Thumm 2000211 Unclear risk Unclear risk Unclear risk
TABLE 24 Shale oil: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Korting 2010212 Low risk Unclear risk High risk
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Benefits
The severity of eczema was assessed using the authors’ own severity assessment of erythema, crusts,
excoriations, scales, lichenification and itch, and the percentage area affected in each body site, combined
into one score, with a maximum possible score of 45, as for other measures such as EASI or SCORAD.
A statistically significant reduction in severity of 8.9 (SD± 7.4) was found after 4 weeks of using the pale
sulfonated shale oil cream compared with a reduction of 1.3 (SD± 8.3) using the vehicle cream, which was
also present after 1 week. Participant-assessed tolerability also showed a significant difference in favour of
pale sulfonated shale oil, with 73 participants in the pale sulfonated shale oil group compared with
42 participants in the vehicle group rating the treatment as ‘very good’. All individual signs and symptoms
assessed, including itch, were reported as significantly better in the pale sulfonated shale oil group from
2 weeks onwards.
Harms
There were no serious adverse events reported during this trial. The other adverse events reported resulted
in the participants withdrawing from the study: two in the pale sulfonated shale oil group, because of
pruritus, erythema and spreading of eczema, and four in the vehicle group, one because of bacterial
superinfection and three who experienced itch plus worsening/spreading of eczema or erythema.
Overall implications for research and practice
Even though the two treatments were matched for colour, the slight odour of the shale oil cream means
that there is a risk that participants and possibly the investigators who were outcome assessors were
unblinded. Nevertheless, this trial212 demonstrated a reasonable beneficial effect of adding pale sulfonated
shale oil to a topical cream for the treatment of mild to moderate eczema in Caucasian children, with no
evidence of any particular adverse events. It is important that this trial is followed up with further
long-term, large-scale research that incorporates a range of skin tones and pays attention to blinding the
outcome assessors of the objective outcomes by making sure that the cream is not applied close to
an assessment.
Vitreoscilla filiformis
Vitreoscilla filiformis is an aerobic bacterium found in sulfurous thermal springs. Laboratory research has
shown that extracts from V. filiformis have anti-irritant properties.
Studies
No RCTs on V. filiformis for eczema were reported before 2000.
Two new trials were reported after 2000.213,214 These two manufacturer-funded trials by Guéniche and
colleagues213,214 compared a cream with V. filiformis lysate (5%) against vehicle cream. The first trial213
involved 13 participants with mild to moderate eczema, who used the treatments on either side of the
body twice daily for 4 weeks. The second trial214 involved 75 participants (aged 6–70 years) with mild
eczema and a history of atopy.
Assessment of risk of bias
Table 25 provides the risk-of-bias assessment for the new studies.
Benefits
In the first study213 a statistically significant but relatively small difference in the severity of eczema of
around half a point using the EASI score (p= 0.012) and the modified EASI score (p= 0.008), which
included itch scores, was reported after 28 days of treatment.
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In the second, larger, study,214 the V. filiformis lysate cream showed a significant beneficial effect on
eczema severity and pruritus after 30 days. Mean SCORAD scores at the end of treatment were 24.9 in
the placebo group and 15.1 in the V. filiformis group (p= 0.004). Baseline scores were 29 (SD ±9.7) in the
placebo group and 31 (SD ±11.9) in the V. filiformis group. The severity scores were analysed over time
and also gave a significant result in favour of the bacterial lysate cream.
Harms
The first study213 reported the most common adverse event as pricking and burning sensations (at the
same rate for both treatments). The authors suggest that this may have been caused by the composition of
the vehicle cream, which was not designed specifically for eczema. The trial also reported that few
participants reported dryness for both sides of the body.
Although it was reported in the second study214 that adverse events were monitored, no information was
given on whether any occurred or not.
Overall implications for research and practice
These trials213,214 suggest a possible beneficial effect of V. filiformis on eczema severity. It is not clear if
participants were allowed any other eczema treatments during the trials and so we are left guessing
whether the beneficial treatment effect seen is the result of use of the V. filiformis lysate cream or an
increase in the use of standard eczema treatments. Frustratingly, information on adverse event monitoring
is not provided at all for the second, larger, trial, making it impossible to weigh up benefits compared with
any potential harms. With so little practical information in the context of potential use in a clinical setting,
more independent research with a longer treatment period, full information on any adverse events and a
clear report of any concomitant eczema treatments used are needed before the true potential of this
treatment can be assessed.
Miltefosine
Background
Miltefosine is a phospholipid analogue that was originally developed as a chemotherapy treatment. It has also
been found to have antiprotozoal activity and it is effective against both visceral and cutaneous leishmaniasis.
Studies
No RCTs on miltefosine for eczema were reported before 2000.
One new trial was reported after 2000.215 This part industry-sponsored within-person trial by Dolle and
colleagues215 compared a solution containing miltefosine against a hydrocortisone solution for 3 weeks.
The dose for both treatments was gradually increased from two drops per lesion once a day for the first
week to two drops per lesion twice a day for the second and third weeks. Sixteen adults with moderate to
severe eczema according to the criteria of the Hanifin and Rajka8 and having at least two comparable
lesions were recruited.
TABLE 25 Vitreoscilla filiformis: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Guéniche 2006213 Unclear risk Unclear risk Low risk
Guéniche 2008214 Unclear risk Unclear risk Low risk Areas to be treated were predefined; however, it is
not clear whether this differed from one participant
to another or whether the person predefining the
treatment areas was aware of treatment allocation
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Assessment of risk of bias
Table 26 provides the risk-of-bias assessment for the new study.
Benefits
The severity of the eczema lesions treated with hydrocortisone improved slightly more than the severity of
the miltefosine-treated lesions after 3 weeks of treatment. The primary outcome of ‘improvement’ in
eczema severity, defined as a > 1.5-point drop in Three-Item Severity (TIS)63 score, occurred in 10 out of
16 participants for the miltefosine-treated lesion. The results of the primary outcome for hydrocortisone
treatment were reported only in a graphical form, although this appears to show a greater reduction in
severity for the hydrocortisone group. Four weeks after treatment was stopped, the hydrocortisone-treated
lesions increased in severity by a median of 0.5 TIS points to 2 (minimum 1.5, maximum 3), whereas the
miltefosine-treated lesions decreased by a median of 2 TIS points to exactly the same TIS score as
the hydrocortisone-treated lesions.
Harms
There were a relatively high number of local topical adverse events related to the treatments, with
miltefosine treatment producing more of the adverse events (10/16 participants affected) than
hydrocortisone treatment (7/16 participants affected). These adverse events included pruritus, burning,
tingling and dry skin. Dry skin was seen only with miltefosine treatment. There were no withdrawals
because of adverse events and no systemic adverse events.
Overall implications for research and practice
Although the trial authors focused on the deterioration of the hydrocortisone-treated lesions after
treatment was stopped, the rate of deterioration was slow and the lesions only reached the same severity
as those lesions treated with miltefosine. It is interesting that miltefosine seemed to show a perpetuating
beneficial effect on the severity of eczema, although it was slower than the hydrocortisone treatment to
take effect. With the lack of methodological clarity and wide CIs, the evidence for treatment of eczema
with miltefosine is poor. This early trial has not provided a promising signal to justify further trials.
Opiate receptor antagonists
Opiate receptor antagonists have been used mainly as a treatment for alcohol and opioid dependence.
As the opiate receptor antagonist naltrexone can suppress pruritus, it has been examined for its potential
to treat pruritus associated with eczema.
Studies
No RCTs assessing opiate receptor antagonists for eczema were reported before 2000.
One new trial was reported after 2000.216 This multicentre crossover trial by Bigliardi and colleagues216 in
Germany compared naltrexone cream against vehicle cream to be applied for up to 28 days when the
participants were experiencing intense symptoms of itching. Forty-five adults with eczema and experiencing
bouts of itching of > 50mm on a 100-mm VAS were randomised. All participants were allowed to use
topical eczema treatments as rescue medication, except in an itching intensity monitoring period.
Assessment of risk of bias
Table 27 provides the risk-of-bias assessment for the new study.
TABLE 26 Miltefosine: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Dolle 2010215 Unclear risk Unclear risk Unclear risk
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Benefits
A 52.6-mm (26.7%) difference between the decrease in pruritus intensity score for the two treatments in
favour of naltrexone was reported for the 40 out of 45 participants who made up the full analysis set.
This was reported as a statistically significant treatment effect between the treatment groups of p= 0.047.
No confidence limits were given for any of the results in the trial. The results of the per-protocol analysis of
39 participants were similar. This trial did not record the severity of eczema.
Harms
Information on adverse events was not reported.
Overall implications for research and practice
Although a statistically significant effect on pruritus appears to be a positive result, this poorly reported
trial216 does not provide enough data to support the adoption of naltrexone. The severity of the eczema in
the two treatment groups and the amount of topical corticosteroid used is not reported and, although
pruritus levels tend to decrease as the severity of eczema decreases, this trial on its own is not robust
evidence of a beneficial effect of naltrexone. Trials that measure the severity of eczema as well as pruritus
and document any concurrent eczema treatment are needed.
Topical vitamin B12
Studies
No RCTs looking at topical vitamin B12 were reported before 2000.
Two new trials have been reported since 2000.217,218 These two within-person trials,217,218 both industry
funded, compared cyanocobalamin (0.07%) cream with a base cream. In the trial by Stücker and
colleagues,217 48 adults aged 18–70 years applied the treatments twice a day for 8 weeks. In the trial by
Januchowski,218 22 children aged from 6 months to 18 years (no severity inclusion criteria stated) were
randomised to treatment for 4 weeks, but it was not clear how often they were instructed to use
the treatment.
Assessment of risk of bias
Table 28 provides the risk-of-bias assessment for the new studies.
TABLE 27 Opiate receptor antagonist: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Bigliardi 2007216 Unclear risk Unclear risk Unclear risk
TABLE 28 Topical vitamin B12: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Januchowski 2009218 Low risk Low risk Unclear risk
Stücker 2004217 Low risk Unclear risk Unclear risk
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Benefits
The trial by Stücker and colleagues217 found that there was a significant decrease in eczema severity after
8 weeks of topical vitamin B12 treatment compared with the base cream, as measured using a modified
SASSAD score (maximum of 240 points). The mean decrease for topical vitamin B12 was 55.34 (standard
error of the mean 5.74) whereas the mean decrease for the base cream was 28.87 (standard error of the
mean 4.86; p< 0.0002). This significant difference was seen from week 4 onwards. Participant- and
investigator-assessed efficacy both showed a significant difference in favour of topical vitamin B12
treatment after 8 weeks when the responses were grouped as ‘effective’ or ‘non-effective’ (p< 0.005).
The trial by Januchowski218 also reported a significant decrease in eczema severity, measured using
modified SCORAD scores (maximum of 27 points), for topical vitamin B12 cream compared with the base
cream after 4 weeks of treatment. Taking data from a graph, the decrease in total SCORAD scores for
topical B12 treatment after 4 weeks was 4.5 whereas that for the placebo treatment was 1.7 (p= 0.011).
The objective SCORAD score mirrored this result and the subjective SCORAD score also showed a
significant difference, although not as pronounced, by week 4.
Harms
In the trial by Stücker and colleagues,217 33 cutaneous events were reported, which were all mild except
for one, which involved a moderate reaction after applying the placebo cream. Of these cutaneous events,
four cases were considered ‘probably related’ and two cases were ‘possibly related’ to the application of
vitamin B12.
In the trial by Januchowski,218 only one adverse event was reported, which resulted in withdrawal from the
trial. The participant had a reaction to both the active and placebo treatments but the nature of the
reaction was not reported.
Overall implications for research and practice
The two trials217,218 appear to show a significant beneficial effect of topical vitamin B12 cream on the
severity of eczema. The lack of CIs for the results presented in both trials means that there is no way to
judge the statistical robustness of the results. There were a number of adverse events relating to skin
irritation, probably caused by topical vitamin B12. Whether or not to try this topical treatment will probably
remain a decision based on individual circumstance and preference.
WBI-1001
Studies
No RCTs looking at WBI-1001 were reported before 2000.
Two new trials were reported after 2000.219,220 The trial by Bissonnette and colleagues in 2010,219 reported
as a research letter, compared the synthetic compound 2-isopropyl-5-[(E)–2-phenylethenyl] benzene-1,3-diol
(WBI-1001; Welichem Biotech Inc.) at both 0.5% and 1.0% concentrations against vehicle cream. The 37
participants had eczema scores of ≤ 12 on the EASI scale and scored 2 (mild) or 3 (moderate) for IGA; they
were randomised to one of the three treatment groups and applied the treatment twice daily for 4 weeks.
Bissonnette and colleagues220 published a second trial in 2012, again comparing the same topical
treatment WBI-1001 at 0.5% and 1% concentrations with vehicle as the placebo. This was a larger and
slightly longer trial. In total, 148 adults aged 18–65 years with ‘chronic’ eczema for ≥ 6 months, diagnosed
according to the criteria of Hanifin and Rajka,8 a body surface area of 3–20% and an eczema severity of
mild to severe (IGA 2–4) were included.
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Assessment of risk of bias
Table 29 provides the risk-of-bias assessment for the new studies.
Benefits
The earlier trial by Bissonnette and colleagues219 stated that all efficacy analyses were not planned before
database lock and so should be considered post hoc. Change in the severity of eczema from baseline
measured by IGA, SCORAD and EASI showed significant differences in favour of WBI-1001. For the IGA
after 4 weeks’ treatment, the percentage decreases from baseline were 5.6% for placebo, 38.9% for
WBI-1001 0.5% and 45.8% for WBI-1001 1%. Active treatment (WBI-1001 0.5% and 1.0%) was
significantly beneficial compared with placebo (p= 0.003). The severity of eczema measured by EASI and
SCORAD closely mirrored these results. Body surface area also showed almost the same significant
percentage decreases by week 4. Pruritus scores showed the same pattern but no between-group analyses
were reported.
The larger trial by Bissonnette and colleagues in 2012220 reported a significant reduction in pruritus at day
42 from baseline for the WBI-1001 0.5% group (29.8%) and the WBI-1001 1.0% group (66.9%)
compared with placebo (9.5%) (p< 0.001 for both WBI-1001 treatments). There was also a significant
reduction in eczema severity at day 42 from baseline, measured using IGA, for both of the WBI-1001
treatments (0.5% and 1.0%) compared with placebo (WBI-1001 0.5%: –1.3 SD± 0.97, 95% CI –1.2 to
–0.5; WBI-1001 1.0%: –1.8 SD± 1.02, 95% CI –1.6 to –0.9; placebo: –0.5 SD± 0.89, 95% CI was not
reported) (p< 0.001 for both WBI-1001 treatments). Significant reductions in eczema severity as measured
by EASI and SCORAD were also reported for the WBI-1001 creams compared with placebo.
Harms
In the earlier trial by Bissonnette and colleagues219 there were no serious adverse events and no
withdrawals as a result of adverse events. One participant in the WBI-1001 group had a T-wave anomaly,
although it is not reported if this was related to treatment. Two participants in the placebo group and one
in the WBI-1001 group had mild papules and two participants in the placebo group had pruritus.
Two serious adverse events were reported in the trial by Bissonnette and colleagues220 published in 2012:
one case of cellulitis in the WBI-1001 0.5% group and one case of acute cholecystitis in the WBI-1001
1.0% group. Neither of these events was reported as being related to study treatment. Nine participants
stopped treatment because of adverse events. In the placebo group four events were eczema and one was
worsening eczema. Two events, one of eczema and one of contact dermatitis, were reported in the
WBI-1001 0.5% group and two events of contact dermatitis were reported in the WBI-1001 1.0% group.
Overall implications for research and practice
The small Phase 2 trial,219 which did not prespecify the efficacy outcomes reported, offered a hint that it
may be worth carrying out a larger, long-term Phase 3 trial of WBI-1001. The trial was not designed to
determine clinical efficacy and included a small number of participants. The same group conducted a
larger, slightly longer-term trial aimed at assessing the clinical benefits and harms of WBI-1001 and found
TABLE 29 WBI-1001: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Bissonnette 2010219 Unclear risk Unclear risk Unclear risk It is not clear how many participants withdrew
and how many were included in the final analyses
Bissonnette 2012220 Low risk Unclear risk Unclear risk
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clear evidence of benefit compared with placebo for clinician-assessed severity of eczema. The trial did not
use any patient-reported outcome measures such as itching as separate outcomes. Longer trials that
use a pragmatic comparator such as topical corticosteroids or topical immunomodulators and measure
patient-reported outcomes are now needed to be clearer about whether this treatment could be useful in
routine clinical care. Adverse events such as contact dermatitis should also be assessed in more detail.
Carbohydrate-derived fulvic acid
Fulvic acids are formed during organic matter biodegradation. A few studies have investigated the
antifungal and antibacterial properties of fulvic acids, but this has mainly been in laboratory settings.
Studies
No RCTs of carbohydrate-derived fulvic acid treatments for eczema were reported before 2000.
Gandy and colleagues221 compared carbohydrate-derived fulvic acid in an emollient base with the emollient
base only in 36 participants aged > 2 years. The participants applied the emollient twice daily for 4 weeks
on the affected area. All participants were allowed to use Epizone (VanDyk Pharmaceutical Products)
(an emollient buffered with acetic acid) as needed.
Assessment of risk of bias
Table 30 provides the risk-of-bias assessment for the new study.
Benefits
Although the report states that there were statistically significant decreases in the carbohydrate-derived
fulvic acid group for investigator global response to treatment, investigator-assessed severity of disease and
participant-assessed severity of disease, there were also significant decreases in the emollient placebo
group. The trial does not report between-group differences but it seems unlikely from the data that there
were any statistically significant differences between the treatments.
Harms
The only adverse event reported was a short-lived burning sensation after treatment, although the report
does not state which treatment was involved.
Overall implications for research and practice
This short trial without a clear methodology seems to show no additional benefit of adding
carbohydrate-derived fulvic acid to emollient treatment. The trial did not include two participants in
the final analyses as they used concomitant treatments. The extent to which participants and investigators,
both of whom were the outcome assessors, were blinded is not known. Perhaps reassuringly, this trial
adds to evidence that regular emollient use improves the severity of eczema.
TABLE 30 Fulvic acid: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Gandy 2011221 Unclear risk Unclear risk Unclear risk Two participants who completed the trial were
excluded from the analysis for use of concomitant
medication
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Protease inhibitor SRD441
Studies
No RCTs looking at the topical matrix metalloproteinase and aureolysin inhibitor SRD441 for eczema were
reported before 2000.
One new trial was reported after 2000. This industry-funded study by Foelster-Holst and colleagues222
compared SRD441 against vehicle in 93 adults with mild to moderate atopic eczema confirmed by a
dermatologist. The participants used SRD441 cream (1mg/g) or vehicle cream on all affected and
commonly affected areas twice a day for 28 days. The trial was run in 13 centres in Germany, Bulgaria
and Finland.
Assessment of risk of bias
Table 31 provides the risk-of-bias assessment for the new study.
Benefits
There was no significant difference between the treatments for the primary outcome of rate of ‘success’
(defined as an IGA score of 0 or 1) at day 21. There were also no significant differences in any of the
secondary outcomes, which included time to resolution of the primary exacerbation (IGA score of 0 or 1),
IGA score (all visits), participant-assessed total pruritus over the previous 24 hours, number of participants
requiring rescue medication and quality of life measured using the Dermatology Life Quality Index (DLQI).
Harms
In total, 60.0% (n= 27) of the SRD441 group and 70.8% (n= 34) of the vehicle group experienced
adverse events. Of these, 40.0% (n= 18) in the SRD441 group and 58.3% (n= 28) in the vehicle group
were possibly or probably related to study treatment. The adverse events related to treatment were mostly
application site reactions and occurred at roughly equal rates in both groups. Seven participants in the
SRD441 group and 11 participants in the vehicle group withdrew because of adverse events. The main
reason for withdrawal from treatment was application site reactions.
Overall implications for research and practice
This is a clearly reported and methodologically sound trial.222 Both the vehicle control and the study
treatment were poorly tolerated, precipitating a higher than expected withdrawal rate because of adverse
events. Although problems with the vehicle control may have masked any potential beneficial effects
elicited by SRD441, this trial shows no evidence of benefit for SRD441 in the treatment of eczema.
TABLE 31 Protease inhibitor SRD441: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Foelster-Holst 2010222 Low risk Low risk Unclear risk The extent to which any of the stakeholders
were blinded is unclear
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Raffinose
Raffinose is an indigestible oligosaccharide composed of galactose, fructose and glucose that is abundant
in plants, with high concentrations found in legumes and whole grains.
Studies
No RCTs looking at the oligosaccharide raffinose for eczema were reported before 2000.
One new trial was reported after 2000.223 This trial, conducted in France by Misery and colleagues,223
compared a lipiderm cream with raffinose (1%) added (Tefirax®; Laboratoire G-pharm) against the lipiderm
cream alone. Participants were instructed to apply as much as necessary for 3 days and as needed for
persistent symptoms of pruritus. The 11 adults in the trial all had eczema and current pruritus.
Assessment of risk of bias
Table 32 provides the risk-of-bias assessment for the new study.
Benefits
The short trial report223 does not give any detailed data apart from a graph of pruritus intensity on the first
application and a graph of the mean pruritus intensity for all applications of treatment (67 applications
between 11 participants). After treatment, six out of 11 participants reported a benefit from the cream
containing raffinose, four participants reported a benefit from both treatments and one participant
reported no benefit from either treatment. The report states that the study is too small to analyse whether
the treatment showed significant benefit and no between-group analyses were reported. Although the
primary outcome results (intensity of pruritus) were presented, the results of other specified outcomes
were not reported.
Harms
The report states that the cream containing raffinose produced application site burning.
Overall implications for research and practice
It is debatable whether a crossover trial223 of 11 participants, which the trial authors admit was not
appropriately sized to assess the treatment’s potential benefits, just serves to confuse more than aid those
looking for evidence of treatment benefits. If the relative merits or otherwise of topically applied raffinose
are to be considered at all, an appropriately designed trial will need to be conducted.
TABLE 32 Raffinose: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Misery 2005223 Unclear risk Unclear risk Unclear risk
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Atopiclair
Atopiclair is medical device emollient cream containing 2% glycyrrhetinic acid and shea butter as well as
other ingredients in a hydrolipid base.
Studies
There were no trials on Atopiclair reported before 2000.
Five new trials were reported after 2000.199,224–227
Children
One trial conducted in Italy by Patrizi and colleagues226 compared Atopiclair™ (Graceway Pharmaceuticals),
Atopiclair light (oil-in-water formulation containing a lower concentration of key ingredients) and vehicle
for the treatment of childhood eczema. The 60 participants aged 2–17 years with mild to moderate
eczema applied the treatments three times a day for 43 days.
A larger trial by Boguniewicz and colleagues227 also compared Atopiclair against vehicle using the same
treatment regimen (three times a day for 43 days). In this larger trial, 142 children aged from 6 months to
12 years with mild to moderate eczema applied the treatments to affected areas and those areas likely
to be affected during the trial.
A 3-week trial by Miller and colleagues,199 conducted in the USA, compared Atopiclair with EpiCeram™
(Ceragenix Pharmaceuticals) and Aquaphor healing ointment® (Beiersdorf). Thirty-nine children aged
2–17 years with mild to moderate eczema applied the treatments three times a day using the smallest
amount needed.
Adults
Two trials, one with 30 participants224 and one with 218 articipants,225 both with very similar methodologies,
compared Atopiclair against a vehicle cream (placebo) in adults, who were instructed to apply the cream
three times a day. In the small study by Belloni and colleagues,224 participants applied the treatments for
5 weeks. Only those with light/fair skin without a recent suntan and a Rajka and Langeland228 diagnostic
criteria score of 3.0–7.5 were enrolled.
Assessment of risk of bias
Table 33 provides the risk-of-bias assessment for the new studies.
TABLE 33 Atopiclair: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Children
Boguniewicz 2008227 Low risk Unclear risk Unclear risk
Miller 2011199 Unclear risk Unclear risk Low risk
Patrizi 2008226 Low risk Unclear risk Low risk
Adults
Abramovits 2006225 Low risk Unclear risk Unclear risk
Belloni 2005224 Low risk Low risk Low risk Power calculations to determine study
size were not performed
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Benefits
Children
The smaller multicentre trial by Patrizi and colleagues226 showed a significant difference in the primary
outcome of ‘success’ (defined as an IGA score of 0 or 1) after 22 days of treatment. The Atopiclair group
had an 80% (16/20) ‘success’ rate compared with 16.6% (3/20) for the Atopiclair light group and 26.3%
(5/20) for the vehicle group. Atopiclair had significantly more successes than the vehicle treatment
(p< 0.0001) and Atopiclair light (p= 0.001). The change in participant-assessed pruritus from baseline was
significant only for Atopiclair light compared with vehicle (p< 0.05 using Tukey’s test). The data on
pruritus were reported only in a graph, which showed roughly a mean decrease from baseline of 24 points
for Atopiclair compared with 1.5 for Atopiclair light and no discernible decrease or increase in the
vehicle group.
In the trial by Boguniewicz and colleagues,227 for all of the secondary end points, apart from the need for
rescue medication, there was a statistically significant difference between the two treatment groups at all
time points. The mean change in severity of eczema measured using EASI at day 22 was – 5.15 SD± 7.24
in the Atopiclair group and 0.84 SD± 3.52 in the placebo group.
The severity of eczema measured using IGA at day 22 (primary end point) was significantly reduced in the
Atopiclair group compared with the vehicle group (p< 0.001). For the 26 out of 139 participants (18.7%)
in the whole population who needed rescue medication to treat a flare (six participants in the Atopiclair
group and 20 participants in the vehicle group), the mean duration of rescue treatment was 4.17 days
(range 3–8 days) in the Atopiclair group and 5.65 days (range 2–12 days) in the vehicle group.
In the trial by Miller and colleagues199 there was a very clear lack of statistical significance between the
three emollients after 21 days of treatment. The trial measured eczema severity using the IGA, EASI and
participant-assessed global assessment of improvement. Itching also did not show any statistically
significant differences between Atopiclair and EpiCeram or the Aquaphor healing ointment. The trial also
looked at costs and reported that the Aquaphor healing ointment was 47 times more cost-effective than
Atopiclair and EpiCeram. All treatments had a 15–40% ‘success’ rate (0 or 1, clear or almost clear IGA,
≥ 75% improvement in EASI score from baseline) after 21 days of treatment.
Adults
In the trial by Belloni and colleagues,224 the affected area and itch score were improved after 21 days of
Atopiclair treatment compared with baseline values. No between-group comparison was performed.
A much larger, multicentre trial was conducted by Abramovits and colleagues,225 enrolling participants with
mild to moderate eczema on the Rajka and Langeland228 scale and scoring at least 40mm out of 100mm
on a VAS for itch. After 50 days, the end of the trial, there was a significant difference in the level of
itch in a target lesion in favour of Atopiclair. The Atopiclair group reduced by 58mm and the vehicle
group reduced by 20mm on the VAS (p< 0.0001). The percentage body surface area affected improved
significantly more in the Atopiclair group throughout the trial. The severity of eczema measured using the
EASI score (mean± SD) improved significantly using Atopiclair treatment (3.82± 3.44) compared with
the vehicle treatment (0.15± 4.78; p< 0.0001) at day 22. The mean difference was –3.67 (95% CI –4.789
to –2.543; p< 0.0001) at day 22, but this was also significant from day 8 throughout the trial.
Harms
Children
The trial by Patrizi and colleagues226 reported that 10% of the participants in each of the two Atopiclair
treatment groups and 20% of the vehicle group experienced at least one adverse event. One adverse
event in the Atopiclair group was judged to be probably related to treatment and two events in the vehicle
group were judged to be possibly related. Five out of the nine adverse events reported resulted in the
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treatment being stopped. There were no serious adverse events reported for this trial. In the trial by
Boguniewicz and colleagues227 there was an average of 0.83 events per participant in the Atopiclair group
compared with 0.80 events per participant in the vehicle group. Adverse events judged to be probably
related to treatment were reported in 16.6% of the vehicle group compared with 12.5% of the Atopiclair
group. There were no serious adverse events thought to be related to treatment. In the trial by Miller and
colleagues199 no adverse events were observed.
Adults
The trial by Belloni and colleagues224 did not observe any adverse events during the trial. In the trial by
Abramovits and colleagues225 there were 92 adverse events, 66 in the Atopiclair group and 26 in the
vehicle group.
Overall implications for research and practice
Three of the five trials show a significant improvement in IGA for participants treated with Atopiclair
compared with those treated with vehicle, with two also reporting an improvement in EASI score.225–227
No conclusions can be drawn from the trial by Belloni and colleagues224 as no between-treatment
comparison was performed. One trial showed no difference between Atopiclair and two other emollients
for IGA and EASI.199
Overall, there is reasonable evidence of benefit for Atopiclair compared with vehicle. Further trials
comparing Atopiclair against other active treatments are required and these should ideally be independent
from the manufacturers of any interventions involved.
Farnesol and xylitol
Farnesol is an acyclic sesquiterpene alcohol that occurs naturally in plants and is present in many essential
oils, such as citronella and neroli; research has also shown it to have antibacterial properties. Xylitol is a
sugar alcohol, commonly used as a sweetener, which has been found to have antibacterial properties.
Laboratory research has shown that a combination of farnesol and xylitol can inhibit the growth of
some bacteria.
Studies
No RCTs looking at farnesol or xylitol for eczema were reported before 2000.
One new trial was reported after 2000.229 This within-person trial by Katsuyama and colleagues229
compared an oil-in-water 17% moisturiser cream containing 0.02% farnesol and 5% xylitol against the
oil-in-water 17% moisturiser cream only. The treatments were applied for 7 days by 17 participants to
their left and right forearms.
Assessment of risk of bias
Table 34 provides the risk-of-bias assessment for the new study.
TABLE 34 Farnesol and xylitol: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Katsuyama 2005229 Unclear risk Unclear risk Unclear risk
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Benefits
Although this trial was focused on physiological indicators of efficacy and numbers of S. aureus, changes
in dryness, redness, excoriation, scaling and papules were assessed by a dermatologist. The trial reported
no significant differences between the treatments; however, no detailed data were presented in
the report.
Harms
It was reported that no adverse events occurred during the trial.
Overall implications for research and practice
The changes in dermatologist-assessed skin condition were not significantly different between the
two treatments.
Levomenol and heparin
Levomenol (bisabolol) is a monocyclic sesquiterpene alcohol present in many essential oils. It is one of the
primary components of chamomile (Matricaria chamomilla) essential oil. Levomenol can cause contact
dermatitis in some people but laboratory studies have shown it may have anti-inflammatory, anti-irritant
and antimicrobial properties. Heparin is most commonly used as anticoagulant (a blood thinner) to prevent
the formation of blood clots, but has been investigated for its potential to treat many allergic diseases.
It has been suggested that it has a role in defence against invading microbes and other foreign substances.
Studies
No RCTs that assessed a combination of levomenol and heparin for eczema were reported before 2000.
One new trial was reported after 2000. This trial by Arenberger and colleagues, published separately in
both German230 and English,231 compared a cream containing a combination of levomenol and heparin
with a cream containing levomenol alone, a cream containing heparin alone and a cream without any
active ingredient.
Assessment of risk of bias
Table 35 provides the risk-of-bias assessment for the new study.
Benefits
The primary outcome of intensity of itching (on a VAS) was significantly reduced in the combined
levomenol and heparin group compared with the levomenol, heparin and vehicle groups. The most
significant difference (mean± SD) was between the vehicle group and the combined levomenol and
heparin group at week 8 (24.3 mm± 2.1 mm, 95% CI 20.2mm to 28.5mm), although the two separate
levomenol and heparin groups were not compared against vehicle. The severity of eczema measured by
SCORAD mirrored the pruritus results, with the most significant difference (mean± SD) being between the
combined levomenol and heparin group and the vehicle group after 8 weeks of treatment (14.6± 1.3,
95% CI 12.8 to 17.1). The participants were asked to rate the efficacy of the treatment on a 4-point scale
and the combined treatment had the highest percentage of assessments rated as ‘good’ or ‘very good’
(97%). This assessment was not analysed across treatment groups, except in a subgroup of children aged
TABLE 35 Levomenol and heparin: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Arenberger 2010,230 2011231 Unclear risk Unclear risk Unclear risk
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0–12 years, with 100% in the combined group and 42.9% in the vehicle group assessing the treatment as
‘good’ or very good’ (p= 0.002). It is not clear whether this subgroup was prespecified or not from the
trial report.
Harms
One participant in the heparin group reported a transient increase in itching, which the investigators
assessed as most likely being caused by the participant’s eczema. No other adverse events were reported.
Overall implications for research and practice
There is reasonable evidence from this one trial230,231 of benefit from combined heparin and levomenol
treatment compared with vehicle and some evidence that the combination is significantly more effective
than each of the treatments given separately. The subgroup analysis of children aged ≤ 12 years must be
treated with caution as the numbers of participants were low and it is not clear whether this was a post hoc
analysis or not. It may be worth comparing this treatment against a more pragmatic comparator of
‘standard care’ with emollients and topical corticosteroids to obtain a clearer picture of its potential benefit.
Bacterial antigens
Lantigen B (Bruschettini Srl) is a mixture of the lysate of six (inactivated) bacterial strains that commonly
cause respiratory tract infections.
Studies
No RCTs that assessed a topical bacterial antigen suspension for eczema were reported before 2000.
One new trial was reported after 2000.232 This trial by Mora and colleagues232 compared a topical
suspension containing Lantigen B against a placebo solution used twice a day for 3 months on the eczema
lesions, using one drop per year of age. Eighty children aged between 2 and 6 years with external auditory
eczema lesions were randomised.
Assessment of risk of bias
Table 36 provides the risk-of-bias assessment for the new study.
Benefits
The trial report states that the clinical efficacy scores were lower for the antigen suspension than for the
placebo in the second study period, which is possibly referring to the period of 1 year after finishing
treatment, but no values were reported. For the 3-month treatment period, the clinical efficacy score
decreased from 7.1 to 3.4 in the antigen group and from 7.3 to 6.4 in the placebo group; however, the
difference between the groups was not statistically analysed.
Harms
The authors reported that no participants experienced side effects.
Overall implications for research and practice
The trial report232 does not give enough detail about the trial methodology and results to be able to gather
any good evidence of benefits or harms of this topical bacterial antigen treatment.
TABLE 36 Bacterial antigens: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Mora 2004232 Unclear risk Unclear risk Unclear risk
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Chamomile extract
Chamomile contains a number of different chemicals thought to have biological activity, including
bisabolol, which was discussed earlier in this chapter.
Studies
No trials of chamomile extract for eczema were published before 2000.
One new trial involving camomile extract was reported after 2000.233 This within-person trial by
Patzelt-Wenczler and Ponce-Poschl233 randomised 72 participants with eczema whose severity was
described as ‘at least moderate’. Participants applied Kamillosan® cream (Dales Pharmaceuticals Ltd)
(containing 2% ethanolic extract of chamomile flowers), vehicle or hydrocortisone twice daily to a specified
arm. The severity of eczema was recorded as the sum of the pruritus, erythema and desquamation scores.
The IGA scores for each arm separately were also recorded. Five individual signs of oedema, papules/
pustules, lichenification, excoriation and fissures were each assessed on a 4-point scale and combined into
one score. Adverse events were also measured. It is not clear how long the participants used the
interventions for; however, the participants were followed up for 2 weeks from baseline.
Assessment of risk of bias
Table 37 provides the risk-of-bias assessment for the new study.
Benefits
The trial report233 does not compare the interventions against each other for any of the outcomes
measured. The assessment of Kamillosan, hydrocortisone or the vehicle cream, which has emollient
properties in its own right, did not show any big differences in effect apart from hydrocortisone not
performing quite as well as the other two comparators. This is not surprising as the potency of the
hydrocortisone used (0.5%) falls well below the potency required to effectively treat nearly all cases
of eczema.
Harms
The only information given on adverse events in this trial was that three participants in the combined
Kamillosan/placebo group withdrew early because of intolerability.
Overall implications for research and practice
This trial fails to compare the interventions and hence does not provide any evidence regarding the use of
Kamillosan for eczema. A methodologically robust trial of Kamillosan compared with other topical
treatments that pays greater attention to recording adverse events is needed to better inform the many
people with eczema who buy this relatively expensive treatment over the counter and the clinicians who
are asked to give advice on this treatment.
TABLE 37 Camomile extract: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Patzelt-Wenczler 2000233 Unclear risk Unclear risk High risk It is likely that the participants knew which
intervention was which because of the
difference in colour and aroma between
Kamillosan and the placebo or hydrocortisone
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Camellia oil
Camellia (japonica) oil is derived from the seeds of Camellia japonica, a flowering shrub found in parts of
East Asia. It is frequently used in cosmetics, including those designed for use on the skin.
Studies
No trials involving camellia oil were published before 2000.
One new trial involving camellia oil was published after 2000.234 This small crossover study by Hamada and
colleagues234 investigated the use of a spray containing camellia oil against a spray containing purified
water. Forty-two participants with eczema described as ‘less than moderate’ used the spray in addition to
their usual care, as desired, for 2 weeks. After 2 weeks, participants switched to the other spray.
Assessment of risk of bias
Table 38 provides the risk-of-bias assessment for the new study.
Benefits
The camellia oil spray showed significant benefits for itching (p< 0.01) and moisturising (p< 0.01)
compared with the purified water spray. The amount of ointment being used was significantly decreased
when using camellia oil.
Harms
There were no adverse events reported in this trial.234
Overall implications for research and practice
This one small trial234 hints at the potential benefit of this treatment and has not reported any adverse
events. A large trial that addresses the issue of blinding an intervention that has a distinctive aroma is
needed to assess this treatment further.
TABLE 38 Camellia oil: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Hamada 2008234 Unclear risk Unclear risk High risk The trial was reported as double blind; however,
camellia oil is pale yellow and has an aroma and
so it is unlikely that blinding was totally successful
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Cipamfylline cream
Cipamfylline is a theophylline analogue that acts as an inhibitor of phosphodiesterase-4, which is found in
high levels in the leucocytes of people with eczema.
Studies
There were no trials of topical cipamfylline cream reported before 2000.
One new trial of cipamfylline cream has been reported since 2000.124 This trial by Griffiths and
colleagues124 compared cipamfylline cream (1.5mg of cipamfylline per gram of cream) used up to a
maximum of 2 g of cream per day against hydrocortisone 17-butyrate cream (0.1%) or vehicle of
cipamfylline. The 103 adults with eczema according to the Hanifin and Rajka8 criteria, who had stable
symmetrical lesions on the arms, applied up to 2 g of study treatment per day for 14 days.
Assessment of risk of bias
Table 39 provides the risk-of-bias assessment for the new study.
Benefits
For the primary outcome of eczema severity measured using a total severity score, cipamfylline cream was
significantly more effective than vehicle after 14 days (mean difference 1.67, 95% CI 1.06 to 2.28;
p< 0.001) and hydrocortisone 17-butyrate was significantly more effective than cipamfylline cream (mean
difference –2.10, 95% CI –2.93 to –1.27; p< 0.001). For both the investigator- and the participant-assessed
overall response, the cipamfylline cream was significantly more effective than the vehicle and hydrocortisone
17-butyrate cream was significantly more effective than the cipamfylline cream. For participant-assessed
pruritus after 14 days, the cipamfylline cream was significantly more effective than the vehicle and
hydrocortisone 17-butyrate cream was significantly more effective than the cipamfylline cream. The
participants found the hydrocortisone 17-butyrate cream to be significantly more cosmetically acceptable
than the cipamfylline cream and the cipamfylline cream significantly more acceptable than the vehicle. For
those who only needed emollient on treated areas after 14 days of study treatment, there was no significant
difference in the relapse rate after 7 days for cipamfylline cream compared with vehicle. The relapse rate was
significantly lower after hydrocortisone 17-butyrate cream compared with cipamfylline cream (p= 0.022).
Harms
There was no difference in cutaneous adverse events assessed as possibly or probably related to trial
treatment on the treatment sites in either group (p= 0.13 for both treatment comparison groups).
In the cipamfylline/vehicle comparison group, 29 (55.8%) participants reported 63 adverse events in total.
In the hydrocortisone/cipamfylline group, 20 (40.8%) participants reported 41 adverse events in total.
The adverse events were mostly application site reactions, including itching, stinging or burning, and
drug reactions.
Overall implications for research and practice
This trial has clearly placed cipamfylline cream as less effective than hydrocortisone cream but more
effective than vehicle for both participant-assessed and objective outcomes. The methodology of the trial
was fairly clear and robust enough to exclude further testing of topical cipamfylline cream. Topical
cipamfylline may have some limited short-term benefits for those with difficult to manage eczema because
of steroid phobia, steroid resistance or contraindications for steroids, but it should be used with caution as
there are no data on the safety of long-term treatment with this cream.
TABLE 39 Cipamfylline cream: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Griffiths 2002124 Low risk Unclear risk Low risk
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Lipoxin A4
Lipoxin A4 antagonises many cell responses evoked by pathogens and pro-inflammatory mediators,
acting to counter-regulate inflammation. Lipoxin A4 also inhibits the production of leukotriene and
interleukins. Lipoxin A4 stable analogues have been designed to mimic this function; one such drug is
15(R/S)-methyl-lipoxin A4.
Studies
There were no trials of lipoxin A4 reported before 2000.
One new trial conducted in China by Wu and colleagues235 compared 15(R/S)-methyl-lipoxin A4 0.1%
cream against mometasone furoate 0.1% cream and also a placebo of distilled water in 1% dimethyl
sulfoxide mixed with the identical cream base as used for the 15(R/S)-methyl-lipoxin A4. All treatments
were applied to the face twice a day for 10 days using cotton sticks. Sixty participants with infantile acute
or subacute facial eczema were randomised, 20 to each group.
Assessment of risk of bias
Table 40 provides the risk-of-bias assessment for the new study.
Benefits
The efficacy of 15(R/S)-methyl-lipoxin A4 cream was not directly compared with that of mometasone
furoate cream or placebo in the trial report, making it impossible to assess the results of the trial. It was
reported that of the six components of the Severity Scale Score, the 15(R/S)-methyl-lipoxin A4 cream
significantly reduced erythema and pruritus/scratching at day 3, papulation, vesiculation and scaling
at day 5 and lichenification at day 10 compared with baseline. Mometasone furoate cream
significantly reduced erythema, papulation, vesiculation, scaling and pruritus/scratching at day 3.
Placebo significantly reduced scaling at day 5.
Harms
No clinical adverse events were reported and none of the safety tests, including full blood count and
kidney and liver function tests as well as an electrocardiogram, showed any significant differences
compared with baseline for all three treatment groups.
Overall implications for research and practice
There is no attempt to compare the results of one treatment against another in this trial report.
An appropriate analysis of between-group differences is needed before being able to assess this
potential treatment.
TABLE 40 15(R/S)-methyl-lipoxin A4: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Wu 2013235 Low risk Unclear risk Unclear risk Two out of 60 participants were excluded from
the analyses as they used concomitant medication
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N-acetyl-L-hydroxyproline
N-acetyl-L-hydroxyproline has previously been used to treat rheumatoid arthritis and osteoarthritis,
both orally and topically. The effects when used topically for eczema have not been ascertained.
Studies
There were no trials of N-acetyl-L-hydroxyproline reported before 2000.
One new trial of N-acetyl-L-hydroxyproline has been reported since 2000.236 This within-person trial
conducted in Japan randomised 15 adults with slight eczema as assessed by a dermatologist according to
the guidelines of the Japanese Dermatological Association to N-acetyl-L-hydroxyproline 1% cream and the
vehicle cream for 4 weeks, with the treatments being applied twice daily to each forearm.
Assessment of risk of bias
Table 41 provides the risk-of-bias assessment for the new study.
Benefits
The only clinically relevant efficacy outcome assessed was the reduction in pruritus, assessed using a
100-mm VAS; however, the change in pruritus was not compared between the two treatments. The
control treatment resulted in a reduction in pruritus from 27.1 SD± 5.9mm at baseline to 19.6
SD± 6.0mm at 4 weeks whereas the N-acetyl-L-hydroxyproline treatment resulted in a reduction in
pruritus from 27.8 SD± 5.9mm at baseline to 16.4 SD± 5.0mm at week 4. The only scores to be
statistically compared between groups were the pruritus scores at 4 weeks (p= 0.07).
Harms
It was reported that there were no adverse events, defined as no inflammation, no irritation and no allergic
reactions, during the trial.
Overall implications for research and practice
This trial report does not appropriately compare the results of the two treatment groups and so does not
provide any evidence about the comparative effectiveness of this potential treatment.
TABLE 41 N-acetyl-L-hydroxyproline: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Hashizume 2013236 Unclear risk Unclear risk Unclear risk
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Nalmefene hydrochloride monohydrate (SRD174)
Nalmefene hydrochloride monohydrate (SRD174) is a µ-opioid receptor antagonist. It is similar to
naltrexone but has a greater affinity for opioid receptors.
Studies
There were no trials of nalmefene hydrochloride monohydrate (SRD174) reported before 2000.
A new crossover trial compared SRD174 cream against vehicle cream.237 The participants had to have
active and pruritic eczema covering a body surface area of ≤ 20% and at least three episodes of moderate
to severe pruritus defined as ≥ 40 on a 101-point VAS in the 7 days prior to randomisation. The study
treatments were applied when a participant experienced an itch of ≥ 40 on a 101-point VAS during two
treatment periods of 7 days each. The 62 participants randomised had to identify a target area of highest
intensity and treat both the target area and other areas of bothersome itch. Participants could treat more
than one episode of itch in a day provided that the episodes were > 8 hours apart and the total amount of
study drug used in a day was less than one 10-g tube.
Assessment of risk of bias
Table 42 provides the risk-of-bias assessment for the new study.
Benefits
The primary outcome of the sum of pruritus intensity difference between 0 and 4 hours was 210.7
(SD± 20.4) in the SRD174 group and 212 (SD± 20.2) in the vehicle group, a difference of –1.3 (95% CI
–25.9 to 23.3; p= 0.91).
None of the secondary efficacy end points tested (sum of pruritus intensity difference between 0 and
8 hours, pruritus intensity difference at each assessed time point) demonstrated a statistically significant or
clinically important difference between the test product and the vehicle. Change in EASI score during each
time period, IGA during each treatment period, quality of sleep recorded during each treatment period,
pruritus relief, time to achieve > 30%, > 50% and 80% reduction in itch sensation, time to achieve a
reduction in itch sensation to below a VAS score of 40 and use of rescue medication for pruritus were also
not significantly different between the groups.
Harms
There was a higher incidence of adverse events in the SRD174 group than in the vehicle group: 22
(36.7%) participants reported a treatment-emergent adverse event in the SRD174 group and 14 (23.3%)
participants reported a treatment-emergent adverse event in the vehicle group.
Overall implications for research and practice
This trial, although lacking some methodological clarity, does not provide any supportive evidence of a
potential benefit for this treatment for any of the large number of outcomes. The trial authors are also
clear in the report that there is no evidence of benefit for this treatment. It is probably not worth pursuing
this treatment further.
TABLE 42 Nalmefene hydrochloride monohydrate: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Herzog 2011237 Low risk Unclear risk Unclear risk
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Licochalcone A
Studies
There were no trials of licochalcone A reported before 2000.
A new within-person trial by Udompataikul and Srisatwaja238 compared a cream containing licochalcone A
(0.025%) in a ceramide and linoleic acid lipid base (12% omega-6-fatty acids, 0.05% ceramide and 10%
glycerine) for 6 weeks against hydrocortisone 1% lotion for 4 weeks followed by 2 weeks of ‘cream base’,
which was not described further. Thirty children aged 2–15 years with mild to moderate eczema (SCORAD
1–40) that was present in the flexures on both sides of the body applied each treatment to one side of the
body twice daily. Before starting treatment, those taking oral treatments had a washout period of 4 weeks
and those using topical treatments had a washout period of 2 weeks.
Assessment of risk of bias
Table 43 provides the risk-of-bias assessment for the new study.
Benefits
The trial report stated that there were no significant differences between treatments in the proportion of
participants who rated their satisfaction as ‘good’ or ‘excellent’ (licochalcone A cream: 10/26 excellent,
12/26 good, total 84.6%; hydrocortisone/base cream: 12/26 excellent, 10/26 good, total 84.6%). It is clear
that there were some differences if those rating their satisfaction as ‘good’ or ‘excellent’ were assessed
separately. There was no significant difference between groups in the reduction of the severity of eczema,
measured using SCORAD (p= 0.199), although it was unclear which data this statistical comparison
referred to. The last 2 weeks of the trial are described as a follow-up phase to evaluate relapse, but the
participants were still using the active licochalcone A treatment on one side of their body. There was no
significant difference between the treatments in relapse rate in the follow-up period using a Kaplan–Meier
survival analysis (p= 0.240).
Harms
The trial report stated that there were no side effects of either treatment.
Overall implications for research and practice
Although the trial authors appear to suggest that the trial provides evidence that treatment with
licochalcone A cream is beneficial compared with hydrocortisone, there was no evidence of superiority
from this trial.
TABLE 43 Licochalcone A: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Udompataikul 2011238 Unclear risk Low risk Unclear risk
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AR-GG27
Studies
There were no trials of AR-GG27® (Giuliana SpA) reported before 2000.
A new single-centre trial by Patrizi and colleagues239 compared AR-GG27 cream, which contains many
different ingredients, with placebo cream, which contained 10 ingredients that are in the AR-GG27 cream
and citric acid. Sixty children aged from 2 months to 15 years with pityriasis alba on the face and/or limbs
and/or trunk, and eczema diagnosed using the Hanifin and Rajka8 criteria, with xerosis and pruritus
present, were randomised to either AR-GG27 cream or placebo cream applied twice daily about 12 hours
apart on affected and perilesional areas for 30 days. No other topical or systemic treatments were allowed
during the trial, including sun exposure.
Assessment of risk of bias
Table 44 provides the risk-of-bias assessment for the new study.
Benefits
The intensity of itching (mean± SD) in the intention-to-treat population was significantly reduced in the
AR-GG27 group (–2.048mm± 2.330mm) compared with the placebo group (–0.388mm± 2.22mm) after
15 days of treatment (p= 0.011). The significant reduction in itch after 15 days was also reported in the
population of participants who began the trial with itching (AR-GG27 group n= 18, placebo group
n= 11). The severity of eczema (mean± SD) using the IGA was significantly reduced in the AR-GG27
group (–6.30± 3.27) compared with the placebo group (–2.80± 3.19) after 15 days of treatment
(p= 0.0007). This was also significant after 30 days of treatment.
Harms
There were no serious adverse events reported. There were seven adverse events in six participants in the
placebo group, with one case of urticaria and one case of worsening eczema and pityriasis alba. These two
events, which were reported as being possibly correlated with treatment, caused discontinuation. It is not
reported whether these two events occurred in the same participant or not. Five of the events were
not related to study treatment and were mild.
Overall implications for research and practice
This trial provides some evidence of short-term clinical benefit from using AR-GG27 cream compared with
placebo. The trial methodology is unclear and it is not known how this treatment compares with any of
the current standard treatments for eczema. Also, as the participants had both pityriasis alba and eczema,
it is unclear how much beneficial effect would be seen when applied to those with only eczema. If this
treatment is trialled again for eczema, particular attention needs to be paid to the adverse effects of
the treatment.
TABLE 44 AR-GG27: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Patrizi 2012239 Unclear risk Unclear risk Unclear risk 8/60 participants not included in the analysis
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Summary of emollients
Emollients
l Five trials of emollients were reported before 2000, which found no significant difference between
using one emollient and using another, some evidence of benefit for using an emollient in addition to
a topical corticosteroid compared with a topical corticosteroid alone and evidence of benefit for using
an emollient containing urea (10%) compared with the vehicle base, but no evidence of any difference
in beneficial effect for different concentrations of urea.
l There were 12 new trials of emollients reported from 2000 onwards:
¢ Four trials, three large and one small, with an overall unclear risk of bias, did not provide any
evidence of benefit from using one emollient compared with another emollient. Participants were
allowed to use topical corticosteroid treatment as well as the emollients in two of the trials.
¢ Four trials, three small and one medium sized, with a mostly unclear risk of bias, did not provide
evidence of benefit or equivalence for emollient treatment compared with topical
corticosteroid treatment.
¢ One small trial, with a mostly unclear risk of bias, did not provide any evidence of benefit for a
combination of emollient and topical corticosteroid compared with emollient alone.
¢ One medium-sized trial, with a mostly unclear risk of bias, provided evidence of benefit for an
emollient compared with no treatment. All participants were allowed to use topical corticosteroids.
¢ One moderately sized trial, with an overall unclear risk of bias, provided evidence of benefit for an
emollient compared with a cleansing wash.
¢ One small proactive therapy trial, with an overall unclear risk of bias, provided evidence of benefit for
an emollient compared with no emollient after induction of remission with topical corticosteroids.
Bath additives
l One trial of bath additives published before 2000 compared Oilatum® with Oilatum® Plus (Stiefel
Laboratories) (which contained an added antiseptic) and found some evidence of a beneficial effect of
the emollient/antiseptic combination compared with Oilatum alone.
l There were two trials of bath additives reported since 2000:
¢ One trial, with a mostly unclear risk of bias, compared a dilute bleach bath and a once-a-month
mupirocin treatment of the nares against placebo in children with infected eczema and found a
significant beneficial effect for the bleach and mupirocin treatment.
¢ Another trial, with a mostly unclear risk of bias, did not find any significant benefit from using a
bath additive containing a diamide derivative compared with the same bath additive without the
diamide derivative.
l We did not find any trials comparing a bath additive in which there is no antimicrobial component
against no bath additive, nor did we find any trials comparing bath emollients against direct application
of emollients to the skin after bathing.
Summary of other topical treatments
l There were no trials for the other topical treatments summarised in this chapter up to 2000.
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Cipamfylline cream
l One trial, with a mostly low risk of bias, provided evidence of a modest benefit from using cipamfylline
cream compared with vehicle. However, it also provided evidence that hydrocortisone 17-butyrate was
more beneficial than cipamfylline cream.
Camellia oil (Camellia japonica extract)
l One small trial, with a mostly unclear risk of bias, provided evidence of benefit for camellia oil spray for
2 weeks compared with placebo spray.
Furfuryl palmitate (antioxidant)
l One small trial, with an overall low risk of bias, provided evidence of benefit for an emollient when
furfuryl palmitate was removed (vehicle) compared with the emollient when furfuryl palmitate
was added.
Atopiclair
l There were five trials overall, four funded by the makers of Atopiclair, with a mixed risk of bias. Three
of the five trials showed improvements for the Atopiclair group compared with vehicle, one showed no
difference between Atopiclair and other available emollients and one trial failed to compare groups.
SRD441 (protease inhibitor)
l One small industry-funded trial, with a mostly low risk of bias, did not provide evidence of benefit for
the protease inhibitor SRD441 compared with vehicle.
Vitamin B12
l Two small trials, one with a mostly low risk of bias and one with a mostly unclear risk of bias, provided
evidence of benefit for topical vitamin B12 cream compared with vehicle.
WBI-1001 (an inhibitor of T-cell inflammatory cytokine secretion)
l Two small trials, with a mostly unclear risk of bias, provided evidence of benefit for WBI-1001 (0.5%)
and (1.0%) compared with vehicle, although the smaller trial did not prespecify outcomes before
data lock.
Other topical treatments [Hippophae rhamnoides, black seed oil, pill mask,
rosmarinic acid, Vitreoscilla filiformis, shale oil, miltefosine, opiate receptor
antagonist, carbohydrate-derived fulvic acid, raffinose, farnesol and
xylitol, bacterial antigens, chamomile extract, heparin and levomenol,
15(R/S)-methyl-lipoxin A4, N-acetyl-L-hydroxyproline, nalmefene
hydrochloride monohydrate (SRD174)]
l Each of these treatments were tested in one trial reported from 2000 onwards. None of the trials
found any evidence of benefit for the treatment tested compared with placebo or, in the case of
licochalcone A, compared with hydrocortisone.
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Chapter 6 Antimicrobials including antibiotics,
antiseptics and antifungal agents
Background
Antimicrobials refer to a group of agents that share the common aim of reducing the possibility of
infection and sepsis. Antibiotics are often derived from moulds or are made synthetically and are absorbed
into the body with the aim of killing bacteria (bactericidal) or preventing their multiplication (bacteriostatic).
Antibiotics can be given parenterally (intramuscularly, intravenously), orally, or applied topically to the skin
in the form of a cream or ointment. Antiseptics on the other hand are substances that are applied to the
skin but not absorbed significantly and which are able to reduce the possibility of infection. Disinfectants
can destroy micro-organisms including bacteria on non-living objects such as toilets. Antifungal agents are
drugs that share the common property of killing or inhibiting the growth of fungi, including yeasts.
Antifungals can be given intravenously, orally or topically.
Rationale
The relationship between secondary infection or skin colonisation with the bacterium S. aureus and atopic
eczema disease activity has been debated for many years. People with atopic eczema carry S. aureus in
about 90% of clinically involved areas and about 75% of clinically uninvolved areas. S. aureus represents
about 90% of the total aerobic bacterial flora of such individuals compared with 30% in normal skin.
The density of S. aureus tends to increase with the clinical severity of the atopic eczema lesions. It has
been suggested that the dry skin of atopic eczema is deficient in certain inhibitory fatty acids, which may
encourage growth of the organism. S. aureus may also show enhanced adherence properties to skin cells,
which has been shown when comparing atopic eczema sufferers with normal control subjects.240,241 Other
studies reviewed elsewhere242,243 have suggested that the balance of pathogenic and synbiotic bacterial
species on the skin is altered in atopic eczema, resulting in an agitated skin microbiome.
Few clinicians would dispute that grossly infected atopic eczema with oozing and sore pus spots requires
treatment with some form of antibiotic or antiseptic, and that the bacteria are contributing at least in part
to that particular flare-up. However, the role of S. aureus in non-clinically infected atopic eczema skin or
for borderline infection (e.g. with just redness and oozing) is far from clear and the definition of what
constitutes ‘clinically infected atopic eczema’ among physicians is also not clear. Skin swabs taken for
bacteriological culture are of little use because of the almost universal colonisation of atopic eczema skin
with S. aureus, although such swabs may reveal additional bacteria such as streptococci species.
If S. aureus does play a pathogenic role in atopic eczema, then this could be mediated in a number of
ways including direct chemical irritation, a non-specific reaction of the protein A component of the
bacterium to immune cells and by the production of specific exotoxins called superantigens. Superantigens
are capable of activating large populations of T lymphocytes distant from the site of colonisation, giving
rise to widespread eczematous inflammation.
Although in many cases of non-clinically infected atopic eczema, the presence of S. aureus could be
considered as an ‘innocent bystander’, which has simply colonised a dry and broken skin surface, there is
at least some rationale for considering the role of S. aureus in more acute forms of atopic eczema. This has
led to the use of many antimicrobial compounds, such as oral antibiotics that are active against S. aureus
given in short or prolonged courses, topically applied antibiotics and antiseptic agents applied directly or by
mixing with emollients applied directly to the skin or within bath additives.
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Existing systematic reviews
The efficacy of antimicrobials and antiseptics for eczema has been reviewed in a Cochrane review that was
published in 2008 by Birnie and colleagues.244 This has since been updated in 2010, although not as a
Cochrane review, with a new search ending in March 2009.245 A systematic review in 2007, with a search
end date in September 2005, assessed the safety of topical therapies for atopic dermatitis and this
included topical antibiotics and antiseptic treatments.80 All three of the current eczema guidelines from the
AAD,94 SIGN42 and NICE41 cover antimicrobials and antiseptics.
Scope of this chapter
This chapter is divided into different sections describing the antibiotic, antiseptic and antifungal treatments
for which RCTs have been published:
l antibacterials:
¢ topical: fusidic acid, mupirocin, tetracycline
¢ oral: clarithromycin, tetracycline
l antiseptics: triclosan, bleach
l antifungals:
¢ oral: itraconazole, ketoconazole
¢ topical: ciclopirox olamine, ketoconazole shampoo, miconazole.
Antibacterials (topical)
Fusidic acid
Fusidic acid (Fucidin®; Leo Laboratories Ltd) is a bacteriostatic agent that inhibits bacterial protein synthesis.
Its biological action is attributed to its effect on Gram-positive bacteria such as staphylococcus and
streptococcus species.
Studies
There were no studies looking at fusidic acid for eczema before the year 2000.
Three new studies have emerged since 2000.102,150,246 One of the trials, by Ravenscroft and colleagues,246
is discussed in more detail later in this chapter (see Mupirocin).
A four-arm, open-label, parallel-group trial conducted in a single centre in Taiwan by Hung and
colleagues150 compared four treatments or treatment combinations: 0.05% fluticasone propionate with
2% fusidic acid cream; 0.05% fluticasone propionate; 0.03% tacrolimus ointment with 2% fusidic acid;
and 0.03% tacrolimus ointment. All 60 participants had eczema diagnosed according to the Hanifin
and Rajka8 criteria, without overt infection.
Larsen and colleagues102 conducted a European parallel-group multicentre trial consisting of three arms.
The trial had industry sponsorship. The three arms consisted of Fucicort® Lipid cream (20mg/g fusidic acid plus
1mg/g betamethasone 17-valerate) (LEO Pharma), Fucicort® in a new lipid cream formulation and the lipid
cream vehicle alone. The constituents of the new lipid cream were not reported. The 629 participants with a
clinical diagnosis of infected eczema aged ≥ 6 years applied the treatments to all areas of eczema apart from
the face, twice a day for 2 weeks. If required, participants could use hydrocortisone in a lipocream (Mildison®;
Yamanouchi Pharmaceutical Co.) for facial lesions. The participants were also allowed to use an emollient
cream (Locobase®; Yamanouchi Pharmaceutical Co.) on the areas not being treated with the trial medication.
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Assessment of risk of bias
Table 45 provides the risk-of-bias assessment for the new studies.
Benefits
As reported later in the section on mupirocin, the trial by Ravenscroft and colleagues246 showed a
difference in reduction in eczema severity as assessed by the participant-assessed global severity score
between those treated with mupirocin and betamethasone and those treated with fusidic acid
and betamethasone.
The trial by Hung and colleagues150 found no statistically significant differences in severity (p= 0.81) after
2 weeks of treatment between the group using tacrolimus only and the group using tacrolimus and fusidic
acid. There was also no statistically significant difference in severity after 2 weeks between the group
treated with fluticasone propionate only and the group using fluticasone propionate and fusidic acid
(p= 0.82). There was also no significant difference between these groups after 8 weeks.
The non-inferiority trial by Larsen and colleagues102 reported that the lipid formation of Fucicort was not
inferior to the Fucicort cream after 2 weeks of treatment. The difference in the total severity score between
the treatments was 0.23% (95% CI –3.83% to 4.30%). However, the Fucicort lipid preparation was
superior to the vehicle preparation alone, with an estimated treatment difference for the total severity
score of 48.3% (95% CI 41.0% to 55.7%; p< 0.001).
Harms
The only adverse events reported in the trial by Ravenscroft and colleagues246 were minor skin irritation in
two participants treated with mupirocin and one participant treated with fusidic acid.
In the trial by Hung and colleagues150 information about adverse events was not reported. Two participants
who used a treatment with fusidic acid added were found to have fusidic acid-resistant strains of S. aureus
on their skin at the end of the study period.
In the trial by Larsen and colleagues102 the proportion of adverse events in each group was similar; however,
only the nature and distribution of the adverse events relating to the skin reactions were reported.
Overall implications for research and practice
The largest trial on fusidic acid serves only to deliver a different vehicle preparation of a topical
corticosteroid and fusidic acid preparation to market and is not clinically relevant as there is no comparison
with another active treatment.102 The two remaining trials,150,246 which compare different active treatment
regimens, were not designed with a primary research question to investigate the effect of fusidic acid on
the severity of eczema and so may not be appropriately powered to answer this question. These trials
also have a high risk of bias because of inadequate blinding. For clinically infected eczema there is
currently no evidence of additional benefit from adding fusidic acid to other topical treatments over adding
TABLE 45 Fusidic acid: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Hung 2007150 Unclear risk Unclear risk High risk Design and power calculation of trial not reported
but non-inferiority is claimed
Larsen 2007102 Low risk Unclear risk Unclear risk Non-inferiority trial but used to claim superiority
over vehicle as well
Ravenscroft 2003246 Low risk High risk Low risk Powered to evaluate the change in carriage rates of
fusidic acid resistant S. aureus
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mupirocin.246 For non-infected eczema, there is no evidence of benefit from adding fusidic acid to short-
term topical corticosteroid treatment. Trials that seek to pragmatically answer the question, ‘Which is the
most effective treatment regimen for reducing severity and clearing infection in infected eczema?’, are
needed to give clinicians the most relevant information for clinical practice. The ChildRen with Eczema,
Antibiotic Management (CREAM) trial (HTA 09/118/03) is currently addressing this question [see www.
nets.nihr.ac.uk/projects/hta/0911803 (accessed 14 January 2016)].
Mupirocin
Mupirocin (Bactroban®; GlaxoSmithKline) is an antibiotic that is bacteriostatic at low concentrations
and bactericidal at high concentrations. It is effective against Gram-positive bacteria, including
methicillin-resistant Staphylococcus aureus (MRSA).
Studies
One trial was reported before 200055 (see Appendix 3).
Four new studies have emerged since the 2000 HTA report.55 One of the trials, by Huang and colleagues,205
which used topical mupirocin applied to nasal carriage sites as part of an anti-infective intervention that
included bleach baths, is discussed in more detail in the antiseptics section of this chapter.
A trial by Gong and colleagues247 conducted in China compared a dual treatment regimen of the topical
corticosteroid hydrocortisone butyrate (Pandel®; Tianjing Yaoye Ji-tuan Co., Ltd) followed by topical mupirocin
1–2 hours later against the dual treatment regimen of the topical corticosteroid hydrocortisone butyrate and
the base ointment only 1–2 hours later. The treatments were applied every morning for 28 days. The 119
participants were aged between 2 and 65 years and had eczema as defined by the Hanifin and Rajka8 criteria.
A UK trial by Ravenscroft and colleagues246 compared 2% fusidic acid plus 0.1% betamethasone cream
with mupirocin ointment plus 0.1% betamethasone cream. The treatments were applied to all affected
areas twice daily for 2 weeks. The trial included 46 participants from the community who had eczema that
warranted the use of potent topical corticosteroids for 2 weeks according to an assessing clinician.
A three-arm trial by Canpolat and colleagues248 compared hydrocortisone used concurrently with
mupirocin or hydrocortisone with emollient only as a control. All treatments were applied twice daily to
affected areas for up to 7 days. The potency of the hydrocortisone and the mupirocin ointment were not
reported. Eighty-three infants aged from 6 months to 2 years with mild to moderate eczema based on the
Hanifin and Rajka8 criteria and with 2–30% body surface area involvement were randomised.
Assessment of risk of bias
Table 46 provides the risk-of-bias assessment for the new studies.
TABLE 46 Mupirocin: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Canpolat 2012248 Unclear risk Unclear risk Low risk Although the term ‘randomised’ is used, the method
of randomisation is not reported and it is stated that
those in the control group were infants whose
parents did not want to use pharmacological
treatments on their child
Gong 2006247 Unclear risk Unclear risk Low risk Although the trial report states that an
intention-to-treat population was analysed, it is
unclear which analyses this was used for
Ravenscroft 2003246 Low risk High risk Low risk Powered to evaluate the change in carriage rates of
fusidic acid-resistant S. aureus
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Benefits
The trial by Gong and colleagues247 did not find any difference in eczema severity, measured using the
EASI scoring system, between treatment with mupirocin plus hydrocortisone butyrate and treatment with
hydrocortisone butyrate alone in the whole trial population. The mupirocin group decreased from a score
of 13.9 (SD 8.4) to 1.4 (SD 2.3) and the control group decreased from 13.6 (SD 8.5) to 2.5 (SD 5.2). In
what appears to be a post hoc subgroup analysis, a significant beneficial effect was reported from the
addition of mupirocin when the EASI severity score was ≥ 7 on the seventh day of treatment; however,
this effect was not apparent during the rest of the treatment period. The rates of colonisation by S. aureus
showed no significant difference and were reported as matching the improvements in eczema severity.
In the trial by Ravenscroft and colleagues246 the primary objective was not to investigate clinical
improvements in eczema; however, the severity of eczema was assessed using both objective and
subjective outcomes. A modification of Costa and colleagues’ simple scoring system,249 with a maximum
score of 98, showed no significant difference in the change in severity between the two combinations of
treatment after 2 weeks. Participant-assessed global severity also showed no significant difference in the
change in severity after 2 weeks. Both treatments showed clinically relevant reductions in severity, from
23 to 6 for the fusidic acid group and from 28.5 to 8 for the mupirocin group for the objective severity
measure. There was a strong correlation between improvement in eczema severity and reduction in
carriage of S. aureus (p= 0.866) analysed over three time points for the entire trial population, but this
was not significant when assessed for each individual participant.
The trial by Canpolat and colleagues248 did not include any patient-reported outcomes. There was a
significant difference in eczema severity, measured by the EASI scoring system, for the mupirocin and
hydrocortisone group compared with the hydrocortisone-only group at the end of treatment (day 8)
[4.2 (range 2–6) vs. 5.1 (range 2–7)]. The emollient-only group had an EASI score of 5.5 (range 2–8) at
the end of treatment. For eczema measured by the SCORAD system, at day 8 the difference between the
emollient-only group [30 (range 23–34)] and the hydrocortisone-only group [27 (range 20–33); p= 0.014]
and between the hydrocortisone-only group [range 27 (20–33)] and the hydrocortisone and mupirocin
group [26 (range 21–32); p= 0.006], was significant. There was a significant difference in treatment
success, defined as a ≥ 50% reduction in lesion severity scores (measured using EASI/SCORAD), between
the emollient-only group (36%) and the hydrocortisone-only group (65%) and the hydrocortisone and
mupirocin group (74%) (p= 0.014 and p= 0.006, respectively) after 60 days.
Harms
No information about adverse events was reported for the trial by Gong and colleagues.247 In the trial by
Ravenscroft and colleagues246 minor skin irritation was reported for 1 out of 28 participants treated with
fusidic acid and 2 out of 18 participants treated with mupirocin. No participants stopped study treatment
early. The trial by Canpolat and colleagues248 did not report any information about adverse events, despite
stating that they would record these in the trial.
Overall implications for research and practice
In the trial by Gong and colleagues247 many methodological aspects are unclear, such as prespecified
outcomes and the amount of study treatments and co-treatments applied. The trial does show a beneficial
effect from adding mupirocin, but this must be treated with caution as so little methodological information
is reported. The trial by Ravenscroft and colleagues246 provided no evidence of benefit for the addition of
antibiotics to steroid treatment for non-infected eczema over a 2-week period. It is important to remember
that this trial was powered to answer the question, ‘Does treatment with a topical corticosteroid/fusidic
acid combination lead to an increased rate of carriage of fusidic acid-resistant S. aureus’, and may not be
as appropriate for assessing any potential clinical benefit. The trial by Canpolat and colleagues248 also
provides some evidence of benefit by statistical comparison, but the magnitude of effect appears quite
small for the treatment period and it is possible that some participants may have been added to the
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control group because of their preference for not using pharmacological treatment. The long-term follow-
up results seem to provide more clinically relevant reductions for steroid or combined treatment than for
emollient, but the hydrocortisone-only and hydrocortisone and mupirocin groups are not compared and
participants could use other eczema treatments, the levels of use of which are not reported.
The current trials do not provide any convincing evidence of benefit for the addition of mupirocin to
topical corticosteroid treatment compared with topical corticosteroid treatment only for non-infected
eczema. Indeed, one trial highlights that it is important to carefully consider the use of antimicrobial
treatment as it carries risks associated with antimicrobial resistance. Researching antimicrobials for clinically
non-infected eczema is unlikely to be taken forward given the lack of beneficial signals to date and
concerns about promoting antimicrobial resistance, and research on antimicrobial therapy should
concentrate on clinically overt, secondarily infected eczema.
Tetracycline
Tetracycline is a broad-spectrum antibiotic produced by Streptomyces species of Actinobacteria.
Studies
No trials investigating tetracycline for eczema were found before 2000.
One new trial has been reported since 2000.250 This trial, conducted in the Netherlands by Schuttelaar and
Coenraads,250 compared a combination of the moderate-potency topical corticosteroid triamcinolone
acetonide (0.1%) plus topical tetracycline (3%) against triamcinolone acetonide alone. The 44 participants
with moderate to severe clinically non-infected eczema (SCORAD score of ≥ 25) diagnosed according to
the Hanifin and Rajka8 criteria applied the treatment twice daily all over the body for 2 weeks. After the
2 weeks of randomised treatment, all participants were then treated with 0.1% triamcinolone acetonide
for a further 6 weeks and followed up to assess maintenance treatment.
Assessment of risk of bias
Table 47 provides the risk-of-bias assessment for the new study.
Benefits
The trial reported that there were no significant differences in the severity of eczema measured by both
objective SCORAD and SASSAD scores after 2 weeks, although the differences in the scores were not
reported. No significant differences in severity between the two treatment groups were found in the
6-week maintenance period. No participant-assessed outcomes were recorded for this trial. The tetracycline
and triamcinolone acetonide combination was reported as having a significantly better rate of antibacterial
efficacy, with 14 out of 22 participants having their colonisation with S. aureus eradicated, compared with
5 out of 22 participants in the placebo group.
Harms
The authors reported a low to moderate level of folliculitis in both groups but there is no information
whether this occurred in the RCT phase, the maintenance phase of therapy or the maintenance
open-label period.
TABLE 47 Tetracycline: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Schuttelaar 2008250 Low risk Low risk Low risk
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Overall implications for research and practice
This fairly well-reported trial did not find any benefit of adding tetracycline to topical corticosteroid
treatment in people with eczema without overt signs of clinical infection. Although bacterial counts were
reduced in the intervention group, these were not matched by clinical benefit, raising doubts about
whether the bacteria (S. aureus) are playing a pathogenic role. Additional research evidence on combining
tetracycline with topical corticosteroids in uninfected eczema is probably not needed.
Antibacterial (oral)
Clarithromycin
One trial by Capella and colleagues251 compared oral montelukast against a ‘standard’ treatment
combination of clarithromycin, cetirizine and mometasone furoate. No data were presented for
clarithromycin treatment alone and so it is impossible to draw any conclusions about the use of
clarithromycin for eczema on its own from this one trial.
Antiseptics
Triclosan
This antiseptic and disinfectant is widely used in everyday items such as toothpaste, chopping boards and
rubbish bags.
Studies
Two trials were reported that tested triclosan before 200055 (see Appendix 3).
Two new trials have been reported since 2000. A small manufacturer-sponsored trial by Tan and
colleagues252 of a 1% triclosan-containing emollient compared with vehicle emollient was conducted in
60 participants aged between 12 and 40 years. All participants were required to use 0.025% betamethasone
valerate cream once a day for 27 days as well as the study treatment; after this, participants could choose
to discontinue betamethasone valerate use. It was reported that most participants did use the topical
corticosteroid during the trial period.
A small manufacturer-sponsored trial by Breneman and colleagues253 compared a soap bar containing
triclosan (1.5%) against a ‘placebo’ soap bar that did not contain any antibacterials. Fifty participants
(age not reported) with moderate eczema defined using the Hanifin and Rajka8 criteria were randomised
to wash their whole body at least once a day for 63 days using the treatment. The participants had their
other eczema treatments standardised so that all participants used a non-medicated cleansing bar,
non-medicated moisturising cream and only 0.025% triamcinolone acetonide as the topical corticosteroid
treatment. For the last 21 days of treatment, no topical corticosteroid was allowed.
Assessment of risk of bias
Table 48 provides the risk-of-bias assessment for the new studies.
TABLE 48 Triclosan: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Breneman 2000253 Unclear risk Unclear risk Unclear risk
Tan 2010252 Low risk Unclear risk Unclear risk
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Benefits
The trial by Tan and colleagues252 measured the use of topical corticosteroids and noted that the triclosan
group used significantly less than the vehicle group. However, no data were reported to support this
statement. The primary outcome, which was the number of participants achieving a ≥ 20-point
improvement on the SCORAD index from baseline, was statistically significantly different between the
groups (triclosan group, n= 9; vehicle group, n= 4; p< 0.05). The secondary outcome, change in eczema
severity from baseline using the SCORAD score, was significantly different only at day 14 (triclosan group
–8.86, vehicle group –4.75, 95% CI –8.58 to 0.32; p> 0.05).
The trial report by Breneman and colleagues253 contained mostly summary results with no additional data,
including no baseline data. The trial report states that, for itching, the participants using the soap bar
containing triclosan experienced less itching than those using the placebo soap bar and that this effect was
carried through the final 21 days of treatment without use of topical corticosteroids. For the dermatologist
global assessment, no baseline scores are provided on the graph and the scores do not appear to differ
between the groups, but no statistical analysis between groups is provided. The report states that there
was a significant difference in favour of the triclosan-containing soap bar for disease extent and severity
components of SASSAD but the total SASSAD scores are not reported.
Harms
A quarter of the study population in the trial by Tan and colleagues252 reported adverse events, but only
four adverse events were considered to be related to treatment. Three participants in the triclosan group
experienced application site stinging and one participant in the vehicle group experienced application
site pruritus.
In the trial by Breneman and colleagues253 it was reported that there was only one study-related event.
One participant withdrew because of worsening of eczema but it was not stated which treatment group
they were in. No other information about adverse events was reported.
Overall implications for research and practice
Although the sample size in the trial by Tan and colleagues252 was powered as per an appropriate
calculation, it is not clear what previous work the assumption of a SCORAD response rate of 90% for the
triclosan group and 50% for the vehicle group was based on and this perhaps seems overly optimistic.
Also, the amount of the study emollient used in each group, an essential factor in assessing the
comparative effectiveness of these two active treatments, was not recorded. The trial report by Breneman
and colleagues253 provides so few data that it is impossible to interpret the slight beneficial effect reported
for the triclosan soap bar. The two pre-2000 previous trials added triclosan and benzalkonium chloride
together, making it impossible to assess the impact of triclosan alone, and these trials were also difficult to
interpret. Until trials that assess triclosan with clear, appropriate methodology are published it is impossible
to assess the potential benefits and harms of this antimicrobial agent.
Bleach baths
Common household bleach should not be applied to the skin as it can cause burns on contact and is toxic
if ingested. However, research has investigated the use of extremely small amounts of a certain form of
bleach. The amount of bleach added to the bath makes the concentration very dilute.
Studies
There were no studies looking at bleach baths for eczema before 2000.
One new trial was reported after 2000.205 This trial, by Huang and colleagues,205 compared a regimen of
half a cup of bleach in a bath (0.005%) twice weekly for 5–10 minutes and topical mupirocin applied to
the nares of the nose for 5 consecutive days per month with a regimen of half a cup of water in the bath
twice weekly for 5–10 minutes and petroleum ointment applied to the nares of the nose for 5 consecutive
days per month. The treatment regimen was followed for 3 months and 31 children aged from 6 months
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to 17 years with moderate to severe infected eczema were randomised. Children who were currently or
recurrently using topical antimicrobials were excluded from the trial. In addition to the participants, all
other members in each participant’s household had to apply mupirocin (treatment arm) or petroleum
(placebo arm) intranasally twice a day for 5 consecutive days of the month.
The participants could bathe without the treatment as often as they wished. All of the participants had to
use a stable treatment regimen of emollients and topical corticosteroids throughout the trial. Additionally,
patients received Cefalexin (Keflex®; Flynn Pharma) at 50mg/kg per day (maximum daily dose 2 g) divided
into three daily doses for 2 weeks.
Assessment of risk of bias
Table 49 provides the risk-of-bias assessment for the new study.
Benefits
This trial by Huang and colleagues205 reported a statistically significant difference in the change in severity
compared with baseline between the treatments, as assessed using the EASI score, favouring the bleach
bath and mupirocin for the area of the body in contact with the bath water. This was based on a post hoc
subgroup analysis at 1 month and 3 months [bleach bath and mupirocin group (mean± standard error)
–15.3± 3.8, placebo group (mean± standard error) –3.2± 1.6; p= 0.004]. The baseline EASI scores were
quite different between the groups [bleach bath and mupirocin group (mean± SD) 22.1± 13.3, placebo
group (mean± SD) 16.6± 9.8] as was the body surface area affected [bleach bath and mupirocin group
(mean± SD) 37.8± 21.6, placebo group (mean± SD) 28.1± 18.2] and it was unclear if these baseline
imbalances were adjusted for in the final analyses. For the IGA, the treatment groups were significantly
different at month 1 (p= 0.024) but not at month 3. There was a decrease of 67% in eczema severity
score measured using the IGA in the bleach bath and mupirocin group and a 15% decrease in the placebo
group at month 3.
Harms
One participant in the treatment group developed irritation and itching; he then failed to comply with the
treatment regimen and subsequently developed a community-acquired MRSA infection, was hospitalised
and received intravenous antibiotics; he resumed the study once he had recovered.
Overall implications for research and practice
The use of dilute bleach baths and 5 out of 28 days of intranasal mupirocin application (by participants and
members of their household) resulted in a significant improvement in eczema severity over 3 months.
Because of this, the low cost of treatment and ease of administration this intervention shows promise.
The evidence from this trial should be treated with caution, however, as baseline severity and body surface
area were very different at baseline, being higher in the treatment group. The analysis of the area of the
body submerged in the bath against the head and neck was a post hoc analysis and was unlikely to have
been powered correctly. It is interesting that the IGA does not show the same significant difference between
groups. As the mupirocin and bleach baths were trialled only as a combined treatment, it is impossible to
know how effective each treatment would be on its own. It is disappointing that no participant-assessed
outcomes were reported. Only one adverse event was reported; a patient who failed to follow the treatment
TABLE 49 Bleach bath: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Huang 2009205 Unclear risk Unclear risk Low risk Severity and percentage body surface area affected
were higher in the treatment group at baseline
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regime after developing skin irritation and pruritus subsequently developed an MRSA infection for which
hospitalisation and intravenous antibiotics were needed. Although this could easily be just ‘bad luck’, the
potential side effects of this intervention need greater scrutiny. Although there is not enough strong
evidence from one trial, this intervention is worth pursuing in larger, long-term treatment trials.
Antifungal agents
Rationale for antifungal agents
The role of fungi and yeasts in eczema is not clear. Although fungal infections such as athlete’s foot (tinea
pedis) can result in secondary eczematisation, secondary fungal infection co-existing or superimposed on
atopic eczema lesions is apparently uncommon. However, it has been suggested that allergic sensitisation
to Malassezia yeast species, which is common on the scalp and head, may contribute to some patterns of
atopic eczema affecting the head and neck in adults. Although the role of fungi and yeasts in atopic
eczema is tenuous, some have used antifungal agents combined with topical corticosteroids and some
have used antifungals in shampoo or tablet form in an attempt to improve atopic eczema, and these will
be discussed at the end of this chapter.
Ketoconazole (oral and topical)
Ketoconazole is an antifungal agent available in oral and topical forms. The topical form (Nizoral®
shampoo; Janssen-Cilag) is used in shampoos for dandruff and scalp psoriasis but is not currently licensed
for the treatment of eczema.
In July 2013, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a
statement that oral medicines containing ketoconazole should no longer be used for the treatment of
fungal infections because of safety concerns regarding the risk of developing hepatotoxicity and adrenal
insufficiency, and the potential for fatal drug interactions.254 As such, the use of ketoconazole in developed
countries has been largely superseded by newer azoles, such as itraconazole (Sporanox®; Janssen-Cilag),
because of a lower risk of liver toxicity and drug interactions.
Studies
One trial involving ketoconazole shampoo was reported before 200055 (see Appendix 3).
Two trials of oral ketoconazole were reported after 2000. A trial in Finland by Lintu and colleagues255
compared 200mg of oral ketoconazole per day with placebo in 80 adults with eczema who were also
shown to be sensitive to the fungi Pityrosporum orbiculare, Candida albicans or Saccharomyces cerevisiae.
The treatment was given for 30 days and the participants were followed up 3 months after treatment.
Topical treatment with 1% hydrocortisone was allowed during the trial as long as the same brand was
used throughout.
A trial in Sweden by Back and Bartosik256 compared 200mg of oral ketoconazole per day against placebo
for 3 months in 32 adults with eczema and specific serum antibodies to Malassezia furfur or P. orbiculare
above 3.5 kU/l and an elevated serum IgE level (> 400 kU/l).
Assessment of risk of bias
Table 50 provides the risk-of-bias assessment for the new studies.
Benefits
The trial by Lintu and colleagues255 looked at the severity of eczema using the SCORAD index, total serum
IgE level, sensitivity and allergy, and presence of P. orbiculare, C. albicans or S. cerevisiae. This trial gave
results of the improvement within each treatment group after the treatment period but did not compare
the two treatment groups against each other. The mean SCORAD score in the ketoconazole group
reduced by 7.9 (SD 13.1) points, whereas that in the placebo group reduced by 2.9 (15.3) points. The trial
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report states that the data for the follow-up period, when study treatment had stopped, were not reliable
for therapeutic effect because of the use of extra topical treatment. No participant-assessed outcomes
were reported for this trial.
The trial by Back and Bartosik256 did not find any significant difference in the severity of eczema measured
using the SCORAD index after 3 months of treatment (p= 0.533), but the actual SCORAD values were
regrettably not reported. The report states that the use of betamethasone was correlated with the
improvement in the placebo group in the second and third months (r= 0.66, p= 0.013) but not in the
ketoconazole group (r= 0.15, p= 0.61), but no values were reported. The participants’ evaluation of eczema
improvement was reported as not significantly different between the groups, but no data were reported.
Harms
The trial by Lintu and colleagues255 did not report any information about adverse events. The trial by
Back and Bartosik256 reported that there were only rare adverse events in the ketoconazole group,
with two participants complaining of intense dreams, nausea and abdominal pain.
Overall implications for research and practice
The evidence for or against oral ketoconazole is difficult to interpret as neither trial reported the appropriate
data for evaluating whether one treatment arm was better than the other. Both trials also allowed all
participants to use topical corticosteroids as required and have not provided enough data on the levels used
to be certain whether any beneficial or harmful effects seen are likely to be from use of ketoconazole or use
of rescue treatment with topical corticosteroids. Difficulties with recruitment to these trials were mentioned
because of pre-treatment ‘washout’ of topical ketoconazole being required. Potential participants were
satisfied with their current treatment of topical ketoconazole, especially ketoconazole shampoo, and topical
corticosteroids as required and so were not motivated to join the trial. This would indicate little need to
pursue treatment alternatives such as oral ketoconazole. There is no good evidence of benefit for oral
ketoconazole from these trials and it is probably not an area where further trials are needed.
Miconazole (topical)
Miconazole is an imidazole agent that is used topically to treat fungal infections. When taken orally it has also
been shown to be effective against some forms of leishmaniasis and it also has some antibacterial properties.
Studies
One trial involving miconazole was reported before 200055 (see Appendix 3).
One trial has been reported since 2000. A within-person trial by Wong and colleagues115 in Hong Kong
compared a combined treatment regimen of miconazole and 1% hydrocortisone against 1% hydrocortisone
only, applied twice daily for 2 weeks. The trial included 30 children aged between 5 and 14 years with
eczema, defined according to the UK Working Party’s criteria,9 symmetrically distributed (at knees or
elbows), of whom 80% were classified as severe using the Nottingham Eczema Severity Score.257
TABLE 50 Ketoconazole: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Back 2001256 Unclear risk Unclear risk Unclear risk
Lintu 2001255 Unclear risk Unclear risk Unclear risk The participants were allowed to use stronger topical
treatment in the follow-up period if needed. Many of
the withdrawals were a result of exacerbation of
eczema and these were not included in the analyses
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Assessment of risk of bias
Table 51 provides the risk-of-bias assessment for the new study.
Benefits
The trial mainly relied on participants reporting which treatment gave better relief of eczema symptoms
after 2 weeks of treatment and after another 6 weeks with no treatment. Two independent dermatologists
also assessed outcomes using photographs. The two dermatologists gave vastly different interpretations of
the eczema photographs, with one recording nearly all as ‘no difference’ and the other being equally split
between ‘better with miconazole’, ‘better with hydrocortisone only’ and ‘no difference’, so this method
proved to be unreliable and therefore difficult to interpret. The participants also reported no differences
between the treatments using the same scoring system. There was also no difference in topical
corticosteroid-free days between the two treatment groups in the follow-up period.
Harms
The trial report stated that there were no reported side effects.
Overall implications for research and practice
This small and poorly reported trial did not show any evidence of a beneficial effect of a topical
combination of hydrocortisone and miconazole over hydrocortisone alone. The trial did not use any reliable
objective or subjective measures of eczema severity.
Itraconazole (oral)
Itraconazole belongs to the triazole group of antifungal medications. It has a broad spectrum of action against
fungi including yeasts and dermatophytes. It is similar to fluconazole but also treats Aspergillus infections.
Studies
There were no trials before 2000 looking at the use of itraconazole for eczema.
One new, small, three-arm trial258 concentrating on the head and neck area compared 200mg or 400mg
of itraconazole against placebo in adults whose head and neck eczema was more severe than the eczema
elsewhere on their body. The treatment was given for only 7 days but the follow-up period lasted for
105 days. The results reported do not include the follow-up at 105 days and concentrate on day 7 and
day 14 measurements, thus giving only a short-term picture of any treatment effect. If a participant required
adjuvant treatment during the trial then the trial protocol was violated and the participant was withdrawn.
Assessment of risk of bias
Table 52 provides the risk-of-bias assessment for the new study.
TABLE 51 Miconazole: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Wong 2008115 Unclear risk Unclear risk Unclear risk
TABLE 52 Itraconazole: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Svejgaard 2004258 Unclear risk Unclear risk Unclear risk
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Benefits
The severity of eczema in the head and neck region was significantly reduced compared with baseline for
both 200mg and 400mg of itraconazole. Comparison of improvement between all three groups showed
a statistically significant difference only for 200mg of itraconazole (mean difference of 4.5, extrapolated
from a graph) compared with placebo (mean difference of 16, extrapolated from a graph) at day 14
(p= 0.0318). For the primary success criterion, measured using the SCORAD index, 8 out of
35 participants using itraconazole reported a reduction in severity of > 50% compared with baseline
compared with 2 out of 18 participants using placebo. Both the participant and investigator global
assessment were reported as showing no significant differences in overall improvement in eczema severity,
but the complete data for these outcomes were not reported.
Harms
This trial reported no adverse events in the itraconazole groups and there were no withdrawals because of
adverse events. Over half of each treatment group withdrew, mainly because of exacerbations of eczema
requiring additional treatment. Most of the withdrawals occurred after study treatment had stopped.
Overall implications for research and practice
Giving itraconazole as the first-line treatment without the use of adjuvant treatments resulted in over half
of the trial population withdrawing from the study, mostly between days 14 and 56 because of the need
for additional treatments. A post hoc decision to report the results for day 14 and draw conclusions about
this 7-day treatment course accordingly diverts attention away from the potential unsuitability of a 7-day
course of itraconazole as a long-term treatment for eczema. The number of participants was small and no
formal power calculation was reported. Although there is some evidence of a beneficial effect of 200mg
of itraconazole after 14 days, the 400-mg dose appears to be no more effective than placebo, a result that
is counterintuitive and raises the suspicion that the positive finding at 14 days for the lower-dose group
was just a chance finding. Given that another similar oral antifungal, ketoconazole, has failed to provide
any clear benefit for people with mainly head and neck eczema, further trials of oral antifungals are
probably not a priority.
Ciclopirox olamine (topical)
Ciclopirox olamine is a hydroxypyridine antifungal agent. It has been shown to be highly effective against
Malassezia species, which have been implicated in difficult-to-treat atopic eczema in the head and
neck area.
Studies
There were no studies on ciclopirox olamine for eczema before the year 2000.
One study was reported after 2000. This trial, by Mayser and colleagues,259 compared 1% topical ciclopirox
olamine against the base cream, which was applied twice daily to the head and neck region for 28 days.
The 50 randomised participants had had moderate to severe eczema for at least 6 months. The eczema
was defined according to the Hanifin and Rajka8 criteria and an IGA of score of ≥ 3, and all presented with
≥ 10% coverage in the head and neck region. All of the participants had to have at least a class I reaction
for specific IgE to M. sympodialis and M. furfur and enterotoxin A and B. The trial followed the participants
until 2 weeks after treatment had stopped.
Assessment of risk of bias
Table 53 provides the risk-of-bias assessment for the new study.
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Benefits
Only 29 out of the 50 participants who completed the study were included in the analysis. The
assessments of eczema severity on the head and neck using the IGA tool and EASI showed significant
between group differences at 28 days compared with baseline.
Harms
The trial report did not provide any information about adverse events or other potential harms.
Overall implications for research and practice
The results of this trial should be treated with caution because of the high dropout rate and failure to perform
an intention-to-treat analysis. In a group with moderate to severe eczema, failure to permit rescue therapy
was perhaps unethical given the lack of a priori evidence of benefit of ciclopirox olamine; instead, the use of
rescue therapy could have been recorded as a study outcome. The results of this one small, short-term trial in
those with moderate to severe eczema on the head and neck and sensitive toM. sympodialis, M. furfur and
enterotoxin A and B do not provide any clear evidence of benefit from ciclopirox olamine, but do provide
some weak evidence of a worsening in severity when the treatment is stopped. Given the lack of a beneficial
signal in this study, further research with ciclopirox olamine is probably not a priority.
Summary of antimicrobials including antiseptics
and antifungals
Antibiotics
Topical fusidic acid
l There were no trials on fusidic acid reported before 2000.
l For non-infected eczema, one trial reported in 2003, with a mostly high risk of bias, did not provide
any evidence of benefit for a combination of fusidic acid (2%) and topical corticosteroid compared with
a combination of mupirocin and topical corticosteroid.
l For non-infected eczema, one four-arm trial reported in 2007, with a mostly unclear risk of bias and a
high risk of blinding bias, did not provide any evidence of benefit for a combination of fusidic acid
(2%) and topical corticosteroid treatment compared with topical corticosteroid alone or for a
combination of fusidic acid (2%) and topical tacrolimus compared with topical tacrolimus alone.
l The largest trial, reported in 2007, with a mixed risk of bias, provided evidence of benefit for a
combination of fusidic acid and betamethasone 17-valerate in a lipid base compared with the lipid
base alone for people with infected eczema. This trial also compared a combination of fusidic acid and
betamethasone 17-valerate in a cream base against the same treatments in the lipid base and provided
evidence of non-inferiority.
TABLE 53 Ciclopirox olamine: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Mayser 2006259 Unclear risk Unclear risk Low risk Concomitant medication given to the groups
appears to have differed. Only 29 out of
50 participants included in the analysis
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Topical mupirocin
l One small pre 2000 trial, with a mostly unclear risk of bias, provided evidence of a large beneficial
effect for mupirocin ointment compared with placebo in people whose eczema was not overtly
infected. The participants could use emollients and topical corticosteroids.
l Three trials, two small and one moderately sized, reported in 2003, 2012 and 2006, respectively, and
with a mixed risk of bias, did not provide any evidence of benefit from using mupirocin in combination
with topical corticosteroids compared with topical corticosteroids alone in people with non-infected
eczema. One of these trials primarily evaluated the carriage of fusidic acid-resistant S. aureus.
l A fourth small trial, reported in 2009, with a mostly unclear risk of bias, provided evidence for
combined mupirocin treatment of the nostrils and bleach baths against compared with placebo for
children with infected eczema.
Topical tetracycline
l There were no trials using tetracycline for eczema reported before 2000.
l One small trial reported in 2008, with an overall low risk of bias, did not provide any evidence of
benefit for a combination of tetracycline and topical corticosteroid compared with topical corticosteroid
alone in people with clinically non-infected eczema.
Clarithromycin
l One trial compared oral montelukast against a ‘standard’ treatment combination of clarithromycin,
cetirizine and mometasone furoate. No data were presented for clarithromycin treatment alone and so
it is impossible to draw any conclusions about the use of clarithromycin for eczema on its own from
this one trial.
Antiseptics
Triclosan
l Two very small trials reported pre 2000 provided evidence of benefit for a bath additive containing 2%
triclosan and benzalkonium chloride (6% w/w) compared with the same bath additive without antiseptics.
l Two small trials funded by the manufacturer reported in 2000 and 2010, with a mostly unclear risk of
bias, provided evidence of benefit for a triclosan 1.5%- or 1.0%-containing soap bar or emollient,
respectively, compared with vehicle in people with eczema that was not infected. One of the trials
provided hardly any data in the trial report.
l The four trials using triclosan for eczema have been designed and reported in a way that makes it
difficult to interpret the results and therefore there is no clear evidence on the benefits or harms of
triclosan for eczema.
Bleach baths
l There were no trials of bleach baths reported before 2000.
l One small trial reported in 2009, with a mostly unclear risk of bias, provided evidence of a benefit at
1 month in a post hoc subgroup analysis, but not at 3 months, for bleach baths once a week and a
5-day treatment of mupirocin to the nostrils once a month compared with placebo.
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Antifungals
Oral ketoconazole
l There were no trials of oral ketoconazole for eczema reported before 2000.
l Two small trials reported in 2001, with an overall unclear risk of bias, did not provide any evidence of
benefit for oral ketoconazole (200mg) compared with placebo in people with eczema who were
sensitive to fungi.
Topical miconazole
l One small trial reported pre 2000, with a mostly unclear risk of bias, did not provide any evidence of
benefit for a combination of miconazole, topical corticosteroid and ketoconazole shampoo compared
with topical corticosteroid and shampoo.
l One very small trial reported in 2008, with an overall unclear risk of bias, did not provide any evidence
of benefit for a combination of miconazole and topical hydrocortisone compared with
hydrocortisone alone.
Oral itraconazole
l One small trial reported in 2004, with an unclear risk of bias, did not find any evidence of benefit for
itraconazole compared with placebo.
Topical ciclopirox olamine
l One trial reported in 2006, with a mostly unclear risk of bias, did not find any evidence of benefit for
topical ciclopirox olamine compared with the base cream.
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Chapter 7 Antihistamines and mast cell stabilisers
Background
Antihistamines have long been prescribed for atopic eczema in the belief that they reduce itching by
blocking the action of histamine on its receptors in the skin. The role of histamine in mediating pruritus in
atopic eczema is unclear and it may play only a small part. There are four types of histamine receptor;
however, current antihistamines have mainly been developed to target the H1 and H2 receptors, which are
both found in the skin. Most antihistamines that have been trialled as treatments for atopic eczema are H1
receptor antagonists. H1 antihistamines can be further subdivided into those with a sedating action (e.g.
chlorpheniramine) and those with a less sedating action (e.g. cetirizine). Although lack of sedation may be
desirable in the daytime, it is often stated that antihistamines are effective in atopic eczema only if they are
sedative. It is suggested that sedating antihistamines are effective because of their central sedating effect
rather than because of any action on peripheral histamine blockade. Regardless of how antihistamines
might work in atopic eczema, it is useful to consider the evidence of whether they help at all.
Mast cell stabilisers block a calcium channel essential for mast cell degranulation, preventing the release of
histamine and related mediators.
Existing systematic reviews
The NICE,41 SIGN42 and AAD94 guidelines and associated evidence reviews cover antihistamines. A
systematic review covering the safety of eczema treatments80 also covers topical doxepin. A systematic
review of interventions to reduce itching for eczema93 also covers many of the antihistamines in
this chapter.
Scope of this chapter
This chapter covers the following treatments
l H1 antihistamines (less sedating)
¢ loratidine (oral)
¢ ketotifen (oral)
¢ epinastine (oral)
¢ cetirizine (oral)
¢ fexofenadine (oral)
l Antihistamine (non-sedating)
¢ Olopatadine hydrochloride (oral)
l H1 antihistamines (sedating)
¢ chlorpheniramine (oral)
¢ doxepin (topical)
l mast cell stabiliser
¢ sodium chromoglycate (topical)
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Antihistamines
Cetirizine (oral) (less sedating)
Cetirizine (Zirtek™; UCB Pharma) is a potent antihistamine and is used in adults and children.
Studies
Five trials involving cetirizine were reported before 200055 (see Appendix 3).
One new trial by Diepgen and colleagues260 compared cetirizine oral solution (10mg/ml, 0.25mg/kg)
against placebo twice daily for 18 months. The trial included 817 children aged 1–2 years who had had
active eczema for at least a month before recruitment and who had at least one parent who had a history
of asthma, atopic eczema or allergic rhinitis. The trial was primarily looking at the rate of development of
asthma in the infants but also assessed the effect of the intervention on the eczema.
One new trial by Capella and colleagues251 compared oral montelukast against a ‘standard’ treatment
combination of clarithromycin, cetirizine and mometasone furoate. No data were presented for cetirizine
treatment alone and so it is impossible to draw any conclusions about the use of cetirizine for eczema on
its own from this trial.
Assessment of risk of bias
Table 54 provides the risk-of-bias assessment for the new study.
Benefits
Diepgen and colleagues260 did not provide many methodological details in the trial report, instead referring
the reader to a previous publication containing this information.261 Cetirizine was described as having a
similar appearance and taste to the placebo. The severity of eczema and use of mild and moderate to
potent corticosteroids (secondary outcomes) did not significantly differ between the cetirizine group and
the placebo group during the trial. The only significant differences between the groups were a lower use
of other oral H1 antihistamines in the cetirizine group and a lower rate of development of urticaria in the
cetirizine group, with the latter not being listed as an outcome of the trial in the report.
Harms
Very few details were provided about the adverse events recorded in the trial by Diepgen and colleagues260
apart from the levels of urticaria, for which there was a beneficial effect of treatment with cetirizine.
Overall implications for research and practice
The large, long-term trial by Diepgen and colleagues260 failed to find any significant difference between the
groups in the severity of eczema or any topical corticosteroid-sparing effect from the use of 0.25mg/kg of
cetirizine twice daily. The lower rate of use of other H1 antihistamines in the cetirizine group makes it
difficult to draw conclusions as antihistamines can be used to treat a variety of other, mostly allergic
diseases, the level of which may have differed between the two groups, although the levels of sensitisation
to milk, egg, grass pollen and house dust mite were similar between the groups.
TABLE 54 Cetirizine: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Diepgen 2002260 Unclear risk Unclear risk Unclear risk Powered to detect the primary outcome,
which was not relevant to eczema
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Loratidine (oral) (less sedating)
Loratidine is a non-sedating second-generation H1 antihistamine used to treat allergies. In the UK it is sold
over the counter (Clarityn®; Merck Sharp & Dohme Ltd) as well as being available on prescription.
Studies
Three trials involving loratidine were reported before 200055 (see Appendix 3).
Only one new trial262 used loratidine for the treatment of eczema and this was as the comparator to test
the addition of modified Jiawei Danggui Decection (a type of Chinese medicine). As loratidine was used in
both groups, this trial cannot be used to assess the effectiveness of loratidine.
Fexofenadine (oral) (less sedating)
Fexofenadine (Telfast®; Sanofi) is used for hay fever and other allergic conditions with similar symptoms.
It is not as sedating as some other H1 antihistamines.
Studies
No studies of fexofenadine were reported before 2000.
Two trials involving fexofenadine were reported after 2000. One new trial, by Kawashima and
colleagues,263 compared fexofenadine hydrochloride (60mg) given twice daily (morning and evening) for
1 week against placebo. The study population of 411 adults had a diagnosis of eczema according to the
Japanese Dermatological Association criteria26 and a pruritus score between 4 and 8 after 3 days of
placebo treatment prior to enrolment. All participants received placebo for 1 week prior to the trial and
used hydrocortisone butyrate (0.1%) twice a day for the placebo period before randomisation and during
the treatment period.
A multicentre trial by Nakagawa and Kawashima264 compared fexofenadine hydrochloride (30mg or 60mg
twice a day, depending on the age of the participant) against another antihistamine, ketotifen (1mg twice
a day), for 4 weeks. In total, 190 children aged 7–15 years with an average score of ≥ 2 for itching in the
3 days before allocation and requiring 0.1% hydrocortisone butyrate on ≥ 70% of their body
were randomised.
Assessment of risk of bias
Table 55 provides the risk-of-bias assessment for the new studies.
Benefits
The trial by Kawashima and colleagues263 found a significant benefit of fexofenadine for itching as judged
by the participants and also as measured by the ratio of area of pruritus to body surface area, assessed by
an investigator.
In the trial by Nakagawa and colleagues264 there were no significant differences between the treatment
groups in the mean change in itching score, daily change in itchiness, improvement of rash, participant
assessment of the eczema and rate of adverse events.
TABLE 55 Fexofenadine: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Kawashima 2003263 Unclear risk Unclear risk Unclear risk
Nakagawa 2006264 Unclear risk Unclear risk Unclear risk
DOI: 10.3310/pgfar04070 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 7
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nankervis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
Harms
In the trial by Kawashima and colleagues263 the number of participants who experienced adverse events
was approximately the same in each group (48 in the fexofenadine group and 45 in the placebo group),
with no serious adverse events and one withdrawal because of adverse events in each group. The most
common adverse events reported were drowsiness, increases in serum bilirubin and glutamic-pyruvic
transaminase, and positive urinary protein. The incidence of these events was similar between the
two groups.
There were no serious adverse events reported in the trial by Nakagawa and Kawashima.264
Overall implications for research and practice
Without an objective measure of severity in the trial by Kawashima and colleagues263 and because of the
likelihood that judging the surface area of pruritus could be extremely difficult for an investigator, it is
difficult to assess the significance of the efficacy results from this trial. Longer-term trials with at least one
validated objective measure of eczema severity are needed. The trial by Nakagawa and Kawashima264 does
not provide any evidence of benefit for fexofenadine compared with ketotifen.
There is not yet any positive RCT evidence for this treatment in children, in whom drowsiness is sometimes
less of a problem or even a potential benefit for reducing sleep loss as a result of eczema.
Ketotifen fumarate and epinastine hydrochloride (oral) (less sedating)
Ketotifen fumarate (Zaditen®; Swedish Orphan Biovitrum) functions as a mast cell stabiliser and has been
used as a treatment for chronic idiopathic urticaria because of its antipruritic properties. Similarly,
epinastine hydrochloride is both an antihistamine and a mast cell stabiliser.
Studies
Two trials on ketotifen fumarate were reported before 200055 (see Appendix 3). There were no studies on
epinastine hydrochloride reported before 2000.
Two trials involving ketotifen fumarate, one of which used epinastine hydrochloride as the comparator,
have been published since 2000. The trial by Nakagawa and Kawashima264 compared fexofenadine against
ketotifen fumarate and is discussed in the previous section.
The trial by the Epinastine Hydrochloride Dry Syrup Clinical Study Group265 compared epinastine
hydrochloride (10mg in 1 g of dry syrup) 1.0 g/day (body weight 14–24 kg) or 2.0 g/day (body weight
> 24 kg) against ketotifen fumarate (1.38mg in 1 g of dry syrup) 1.2 g/day (body weight 14–24 kg) or
2.0 g/day (body weight > 24 kg). The treatments were given as dry syrup for 4 weeks. The trial included
163 children aged up to 15 years. The trial was blinded using a double dummy design so that each group
received one dose of treatment and one dose of placebo per day. Children who had been using mild or
moderate topical corticosteroid for at least 1 week and who had an itching score of ≥ 2 were included.
Assessment of risk of bias
Table 56 provides the risk-of-bias assessment for the new study.
TABLE 56 Ketotifen fumarate and epinastine hydrochloride: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Epinastine Hydrochloride
Dry Syrup Clinical Study
Group 2004265
Unclear risk Unclear risk Unclear risk
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Benefits
This trial carried out in Japan measured itching using three different outcomes and severity using two
separate outcomes. The objective of the trial was to prove the non-inferiority of epinastine hydrochloride
to ketotifen fumarate. The trial found no significant differences between the treatments at 2 or 4 weeks in
terms of itching or severity of rash in a per-protocol population of 148 children.
Harms
There was a high rate of adverse events in the ketotifen fumarate group, with 22 out of 78 participants
undergoing events that were considered to be related to the study treatment, compared with 9 out of 84
in the epinastine hydrochloride group. In particular, drowsiness (seven in the epinastine hydrochloride
group and 18 in the ketotifen fumarate group) and nasopharyngitis (14 in the epinastine hydrochloride
group and 11 in the ketotifen fumarate group) were common problems.
Overall implications for research and practice
The trial by the Epinastine Hydrochloride Dry Syrup Clinical Study Group265 was the only RCT found that
investigated the use of epinastine hydrochloride for the treatment of eczema. This trial was short term and
did not compare the treatments against a placebo or another non-antihistamine comparator. Both of the
treatments considered resulted in fairly high levels of adverse events, most commonly drowsiness and
nasopharyngitis. The evidence for a reduction in itching in adults using ketotifen fumarate has previously
(published before 2000) been contradictory, with one trial providing evidence of a reduction from baseline
after 3 months in adults and another not providing any evidence of a difference in itching or erythema
compared with placebo after 4 months in children.55 Longer-term studies comparing ketotifen fumarate
and epinastine hydrochloride with other active eczema treatments in common use are needed to clarify
whether their use for treating eczema is beneficial, especially when weighed against the level of
adverse events.
Olopatadine hydrochloride (oral) (non-sedating)
Studies
One ‘double dummy’ multicentre trial conducted in Japan266 randomised 305 children aged 7–16 years
with eczema according to the Japanese Dermatological Association criteria26 to olopatadine hydrochloride
(10mg/day) as a tablet or ketotifen fumarate dry syrup (2mg per day) for 2 weeks. The children had to
have an eczema lesion on the head, neck or face that was expected to be cleared by hydrocortisone
butyrate ointment and at least a mild pruritus score (score of 2), with the score being different between
night-time and daytime. All participants used hydrocortisone ointment twice a day in an observation period
before starting the trial.
Assessment of risk of bias
Table 57 provides the risk-of-bias assessment for the new study.
Benefits
The primary outcome of change in pruritus score and the secondary outcomes of change in global score
assessed by a clinician and response score for itching, measured by participants on a 5-point narrative
scale, were not significantly different between treatments.
TABLE 57 Olopatadine hydrochloride: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Kawashima 2011266 Unclear risk Unclear risk Unclear risk
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Harms
In the olopatadine hydrochloride group, 29 out of 152 (19.1%) participants reported adverse events,
including 18 adverse drug reactions. In the ketotifen fumarate group, 37 out of 153 (24.2%) participants
reported adverse events, including 10 adverse drug reactions. None of the events were serious or severe.
Overall implications for research and practice
This trial of olopatadine compared with ketotifen fumarate, which was reported to be a non-inferiority
trial, did not provide any evidence of a difference between the two treatments in the reduction of pruritus
or eczema severity in children. It is impossible to assess whether or not olopatadine has any clinically
relevant benefit for eczema compared with other treatments such as topical corticosteroids and emollients.
Both treatment groups changed by an average of < 1 point on a 5-point scale for all outcomes measured.
This raises doubts about the clinical relevance of both treatments. The lack of change could be because
the severity of the eczema was potentially quite low at baseline because of the 1-week treatment period
with topical corticosteroids before starting the study treatment.
Chlorpheniramine (oral) (sedating)
Chlorpheniramine (Piriton®; GlaxoSmithKline) is a relatively weak sedative antihistamine that is used for the
prevention of rhinitis and urticaria.
Studies
One trial involving chlorpheniramine was reported before 200055 (see Appendix 3).
One new trial by Munday and colleagues267 compared chlorpheniramine elixir 2.5 ml (those aged 1–5 years)
or 5ml (those aged 6–12 years) before bedtime every evening with placebo for a period of 1 month.
Participants were allowed a second dose after 3 hours. After 2 weeks, if sleeplessness was still present the
dose could be doubled to 5ml (those aged 1–5 years) or 10ml (those aged 6–12 years) before bedtime
every evening. The trial included 155 children aged 1–12 years with atopic eczema. All participants were
given Unguentum M emollient (100 g) (Almirall Hermal GmbH), Efcortelan® (30 g) (GlaxoSmithKline) and
hydrocortisone (1%) cream to use as necessary.
Assessment of risk of bias
Table 58 provides the risk-of-bias assessment for the new study.
Benefits
This trial assessed an intention-to-treat population of 151 participants and did not find any significant
differences in the investigator- and participant-assessed severity of itching score, assessed on a 5-point
scale; participant-assessed sleeplessness because of itching and scratching; participant-assessed daytime
drowsiness; investigator-assessed severity of eczema for excoriation; dryness; lichenification; exudation
and crusting assessed on a VAS; and adherence with treatment by weighing the medication. The only
significant finding was a reduction in erythema in the chlorpheniramine group.
TABLE 58 Chlorpheniramine: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Munday 2002267 Unclear risk Unclear risk Unclear risk Twelve participants left the study because
of withdrawal of parental consent
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Harms
Twenty participants out of 151 reported a total of 29 adverse events, of which none was serious. The rate
of events was the same in the chlorpheniramine and placebo groups. The trial report did not provide any
details about the nature of the adverse events. Three participants were reported to have withdrawn
because of adverse events.
Overall implications for research and practice
The weight of evidence from one small study published before 2000 and one large study published in
2002 suggests that there is no beneficial effect of chlorpheniramine for eczema, although the studies were
both short term. The fact that the large trial by Munday and colleagues267 attempted to detect a beneficial
effect using several different outcomes, with none of these showing a beneficial effect, is all the more
convincing. As yet, there is no evidence that using chlorpheniramine has a beneficial effect and some fairly
strong evidence to suggest that it has no beneficial effect for eczema.
Doxepin (topical) (sedating)
Doxepin (a tricyclic antidepressant) has powerful antihistamine properties by antagonising the H1 and H4
receptors. It is available in oral and topical formulations (Xepin®; Cambridge Healthcare Supplies).
Studies
Four trials involving topical doxepin for eczema were reported before 200055 (see Appendix 3).
One new trial, by Lee and colleagues,268 compared topical doxepin (5%) cream applied four times a day for
7 days against placebo. The trial included 44 adults with eczema who had moderate to severe daily
pruritus for at least 1 week before entering the trial.
Assessment of risk of bias
Table 59 provides the risk-of-bias assessment for the new study.
Benefits
This small trial by Lee and colleagues,268 carried out in a Korean population, showed a significant effect of
doxepin for the relief of itching. The study concentrated on itching outcomes, using two different
measures, and also used EASI scores to assess the severity of eczema. As in the previous trials on this
treatment,55 a significant improvement in pruritus was found but no significant effect on the severity of
eczema. A 15.5% improvement in pruritus on day 1 in the doxepin group was found, rising to 42.6% by
day 7. This was reported to be statistically significant in favour of doxepin but the data for the placebo
group were not reported.
Harms
The most common adverse event was erythema and xerosis at the site of application, which affected five
participants in the doxepin group and three participants in the placebo group. Drowsiness was also a
problem for two participants in the doxepin group, with one of these participants withdrawing from
the trial.
TABLE 59 Doxepin: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Lee 2006268 Unclear risk Unclear risk Unclear risk Intention-to-treat analysis not used
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Overall implications for practice and research
The results of this trial in a Korean population are in agreement with those of the previously reported trials
by Drake and colleagues,269,270 which had a very similar protocol. This trial also looked at 7 days of
treatment and noted problems with drowsiness and application site erythema and xerosis. These additional
data expand the evidence base for this treatment by confirming the results of the trials by Drake and
colleagues.269,270 Future trials could focus on the long-term relief of itching and levels of adverse events in
comparison with other active treatments for the relief of itching, although it seems unlikely that these will
be pursued. A clearer picture in specific groups such as infants and young children would be valuable to
inform the best use of this treatment.
Mast cell stabilisers
Sodium chromoglycate (topical)
Sodium chromoglycate has been used as an inhaled powder for the treatment of asthma for over 30 years
and has a very strong safety profile. The mechanism of action is partly the result of the drug inhibiting the
release of inflammatory mediators from mast cells. It is now being investigated as a treatment for diseases
such as eczema, for which it is added to topical preparations.
Studies
Ten trials of sodium chromoglycate for eczema were reported before 200055 (see Appendix 3).
One new trial, by Stainer and colleagues,271 compared topical sodium chromoglycate (4%) (Altoderm™;
Thornton & Ross Ltd) against topical lotion vehicle, applied twice daily for 12 weeks. The trial included
114 children aged 2–12 years who were diagnosed with atopic eczema according to the UK Working
Party’s criteria9 and who also had a SCORAD score between 25 and 60. The same diagnostic criteria were
required at both of two assessments carried out 14 days apart. Also, overall skin condition and itching
were required to be assessed as a score of at least 2 on a scale of 0–3 on at least four separate days
within the 14-day baseline period.
Assessment of risk of bias
Table 60 provides the risk-of-bias assessment for the new study.
Benefits
The trial by Stainer and colleagues271 showed a significant difference in the severity of eczema in favour of
sodium chromoglycate as measured by SCORAD scores and the participant-assessed overall skin condition
scores. Interestingly, the participant-assessed itching and sleep loss scores were not significantly different
between the topical sodium chromoglycate group and the vehicle group. The lack of reduction in itching
differs from the results found in previous studies using different formulations of sodium chromoglycate.
Harms
The rate of participant-reported adverse events was quite high, at 66 out of 114, but there was no
difference between the groups (34 placebo group, 32 sodium chromoglycate group). Eleven participants
had an adverse event that was considered to be treatment related, four in the placebo group and seven in
the sodium chromoglycate group. No severe adverse events were reported; however, there were more
withdrawals assessed as being possibly, probably or highly related to the study treatment in the sodium
chromoglycate group, with five in the sodium chromoglycate group and one in the placebo group.
TABLE 60 Sodium chromoglycate: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Stainer 2005271 Low risk Low risk Unclear risk
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Overall implications for research and practice
The body of evidence for topical sodium chromoglycate treatment is still mixed; however, a medium-sized
methodologically robust trial in children did not find any beneficial effect on itching or sleep loss. This
could be because of the formulation used or the population included in this study, with participants having
to have a moderately high level of itching on at least 4 days out of 14 to be included in the study, as in
some of the previous trials. The higher rate of withdrawal in the topical sodium chromoglycate group
because of adverse events that were assessed as being possibly, probably or highly related to the study
treatment needs further research, although there appears to be a low number of events possibly, probably
or highly related to the study treatment overall.
Summary of antihistamines
Cetirizine (oral) (less sedating)
l Four trials, two small and two medium sized, involving cetirizine for eczema were reported before
2000. The largest of these trials provided evidence of benefit for cetirizine but only at four times the
normal dose. The other three trials did not provide any evidence of benefit.
l One very large trial published in 2005, with an overall unclear risk of bias, provided evidence of no
benefit of long-term twice-daily cetirizine (0.25mg/kg) treatment.
Loratadine (oral) (less sedating)
l Three trials involving loratadine were reported before 2000. Two trials, one small and one very small,
with an overall unclear risk of bias, provided evidence of benefit for loratadine compared with placebo.
The largest trial did not provide any evidence of benefit for loratadine compared with cetirizine.
l Only one new trial, published in 2008, used loratadine for the treatment of eczema, comparing
loratadine with and without the addition of modified Jiawei Danggui Decection (a type of Chinese
medicine). As loratadine was used in both groups, this trial cannot be used to assess the effectiveness
of loratadine.
Fexofenadine (oral) (less sedating)
l No trials of fexofenadine were reported before 2000.
l One large trial reported in 2006, with an overall unclear risk of bias, provided evidence of benefit for
fexofenadine (60mg twice daily) compared with placebo.
l A further medium-sized trial reported in 2006, with an overall unclear risk of bias, did not provide any
evidence of benefit for fexofenadine (30 or 60mg twice daily) compared with ketotifen (1mg once daily).
Ketotifen and epinastine (oral) (less sedating)
l Two small trials on ketotifen compared with placebo reported pre 2000 gave conflicting results.
l There were no trials involving epinastine for eczema reported before 2000.
l One medium-sized trial reported in 2003, with an overall unclear risk of bias, provided evidence of the
non-inferiority of ketotifen to epinastine.
Olopatadine hydrochloride (oral) (non-sedating)
l There were no trials involving olopatadine hydrochloride for eczema treatment reported before 2000.
l One large trial reported in 2011, with an overall unclear risk of bias, did not show a difference for
children treated with olopatadine hydrochloride compared with ketotifen fumarate in terms of itch or
eczema severity.
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Chlorpheniramine (oral) (sedating)
l One very small trial involving chlorpheniramine, with missing baseline data, was reported pre 2000;
however, this trial did not compare the chlorpheniramine-only group with the placebo group and so
did not provide any information on the possible benefit of chlorpheniramine compared with placebo.
l One medium-sized trial reported in 2002, with an overall unclear risk of bias, did not provide any
evidence of benefit for chlorpheniramine compared with placebo.
Doxepin (topical) (sedating)
l Four fairly well-reported manufacturer-sponsored trials involving topical doxepin, two large and two
small, were reported before 2000. Two of the trials provided evidence of benefit for topical doxepin
compared with placebo and two did not.
l One small trial reported in 2006, with an overall unclear risk of bias, provided evidence of benefit for
doxepin compared with placebo.
Sodium chromoglycate (topical)
l Ten trials of sodium chromoglycate were reported before 2000.
l One new medium-sized trial, with a mostly low risk of bias, provided evidence of benefit for sodium
chromoglycate (4%) compared with vehicle.
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Chapter 8 Dietary interventions
Background
Polyunsaturated fatty acids are essential components of all cell membranes. There are two families of such
essential fatty acids (EFAs): omega-6 fatty acids (n-6) (e.g. linoleic and arachidonic acid) and omega-3 fatty
acids (n-3) [e.g. eicosapentaenoic acid (EPA)]. Eicosanoids are signalling molecules derived from fatty acids
that play an important part in the inflammatory and immunological processes of atopic eczema. Alterations
in linoleic acid metabolism have been demonstrated in some patients with atopic eczema, suggesting that
a defect in the enzymatic conversion of this EFA by δ-6-desaturase might be responsible for defects in the
lipid barrier of the skin and a decreased production of anti-inflammatory metabolites in the skin. These
observations provide the rationale for dietary supplementation with EFAs in atopic eczema.
Supplementation with bacteria that may confer benefit (probiotics) or oligosaccharides that encourage the
growth of beneficial bacteria (prebiotics) has become a focus of eczema research in the last decade.
Evidence of changes in the balance of the gut microflora in those with eczema compared with those
without eczema raised interest in interventions that could redress the balance, in the hope of a decrease in
eczema severity.
Existing systematic reviews
There have been 20 systematic reviews of dietary interventions for established eczema. Five reviews79,272–275
specifically examine probiotic supplementation, a Cochrane review276 and subsequent non-Cochrane
updated review277 specifically evaluate dietary exclusions, another Cochrane review278 specifically explores
dietary supplementation and other reviews35,41,42,93,94,279–283 cover more than one dietary intervention.
A Cochrane review of evening primrose oil and borage oil supplementation has also recently
been published.189
Scope of this chapter
The trials included in this chapter cover the following treatments:
l probiotics
l prebiotics
l synbiotics
l EFA supplementation
¢ borage oil
¢ evening primrose oil
¢ fish oil (omega-3)/soybean oil (omega-6)
¢ docosahexaenoic acid (DHA)
¢ hempseed oil
l oral vitamins D and E
l goat’s/ass’s milk
l hypoallergenic formula
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Probiotics
Probiotics are live micro-organisms that can confer a health benefit on the host. The mechanism of action
may involve reducing inflammation and permeability in the gut and modifying the microbiota or
modulating immune responses in the host.
Mixed-strain probiotics
Studies
No RCTs were reported up to the year 2000 for mixed-strain probiotic treatment for eczema.
Five trials have been published since 2000. The trial by Rosenfeldt and colleagues284 compared a powdered
mixture of lyophilised Lactobacillus rhamnosus 19070–2 and Lactobacillus reuteri DSM 122460 against
powdered skimmed milk powder as a placebo. Fifty-eight children aged 1–13 years with eczema
diagnosed using the UK Working Party’s criteria9 were given the active and the placebo treatment twice
daily for 6 weeks in a randomised order, with a 6-week washout phase in between.
Sistek and colleagues285 compared a powdered mixture of L. rhamnosus and Bifidobacterium lactis against a
placebo of microcrystalline cellulose. Sixty-two children aged 1–10 years were randomised to once-daily
treatment for 12 weeks. Some older children took the treatments in the opaque capsules, but most children
took the treatment as the powder mixed with water. The participants were followed for 16 weeks.
The trial by Cukrowska and colleagues286 specifically recruited children aged < 24 months who had eczema
and symptoms of cow’s milk allergy when taking cow’s milk protein and who were currently not having
milk in their diet or being breastfed. The trial compared a mixture of lyophilised Lactobacillus casein
LOCK0900, Lactobacillus casein LOCK0908 and Lactobacillus species LOCK0919 on hydrolysed casein
against a placebo of hydrolysed casein. Both treatments were taken for 3 months.
Yesilova and colleagues287 conducted an 8-week study comparing a mixture of four probiotic strains
(Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarius) with a
‘placebo’ of skimmed milk powder. Forty children aged 1–13 years with moderate to severe eczema
according to the Hanifin and Rajkas8 criteria were randomised. Participants did not use any eczema
medication during the 2 weeks before enrolment to the study. It is not clear whether the participants were
allowed to use other treatments during the study.
The trial by Iemoli and colleagues288 compared a combination of two probiotic strains, L. salivarius LS01
and Bifidobacterium breve BR03, given twice daily for 12 weeks against placebo in 48 adults with eczema.
Assessment of risk of bias
Table 61 provides the risk-of-bias assessment for the new studies.
TABLE 61 Mixed-strain probiotics: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Cukrowska 2008286 Unclear risk Unclear risk Unclear risk
Iemoli 2012288 Unclear risk Unclear risk Unclear risk
Rosenfeldt 2003284 Unclear risk Unclear risk Unclear risk
Sistek 2006285 Low risk Unclear risk Low risk
Yesilova 2012287 Unclear risk Unclear risk Unclear risk Disease severity was different
between the groups at baseline
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Benefits
The trial by Rosenfeldt and colleagues284 showed no significant difference in the change in severity and
itching during probiotic treatment compared with placebo treatment. The trial analysed the subgroup of
participants who had one or more positive skin-prick tests and raised IgE and found a significant difference
between the groups in the change in eczema severity from baseline. It is not clear whether this was a
preplanned subgroup analysis.
The trial by Sistek and colleagues285 did not find any significant difference in change in severity from
baseline between probiotic treatment and placebo treatment in the whole trial population when the
results were adjusted because of significantly higher eczema severity in the treatment group at baseline.
A significant difference in change in severity from baseline was found in a post hoc subgroup analysis of
43 children who were found to be sensitised to food (geometric mean ratio 0.73, 95% CI 0.54 to 1.00;
p= 0.047). These results were also mirrored for the number of food-sensitised children who had an
improvement in SCORAD score at the end of the 12 weeks of treatment (probiotic treatment 18/19,
placebo group 15/24; p= 0.01). A post hoc analysis of those children who were not sensitised to food did
not show any significant differences between groups.
The trial by Cukrowska and colleagues286 did not find any significant difference between the treatment
groups in the number of participants with improved severity compared with the number of participants
with no improvement or deterioration, either at the end of treatment (3 months) or after 8 months, for the
whole treatment population, who all displayed symptoms of allergy to cow’s milk. A significant difference
between the groups at the end of treatment was found in an identical post hoc analysis of participants
with ‘IgE-dependant eczema’, with the number of participants in this subgroup not reported (odds ratio
11, 95% CI 1.108 to 112.08; p= 0.0329). No significant difference between the groups was found in an
identical post hoc analysis of participants with ‘IgE-independent eczema’; again, the number of participants
in this subgroup was not reported.
The trial by Yesilova287 reported a significant difference in SCORAD eczema severity from baseline to
8 weeks between the probiotic group (from 35.4 SD± 13.4 to 12.4 SD± 7.2) and the placebo group (from
28.1 SD± 6.1 to 15.3 SD± 5.1; p= 0.0015).
In the trial by Iemoli and colleagues,288 the changes in severity were not compared between the two
groups, making it impossible to assess the results of the trial. The authors simply stated that there was a
significant reduction in SCORAD score in the mixed probiotic group from baseline to the end of the study
(from 46.2 to 29.4; p< 0.001) and not in the placebo group (from 45 to 40.2; not significant) and that
this effect continued for 2 months after suspension of treatment. They also stated that there were
significant changes in quality of life as measured by the DLQI in the probiotic group but not in the
placebo group.
Harms
Four of the trials284–287 did not report any information about adverse events. The trial by Iemoli and
colleagues288 reported that no significant adverse events were recorded in the study.
Single-strain probiotics
Studies
No trials were reported before 2000 on single-strain probiotic treatment for eczema.
Sixteen289–304 new trials were reported after 2000. Nearly all of the 16 trials reported compared a probiotic
against an inactive placebo or occasionally against no treatment. Treatment was given for periods ranging
from 4 weeks to 1 year (mostly 8 or 12 weeks) and some trials followed up the participants for a few more
weeks. Three trials290,291,297 administered the probiotic in a hydrolysed cow’s milk formula and compared
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this against hydrolysed milk formula only in infants. Only one trial compared two strains of probiotics in
hydrolysed milk formula against each other and a placebo of maltodextrin in a three-arm comparison
trial.302 In 13289–293,295–298,300,302 of the 16 trials the participants were children, particularly infants. Only three
trials,294,299,301 conducted in Japan and Italy, included adult participants.
Assessment of risk of bias
Table 62 provides the risk-of-bias assessment for the new studies.
Lactobacillus rhamnosis GG
Benefits
The trial by Nermes and colleagues290 found no significant difference in eczema severity between
L. rhamnosis GG in extensively hydrolysed casein formula and the same formula only at either 1 month or
3 months (end of treatment). The trial by Grüber and colleagues289 found no significant differences in
either severity or itching at any time point between placebo and L. rhamnosis GG groups.
TABLE 62 Single-strain probiotics: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
L. rhamnosis GG
Brouwer 2006291 Unclear risk Unclear risk Unclear risk
Fölster-Holst 2006292 Unclear risk Unclear risk Unclear risk
Grüber 2007289 Low risk Unclear risk Low risk
Nermes 2011290 Unclear risk Unclear risk Unclear risk
Viljanen 2005293 Low risk Unclear risk Unclear risk
Other lactobacilli
Drago 2012301 Low risk Low risk Unclear risk
Gøbel 2010300 Unclear risk Unclear risk Unclear risk
Gore 2012302 Unclear risk Unclear risk Unclear risk It is unclear whether intention-to-treat
rules have been used in this study
Han 2012304 Low risk Low risk Unclear risk
Moroi 2011294 Unclear risk Unclear risk Unclear risk
Torii 2011296 Low risk Unclear risk Unclear risk
Weston 2005303 Unclear risk Unclear risk Unclear risk
Woo 2010295 Unclear risk Unclear risk Unclear risk
Bifidobacterium
Isolauri 2000297 Unclear risk Unclear risk Unclear risk
Taniuchi 2005298 Unclear risk Unclear risk Unclear risk
Yoshida 2010299 Unclear risk Unclear risk Unclear risk
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In the trial by Brouwer and colleagues291 the change in severity of eczema was not significantly different
between the L. rhamnosis in extensively hydrolysed whey formula group, the L. rhamnosis GG in
extensively hydrolysed whey formula group and the extensively hydrolysed whey formula-only group and
the change from baseline was significant in all three groups. In the trial by Fölster-Holst and colleagues292
there was no significant difference between the L. rhamnosis GG group and the placebo group in change
in eczema severity, itching and sleep loss, quality of life and use of corticosteroids at any time point. The
trial by Viljanen and colleagues293 found no significant difference in change in eczema severity in the whole
population between the L. rhamnosis GG group, the mix of five probiotics group and the placebo group
and also in subgroups of participants who were cow’s milk allergy positive, cow’s milk allergy negative and
IgE association negative. There was a significant difference in change in eczema severity in the subgroup of
participants who were IgE association positive; however, this was not reported as being a prespecified
subgroup analysis.
Harms
Three of the trials290,291,293 did not report any data on adverse events. The two trials289,292 that reported
adverse events did not find any serious adverse events. Other adverse events included lower respiratory
tract infections, ear, nose and throat infections, gastrointestinal complaints, nausea and vomiting and
other infections, but all of these were not significantly different between the treatment groups.
Other lactobacilli
Lactobacillus sakei KCTC 10755BP
The trial by Woo and colleagues295 compared Lactobacillus sakei KCTC 10755BP in microcrystalline
cellulose twice daily for 12 weeks with placebo in children aged 2–10 years with stable, moderate to
severe eczema (SCORAD score of > 25). All participants were told to bathe for 10 minutes a day and then
apply emollients; they could also use prednicarbate (0.1%) as required during the trial. Although the
severity of eczema, reported to be adjusted for SCORAD score and cytokines, was significantly different
between the groups after 12 weeks of treatment, the trial report gives statements that seem to conflict
with this result and make the results of this trial impossible to interpret.
Lactobacillus fermentum VRI-003 PCC
The trial by Weston and colleagues303 in Perth, Australia, compared treatment with Lactobacillus
fermentum VRI-003 PCC twice a day for 8 weeks against placebo in 56 children aged between 6 and
18 months with moderate to severe eczema (modified SCORAD score of ≥ 25). The change in severity of
eczema was recorded and decreased in both groups: the probiotics group decreased by a median of 17
(25th to 75th percentile: 9.8 to 24.6) and the placebo group decreased by a median of 12 (25th to 75th
percentile: –5 to 20); however, a between-group analysis of these decreases was not reported. The
percentage of participants with an improved SCORAD score at week 16 was reported as 92% in the
probiotics group and 63% in the placebo group. There were no particular differences between the groups
in parents’ perception of the eczema, both during treatment and after stopping treatment. Dermatitis
Family Impact scores also hardly differed between the interventions. No specific adverse events were
reported; however, one child’s vomiting did cause concern for the parents.
Lactobacillus acidophilus NCFM (ATCC700396)
A government-funded trial by Gøbel and colleagues300 in Denmark compared L. acidophilus NCFM
(ATCC 700396) treatment once a day for 8 weeks against treatment with Bifidobacterium animalis
subspecies Lactis Bi-07 (ATCC SD5220) or placebo. The trial included 50 children aged 7–24 months with
eczema involving continuous itching. All but one participant had a first-degree relative with allergy. No
significant differences were found between the groups in terms of change in severity of eczema, with or
without adjustment for confounding factors: gender, predisposition to allergy, age and whether IgE values
had increased. The analysis of severity included all 50 participants who were randomised to treatment.
Objective SCORAD scores were also reported to show no differences. It is not clear whether this was a
post hoc analysis. Data on adverse events were not reported.
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Lactobacillus paracasei K71 (heat killed)
A government-funded trial carried out in Japan by Moroi and colleagues294 compared a once-daily dose of
heat-killed Lactobacillus paracasei K71 for at least 12 weeks against placebo in 34 adults with mild to
moderate eczema. There was no significant difference between the groups in change in eczema severity or
change in itch scores or quality of life. There was greater use of topical corticosteroids in the placebo
group but this was not significant. One participant in the treatment group suffered from headache and
nausea and four participants in the placebo group had six adverse events (headache, toothache, diarrhoea,
stomach ache, nausea and vomiting).
Lactobacillus paracasei CNCM I-2116
A trial by Gore and colleagues302 compared a once-daily dose of L. paracasei CNCM I-2116 with a once-
daily dose of Bifidobacterium lactis CNCM I-3446 or placebo for 3 months in 137 babies aged 3–6 months
with physician-diagnosed eczema. All participants were fed an extensively hydrolysed whey formula during
the study. There was an open observational group including excluded babies (those who were exclusively
breastfed and those whose parents did not want to substitute the study formula). In the highly selected
trial population there was no significant difference in severity of eczema measured by the SCORAD index
between randomised groups at any time point up to age 3 years. Results were similar when analysis was
controlled for allergen sensitisation or when only sensitised infants were analysed. No steroid-sparing
effect, measured using frequency of use and potency of topical steroids, was observed between groups.
At the 4-week visit, 42 out of 137 (30.7%) parents reported some difficulties (e.g. green loose stools,
increased vomiting, feed refusal or colic) related to the change in formula and 24 out of 137 (17.5%) had
stopped using the study formula.
Lactobacillus acidophilus L-92
A trial by Torii and colleagues296 conducted in Japan compared heat-treated L. acidophilus L-92 given for
8 weeks against placebo in 60 children with eczema who were tolerant to cow’s milk. The severity of
eczema, measured using an adaptation of the Atopic Dermatitis Area and Severity Index (ADASI),
significantly decreased over time in the treatment group compared with the placebo group (p= 0.0474).
No other measures of clinical benefit were performed. No information about adverse events was reported.
Lactobacillus salivarius LS01
A trial by Drago and colleagues conducted in Italy301 compared Lactobacillus salivarius LS01 given twice
daily for 16 weeks against a placebo of maltodextrin in 38 adults with moderate to severe eczema. The
authors did not compare the changes in severity between the two groups, making it impossible to assess
the comparative effectiveness of the treatments being tested. They stated only that there was a significant
reduction in SCORAD score in the probiotic group from baseline to the end of the study (from 27.6 to
13.1; p< 0.001) but not in the placebo group (from 24.3 to 20.1; not significant). Likewise, the authors
reported significant changes in quality of life, measured using the DLQI, in the probiotic group [from 8.28
SD± 1.79 at baseline to 4.57 SD± 1.11 after 8 weeks (p= 0.02) and 4.42 SD± 0.27 after 16 weeks
(p= 0.04)] but not in the placebo group. No significant adverse events were recorded.
Lactobacillus plantarum CJLP133
A 16-week trial by Han and colleagues304 conducted in South Korea compared twice-daily Lactobacillus
plantarum CJLP133 for 12 weeks against placebo in 118 children aged 1–13 years with eczema according
to the Hanifin and Rajkas8 criteria. Disease severity measured by the SCORAD index was significantly lower
in the probiotic group than in the placebo group after 14 weeks (20.4 vs. 25.6; p= 0.044). Changes in
disease severity measured by the SCORAD index were significantly higher in the probiotic group than
in the placebo group at 14 weeks (9.1 vs. 1.8; p= 0.004). The changes were also significantly different at
16 weeks (7.6 vs. 2.6; p= 0.041). Overall, the changes were significantly different in the intention-to-treat
population and in patients who did not use topical steroids but not in patients who did use topical steroids
as a rescue treatment during the study. However, the total amounts of topical corticosteroids used through
the trial in the probiotic and placebo groups were the same. Adverse events were not reported in this study.
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Bifidobacterium
Bifidobacterium breve YY
A small pilot study carried out in Japan with an 8-week duration299 compared twice-daily treatment with
capsules of live lyophilised B. breve YY against placebo in 24 adults with eczema diagnosed according to
the Japanese Dermatological Association26 criteria. Severity measured by objective SCORAD score and
quality of life were both reported as significantly different between the groups, with a decrease from a
mean objective SCORAD score of 33.7 to 28.9 in the treatment group of 16 adults compared with a
decrease from a mean objective SCORAD score of 21.8 to 21.1 in the placebo group of eight adults. The
baseline values for both total and objective SCORAD scores and quality of life, as well as other indicators
of severity such as thymus and activation-regulated chemokine and serum IgE levels, were significantly
higher in the treatment group at baseline, which calls into question the randomisation process and makes
the changes in severity and quality of life in this trial impossible to interpret. No data on adverse events
were reported for this trial.
Bifidobacterium lactis Bb-12
A trial by Isolauri and colleagues297 randomised 27 exclusively breastfed infants to three treatment groups:
B. lactis Bb-12-supplemented extensively hydrolysed formula, L. rhamnosis GG-supplemented extensively
hydrolysed formula or unsupplemented extensively hydrolysed formula. It is not clear how long the
participants were given treatment for but all participants were weaned on to the formula at the start of
the study. The probiotic-supplemented formulas both showed significant decreases in eczema severity after
2 months compared with the unsupplemented formula, which showed an increase in eczema severity
[B. lactis Bb-12: from median of 12 to 0 (range 0–3.8); L. rhamnosis GG: from median of 14.5 to 1
(range 0.1–8.7); unsupplemented formula: from median of 10 to 13.4 (range 4.5–18.2)]. All baseline
values were extrapolated from a graph in the trial report. Interestingly, all three treatment groups had a
median SCORAD score of 0 (range 0–6.6) at 6 months.
Bifidobacterium breve M-16V
A trial by Taniuchi and colleagues298 compared B. breve M-16V with placebo. The trial included
participants with cow’s milk allergy proven by clinical symptoms, a positive radioallergosorbent test (RAST),
a positive skin-prick test and < 30% Bifidobacterium in their intestinal microflora after being fed casein-
hydrolysed formula milk for at least 1 week. The planned outcome of eczema severity was not reported
and so it is impossible to assess the impact of this probiotic on eczema.
Overall implications for research and practice for mixed-strain and
single-strain probiotics
There is reasonably strong evidence from three trials284–286 that mixtures of probiotic strains do not show
any benefit over placebo for children with eczema, whether or not they have symptoms of cow’s milk
allergy or are sensitised to one or more allergens. All three trials undertook subgroup analyses that were
not prespecified and reported a significant benefit for those children with raised IgE levels. Only one small
trial comparing a mixture of four different probiotic strains compared with skimmed milk powder in
children reported a significant difference in change in disease severity between the probiotic group and
the placebo group.287 However, although not compared statistically, the severity of eczema in the active
treatment group was noticeably higher than in the placebo group at baseline and it was unclear whether
this imbalance had been adjusted for in the statistical comparisons. In the absence of any trials specifically
designed and powered to test mixtures of probiotic strains in people with eczema who are proven as
‘atopic’ with raised circulating IgE antibodies, it is impossible to assess whether probiotics are of true
benefit over placebo. In reality, routine tests for atopy are not conducted, especially in primary care, and
with up to two-thirds of those with eczema not ‘atopic’ there is only limited potential for mixtures of
probiotic strains for the treatment of established eczema.
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Probiotic strains of lactobacilli mostly do not show any good evidence of significant benefit over placebo in
addition to standard treatments for eczema over a period of 8–12 weeks. Most of the trials do not give
enough information about the methodology used, especially for allocation concealment, blinding and
which outcome and statistical analyses were prespecified. The trials have mostly been small and often raise
questions about the generalisability of the results, as selective trial populations have been studied. All five
trials on L. rhamnosis have not shown any evidence of clinical benefit for eczema compared with placebo
and probably now equate to evidence of no benefit, given the overall weight of evidence. One moderately
sized trial involving L. paracasei in unselected infants provided no evidence of benefit of this treatment
compared with placebo. Another trial involving L. plantarum provided some weak evidence of benefit
compared with placebo. The only potential evidence of benefit may be for people with truly ‘atopic’
eczema, as suggested by a few reported subgroup analyses; however, this requires further specific research
as none of these subgroups appears to have been prespecified. Even though there is a large amount of
‘noise’ in these trials because of a lack of clarity of reporting, it seems likely that, with the majority of trials
on lactobacilli probiotics not showing any significant benefit for the treatment of eczema, there is no
beneficial effect to be found.
Prebiotics
Prebiotics are short-chain carbohydrates (oligosaccharides) that stimulate the growth of beneficial gut
bacteria such as lactobacilli and bifidobacteria species.
Studies
No RCTs involving prebiotics were reported before 2000.
Two new trials have been published since 2000. A trial conducted in Japan by Shibata and colleagues305
included children under 3 years of age with atopic eczema defined according to the criteria of the
Japanese Dermatological Association.26 The trial compared oral kestose, an oligosaccharide that
encourages the growth of bifidobacteria, every day for 12 weeks against no treatment. The participants
were able to use topical corticosteroids during the trial.
A trial by Ghanei and colleagues306 carried out in Iran compared fructo-oligosaccharides and inulin in
powder added to milk against a placebo of dextrin powder. The trial included 90 children aged between
7 and 24 months who were full term and a normal birth weight. The children had been delivered by
caesarean section and diagnosed with eczema by a physician and had started solid food by the age of
6 months. The treatment was given every day for 90 days (5 g for those aged 7–12 months, 7.5 g for
those aged 13–18 months and 10 g for those aged 19–24 months).
Assessment of risk of bias
Table 63 provides the risk-of-bias assessment for the new studies.
TABLE 63 Prebiotics: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Ghanei 2011306 Unclear risk Unclear risk Unclear risk Baseline severity of eczema in the active
group was twice as high as that in the
control group. No intention-to-treat
analysis reported and final number
analysed was only 70 out of 90
randomised
Shibata 2009305 Low risk Unclear risk Low risk
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Benefits
The trial by Shibata and colleagues305 showed a significant reduction in eczema severity for the participants
using the kestose probiotic compared with those using the placebo after 12 weeks, with a median
SCORAD score in the kestose group of 19.5 (range 25.6–22.0) and in the placebo group of 37.5 (range
25.5–43.5; p< 0.001). The baseline SCORAD values were 41.3 (range 36.2–46.4) in the kestose group and
38.3 (range 26.3–41.8) in the placebo group and, although the change in severity of each group was not
compared, it does seem to show a greater decrease in the kestose group; however, no analysis for this
was performed. This apparent benefit was reflected in the measurement of eczema severity using the
Intensity of Atopic Dermatitis (maximum score 12 points), although, again, no analysis of the difference
between the groups in change in severity was carried out.
The trial by Ghanei and colleagues306 reported a significant difference between the groups in eczema
severity at the end of treatment; however, again, no comparison was made of the change in eczema
severity between the groups over the treatment period. This change was reported as significant for both
groups and so it is unlikely that there is a significant benefit from the fructo-oligosaccharide and inulin
powder compared with placebo for the treatment of eczema.
Harms
The trial by Shibata and colleagues305 did not report information on adverse events. In the trial by Ghanei
and colleagues306 there was one report of diarrhoea lasting for > 1 week in the placebo group; no other
information was reported.
Overall implications for research and practice
The lack of information on the relative use of other eczema treatments by participants and the appropriate
comparisons of eczema severity, coupled with a large difference in baseline eczema severity in one trial,
make interpretation of the clinical significance of these trials very difficult. The relatively large number
of withdrawals of those not taking the treatment for > 75 out of 90 days in the trial by Ghanei and
colleagues306 may be masking potential problems with the treatment, such as unpalatability or even
adverse events. Trials that pay detailed attention to randomisation, allocation concealment and blinding of
all stakeholders, especially the outcome assessors and the participants, are needed. The age range of the
participants in these trials also poses a problem as there is a large change in the prevalence of eczema over
the age range from 6 months to 3 years.
Synbiotics
Synbiotics are optimal combinations of prebiotics and probiotics.
Studies
No trials involving synbiotics were reported up to the year 2000.
Eight trials307–314 involving synbiotics were reported from 2000. The eight trials on synbiotics all tested
different combinations of probiotics and prebiotics. All but two trials309,313 compared the synbiotics against
an inactive placebo or a placebo of the hydrolysed formula given to both groups. These other two trials
compared the synbiotic against the probiotic or the prebiotic only.
Assessment of risk of bias
Table 64 provides the risk-of-bias assessment for the new studies.
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Benefits
Farid and colleagues312 found a significant difference in change in eczema severity according to SCORAD
scores from baseline to 4 weeks [treatment group mean –29.51 (SD 19.09) vs. control group mean –11.06
(SD 10.96); p= 0.001] and 8 weeks [treatment group mean –39.2 (SD 24.22) vs. control group mean
–20.10 (SD 8.63); p= 0.005], but the difference was not significant between week 4 and week 8.
Gerasimov and colleagues307 found a significant difference in change in eczema severity from baseline after
8 weeks of treatment [L. acidophilus DDS-1 and B. lactis UABLA-12 combined with fructo-oligosaccharide
group mean –14.2 (SD 9.9) vs. placebo group mean –7.8 (SD 7.7); p= 0.001]. It is not clear whether the
analysis was carried out on an intention-to-treat basis including the five participants in the treatment group
and one in the placebo group who withdrew during the trial.
Van der Aa and colleagues308 compared a mixture of B. breve M-16V and galacto-/fructo-oligosaccharide
against placebo and found no significant difference in change in eczema severity after 12 weeks in the
whole trial population. There was, however, a significant difference in change in severity within the
IgE-associated eczema subgroup of 45 participants (synbiotic group –18.1 SD± 1.6 vs. control group
–13.5 SD± 1.6; p= 0.04), although it was not clear whether this was a preplanned analysis.
Hattori and colleagues310 also found a significant difference in change in eczema severity from baseline,
measured using cutaneous signs, between B. breve M-16V with raffinose and placebo (p= 0.0344).
This analysis involved only 15 participants and the median change in score from baseline was –3.5
(range 0 to –6) for the synbiotics group compared with –1 (range 0 to –4) for the placebo group.
Murosaki and colleagues311 and Passeron and colleagues309 reported no significant difference in change in
severity of eczema, itching or quality of life for synbiotic treatment compared with placebo311 or
probiotic.309 Shafiei and colleagues314 reported no significant difference in change in eczema severity
between synbiotic and placebo treatment for 2 months.
Wu and colleagues313 compared a mixture of L. salivarius plus prebiotic (fructo-oligosaccharide) for 8 weeks
against prebiotic alone in 60 children with moderate to severe eczema. They found a significant difference
in eczema severity measured by the SCORAD index between the experimental group and the control
group at 8 weeks (27.4 vs. 36.3; p= 0.022). No significant differences were found between groups for
quality of life assessed by an unvalidated scale or for medication use.
TABLE 64 Synbiotics: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Farid 2011312 Unclear risk Unclear risk Unclear risk Relatively large number of
withdrawals (12/40), who were not
included in the final analyses
Gerasimov 2010307 Low risk Unclear risk Low risk
Hattori 2003310 Unclear risk Unclear risk Unclear risk
Murosaki 2006311 Unclear risk Unclear risk High risk
Passeron 2006309 Unclear risk Unclear risk Unclear risk
Shafiei 2011314 Low risk Unclear risk Low risk Not clear whether the five participants
who withdrew were included in the
analyses
van der Aa 2010308 Low risk Low risk Low risk Industry sponsored (Danone)
Wu 2012313 Low risk Unclear risk Low risk
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Harms
These trials reported a range of levels of adverse events. Only the trial by Hattori and colleagues310 did not
report any information about adverse events. Serious adverse events in the probiotics group consisted of
one burn and one croup and those in the placebo group consisted of one head injury and two food
poisoning cases.307 Two serious adverse events that resulted in hospitalisation were a case of respiratory
syncytial virus and a severe allergic reaction to cow’s milk.308 Farid and colleagues312 reported no significant
adverse events but did not give any further data on adverse events. Passeron and colleagues309 reported no
serious adverse events and three cases of abdominal pain, two in the synbiotics group and one in the
probiotics group. Murosaki and colleagues311 reported one case of nausea in the placebo group. Van der
Aa and colleagues308 reported that 91.1% of participants in the synbiotic group and 84.1% of participants
in the placebo group experienced adverse events but that none of these was considered to be related to
treatment; one participant used antibiotics in the synbiotics group and five participants used antibiotics in
the placebo group, but this was not significantly different between the groups. Gerasimov and
colleagues307 reported that 60.5% (n= 26) in the synbiotics group and 51.5% (n= 24) in the placebo
group experienced adverse events. The trial by Shafiei and colleagues314 did not specifically report adverse
events; however, two children were withdrawn because of diarrhoea in a twin. Wu and colleagues313
reported mild diarrhoea in two patients in the synbiotics group.
Overall implications for research and practice
A feature of these trials appears to be the level to which ‘data mining’ is taking place, that is, trying to find
a significant result using outcomes and subgroups that were not originally planned. The evidence is
conflicting over whether synbiotics are beneficial for eczema. This may be because of the differences in the
combinations of probiotics and prebiotics tested; however, the lack of methodological detail and small trial
populations also mean that the evidence is not convincing.
Essential fatty acid supplementation
Borage oil
Borage oil is extracted from the seeds of the borage plant (Borago officionalis) and has high levels of
omega-6 fatty acids, higher than evening primrose oil and blackcurrant seed oil.
Studies
Five trials involving borage oil were reported before 200055 (see Appendix 3).
One new trial involving borage oil was reported after 2000. This trial, by Takwale and colleagues,315
compared borage oil capsules (23% gamma-linoleic acid) with liquid paraffin (adults) or olive oil (children),
given twice daily for 12 weeks. In total, 151 participants were randomised.
Assessment of risk of bias
Table 65 provides the risk-of-bias assessment for the new study.
TABLE 65 Borage oil: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Takwale 2003315 Low risk Low risk Unclear risk Although it is reported that the
participants were blinded and that
the capsules for the treatments
‘matched’, it is not reported whether
the outcome assessor for severity of
eczema was blinded
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Benefits
This trial315 focused on participant-assessed outcomes of itching, sleep loss and irritability as well as
response to treatment, tolerability and need for topical corticosteroids. The trial also objectively measured
the severity of eczema using SASSAD scores. The treatments were given for a reasonably long period of
time to potentially see an effect; however, this trial failed to show any significant differences between the
treatments for any of these outcomes. There was also no significant difference between the groups in the
need for topical corticosteroids.
Harms
Many different adverse events were reported, with the most common being upper respiratory tract
infection, which affected 26% of the borage oil group and 38% of the placebo group. The next most
common events were diarrhoea (7% of the borage oil group and 11% of the placebo group) and skin
sepsis (7% of the borage oil group and 13% of the placebo group). The report does not comment on
whether any of the adverse events reported are related to the study treatment.
Evening primrose oil (oral)
Studies
Six trials involving evening primrose oil were reported up to 200055 (see Appendix 3).
One new trial316 by Senapati and colleagues was reported in 2008. Oral evening primrose oil [8–10%
gamma-linolenic acid (GLA) per 500-mg capsule] was compared with oral sunflower oil (300-mg capsules)
for 5 months. The 65 participants took different numbers of capsules per day, split into two doses, ranging
from one to four capsules for those aged < 1 year and 12 capsules for those aged ≥ 16 years. Participants
were always given the maximum dose applicable.
Assessment of risk of bias
Table 66 provides the risk-of-bias assessment for the new study.
Benefits
Both groups showed a significant difference in total severity score (extent, intensity, dryness and itching)
between baseline and 5 months. The number of participants who ‘improved’ after 5 months (≤ 75% of
their baseline score) compared with baseline was 96% (24/25 participants) for treatment with evening
primrose oil and 32% (8/25 participants) for placebo treatment (difference between groups p= 0.00001).
None of the other outcome measures was compared between groups and so it is not clear whether there
were any other significant differences between treatments.
Harms
It was reported that no treatment-related adverse events occurred during the trial.
Fish oil (omega-3)/soybean oil (omega-6)
Fish oils contain the omega-3 fatty acids EPA and DHA. EPA and DHA are precursors to a number of
substances that have been shown to reduce inflammation. Soybean oil is one of the most widely
consumed cooking oils and contains high levels of omega-6 fatty acids.
TABLE 66 Evening primrose oil (oral): risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Senapati 2008316 Low risk Unclear risk Unclear risk Serious concern of attrition bias
as analysis included only the first
25 participants from each group
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Studies
Three trials involving fish oil were reported before 200055 (see Appendix 3).
One new trial involving fish oil was reported after 2000. This trial, by Mayser and colleagues,317 compared
two 10% lipid emulsions, one derived from fish oil (n-3) and one derived from soybean oil (n-6). These
were delivered by intravenous infusion twice a day for 10 days. The trial involved 22 participants with
moderate to severe eczema according to the Hanifin and Rajka8 criteria, with > 10% body surface
area involvement.
Assessment of risk of bias
Table 67 provides the risk-of-bias assessment for the new study.
Benefits
This small industry-funded trial in hospitalised participants found a short-term benefit of fish oil over
soybean oil, which started at day 6 of the infusion treatment and disappeared when the infusions were
stopped, resulting in some cases of a relapse of eczema. In the initial few days of treatment, the fish oil
infusion showed some hint of benefit and from day 6 to day 10 there was a significant difference in favour
of fish oil infusion.
Harms
One participant given the fish oil infusion experienced vertigo, whistling in the ears and pallor after the
infusion. One participant given the soybean oil infusion experienced hypertriglyceridaemia. Three
participants in the fish oil group and one in the soybean oil group had an oily taste in their mouth during
the infusion.
Docosahexaenoic acid
This acid belongs to the group of n-3 polyunsaturated fatty acids and inhibits T-cell activation and
proliferation and reduces the numbers of granulocytes circulating in the blood.
Studies
Docosahexaenoic acid had not previously been tested as a treatment in its own right before 2000.
One new trial involving DHA was reported after 2000. This trial, by Koch and colleagues,318 recruited
54 adults aged between 18 and 40 years who had eczema according to the Hanifin and Rajka8 criteria.
The participants received either 5.35 g of DHA and 0.37 g of EPA as ethyl esters per day or 4.17 g of
caprylic acid and 2.84 g of capric acid per day for 8 weeks as seven capsules per day.
Assessment of risk of bias
Table 68 provides the risk-of-bias assessment for the new study.
Benefits
This fairly small trial318 found no significant difference between the groups in the severity of eczema
measured using the SCORAD index. There was a decrease in the median SCORAD score of 20 for the DHA
treatment group and 12.4 for the placebo treatment group in the participants who completed the trial at
week 20.
TABLE 67 Fish oil (omega-3)/soybean oil (omega-6): risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Mayser 2002317 Unclear risk Unclear risk Unclear risk Withdrawals were replaced with
more randomised participants but it is
not clear whether the withdrawals
were included in the analysis
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Harms
The authors reported that three participants experienced mild abdominal discomfort in the DHA group. It
does not appear from the trial report that there were any withdrawals because of adverse events. Of the
53 participants, 44 completed the entire study course. Six patients failed to complete the study, two
because of ‘hospitals stays’ and four because of ‘non-compliance’. Three patients were excluded from the
analysis, one because of ‘excessive sunbathing’ and two because of a lack of interruptions to the trial
protocol regarding the use of standard medication.
Hempseed oil
Up to 35% of the weight of hempseed is an edible oil with a high EFA content (approximately 80%),
including omega-6 (55%) and omega-3 (22%) fatty acids. This oil is extracted and often used as a
dietary supplement.
Studies
Hempseed oil had not previously been tested as a treatment for eczema before 2000.
One new trial involving hempseed oil was reported after 2000. This crossover trial by Callaway and
colleagues319 compared cold pressed hempseed oil against cold pressed extra virgin olive oil. Twenty adults
aged between 25 and 60 years with eczema according to the Hanifin and Rajka8 criteria and a body mass
index of < 30 kg/m2 were included. Participants supplemented their diet with one type of oil for 8 weeks
and, following a 4-week wash-out period, then supplemented their diets with the other type of oil
for 8 weeks.
Assessment of risk of bias
Table 69 provides the risk-of-bias assessment for the new study.
Benefits
This trial did not show any significant benefit from taking cold pressed hempseed oil for eczema.
Harms
Only 16 patients (one male, 15 female) completed the study. Of the withdrawals, three occurred in the
first week for personal reasons and one patient withdrew in week 14 because of the taste of the
hempseed oil. However, the trial reported no adverse events from the treatments in the trial.
TABLE 68 Docosahexaenoic: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Koch 2008318 Unclear risk Low risk Unclear risk Intention-to-treat principle was not
used for the analyses
TABLE 69 Hempseed oil: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Callaway
2005319
Low risk Unclear risk High risk Lead author had a financial interest in
the production and sale of hempseed
oil. Four out of the 20 participants
withdrew and were not included in
the analysis
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Overall implications for research and practice
The large fairly well-reported trial on borage oil315 showing no evidence of benefit for objective and
participant-assessed outcomes, similar to the results found in a previous large trial,320 adds to the weight
of evidence showing no beneficial effect of borage oil for eczema. The questions around whether there
is a subgroup of the population with eczema who may respond to borage oil and whether increased
adherence may show beneficial effects have not been addressed.
The additional small study on oral evening primrose oil316 showed a significant benefit of taking evening
primrose oil compared with a placebo of sunflower oil. The potential bias introduced by analysing only the
first 25 participants from each treatment group, and the lack of clarity about whether the outcome
assessors were blinded to treatment allocation, means that this result must be treated with caution. This
trial does not change the overall body of evidence on evening primrose oil for eczema, with the largest
and best-reported trials not providing any evidence of benefit and other trials providing conflicting results
(ranging from no hint of benefit to a 10–20% improvement).
A small pilot trial317 showed a short-term but marked improvement in eczema in a small number of
participants treated with fish oil and a slower to develop, but longer-lasting improvement in participants
treated with soybean oil. It is not easy to interpret whether these results are clinically significant because of
the lack of a control group of standard care and a placebo. A concern with this trial is the addition of new
randomised participants when participants were withdrawn as it is not clear which participants were
included in the final analysis. Further trials on these treatments should evaluate whether they can be taken
orally as infusions may not be as readily acceptable to patients and take more resources to administer.
The trial on DHA318 showed a hint of a modest beneficial effect of DHA compared with EPA on eczema
severity after the treatment had been stopped. Larger, longer-term trials are needed that concentrate on
participant-assessed outcomes such as quality of life and acceptability of treatment, as well as on objective
and subjective measures of severity.
The very small pilot trial on hempseed oil,319 in which the participants would have very easily been able to
determine which treatment they were taking, did not show any significant benefit from hempseed oil for
skin dryness and itchiness as assessed by the participants.
Vitamins D and E (oral)
As phototherapy is beneficial for eczema, is has been hypothesised that vitamin D supplementation may
be beneficial for those living with eczema at higher latitudes, as vitamin D deficiency is more common.
The possible association between vitamin D levels, eczema prevalence and severity is unclear.321–325
Studies
No trials reported before 2000 involved oral vitamin D as a treatment for eczema.
Three trials were reported after 2000, with one trial examining oral ergocalciferol (vitamin D2),326 one
examining cholecalciferol (vitamin D3) and one examining vitamin D3 and vitamin E supplementation.
The small pilot trial by Sidbury and colleagues,326 reported in a letter, compared 1000 IU per day of
ergocalciferol with placebo for 1 month in children aged 2–13 years. The eczema must have had a winter
onset or exacerbation and the trial was conducted in the winter. All but one child had mild eczema
(EASI score between 10 and 18.6). The 11 children randomised into the trial were allowed to continue all
current treatments but were not allowed to start any new treatments and were not allowed to travel to
temperate climates during the trial.
DOI: 10.3310/pgfar04070 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 7
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nankervis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
The trial by Amestejani and colleagues327 compared 1600 IU per day of cholecalciferol for 2 months with
placebo in adults and adolescents aged ≥ 14 years. In total, 60 participants diagnosed with eczema using
the Hanifin and Rajka8 criteria and with a mean SCORAD score of 25 were randomised; however; only the
54 participants who completed the study were included in the analysis. Usual treatments (emollients,
topical corticosteroids, oral antihistamines) were permitted during the study period in both
treatment groups.
The trial by Javanbakht and colleagues328 randomised 52 adult participants with eczema according to the
Hanifin and Rajka8 criteria into four treatment groups: 1600 IU per day of vitamin D3 taken concurrently
with placebo; 600 IU per day of vitamin E taken concurrently with placebo; 1600 IU per day of vitamin D3
taken concurrently with 600 IU per day of vitamin E; and placebo. The participants took the treatments
once daily, separately, with a meal (vitamin D or placebo as one capsule, vitamin E or placebo as two soft
gels). All participants could use standard prescription eczema treatments during the trial.
Assessment of risk of bias
Table 70 provides the risk-of-bias assessment for the new studies.
Benefits
In the study by Sidbury and colleagues,326 four out of five children who took vitamin D2 and one out of six
children in the placebo group improved by one category on the IGA scale compared with baseline. One
out of five children who took vitamin D2 and four out of six children in the placebo group did not change
score on the IGA scale compared with baseline. One out of six children in the placebo group worsened by
one category on the IGA scale.
In the trial by Amestejani and colleagues,327 the efficacy of vitamin D3 was not statistically compared with
that of placebo in the trial report, making it impossible to assess the results of the trial. Disease severity in
the vitamin D3 group measured by the SCORAD index showed a significant improvement between baseline
and the end of the study (from 24.8 to 15.3; p= 0.01). Likewise, disease severity in the vitamin D3 group
measured by the TIS score also showed a significant improvement. No significant reduction in eczema
severity was observed in the placebo group.
In the study by Javanbakht and colleagues,328 four small groups were included (n= 13) yet the trial failed
to compare the changes in disease severity between the groups. The rates of SCORAD score improvement
from baseline were 34.8% for the vitamin D3 plus placebo group, 35.7% for the vitamin E plus placebo
group, 64.3% for the vitamin D3 plus vitamin E group (p= 0.004) and 28.9% for the placebo group. The
changes in the pruritus VAS in the four groups were from 5.7 to 5, from 6.2 to 3.4, from 5.5 to 2 and
from 7 to 4, respectively. The changes in the sleeplessness VAS were from 2.3 to 1.4, from 4.3 to 1.3,
from 3.2 to 1 and from 1.1 to 1, respectively. The percentage decrease in topical corticosteroid use was
66.8%, 70.2%, 88.7% and 37.5%, respectively (p= 0.05).
TABLE 70 Vitamins D and E (oral): risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Amestejani 2012327 Low risk Unclear risk Unclear risk Intention-to-treat principle was not
used for the analyses
Javanbakht 2011328 Low risk Low risk Low risk It is not clear whether the intention-
to-treat principle was used for the
analysis
Sidbury 2008326 Unclear risk Low risk Unclear risk
DIETARY INTERVENTIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
Harms
Information about adverse events was not reported for these trials.
Overall implications for research and practice
These trials are too small and have not been analysed appropriately to provide any good evidence about
whether oral vitamin D or vitamin E supplementation is beneficial or not for eczema. However, there is
enough of a signal that a full trial of oral vitamin D or vitamin E supplementation may be worth pursuing.
Without additional research evidence, the role of vitamin D or vitamin E supplementation remains unclear.
Goat’s and ass’s milk
Cow’s milk allergy can exacerbate eczema symptoms and, especially in infants, it is important that the
nutrients available in cow’s milk, such as calcium, are replaced.
Studies
Goat’s milk and ass’s milk had not previously been tested as treatments for eczema before 2000.
One new trial involving goat’s and ass’s milk was reported after 2000. This crossover trial by Vita and
colleagues329 randomised 28 children aged from 6 months to 3 years with active (SCORAD score of > 20)
atopic eczema and a clinical history of cow’s milk allergy. The children were randomised to goat’s milk or
ass’s milk for 6 months and then switched to the other milk for a further 3 months.
Assessment of risk of bias
Table 71 provides the risk-of-bias assessment for the new study.
Benefits
This small trial329 found a large magnitude of effect for ass’s milk compared with goat’s milk, with a
median SCORAD score reduction of 34 points for ass’s milk and 11 points for goat’s milk. Despite the
participants being aware of the milk that they were drinking, their assessment of skin symptoms also
showed the same result. Treatment with ass’s milk resulted in a 4.5-point decrease on a VAS whereas
treatment with goat’s milk resulted in a 0.5-point decrease. Treatment with goat’s milk also resulted in
23 out of 26 participants having a positive reaction to a double-blind placebo-controlled food challenge
whereas only one participant out of 26 had a positive reaction to ass’s milk.
Harms
No specific details about adverse events were reported; however, it was stated that one participant had to
withdraw because of a systemic reaction to goat’s milk involving shortness of breath, sneezing and severe
generalised urticaria.
Overall implications for research and practice
This one small crossover trial329 in a very specific eczema population provides some interesting but fairly
weak evidence against the use of goat’s milk for children with eczema and a cow’s milk allergy because of
a lack of a beneficial effect and high levels of development of sensitivity to the goat’s milk. Ass’s milk
appears to show a large beneficial effect in this population but this needs further confirmation in trials
comparing ass’s milk with the commonly used cow’s milk substitute of soy milk.
TABLE 71 Milk: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Vita 2007329 Unclear risk Unclear risk Low risk
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Hypoallergenic formula
Studies
Hypoallergenic milk formula had not previously been tested as a treatment for eczema before 2000.
Two new studies were reported after 2000.330,331 A crossover trial by Leung and colleagues330 involving
hypoallergenic formula was reported in 2004. This trial randomised 15 children aged < 3 years and taking
at least 500ml of soy or cow’s milk-based formula to a hypoallergenic formula that was lactose and
sucrose free (Neocate®, SHS International) or the child’s pre-existing milk formula. Each formula milk was
given for 6 weeks in a randomised order.
Jin and colleagues331 conducted a 12-week study comparing a partially hydrolysed whey and casein
formula milk with conventional cow’s milk formula in 113 babies with mild to moderate eczema according
to the Hanifin and Rajka8 criteria. Twenty-seven infants dropped out of the study (16 infants in the
experimental group because of the taste of the formula being unacceptable to them, the introduction of
solid food, or suffering from other severe diseases that required additional therapy and 11 infants in the
control group because of their eczema not improving).
Assessment of risk of bias
Table 72 provides the risk-of-bias assessment for the new studies.
Benefits
In the Leung study,330 eczema severity, measured using the SCORAD index, showed a significant treatment
by period interaction of 7.23 points (p= 0.012); however, it did not did not show a statistically significant
treatment difference (3.97 points; p= 0.274). For the individual components of the SCORAD index,
intensity and pruritus showed a statistically significant treatment by period interaction (p= 0.036 for both).
The caregiver global health assessment did not show a statistically significant difference for either the
treatment by period interaction or the treatment difference.
In the Jin study,331 there was a significant difference between the groups in eczema severity measured by
the SCORAD index and the Japanese Dermatological Association Scoring System after 12 weeks. Eczema
severity, measured using the SCORAD index, was 13 in the experimental group and 20 in the placebo
group, resulting in a significant difference (p= 0.001). The number of flare-ups was significantly decreased
in the experimental group but not in the control group (but results were not compared between the
groups). The trial report did not state clearly the disease severity at baseline in the two groups.
Harms
These trials did not report whether or not there were any adverse events. In the trial by Jin and
colleagues331 there were no differences in nutritional status between groups after 12 weeks.
TABLE 72 Hypoallergenic milk formula: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Jin 2011331 Low risk Unclear risk Unclear risk It is unclear whether intention-to-treat
rules have been used in this study
Leung 2004330 Unclear risk Unclear risk High risk Dermatologist who assessed eczema
severity was not blinded
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Overall implications for research and practice
These two trials have given some evidence of the benefit of hypoallergenic formulas for the reduction of
eczema severity, especially in very young children. More independent studies are needed to confirm
these results.
Summary of dietary interventions
Probiotics
l There were no trials involving probiotics for eczema treatment reported up to 2000.
l Twenty-one trials were conducted after 2000 and showed varied results depending on the strains of
probiotics examined:
¢ Five small trials, with a mostly unclear risk of bias, provided evidence of benefit for mixed-strain
probiotics compared with placebo, mostly in post hoc subgroups of participants with raised
IgE levels.
¢ Five trials, three small, one medium and one large, with a mostly unclear risk of bias, did not
provide any evidence of benefit for L. rhamnosis GG compared with placebo or vehicle.
¢ One small trial, with an overall unclear risk of bias, provided evidence of benefit for L. sakei KCTC
10755BP compared with placebo.
¢ One small trial, with an overall unclear risk of bias, did not provide any evidence of benefit for
L. fermentum VRI-033 PCC compared with placebo.
¢ One small trial, with an overall unclear risk of bias, did not provide any evidence of benefit for
L. acidophilus NCFM (ATCC 700396) compared with placebo.
¢ One small trial, with an overall unclear risk of bias, did not provide any evidence of benefit for
heat-killed L. paracasei K71 compared with placebo.
¢ One large trial, with an overall unclear risk of bias, did not provide evidence of benefit for
L. paracasei CNCM I-2116 compared with placebo in infants.
¢ One small trial, with a mostly unclear risk of bias (low risk of bias for the method of
randomisation), provided evidence of benefit for L. acidophilus L-92 compared with placebo.
¢ One medium trial, with a mostly low risk of bias, provided evidence of benefit for L. plantarum
CJLP133 compared with placebo.
¢ One small trial, with an overall unclear risk of bias, did not provide any evidence of benefit for
L. salivarius LS01 compared with placebo.
¢ One small trial with an overall unclear risk of bias, did not provide any clear evidence for live
lysophilised B. breve YY versus placebo in adults.
¢ One small trial, with an overall unclear risk of bias, provided evidence of benefit for B. lactis Bb-12
supplemented formula or L. rhamnosis GG supplemented formula compared with unsupplemented
formula in previously exclusively breastfed infants.
¢ One small trial, with an overall unclear risk of bias, did not provide any evidence for B. breve M-16
supplemented formula compared with unsupplemented formula in participants with a proven
allergy to cow’s milk.
Prebiotics
l There were no trials involving prebiotics (substances that promote the growth of beneficial
micro-organisms in the gut) for treating established eczema reported up to 2000.
l Two small trials reported after 2000, one with a mostly low risk of bias and the other with an overall
unclear risk of bias, provided evidence of benefit for prebiotic treatment compared with placebo.
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Synbiotics
l There were no trials involving synbiotics (a combination of probiotics and prebiotics) for eczema
reported up to 2000.
l Eight trials were reported after 2000 and provided mixed evidence of benefit for synbiotics:
¢ Six small trials, with a mostly unclear or low risk of bias, provide mixed evidence for synbiotics
compared with placebo. Three trials provided evidence of benefit and three trials did not. The two
largest trials, with a mostly low risk of bias, gave conflicting results.
¢ One small trial, with an overall unclear risk of bias, did not provide any evidence of benefit for
synbiotic treatment compared with probiotic treatment.
¢ One small trial, with a low risk of bias, provided evidence of benefit for synbiotic treatment
compared with prebiotic treatment alone in children.
Essential fatty acid supplementation
Borage oil
l There were five trials involving borage oil for eczema compared with placebo reported before 2000.
The largest trial did not provide any evidence of benefit except in one post hoc subgroup of ‘good
compliers’. The four small trials were split, with two providing evidence of benefit and two not
providing evidence of benefit.
l One large trial, reported in 2003, with a mostly low risk of bias, did not provide evidence of any benefit
for borage oil compared with placebo (olive oil for children and liquid paraffin for adults). This trial
supports the evidence suggesting a lack of benefit of borage oil in the general eczema population.
Evening primrose oil
l Six trials, with a mostly unclear risk of bias, investigating evening primrose oil compared with placebo
were reported up to 2000 and provided conflicting results. The two largest and best-reported trials did
not provide any evidence of benefit. The results of the four smaller trials ranged from not providing any
evidence of benefit to evidence of a modest 10–20% benefit of oral evening primrose oil.
l One small trial reported in 2008, with a mostly unclear risk of bias, provided evidence of benefit for
oral evening primrose oil compared with placebo (sunflower oil). This trial does not clarify the evidence
base for oral evening primrose oil, which on balance is thought to be ineffective for the treatment
of eczema.
Fish oil (omega-3)/soybean oil (omega-6)
l Three trials involving fish oil were reported up to 2000. The largest and best-reported independent trial
did not provide any evidence of benefit for fish oil compared with placebo. The two smaller trials
provided evidence of benefit for fish oils compared with placebo, with a particularly large magnitude of
benefit in one.
l One very small trial reported in 2002, with an overall unclear risk of bias, provided evidence of benefit
for fish oil compared with soybean oil given as twice-daily intravenous infusions. This trial does not
clarify the existing evidence base for fish oil.
Docosahexaenoic acid
l There were no trials of DHA (an omega-3 fatty acid) as a treatment in its own right for eczema
reported up to 2000.
l One small trial reported in 2008, with a mostly unclear risk of bias, did not provide any evidence of
benefit for DHA compared with a mixture of caprylic acid and capric acid.
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Hempseed oil
l There were no trials involving hempseed oil for eczema reported up to 2000.
l One small trial reported in 2005, with a mixed risk of bias, did not provide any evidence of benefit for
hempseed oil compared with cold pressed extra-virgin olive oil.
Oral vitamins D and E
l There were no trials involving oral vitamin D (ergocalciferol or cholecalciferol) for eczema reported up
to 2000.
l Three small trials were reported after 2000 and did not provide evidence of benefit of oral vitamin D
or E:
¢ One very small pilot trial, with a mostly unclear risk of bias, did not provide any evidence of benefit
for ergocalciferol compared with placebo.
¢ Two small trials, with a low or unclear risk of bias, did not provide sufficient evidence of benefit for
cholecalciferol compared with placebo or vitamin E or cholecalciferol plus vitamin E in adolescents
and adults.
Goat’s/ass’s milk
l There were no trials involving goat’s or ass’s milk for eczema reported up to 2000.
l One small trial reported in 2007, with a high risk of bias for blinding, provided evidence of benefit for
ass’s milk compared with goat’s milk. The participants had eczema and a clinically relevant cow’s
milk allergy.
Hypoallergenic formula
l There were no trials involving hypoallergenic formula for established eczema reported up to 2000.
l One very small trial reported in 2004, with a high risk of bias for blinding, provided evidence of benefit
for hypoallergenic formula compared with infants’ previous soy- or cow’s milk-based formula.
l One moderately sized trial reported in 2011, with an overall unclear risk of bias, provided evidence of
benefit for hypoallergenic formula compared with conventional cow’s milk formula in infants.
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Chapter 9 Non-pharmacological interventions
Background
Existing systematic reviews
There have been nine systematic reviews35,244,245,332–337 and three guidelines (NICE,41 SIGN42 and AAD94)
that include non-pharmacological interventions. Eight of these41,42,94,332–336 assessed psychological and/or
educational interventions for eczema; five41,42,94,245,337 assessed textiles and/or specialised clothing for
eczema; and four35,41,42,94 assessed the reduction of allergens, mostly aeroallergens.
Scope of this chapter
The trials included in this chapter cover the following treatments:
l specialised clothing
l education
¢ for adults
¢ for children with eczema and their parents
¢ nurse-led clinics
¢ support groups
¢ e-health portal
l stress management
l ion-exchange water softeners
l living in a different climate
l house dust mite reduction
l additional visits to the doctor
l vaccines.
Specialised clothing
Wearing fabrics next to the skin has been identified as a physical irritant that can be a trigger for eczema.
Wool may cause irritation because of the ‘spiky’ nature of its fibres and even cotton has been shown to
cause irritation when moist. Cotton, silk or smooth man-made fibres have been used to create specialised
clothing for people with eczema. Some specialised clothing also has antimicrobials, such as silver, added to
the material.
Studies
Three trials involving specialised clothing were reported before 200055 (see Appendix 3).
Silk
Three new trials assessing the efficacy of DermaSilk® fabric (Espère Healthcare Ltd) were identified.338–340
In 2007, Koller and colleagues338 published a trial comparing DermaSilk arm tubes against ordinary silk arm
tubes. Twenty-two children with mild to moderate eczema were included in the trial. For the initial 2 weeks,
arms were covered in either silk fabric or DermaSilk fabric; for the remaining 10 weeks, one arm was
covered with a cotton arm tube and the other with a DermaSilk tube. The fabric tubes were randomised to
DOI: 10.3310/pgfar04070 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 7
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nankervis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
137
be worn on the left or right arm so that the interventions were compared within the same person.
The fabric tubes were worn all day and washed daily. The severity of the eczema in the area covered by the
fabric tubes was measured using local SCORAD scores by an assessor who was not aware of the allocation
of the interventions. Participants in the study were not allowed to use any antimicrobial or anti-
inflammatory treatments during the trial.
A double-blind, within-person randomised trial by Stinco and colleagues339 published in 2008 compared
DermaSilk sleeves against the same fabric without the impregnated antimicrobial for 28 days in 30 children
and adults with eczema. The ages of the participants ranged from 3 to 31 years. The fabric arm tubes
were identical apart from the seam colour. No one with an acute infection was included in this trial. Local
SCORAD scores for the arm and participant-assessed pruritus were measured up to 28 days.
A trial by Fontanini and colleagues340 compared a DermaSilk long-sleeve top and trousers against a cotton
long-sleeve top and trousers. Twenty-two infants who were aged < 18 months and who had eczema were
randomised to wear the garments every day for 2 years, except in the summer and on other very hot days.
All of the families taking part were given mite-impermeable mattress and pillow encasings for both the
parents’ and the children’s beds. All of the children were treated with mometasone furoate as needed
during the trial.
Assessment of risk of bias
Table 73 provides the risk-of-bias assessment for the new studies.
Benefits
In the study by Koller and colleagues,338 a statistically significant difference in both objective and subjective
severity scores between DermaSilk and the ordinary silk and cotton was reported after 4 weeks and was
still present at 12 weeks. This represented a difference in the median scores of 2 points out of 18 for the
local SCORAD score and 3 points out of 10 for the subjective severity score.
In the study by Stinco and colleagues,339 both the severity of eczema under the area covered by the fabrics
and participant-assessed itching were significantly better with DermaSilk fabric than with the same fabric
without the impregnated antimicrobial. The difference in the pruritus score was 1.88 SD± 1.7 (p< 0.0001)
on a 10-point VAS and the difference in severity measured by the SCORAD index was a reduction of 10.98
SD± 11.9 (p< 0.0001) more in the DermaSilk group than in the DermaSilk without antimicrobial group.
In the trial by Fontanini and colleagues,340 both the total number of tubes of topical corticosteroid used
over 2 years [3.0, interquartile range (IQR) 1.0 to 6.0 in the cotton group and 1.2, IQR 0.7 to 1.5 in
the DermaSilk group] and the number of tubes of topical corticosteroid used per month (0.17, IQR 0.09
to 0.33 in the cotton group and 0.07, IQR 0.05 to 0.09 in the DermaSilk group) were significantly lower in
TABLE 73 Silk clothing: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Fontanini 2013340 Unclear risk Unclear risk High risk Although the trial report states that both the parents
and the investigators did not know which garments
the children were wearing, DermaSilk can easily be
differentiated
Koller 2007338 Unclear risk Unclear risk Low risk
Stinco 2008339 Low risk Unclear risk Low risk Labelling the interventions using red and green may
have biased the responses and assessment of the
intervention despite blinding
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the DermaSilk group than in the cotton group using non-parametric Somer’s D coefficient (p= 0.023 and
p= 0.000, respectively), but only the number of tubes per month was significant using the Mann–Whitney
test (p= 0.006). There was also a statistically significant difference between the groups in the parent-
reported satisfaction rating of ‘satisfied’ or ‘not satisfied’ with the reduction in itching, with nine out of
nine parents of those using DermaSilk satisfied compared with five out of 11 parents of those using cotton
clothing satisfied (Fisher’s exact test p= 0.014). The severity of eczema was not assessed in this trial.
Harms
The two studies on DermaSilk by Koller and colleagues338 and Stinco and colleagues339 reported that there
were no adverse events during the study periods. The trial by Fontanini and colleagues340 did not report
information about adverse events.
Ethylene vinyl alcohol fibre
Two new small studies341,342 from Japan reported since 2000 looked at ethylene vinyl alcohol fibre fabric as
underwear and compared it with cotton underwear.
Thirty participants who were being well maintained on standard eczema treatment participated in the
8-week crossover study by Ozawa and colleagues.341 Each participant wore each fabric (ethylene vinyl
alcohol fibre and cotton) for 4 weeks without a washout period in between the different fabrics. It is not
known how much of the day and night the participants were instructed to wear the underwear and how
often they were asked to wash it.
A small parallel-group trial342 of 24 children aged 3–9 years also compared ethylene vinyl alcohol fibre
fabric with cotton underwear. The children were not allowed to use topical corticosteroids throughout
the study.
Assessment of risk of bias
Table 74 provides the risk-of-bias assessment for the new studies.
Benefits
The study by Ozawa and colleagues341 reported no significant difference between the fabrics in the severity
of eczema at the end of the study. This was the only clinical efficacy outcome measured.
In the study by Yokoyama and colleagues342 there was also no significant difference in the severity of
eczema, including sleep loss and itching, between ethylene vinyl alcohol fibre fabric and cotton underwear.
Harms
Adverse events were not reported in the study by Ozawa and colleagues.341 The study by Yokoyama and
colleagues342 reported one case of increased itching of the areas of the legs not covered by the fabric and
one case of increased itching before bed, but decreased sleep loss. It was reported that most adverse
events were not related to study treatment.
TABLE 74 Ethylene vinyl alcohol fibre: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Ozawa 2008341 High risk High risk High risk
Yokoyama 2009342 Low risk Low risk High risk
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Textiles with added silver
Padycare®
Gauger and colleagues343 in Germany compared Padycare® (TEXAMED® GmbH), a polyamide and LYCRA®
(INVISTA, Wichita, KS, USA) material with silver filaments woven in to produce a silver content of 20% in
total, with a cotton textile. Both were worn day and night for 2 weeks as either an all-in-one suit for
infants or a long-armed and long-legged suit. All 68 participants had eczema of moderate severity
(SCORAD score of at least 20). The severity of eczema, daytime pruritus, sleep loss, quality of life,
functionality and wearing comfort were all assessed. The study is reported as being double blind but it is
stated only that the investigators were blinded and this is further confirmed as the participants did not
wear the garments to the consultations. It is very unlikely that the participants, who were key outcome
assessors, could have been blinded.
Assessment of risk of bias
Table 75 provides the risk-of-bias assessment for the new study.
Benefits
This trial reported no significant differences in eczema severity, day- and night-time pruritus and sleep loss,
skin condition and quality of life at the end of the 2-week study. The participant-assessed improvement in
pruritus was significantly greater in the silver textile group than in the cotton group (p= 0.02).
Harms
The trial reported that there were no adverse events related to the textiles.
X-STATIC®
Juenger and colleagues344 compared undergarments containing silver-coated nylon fibres (X-STATIC®;
Noble Biomaterials) against either undergarments without the silver-coated fibres or a medium-potency
topical corticosteroid (prednicarbate ointment) in a three-phase trial. Thirty participants were randomised
to three groups; each group (n= 10) used a different comparator (silver textile, silver-free textile or
prednicarbate ointment) in the first 14 days; all participants then used the silver undergarments in the
second 14 days and all groups could use only prednicarbate as needed in the third 14-day phase.
All participants could use prednicarbate as often as required throughout the trial. The amount of
prednicarbate used was recorded along with the severity of eczema using the SCORAD index,
participant-assessed pruritus and participant-assessed disease control on a 4-point scale.
Assessment of risk of bias
Table 76 provides the risk-of-bias assessment for the new study.
TABLE 75 Silver filament clothing: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Gauger 2006343 Unclear risk Unclear risk High risk
TABLE 76 Silver-coated fibre clothing: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Juenger 2006344 Low risk Low risk Unclear risk
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Benefits
This three-phase trial344 with only 10 participants per group was difficult to interpret. The severity of
eczema measured using the SCORAD index over the first 2 weeks of the trial showed a significant benefit
for silver textile (p= 0.003) and regular prednicarbate ointment (p= 0.014) use over the use of non-silver
textiles. In these same 2 weeks, the silver textile group used almost as much prednicarbate ointment as
the prednicarbate group (135 g vs. 145 g) whereas the non-silver textile group used hardly any
prednicarbate (13 g).
In the second 2 weeks of the trial, when all of the participants wore the silver textile, the group who
originally wore the non-silver textile improved significantly compared with the group who originally used
prednicarbate (p= 0.037). In this phase, the group who continued to wear the silver textile also improved.
In this phase, all three groups used very little prednicarbate (silver group 10 g, non-silver group 0 g,
prednicarbate ointment 30 g).
In the final 2 weeks of the trial, all groups used only prednicarbate when necessary. In this period the
group who had worn the silver textile for 4 weeks worsened in severity significantly more than the group
who had worn the non-silver textile for 2 weeks and then the silver textile for 2 weeks. In this final phase
the silver textile group used 45 g of prednicarbate, the non-silver textile group used 0 g of prednicarbate
and the prednicarbate group used 90 g of prednicarbate.
There was a significant improvement in participant-rated itching in the silver textile group and the
non-silver textile group over the weeks that they were wearing the silver textile. The prednicarbate group
had the lowest absolute value of the three groups for the time that they were wearing the sliver textile,
but this was not a significant change from the rest of the trial period for this group. In terms of
participant-rated disease control, a high number of participants rated their disease control as ‘complete or
well controlled’ for the 4 weeks.
Harms
One participant had 1 g/l of silver in their urine at day 28, which disappeared at day 56. No silver deposits
were found on the skin or the mucous membranes.
Garments with added tourmaline
A trial by Kim and colleagues345 compared undergarments made of anion textile, pure polyester fibres
containing nanoparticles of crushed tourmaline, with undergarments made of pure cotton. Fifty-two adults
and children aged between 2 and 30 years with mild to severe eczema were randomised to wear the
undergarments all of the time for 4 weeks. The use of topical or systemic treatments for eczema during
the trial was not permitted.
Assessment of risk of bias
Table 77 provides the risk-of-bias assessment for the new study.
TABLE 77 Garments with added tourmaline: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Kim 2012345 Unclear risk Unclear risk Unclear risk 8/52 participants dropped out and it is not clear
whether these participants were included in the analyses
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Benefits
The improvement in eczema severity from baseline to week 4 was significantly greater in the anion group
than in the cotton group (from 47.2 SD± 14.0 to 36.1 SD± 16.5 in the anion group and from 41.8
SD± 16.3 to 37.7 SD± 17.2 in the cotton group; p= 0.0308). The sleep loss and itching components of
the SCORAD score were also significantly different for the same comparison (p= 0.0064) whereas the
objective components of the SCORAD score were not significantly different. The participants were asked to
rate the wearing comfort of the textiles: 76% (n= 19) in the anion group and 74% (n= 14) in the cotton
group gave a rating of ‘comfortable’.
Harms
The trial report stated that no adverse events were reported from wearing the undergarments. No further
details about adverse events were reported.
Overall implications for research and practice
The study of specialised clothing is challenging because of the inability to blind participants. Interpreting
the clinical significance of participant-rated outcomes in the presence of a lack of blinding raises concerns
about information/detection bias as patients often have high expectations of benefit from these garments.
The studies on specialised clothing collated for this review provide some evidence of potential benefits
without any harms. Unfortunately, when potential bias in the subjective results, because of most
participants being aware of their treatment allocation, is taken into account, the results have to be
interpreted with caution. The objective measures of severity assessed by blinded outcome assessors can be
given more weight. DermaSilk showed statistically significant benefits for the severity of eczema in
comparison to ordinary silk and cotton and DermaSilk fabric without antimicrobial, but the time period of
the trials was very short for such a chronic, long-term condition. The numbers of participants included in
the trials were low and the absolute point differences were so small that they may not be clinically
meaningful. The X-STATIC silver textile trial is difficult to interpret because of confounding from topical
corticosteroid use. One participant in this trial had silver in their urine, which had disappeared by the end
of the trial. The ethylene vinyl alcohol fibre did not show even a hint of efficacy for eczema, although this
has been assessed only in a Japanese population to date. The silver textile Padycare and the anion textile
with tourmaline both resulted in a significant difference in participant-rated improvement in pruritus, a
measure that is prone to detection bias for an unblinded intervention. The anion textile with tourmaline
also provided evidence of significant benefit for the severity of eczema compared with cotton, but this was
not significant when only the objective severity measures were assessed.
Specialised clothing is a relatively expensive treatment both in direct monetary terms and in terms of
hidden indirect costs (for increased washing of clothing, having to have multiple changes of garments and
rapidly growing children needing bigger sizes). For clinicians, guideline writers and people with eczema
and their families to be confident that this clothing has a favourable cost–benefit ratio, more rigorous
long-term trials that compare these textiles against standard care in a pragmatic setting are needed. The
CLOTHing for the relief of Eczema Symptoms (CLOTHES) trial (ref. HTA 11/65/01)346 is currently running in
the UK, comparing the addition of silk clothing to normal eczema treatment against normal eczema
treatment alone.
Education
Efforts to improve the quality of life of eczema sufferers and their families by teaching them more about the
nature and treatment of eczema have been formalised into education programmes in some countries (such
as Germany). The education can take the form of a ‘one-off’ session or regular group or individual sessions.
Interventions covering education are heterogeneous and it would not be appropriate to attempt to
summarise all of the trials together as one. We have therefore divided the trials into what might be
considered useful groupings for the UK health-care system. Education delivered in sessions outside the
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clinic is considered separately to education and treatment delivered in the clinic by the same health-care
professional. Support groups that deliver education indirectly with or without clinical input are also
considered separately. The final group considered is online participant-led education and remote, real-time
treatment advice.
Adults
Studies
No trials involving education for adults with eczema were reported before 2000.
Two new trials347,348 have been published since 2000.
One trial347 in the Netherlands including 54 adults aged 18–35 years compared a 2-week intensive day
school programme made up of two 3-hour sessions per day over 10 days in groups of five participants with
communal breaks allowed against normal outpatient appointments. The education covered coping with
stress, social and psychological aspects, alternative medicine, allergies and aggravating factors, dealing
with itching and habit reversal. Dermatological treatment was allowed three times a week during the
programme. The participants were followed for 40 weeks, with outcomes measured being quality of life
[measured using the Marburger Neurodermitis-Fragebogen (Marburg Atopic Dermatitis Questionnaire)349],
amount of sick leave and the number of medical consultations and time taken for the consultations.
The trial by Armstrong and colleagues348 randomised 80 adults aged ≥ 18 years with eczema to either a
paper pamphlet or an online video with information about eczema including clinical manifestations,
environmental factors, bathing and hand washing, moisturiser vehicles and common treatment modalities.
The pamphlet or online video could be used as often as the participant wished for 12 weeks. Participants’
knowledge was assessed before the intervention and after the 12 weeks of the trial. The severity of
eczema was assessed using POEM49 and participants’ satisfaction with the material was also assessed.
Assessment of risk of bias
Table 78 provides the risk-of-bias assessment for the new studies.
Benefits
In the trial by Span and colleagues347 the intensive day school programme group showed a significant
improvement in quality of life assessed using the Marburg Atopic Dermatitis Questionnaire349 compared
with the control group after 40 weeks. The education group reported a median score decrease of –16
(25th to 75th percentile: –28.2 to –4.7) whereas the control group reported a median score decrease of
–3 (25th to 75th percentile: –17 to 5.5), resulting in a median difference of –13 points (p= 0.03). The trial
also reported a difference between the treatment groups in sick leave at 10 weeks, with the education
group showing an average reduction of –6.7 compared with an average increase of 7 in the control group,
which did not reach statistical significance (p= 0.09) and was not apparent at the end of the trial. The
number of outpatient visits was not significantly different between the two groups, but the time taken in
the consultations was reduced for those who had participated in the education programme and after
40 weeks showed some benefit (difference in the mean reduction –7.2; p= 0.06).
TABLE 78 Education (adults): risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Armstrong 2011348 Low risk Low risk High risk
Span 2001347 Unclear risk Unclear risk Unclear risk
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The participants in the trial by Armstrong and colleagues348 found significantly greater satisfaction from the
online video than from the paper pamphlet (p= 0.0086). The level of knowledge in the online video group was
also significantly better than that in the pamphlet group (video group 3.05, pamphlet group 1.85; p= 0.011).
The severity of eczema was also significantly reduced after 12 weeks in the online video group compared with
the paper pamphlet group (video group 3.30 SD± 3.15, pamphlet group 1.03 SD± 3.75; p= 0.0043).
As it is very unlikely that there was any blinding of any of the outcome assessors for either of these trials,
the significance of these measures, apart from possibly the level of knowledge assessment, should be
treated with caution. Whether or not increased knowledge translates into better eczema relief is
still unclear.
Harms
The level of adverse events from educational interventions is not clear from the existing studies as these
two trials did not measure or describe potential harms or costs in terms of time.
Children with eczema and their parents and carers
Studies
One trial involving education for parents of infants and children with eczema was reported before 200055
(see Appendix 3).
Six new studies reported since 2000350–355 have looked at eczema education sessions for children, parents
and carers, with all using slightly different approaches. Overall, the interventions in this section are quite
diverse with regard to the components and intensity of the interventions, with time spent on the education
ranging from 15 minutes to 2 weeks.
One study in North Carolina by Shaw and colleagues350 of 151 children with eczema used an individual,
tailored session with a trained eczema educator lasting for 15 minutes at the initial visit; the level of
follow-up was dependant on the severity of eczema. This intervention was compared against standard care
by a resident and attending paediatric dermatologist. The educator was available 24 hours a day to
respond to queries. The children’s quality of life and severity of eczema were measured but it is not clear
when these measurements were taken. Both the educator and the parent/caregiver were not blinded to
the intervention and it is unclear whether or not there were any other investigators who assessed the
objective outcome measurements or whether they were blinded or not.
A study by Staab and colleagues352 in 2002 looked at a parental training programme. Ninety-three
participants received 2-hour training sessions (once a week for 6 weeks) and 111 participants did not
receive any training. The intervention was delivered by a multidisciplinary team including a paediatrician, a
psychologist and a dietitian. The content of the course included education on relaxation, triggers, dealing
with itching and sleep disturbances, child nutrition and food allergies, treatment of symptoms, coping and
self-management, and daily skin care. Those in the control group were offered the opportunity to attend
the education sessions after the trial period. The severity of eczema, quality of life, coping, treatment costs
and treatment behaviour were assessed after 1 year.
A larger trial conducted in Germany in 2006 by Staab and colleagues351 investigated the use of a
standardised group education programme in parents of 518 infants and children aged from 3 months to
7 years and 185 children aged 8–12 years and in 120 adolescents aged 13–18 years. The training
programme involved a paediatrician or dermatologist, psychologist, nurse and dietitian providing education
on eczema including relaxation, triggers, dealing with itching and sleep disturbances, stage-related
treatment of symptoms, self-management, daily skin care and coping strategies. The intervention consisted
of 2-hour sessions once a week for 6 weeks. The participants were followed up 1 year after the start of
the study.
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The trial reported by Grillo and colleagues353 involved 61 children with eczema and their parents. The trial
compared a 2-hour group education session in addition to normal care with normal care alone. The
education consisted of understanding atopic eczema, trigger factors, investigations, basic skin care,
practical sessions on wet wrapping and cream application, information on topical corticosteroids and
complementary therapies. During the sessions there was time for questions, sharing experiences and ideas.
The severity of eczema and quality of life were assessed at 4 weeks and 12 weeks.
The trial by Futamura and colleagues354 involved 59 children with eczema aged from 6 months to 6 years and
their parents. This assessor-blinded trial compared a 2-day education programme for children and their parents
with standard treatment against standard treatment alone. The programme consisted of lectures, group
discussions and one practical session. Participants in the active group stayed in hospital for the treatment.
The trial by Kardorff and colleagues355 involved 30 children aged 3–6 years. One group was educated
about eczema using a 10-minute active demonstration with a physical skin model and the other group
received only verbal instruction as in normal routine care.
Assessment of risk of bias
Table 79 provides the risk-of-bias assessment for the new studies.
Benefits
Patient-reported outcomes
For sleeplessness, measured using a 0–10 scale, the trial by Futamura and colleagues354 found a greater
reduction in the education group than in the control group, with a difference of 3.4 SD± 2.4 in the
education group compared with 1.5 SD± –3.4 over 6 months (p= 0.048). Pruritus, also measured using a
0–10 scale, was significantly different at 3 months (education group 4.0 SD± 2.3 vs. control group 1.6
SD± 2.5; p= 0.001), but the difference was not quite significant at 6 months (p= 0.056).
Clinically assessed severity
Four351,352,354,355 of the six trials reported significant beneficial effects of the educational interventions on the
severity of eczema. The larger study by Staab and colleagues351 reported significant between-group
differences for reduction in eczema severity, measured using the SCORAD index, for all three age groups.
The adolescents (aged 13–18 years) receiving the educational intervention had a mean reduction in
eczema severity from 43.1 to 23.4 (mean difference −19.7, 95% CI −23.7 to −15.7) over 12 months
whereas the no treatment group had a mean reduction in eczema severity from 40.4 to 35.2
(mean difference −5.2, 95% CI −10.5 to 0.1), showing a mean difference between treatment groups of
TABLE 79 Education (children with eczema and their parents and carers): risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Futamura 2013354 Low risk Low risk Unclear risk
Grillo 2006353 Low risk Unclear risk High risk
Kardorff 2003355 Unclear risk Unclear risk Low risk
Shaw 2008350 Low risk Low risk Unclear risk Participants lost to follow-up were not included
in the analyses
Staab 2002352 Unclear risk Unclear risk High risk
Staab 2006351 Low risk Low risk High risk Participants lost to follow-up were not included
in the analyses. A large number of participants
dropped out, differentially more in the no
education group
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–14.5 (95% Cl –21.2 to –7.9; p< 0.0001). The older children (aged 8–12 years) in the educational
intervention group had a mean reduction in eczema severity from 41.8 (SD 16.6) to 25.8 (SD 17.7)
whereas those given no treatment had a mean reduction in eczema severity from 40.4 (SD 15.1) to 32.6
(SD 16.5), showing a mean difference between treatment groups of –8.2 (95% Cl –13.6 to –2.8;
p= 0.003). The infants and young children (aged 3 months to 7 years) in the educational intervention
group had a mean reduction in eczema severity from 41.4 (SD 16.6) to 23.7 (SD 16.7) whereas those
having no treatment had a mean reduction in eczema severity from 40.6 (SD 15.2) to 28.4 (SD 16.5),
showing a mean difference between treatment groups of –5.2 (95% Cl –8.2 to –2.2; p= 0.0002).
The other trial by Staab and colleagues352 found no significant difference in severity of eczema, measured
using the SCORAD index, at 1 year (p= 0.43).
In the trial by Futamura and colleagues,354 the primary outcome of the difference in severity of eczema
after 6 months, measured using the SCORAD index, showed a statistically significant reduction in severity
for the education group compared with the control group (mean difference 10, 95% CI 2.3 to 17.7;
p= 0.01). There was no significant difference between the groups in the amount of topical corticosteroid
used. The trial by Kardorff and colleagues355 also reported a significant reduction in the severity of eczema
in the education group compared with the control group after 42 days (skin model group from 38.6
SD± 6.1 to 14.1 SD± 4.3 vs. control group from 38.8 SD± 5.8 to 19.8 SD± 5.9; p< 0.006).
Quality of life
There was a reduction in quality-of-life scores (better quality of life) in the education programme groups
compared with the control groups in three351–353 of the six trials. In the trial by Grillo and colleagues353
the CDLQI at 12 weeks reduced by 7.35 points in the intervention group (education session in addition
to normal care) and 2.61 points in the control group (normal care only) (p= 0.004). Both studies by
Staab and colleagues,351,352 which used very similar interventions, found some significant reductions in
quality-of-life scores using a German scale with five separate subscales, which had been previously
validated. In the smaller 2002 trial352 the confidence in medical treatment subscale was the only one to
show a notable benefit of the education programme (p= 0.016, alpha level set at 0.01 after correction for
the number of scales). In the much larger trial in 2006,351 the youngest age group (3 months to 7 years)
showed a significant benefit of education for all five subscales but the difference in point reduction was
small (between 1 and 3 for all scales). The 8–12 years age group showed a benefit of education for the
confidence in medical treatment, emotional coping and acceptance of disease subscales but again
the point reductions were between 1 and 3 for these scales.
In one trial,351 an assessment of how itching behaviour was affected by education in those aged
8–18 years found that catastrophisation (thoughts of not being able to cope) significantly improved but
that coping did not improve. Statistical logistic regression showed that education was found to be the
biggest predictor of change in treatment behaviour.
Harms
The level of adverse effects from educational interventions is not clear from the existing studies as none of
the trials reported any information about potential harms, except that by Futamura and colleagues,354
which found that there were no adverse events related to topical corticosteroids.
Overall implications for research and practice
Although not being able to blind participants and sometimes assessors to the treatment allocation may
lead to risk of bias, the methodology of these trials was of good quality.
For adults, the intensive education course proposed by Span and colleagues347 would probably have meant
taking 2 weeks off work, which could lead to an improvement in many chronic conditions. As one of
the most important confounding factors, it is important that any future trial uses a carefully chosen
comparator. Further, large pragmatic studies on intensive education programmes are needed to help to
confirm these encouraging results. Studies in other age groups of this format of education should now be
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explored. The format of education should be taken into account for adults as it seems to have a significant
impact on the benefits seen. Offering a choice with regard to how the education is delivered, for example
online or face-to-face, may be a good way to maximise the benefits for individuals. Additional research
evidence comparing two or three different formats of education with normal practice is needed.
Taken as a whole, education programmes for parents, young children and adolescents appear to confer
some benefits, with the greatest body of evidence being the reduction of eczema severity or improvements
in disease-related quality of life or both. Patient-reported symptoms of eczema such as sleeplessness and
itching have not been considered sufficiently and deserve more attention, despite the methodological
difficulties because of participants being unblinded. The effects of education appear to be complex and
may be related to age, presence or absence of parents or children, format, providers and setting of the
education. Further research that investigates the most effective elements and format of delivery of
education programmes for different eczema groups is needed to give clarity to the most effective use of
educational programmes for eczema. It is worth noting that in these trials it was the adolescents, who
were educated mostly without their parents, who saw the greatest effect of education programmes on
eczema severity, although a large number of dropouts were not included in the analyses. This age group is
also more likely than younger children to spontaneously improve and so research targeting this often
difficult-to-treat age group must now be pursued. Whether an educational intervention developed in one
country can be adopted in another country with different cultural norms is another important aspect that
requires exploration, as is the cost-effectiveness of such interventions.
Dermatology nurse consultations
The role of nurses in eczema, as well as for other dermatological conditions, has evolved in the last
10 years, which has resulted in specialist nurses taking on a much more autonomous role within clinics.
For some specialist nurses, such as nurse consultants, this has meant having their own list of patients to
manage through consultations.
Studies
No trials were published before 2000.
Three new trials356–358 have been published since 2000.
A trial carried out in the UK by Chinn and colleagues357 compared an intervention in which participants
had a 30-minute consultation with a newly qualified dermatology nurse with no consultation. The trial
included 225 children with eczema recruited from general practice. The consultation involved an individual
treatment plan, establishing the parents’ and child’s knowledge about eczema, demonstrations of
treatment application, advice about treatments, triggers, bathing and self-management, advice about
the UK’s National Eczema Society and an offer of continued support by telephone and/or a further
appointment. Participants were given written information about the topics in the consultation. Those in
the control group were offered the same consultation intervention at the end of the trial period.
Participant- or caregiver-rated eczema severity and both child and family quality of life were assessed at
4 weeks and 12 weeks after the intervention.
A trial in the Netherlands by Schuttelaar and colleagues358 compared consultations with a dermatologist
with consultations with a nurse practitioner in 160 children with eczema who had been given a new
referral from general practice. No details about the dermatologist consultations were given in the report
apart from the duration of the consultations, which was 20 minutes initially and then 10 minutes for each
subsequent consultation required based on eczema severity and a 5-minute telephone call for allergy test
results. The nurse consultations lasted for 30 minutes initially, with follow-up visits lasting for 20 minutes.
A routine follow-up appointment took place after 2 weeks, either as a second visit or as a 10-minute
telephone consultation. Subsequent consultations depended on eczema severity. The nurse provided
education as part of the intervention, either in the consultations or as a 2-hour group session with up to
eight participants.
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An Australian trial by Moore and colleagues356 compared one 90-minute ‘workshop’ with a dermatology
nurse consultant with an average 40-minute consultation with a dermatologist in 165 children with a new
referral for eczema. The nurse-led workshop involved a history being taken and SCORAD scores being
obtained, an examination, a management plan, a demonstration of techniques for applying treatments
and prescriptions and equipment cards being obtained. The dermatologist consultation involved a history
being taken and SCORAD scores being obtained, an examination, a management plan, a demonstration of
techniques for applying treatments and prescription and equipment cards being issued. Eczema severity
and types of treatments used were assessed at 4 weeks.
Assessment of risk of bias
Table 80 provides the risk-of-bias assessment for the new studies.
Benefits
In the trial by Chinn and colleagues357 a 30-minute dermatology nurse consultation in a primary care
setting did not appear to have any effect on the children’s quality of life. The impact of eczema on the
family improved after 4 weeks compared with having no consultation (mean difference in Family
Dermatitis Index score –0.79, 95% CI 1.62 to 0.04; p= 0.06) but this effect was not present at 12 weeks
and such a small overall difference may not carry any clinical significance. It is not clear whether there was
any effect on the severity of eczema as no data other than baseline were provided in the report.
In the trial by Schuttelaar and colleagues358 both the course of consultations with a nurse practitioner
with 3 years’ experience and the course of consultations with a dermatologist resulted in significant
improvements compared with baseline for both the infants’ and children’s dermatology quality-of-life
scores and the family impact scores (all had reductions of around 5 points to half of the baseline values);
however, none of these measures showed any significant difference between the interventions. The
severity of eczema also showed significant improvement from baseline for both types of consultation
(a reduction of 13 points in the objective SCORAD scores in both groups) but there was no significant
difference between the interventions.
The nurse-led workshops in the study by Moore and colleagues356 were found to confer a statistically
significant decrease in eczema severity compared with the dermatologist consultations, with a mean
difference in SCORAD score between the treatment groups of –9.93 (95% Cl –14.57 to –5.29; p< 0.001).
It is not reported whether the SCORAD assessors were blinded but it is unlikely that this was the case. It is
also worth noting that baseline eczema severities were skewed, with more severe cases in the dermatologist
consultation group, and that the nurse clinic was already well established.
Harms
No data about adverse events were presented in these three trials.356–358
TABLE 80 Dermatology nurse consultations: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Chinn 2002357 Low risk Unclear risk Unclear risk
Moore 2009356 Low risk Low risk High risk There was a greater number of severe participants
in the group allocated to a consultation with a
dermatologist. Did not use an intention-to-treat
principle for the analysis
Schuttelaar 2010358 Low risk Low risk High risk
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Overall implications for research and practice
One trial357 based in two GP practices with a newly qualified dermatology nurse did not find any significant
benefit of the intervention on quality of life in 225 patients. A possible confounder in this trial was that
participants were already receiving treatment before baseline, which could have positively affected the
baseline scores for quality of life, leaving little room to detect any further improvements conferred by the
intervention. It would have been useful to see the effect of the intervention on the severity of eczema but
these data were not reported. There is also no indication from the trial by Schuttelaar and colleagues358 that
an experienced dermatology nurse practitioner compared ‘head to head’ with a dermatologist had a more
beneficial effect, although this is not evidence of equivalence as this was a superiority trial. It is reassuring to
note that both health-care professionals had a significant positive impact on the people with eczema that
they treated. The positive results from a nurse-led clinic in Australia356 should be interpreted with caution as
there were many methodological issues, such as differences in the ways that the separate nurse and
dermatologist clinics were run, that could lead to bias. Good-quality evidence of the particular benefits of
nurse-led clinics and dermatologist-led clinics is needed to inform dermatology services as effectively and
economically as possible in the future.
Support groups
Support groups of people who have or who care for someone with a common condition are often formed
both through the NHS and outside it. These groups offer a good diversity of methods of support and some
of the larger groups offer helplines and written or online educational information. In the UK, the National
Eczema Society is the largest national support group for those with eczema.
Studies
No studies on support groups were reported before 2000.
One new trial was reported after 2000. This small, poorly reported trial359 compared participants attending
fortnightly 90-minute support group sessions (over a 6-month period) with a control group. The trial
randomised 36 families with a child aged between 2 and 16 years with moderate to severe eczema. It was
not clear whether the control group had any intervention or not during the study. For the support group
intervention, the children were taken into a separate session that involved free time to play followed by a
small amount of education about eczema and its treatment, a short discussion around a theme and then
activities around this theme. They then joined the parent group towards the end of the session and
showed them what they had been doing. The adult session involved a theme being explained alongside
written text about the theme; the parents could then discuss their own experiences around that theme but
they were also free to discuss things other than the chosen theme. Session co-ordinators acted as arbiters.
The children’s sessions were run by a child psychiatrist and assisted by volunteer medical students; the
adult sessions were run by a senior dermatologist assisted by two other dermatologists.
Assessment of risk of bias
Table 81 provides the risk-of-bias assessment for the new study.
TABLE 81 Support groups: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Blessmann Weber 2008359 Unclear risk Unclear risk High risk Participants who did not complete the
study were not included in the analysis
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Benefits
The frequency of pruritus decreased in the support group compared with baseline (p= 0.023) but it is
unclear whether this was statistically significant compared with the control group. The influence of itching
on participant mood was statistically significantly reduced in the support group compared with the control
group after the intervention, but the data show a relatively small difference [values after the intervention:
support group 3.63 (SD ±3.30), control group 6.19 (SD ±3.54); p= 0.03].
The overall CDLQI was reported as being statistically significantly different between the groups after the
intervention (p= 0.01). The domains of leisure (p= 0.04) and personal relationships (p= 0.02) were
reported as being statistically significantly improved in their own right for the support group compared
with the control group. No data were given for these reported statistical differences.
Harms
Adverse events were not reported for this trial.
Overall implications for research and practice
The most interesting result from the only trial359 to have looked at the role of support groups in eczema is
that quality of life and effect of itching on mood of the children with eczema significantly improved
whereas impact of eczema on the whole family did not. The children participated in their own separate
group session with only their peers and the support group co-ordinators. This trial hints at the potential
benefit of this kind of child-focused, semistructured support group for children with eczema, although
which particular aspect or aspects of the group support may be conferring this benefit needs much more
detailed investigation. This trial did not give enough methodological detail to be confident of the results.
Support groups exist in many different forms and provide many different kinds of support and other
services. Detailed, pragmatic but thorough trial research around eczema supports groups is needed to
make the most effective use of these resources.
E-health portal
As access to the internet increases, more health services are exploring ways of offering all or part of their
service online. Direct access to care via the internet, termed ‘e-health’ or ‘telemedicine’, has been shown
to have small to moderate benefits on health outcomes for the management of chronic illnesses.
Studies
One trial360 conducted in the Netherlands compared access to a personal eczema portal against standard
face-to-face care by a dermatologist. The personal eczema portal provided internet-guided monitoring,
self-management training, general information about eczema and personal information about each
patient’s treatment regimen. Participants could monitor their eczema via digital photographs and
self-reported data such as a VAS for sleeping and itching and a diary of topical treatment. The participants
using the portal could have e-consultations with a dermatology nurse, who could consult a dermatologist
if needed. In total, 109 adults with moderate eczema and 90 parents of children aged 0–6 years with
moderate eczema were randomised.
Assessment of risk of bias
Table 82 provides the risk-of-bias assessment for the new study.
TABLE 82 E-health portal: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
van Os-Medendorp 2012360 Unclear risk Low risk High risk It is not clear how many participants were
included in the intention-to-treat population
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Benefits
There were no significant differences between the treatment groups in quality of life, measured using the
IDLQI (p= 0.45 interaction over time), and the intensity of itching (p= 1.00 interaction over time). For the
severity of eczema, there was a significant difference between treatment groups (p= 0.04 interaction over
time) but it is not clear which treatment the difference was in favour of. The results for the severity of
eczema were not significantly different at any individual time point during the trial.
Harms
No information was reported about adverse events in this trial.
Overall implications for research and practice
The authors claim from the results of this trial that e-health is as effective as standard care for clinical
outcomes, even though the trial was designed to assess whether there was a large enough economic
saving (€150) to outweigh the cost of the e-health service compared with standard care alone. The trial
found a significant economic cost saving for e-health compared with standard care; however, the
confidence limits for this figure were too wide for this trial to provide any firm evidence.
Stress management
Studies
A trial by Schut and colleagues361 conducted in Germany compared a standardised cognitive behavioural
therapy stress management programme with a waiting list control group. Twenty-eight participants with
eczema diagnosed according to the Hanifin and Rajka8 criteria took part in the trial for 10–14 weeks. The
age of the participants was not reported. The stress management programme consisted of four 3-hour
sessions over 2 weeks, in groups of six to eight participants, which covered cognitive restructuring and
enhancing problem-solving skills. A booster session was then given 3 weeks after the last session. The trial
was primarily concerned with endocrine stress levels but measured clinical outcomes as well.
Assessment of risk of bias
Table 83 provides the risk-of-bias assessment for the new study.
Benefits
The trial reported that there was no significant difference between the treatment groups in the severity of
eczema, measured using the SCORAD index (p= 0.179). Although the data for baseline were not
reported, the values for the severity of eczema appear to have been significantly more severe in the stress
management programme group at baseline according to the graph of the severity of eczema during
the trial.
Harms
The authors did not report any information about adverse events.
Overall implications for research and practice
This very small, short-term trial does not provide any evidence of benefit in terms of improving the severity
of eczema using cognitive behavioural therapy. Future trials in this area need to be larger with longer-term
follow-up and assess patient-reported outcomes such as quality of life and sleep loss to gain a true picture
of the potential of this psychological technique.
TABLE 83 Stress management: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Schut 2013361 Low risk Unclear risk Low risk
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Ion-exchange water softeners
Anecdotal evidence that eczema in soft water areas is less severe362,363 and that people who emigrate find
their eczema suddenly getting much better or worse have led to suspicions that the hardness of the water
could have an impact on the severity of eczema.
Studies
No trials involving ion-exchange water softeners were published before 2000.
One new trial involving ion-exchange water softeners was reported after 2000. This study, conducted in
the UK by Thomas and colleagues,364 included 336 children with moderate to severe eczema who were
living in hard water areas. The trial compared usual eczema care with usual eczema care plus an
ion-exchange water softener to soften the water for bathing and washing. The trial used a parallel-group
design and the primary outcome was analysed at 12 weeks. At the end of the study, participants were
‘crossed over’ for 4 weeks to allow the participants in the control group to experience the intervention and
to monitor the potential decline in beneficial effects in the intervention group. The nurse who recorded
these observations was blinded; however, the participants were not.
Assessment of risk of bias
Table 84 provides the risk-of-bias assessment for the new study.
Benefits
The severity of eczema after 12 weeks was not significantly different in the water softener group
compared with the control group. The CIs for this blinded objective outcome were very tight, making a
robust argument for the lack of additional benefit of softening the water using an ion-exchange water
softener for eczema severity (mean difference in SASSAD scores at 12 weeks –0.66, 95% Cl –1.37 to
2.69). In contrast to the blinded primary outcome, unblinded participant- or carer-assessed secondary
outcomes did show small statistically significant beneficial effects of the water softeners. It is likely that
these positive effects were a result of the bias introduced by the participants’ awareness of treatment
allocation as expectation in the effectiveness of the water softeners was high.
Harms
Adverse events were not formally recorded; however, the parents of three participants reported an
exacerbation of eczema, which they thought may have been due to the softened water. Two water
softener units were removed early for this reason.
Overall implications for research and practice
This large, methodologically robust trial364 of ion-exchange water softeners for eczema clearly shows no
benefit of the softeners for the severity of eczema. The significant differences in favour of the water
softeners in three of the participant- or carer-assessed outcomes were small and are unlikely to be clinically
relevant given the detection bias resulting from participants and carers being aware of the intervention
that they were allocated to. This trial gives a robust message that ion-exchange water softeners cannot be
recommended as an effective treatment for eczema.
TABLE 84 Ion-exchange water softeners: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Thomas 2011364 Low risk Low risk Low risk Objective outcome assessors were
blinded; however, participants were not
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Living in a different climate
Sending people to a warmer climate to treat conditions such as atopic eczema is currently practised in
countries such as Norway.
Studies
No trials involving staying in another climate were published before 2000.
One new trial has been published since 2000. This open trial365 involving 61 participants in Norway
investigated the effect of sending school children to Gran Canaria compared with remaining in Norway for
a duration of 1 month. The children who went to Gran Canaria had to go to school, which included
1 hour of gymnastics a day, and also had to bathe in seawater for 1–2 hours a day. The children in the
control group continued attending school as usual, with only 2–4 hours of gymnastics a week. No
requirement to bathe in seawater was reported for this group. The control group were offered a trip to
Gran Canaria at the end of the study. The severity of eczema and quality of life were measured in all of
the children when the Gran Canaria group returned to Norway after 1 month and again 3 months later.
Assessment of risk of bias
Table 85 provides the risk-of-bias assessment for the new study.
Benefits
A significant improvement in the severity of eczema after 1 month, measured using the SCORAD index,
was reported in the Gran Canaria group, with the score decreasing from a mean of 37.15 (95% CI 29.40
to 44.90) to 21.18 (95% CI 17.24 to 25.13) in the Gran Canaria group and from a mean of 36.84
(95% CI 30.00 to 43.69) to 30.62 (95% CI 24.13 to 37.11) in the control group (p= 0.045). The
improvement was sustained for 3 months after the children’s return. Although quality of life improved
significantly in the Gran Canaria group, it is not reported whether this was significant in comparison with
the control group.
Harms
It was reported that some of the participants in the Gran Canaria group had mild sunburn. No adverse
event data for the control group were provided.
Overall implications for research and practice
It is very difficult to decide how much clinical significance this treatment approach has because of the
many confounding factors that could have affected the severity of eczema that were different between the
two groups, such as bathing in seawater and the amount of exercise undertaken. The application of sun
cream in the Gran Canaria group could potentially have had an effect on eczema because of its emollient
effect. Both the inclusion criteria and the method of randomisation were not clear and so the
generalisability of the treatment effects to the wider eczema population is hard to gauge from this trial.
Even if genuinely effective, these benefits could be attributed to the psychological effects of going to
a different country, the effect of ultraviolet light on skin inflammation and vitamin D synthesis, saltwater
bathing, a changed diet or altered allergen exposure. In the light of the economic and social implications
of removing a person with eczema and possibly other family members from their normal life, choosing this
treatment over other options must be very carefully considered.
TABLE 85 Living in a different climate: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Byremo 2006365 High risk Unclear risk High risk Groups exposed to different complex
interventions, making analysis of results difficult
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House dust mite reduction
A possible link between house dust mite sensitisation, which is relatively common in people with eczema, and
the severity of eczema symptoms has been suggested.366 Measures to reduce house dust exposure, such as
intense vacuuming and mattress encasings, are usually targeted at the bedroom as this environment has the
highest potential for long periods of close contact with higher levels of house dust mite allergen.
Studies
Four trials involving house dust mite reduction were reported before 200055 (see Appendix 3).
Three new trials367–369 have been reported since 2000. Ricci and colleagues369 randomised a group of 41
children aged from 2 to 10 years and sensitised to food or inhalant allergens to either ‘recommended’
house dust mite reduction measures (mattress and pillow encasings, hot wash of bedding at least once
a week, vacuuming the living room and bedroom at least twice a week, carpets vacuumed at least once a
week or removed and no pets) or no recommendations (normal cleaning patterns) for 2 months. After this
all participants followed the house dust mite reduction recommendations for a further 10 months. The
severity of eczema was assessed using SCORAD scores and total dust mite load and the specific load of
Dermatophagoides pteronyssinus and D. farinae was measured.
A larger Dutch mite avoidance study by Oosting and colleagues368 was reported in which 86 participants
with eczema and sensitised to house dust mites were randomised to either mite-impermeable mattress,
duvet and pillow encasings made of GORE-TEX® material or cotton ‘placebo’ encasings for 1 year on all
beds in the participants’ bedroom. The clinical severity and extent of eczema were assessed using the
Leicester Sign Score.61 Sensitivity to house dust mite was measured by intradermal and patch testing
alongside total and specific IgE. It is not clear whether the participants were adults, children or both.
The third trial by Gutgesell and colleagues367 randomised only 20 participants with eczema and sensitised
to house dust mite to either allergen-impermeable polyurethane encasings and acaricide (mite-killing) spray
made up of tannic acid and benzyl benzoate or cotton ‘placebo’ encasings and ‘placebo’ acaricide spray
(water with traces of ethanol) for a year. The severity of eczema was assessed using the SCORAD index;
daytime pruritus and pruritus-induced sleeplessness were assessed using a VAS, and participant-assessed
skin status and the amount of topical corticosteroids used were both recorded. It was unclear whether the
participants were children, adults or both.
Assessment of risk of bias
Table 86 provides the risk-of-bias assessment for the new studies.
Benefits
All three trials367–369 failed to show any benefit of house dust mite reduction interventions for eczema
compared with placebo or normal cleaning practices over a period of up to 12 months. The trial by Ricci
and colleagues369 showed a mean decrease in SCORAD scores from 33 to 24 in the first month for the
mite avoidance group compared with a mean decrease from 27 to 22 in the placebo group. After the
additional 10 months of the mite avoidance intervention for all participants, the groups had SCORAD
values of 16 and 17, respectively. In the trial by Gutgesell and colleagues,367 the SCORAD values in both
TABLE 86 House dust mite reduction: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Gutgesell 2001367 Unclear risk Unclear risk Low risk
Oosting 2002368 Unclear risk Unclear risk Low risk
Ricci 2000369 Unclear risk Unclear risk Low risk
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groups fluctuated throughout the year, with no overall trend, and were almost identical, with a difference
of only 3 points between the groups (p= 0.901). Pruritus-induced sleeplessness (p= 0.399), daytime
pruritus (p= 0.799) and the participant-assessed skin status (p= 0.583) also showed no marked differences
between the groups. The Dutch mite avoidance study by Oosting and colleagues368 reported a significant
reduction in the house dust mite load in the GORE-TEX encasing group whereas the placebo group load
did not change significantly. This effect does not seem to translate into clinical benefit, however, as
sleeplessness, itching, disease activity and extent all decreased by only a few points in both groups, with
no significant difference between the groups.
The three trials367–369 gave only scant details of the trial methodology, with none reporting the method
of randomisation and allocation concealment. It is unlikely that 2 months of intervention in the trial by
Ricci and colleagues369 is long enough to be of clinical relevance when testing house dust mite reduction
for a long-term condition such as eczema. On the other hand, two other trials367,368 with a duration of
1 year saw no significant effects in favour of house dust mite reduction interventions.
Harms
None of these trials specifically reported adverse events, although one participant withdrew from the trial
because of sweating-induced exacerbation of eczema, attributed to the allergen-impermeable encasings.
Overall implications for research and practice
Applying encasings to a bed and having to wash or vacuum more frequently with a high-quality vacuum
cleaner may be fairly achievable in many cases and, if proven to be of significant benefit, could have great
potential for the treatment of eczema. However, a complex intervention such as in the trial by Ricci and
colleagues,369 which could potentially add a large physical and mental burden to members of the family
(because of extra housework, strict regimens and even loss of treasured soft toys), raises questions about
the balance between the effectiveness of the intervention and quality of life for the participant and his or
her family.
No long-lasting, significant clinical benefits of any of these interventions have yet been shown, but the
trials have so far lacked methodological clarity and the important question of the impact on quality of life
must be addressed in any future trials on reduction of house dust mites. There is a need for simple,
pragmatic, long-term clinical trials of individual house dust mite interventions with blinded outcome
assessments. Given that increased exposure to allergens can sometimes induce tolerance, it is also
important to explore whether reducing allergen levels from different baseline levels actually induces more
harm than good by periodically increasing sensitisation.
Additional visits to a doctor
It has been found that patient adherence to treatment has a tendency to increase around the time of
follow-up visits; this has been termed ‘white coat compliance’.370,371 Increased adherence to a treatment
can result in increased benefit of the treatment.372
Studies
There were no trials involving additional clinic visits reported before 2000.
One new trial was reported after 2000. This trial, by Sagransky and colleagues,373 reported as a short
communication, involved 30 children treated with topical tacrolimus 0.03% daily for 4 weeks. The
participants were randomised in an open manner to have either one extra visit to the clinician 1 week after
starting treatment or no extra visit. All participants visited the clinician after 4 weeks of treatment.
Assessment of risk of bias
Table 87 provides the risk-of-bias assessment for the new study.
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Benefits
This pilot trial373 found a significant improvement in eczema severity assessed by EASI scores, IGA score and
participant-assessed itch in both groups, but there were no significant differences between those who had an
extra visit to the clinician at 4 weeks and those who did not. The mean difference in percentage improvement
in severity measured using EASI scores (extra visit group 76% vs. control group 45%; p= 0.06) showed some
difference; however, only 26 out of the 30 participants randomised were included in the analysis.
Harms
The extra visit group reported three adverse events and the control group reported two adverse events,
none of which was assessed as being related to treatment.
Overall implications for research and practice
This small, unblinded pilot trial,373 powered to detect large differences in treatment effect, did not find any
significant beneficial effect of one extra visit to the doctor. The trial also found no correlation between
adherence and reduction in severity and no correlation between baseline severity and adherence, but the
study was underpowered to exclude even moderate differences. Given that visits to the doctor are
expensive, future trials of adherence enhanced by extra clinic visits should include an economic evaluation.
Although the unblinded nature of the intervention may raise concerns about performance bias, in the
context of this intervention blinding is not desirable as the intervention is clearly intended to increase
adherence/performance. Measuring treatment adherence is challenging, especially in the case of
emollients, where the amount applied will depend on severity and the current level of control. Developing
new methods for accurately measuring treatment adherence will be a difficult but necessary move to
further investigate the influence of the number of doctor visits on eczema severity.
Vaccines
Observational studies have suggested that children exposed to unpasteurised milk (which contains harmful
bacteria) may be less likely to develop eczema than control subjects.374 This has led researchers to
investigate whether vaccinating people with some forms of mycobacteria can improve eczema severity
by altering the immune response.
Studies
There were no studies involving vaccines for eczema reported before 2000.
Four new trials involving vaccines for the treatment of established eczema were reported after 2000. The
trial by Arkwright and David,375 reported in 2001, followed 41 participants aged 5–18 years with moderate
to severe eczema for 3 months following a single vaccination or placebo injection. The severity of eczema
and potency of topical corticosteroids used were recorded at 1 and 3 months after vaccination.
Another similar trial376 by the same group compared a vaccination with heat-inactivated Mycobacterium
vaccae against a placebo vaccination. The 56 participants were aged between 2 and 6 years and had
moderate to severe eczema. The severity of eczema scale included the extent of involvement and severity
(dermatitis score), with a maximum score of 300 points. The potency of topical corticosteroids used was
recorded at 1, 3 and 6 months after the vaccination.
TABLE 87 Additional doctor visits: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Sagransky 2010373 Unclear risk Unclear risk High risk Only 26/30 participants completed the trial and were
included in the analysis and so no intention-to-treat
analysis was carried out
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A multicentre, parallel-group trial in the UK and Croatia by Berth-Jones and colleagues377 was reported in
2006. This trial involved 166 children aged between 5 and 16 years with moderate to severe eczema,
diagnosed according to the UK Working Party’s criteria.9 Children were randomised to receive a single
injection containing either heat-inactivated M. vaccae or placebo. The participants were followed up for
24 weeks with assessments at 4, 8, 12 and 24 weeks. The participants could not make any changes to
their eczema medication in the 4 weeks prior to randomisation and could not use any topical or systemic
immunomodulatory treatments, Chinese traditional medicine or phototherapy during the trial.
A trial by Brothers and colleagues378 conducted in New Zealand also compared heat-inactivated M. vaccae
immunisation (three injections at 2-week intervals) with placebo in 129 children aged 5–16 years with
moderate to severe eczema but otherwise good general health. The participants could keep using their
other treatments for eczema or discontinue them, as long as they were not tacrolimus, ciclosporin,
methotrexate, pimecrolimus, ultraviolet A (UVA) or ultraviolet B (UVB) phototherapy, systemic
corticosteroids, high-dose inhaled steroids or traditional Chinese medicines. The participants were followed
up for 6 months after immunisation.
Assessment of risk of bias
Table 88 provides the risk-of-bias assessment for the new studies.
Benefits
The first trial in children and adolescents aged 5–18 years375 showed a greater reduction in eczema severity
and surface area affected in the M. vaccae vaccination group than in the placebo group, with the
dermatitis score significantly improving from month 1 and at month 3 (total mean change from baseline
41 points vs. 10 points; p< 0.01) and the surface area affected also significantly improved by month 3
(total mean change from baseline 17% vs. 0%; p< 0.01).
The trial in children aged 2–6 years376 failed to show any significant difference between M. vaccae and
placebo, although it must be noted that the M. vaccae group had significantly more severe disease than
the placebo group at baseline (p= 0.05; difference in mean dermatitis score of 9 points). Neither of these
trials found a significant decrease or increase in the potency of topical corticosteroids used in the trial.
The largest trial, carried out with children and adolescents aged 5–16 years in the UK and Croatia,377
reported a mean decrease in eczema severity after 12 weeks, measured by SASSAD, of 9.4 in the 1-mg
M. vaccae group, 7.0 in the 0.1-mg M. vaccae group and 8.8 in the placebo group. The decrease in the
1.0-mg group was statistically significant compared with the placebo group (95% CI –4.3 to 5.4; p> 0.05).
There were significant differences in favour of the 0.1-mg M. vaccae group compared with placebo and
also both M. vaccae groups combined compared with placebo for sleep disturbance after 8 weeks. The
trial report states that there were no significant differences in all of the other outcomes of change in
severity of eczema at 24 weeks, change in body surface area affected, participant-assessed global
assessment of response, pruritus severity and frequency of use of topical corticosteroids.
TABLE 88 Vaccines: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Arkwright 2001375 Low risk Low risk Low risk
Arkwright 2003376 Low risk Low risk Low risk
Berth-Jones 2006377 Low risk Low risk Low risk
Brothers 2009378 Low risk Low risk Low risk
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The trial by Brothers and colleagues378 reported that there was no significant change in eczema severity,
measured using SASSAD, between the placebo group and the immunisation group at 3 months (p= 0.77)
and 6 months (p= 0.70) after immunisation. There was also no significant difference in the extent of
eczema (p= 1.0) at 3 months. There was also no significant difference in the change in quality of life,
sleep disturbance and frequency and potency of topical corticosteroid use, but the data for these
outcomes were not reported.
Harms
Both trials by Arkwright and David375,376 showed a very similar pattern of adverse events. There were no
systemic adverse events reported in either trial; however, approximately half of the participants (13/21 and
13/29, respectively) who were vaccinated with M. vaccae developed a temporary localised red lump at the
injection site.
In the trial by Berth-Jones and colleagues,377 103 participants reported 260 adverse events. The most
common adverse event was reported as eczema (53 participants) followed by infected eczema
(24 participants). Forty-one participants (25%) reported one or more adverse events assessed as at least
being possibly related to treatment. There were five serious adverse events assessed as not being related
to study treatment.
The trial by Brothers and colleagues378 reported that 47% of the participants had a local injection site
reaction and that 75% of these had received the M. vaccae vaccine.
Overall implications for research and practice
The evidence from these four trials, comprising almost 400 participants, with a low risk of bias, indicates
that there is insufficient evidence of benefit for vaccination with M. vaccae for atopic eczema treatment.
Additional research evidence on M. vaccae vaccination for treating eczema is not needed.
Summary of non-pharmacological interventions
Specialised clothing
l There were three small trials involving specialised clothing for eczema reported up to 2000. One of
these trials found evidence of benefit for clothing made from cotton compared with clothing made
from two other fibres and another trial found evidence of benefit for warp knits compared with jersey
knits. The third trial found evidence of benefit for gel-filled absorbent core nappies compared with
cellulose absorbent core nappies for nappy rash but not for eczema.
l Eight trials reported after 2000 covered four different types of specialised clothing:
¢ Three trials, with a mostly low and unclear risk of bias, found evidence of benefit for silk
clothing (DermaSilk).
¢ One trial, with a high risk of bias for blinding, provided evidence of benefit for clothing containing
silver (Padycare) and one trial, with a mostly low risk of bias, was difficult to interpret and therefore
did not provide evidence of benefit for clothing containing silver (X-STATIC).
¢ Two trials, with a mostly high risk of bias, did not provide any evidence of benefit for clothing
made from ethylene vinyl alcohol fibre.
¢ One trial, with an overall unclear risk of bias, provided evidence of benefit for anion textile with
added tourmaline.
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Education
l One small unblinded trial was published before 2000 and provided evidence of benefit for an
educational intervention given by a nurse compared with no education.
l Twelve trials reported after 2000, with an overall mixed risk of bias, covered different educational
approaches and provided some evidence of benefit for educational approaches.
E-Health portal
l One small trial, with a mixed risk of bias, did not provide any clear evidence of benefit for an online
health-care portal compared with standard care.
Stress management
l There were no trials of stress management for eczema reported up to 2000.
l One very small trial reported in 2013, with a mostly low risk of bias, did not provide any evidence for
the effectiveness of a stress management treatment for eczema based on cognitive behavioural therapy
compared with no treatment.
Ion-exchange water softeners
l There were no trials of ion-exchange water softeners for eczema reported up to 2000.
l One large trial reported in 2011, with an overall low risk of bias, provided evidence of no benefit from
the use of an ion-exchange water softener in the home compared with no water softener.
Living in a different climate
l There were no trials of living in a different climate for eczema reported up to 2000.
l One small trial, with a mostly high risk of bias, provided evidence of possible benefit of living in a
warmer climate compared with staying at home.
House dust mite reduction
l There were four small trials, with a mostly unclear risk of bias, reported up to 2000. The results were
conflicting, with only one of the trials providing evidence of benefit for a house dust mite reduction
intervention (mite-impermeable encasings, intensive/high-filtration vacuuming, acaricide spray) compared
with placebo (mite-permeable encasings, normal cleaning patterns, vacuuming with reduced suction).
l Three small trials, with an overall unclear risk of bias, did not provide any evidence of benefit for
interventions to reduce house dust mites (more frequent vacuuming, hot washing of bedding and soft toys,
removing pets, mite-impermeable mattress and bedding encasings, acaricide spray) compared with placebo
(normal patterns of cleaning and washing, allowing pets, mite-permeable encasings, placebo spray).
Additional visits to a doctor
l There were no trials of additional visits to a doctor for eczema reported up to 2000.
l One very small trial published in 2010, with a high risk of bias for blinding, provided no evidence of
benefit of one extra visit to the doctor compared with no extra visit.
Vaccines
l There were no trials of vaccination for treating eczema reported up to 2000.
l Three small trials published after 2000, with an overall low risk of bias, did not provide any evidence of
benefit for vaccination with M. vaccae for treating established eczema.
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Chapter 10 Phototherapy treatment
Background
Phototherapy treatment with UVA or UVB light is used in moderate to severe cases of eczema.
Phototherapy is often used as an alternative to other long-term treatment regimens such as topical
corticosteroids. Patients are usually treated in hospital two or three times a week for several weeks and
sometimes months.
Existing systematic reviews
Since 2000, three systematic reviews have been published.83,379,380 The AAD94 and NICE41 guidelines also
cover phototherapy.
Scope of this chapter
This chapter covers the following phototherapy treatments:
l UVB treatments
l UVA treatments
l UVA treatments compared with UVB treatments
l phototherapy in combination with other treatments
l full-spectrum light therapy
l excimer laser (form of UV laser).
Studies
Six trials involving phototherapy were reported before 200055 (see Appendix 3).
Ultraviolet B treatments
Studies
A left/right within-person trial by Selvaag and colleagues,381 reported in 2005, compared standard UVB
fixed-dose increments against UVB using skin reflectance guided dosing. The trial included 20 adults aged
16–38 years with mild to moderate eczema. Treatment was given for up to 6 weeks and was stopped
early if a participant’s SCORAD score fell to < 10 on either side of the body. The whole of the face was
given standard UVB treatment. Emollients and topical corticosteroids were allowed during the trial as long
as they were used symmetrically. It was not reported how many treatments were given per week.
Assessment of risk of bias
Table 89 provides the risk-of-bias assessment for the new study.
TABLE 89 Ultraviolet B treatments: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Selvaag 2005381 Unclear risk Unclear risk High risk
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Benefits
The severity of eczema was recorded using the SCORAD index. It was reported that no significant
difference was found in the reduction of eczema severity between the two treatment regimens, but no
detailed data were reported. The times taken for the SCORAD scores to reduce to < 10 were reported.
The standard treatment regimen had a median time (5th and 95th percentiles) of 3.5 weeks (1.5, 6.0)
and the skin reflectance regimen had a median time (5th and 95th percentiles) of 3.0 weeks (2.0, 5.5).
The cumulative UVB dose was significantly lower for the skin reflectance regimen (median 39 × 10mJ/cm2;
p< 0.01) than for the standard regimen (median 124 × 10mJ/cm2). The initial UVB dose was reported as
higher for the skin reflectance regimen, with a median of 3.4 standard erythemal dose (SED) (×10mJ/cm2
at 298 nm using the CIE erythema action spectrum) compared with 2.6 SED (×10mJ/cm2 at 298 nm using
the CIE erythema action spectrum) for the standard regimen, but this was not statistically significant.
Harms
Data on adverse events were not reported for this trial.
Overall implications for research and practice
The potential to administer low-dose UV radiation and achieve the same clinically beneficial effects as
reported with high-dose UV radiation is encouraging but requires confirmation in larger pragmatic studies.
This one small trial381 indicates that this could be achievable; however, the results must be treated with
caution. Problems with the study include the lack of blinding, the claim of equivalence of non-inferiority
being based on a very small sample size and no methodological details about the study design being
reported. Such an important question should be examined in detail in an appropriately designed and
powered trial to give patients and clinicians clear guidelines on the best treatment regimen for
UV phototherapy.
Ultraviolet A treatments
Studies
Broadband UVA treatment is used alone or in combination with broadband UVB treatment. More recently,
UVA treatment has been combined with other agents such as the photosensitiser psoralen plus ultraviolet
A (PUVA)], which is a naturally occurring chemical found in the common fig and celerys as well as
other plants and seeds. UVA is also being combined with photo(chemo)therapeutic agents in UVA1
phototherapy treatment, narrowband UVA therapy and extracorporeal photopheresis. Narrowband UVA
and UVA1 phototherapy (high-intensity, long-wavelength UVA 340–400 nm) are currently used for eczema
as they have a high output and narrow emission spectrum and so are expected to be the most efficacious
and safe versions of UVA for eczema treatment.
A trial by Dittmar and colleagues382 in 2001 compared three different doses of UVA1 phototherapy against
each other. The low-dose group was given a maximum single dose of 20 J/cm2 and a maximum cumulative
dose of 300 J/cm2; the medium-dose group received a maximum single dose of 65 J/cm2 and a maximum
cumulative dose of 975 J/cm2; and the high-dose group received a maximum single dose of 130 J/cm2 and
a maximum cumulative dose of 1840 J/cm2. The treatment was given five times a week for 3 weeks.
The trial randomised 34 adults with eczema and a SCORAD score of > 30. No other treatments except
for emollient were permitted during the trial. The trial appeared to compare the treatments using a
parallel-group design, but this is not specifically stated.
A crossover trial by Tzaneva and colleagues383 compared UVA1 phototherapy with PUVA provided on an
outpatient basis. The 40 participants were given UVA1 phototherapy at doses of 20 J/cm2 unless the
minimal erythema dose was below this, in which case this value was used initially with an incremental
increase of 10 J/cm2 for each subsequent treatment, up to a maximum of 70 J/cm2 as long as there was no
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erythema. The PUVA treatment (1.2 mg/kg) was given 2 hours before UVA exposures, which had a starting
dose of 70% of the minimal phototoxic dose. The UVA dose was increased by 20% of the minimal
phototoxic dose if there was no erythema and 10% if there was barely perceptible erythema. Other than
the study treatment, participants were allowed to use only emollients.
Assessment of risk of bias
Table 90 provides the risk-of-bias assessment for the new studies.
Benefits
In the trial by Dittmar and colleagues382 comparing three different doses of UVA phototherapy, the
low-dose group did not significantly improve in severity from baseline, with a reduction in SCORAD score
from 54 to 46. The medium- and high-dose groups significantly improved compared with baseline,
reducing from 56.29 to 40.16 and from 70.81 to 33.94, respectively. No between-group severity analyses
were reported. No other efficacy outcomes were reported.
The trial by Tzaneva and colleagues383 primarily measured length of remission after each phototherapy
treatment. The PUVA treatment group had a median time to relapse of 12 weeks (IQR 4–24 weeks)
whereas the UVA1 treatment group had a median time to relapse of 4 weeks (IQR 4–12 weeks), which
was reported as statistically significant (p= 0.012). Severity was reported as a secondary outcome. The
SCORAD scores in the PUVA group decreased from a mean of 62.5 at baseline to 36 after 10 exposures
and to 28.8 after 15 exposures. The SCORAD scores in the UVA1 group decreased from a mean of 63.7 at
baseline to 46.9 after 10 exposures and to 40.1 after 15 exposures. The mean± SD percentage reductions
in SCORAD scores from baseline were 54.3%± 25.7% for PUVA and 37.7%± 22.8% for UVA1. The
difference between the groups was statistically significant.
Harms
The trial report by Dittmar and colleagues382 stated that no adverse events were observed. In the trial by
Tzaneva and colleagues383 only minor adverse events were reported. Two participants treated with UVA1
and nine treated with PUVA reported mild palmoplantar erythema. Seven participants treated with UVA1
reported heat and burning after treatment. Folliculitis was reported by one participant using UVA1 and by
two participants using PUVA. Two participants using PUVA reported photo-onycholysis (nail degradation).
Overall implications for research and practice
The optimal dosing regimen for treatment with UVA1 is still unclear. The trial by Dittmar and colleagues382
has large disparities in both baseline eczema severity and immediate pigmentation dose, and provides no
between-group analysis. The trial does provide a hint of a positive dose–response relationship, which
should be treated with caution. Further methodologically robust research should attempt to clarify the
optimal treatment regimen for phototherapy with a clinically realistic duration of treatment.
TABLE 90 Ultraviolet A treatments: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Dittmar 2001382 Unclear risk Unclear risk Unclear risk 9/34 participants withdrew and it was not
clear whether these were included in the
analyses. Large differences in baseline
immediate pigmentation dose and severity
Tzaneva 2010383 Low risk Unclear risk Unclear risk 17/40 participants withdrew from the trial and
were not included in any subsequent analyses
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The trial of PUVA treatment383 showed a modest superior effect of PUVA over UVA1 treatment after
15 treatments; however, this is a relatively short treatment period. The particularly striking result was the
significantly longer length of remission that PUVA induces compared with UVA1. Inducing long periods of
remission in a chronic, long-term condition such as eczema is vitally important. PUVA therapy is time-
consuming, even more so than phototherapy on its own, and so this must be taken into account.
Short-term adverse events appear to be mild and occur at low levels for both UVA1 and PUVA treatment,
with some indication that UVA1 has a slightly better safety profile than PUVA.
Ultraviolet A compared with ultraviolet B treatments
Studies
A trial by Reynolds and colleagues384 randomised 73 adults with eczema that was not considered to be
mild to either narrowband UVB, broadband UVA or visible light phototherapy. All participants had
treatment twice a week for a total of 24 treatments. All participants were allowed to use emollients
(emulsifying ointment or aqueous cream were advised as some emollients absorb UV radiation) and topical
corticosteroids (except very potent ones) 2 weeks before and during the trial.
A left/right within-person trial by Majoie and colleagues385 compared narrowband UVB (311 nm) against
medium-dose UVA1 (350–400 nm) given three times per week for 8 weeks. Thirteen adults with a
symmetrical eczema distribution were included. For narrowband UVB, the first dose was 70% of the
minimal erythema dose; the dose was increased by 20% if there was no erythema or by 10% if the
previous dose produced slight erythema. For UVA1 phototherapy, the first dose was 30 J/cm2, and this was
increased to 45 J/cm2 in two treatments. The dose was decreased if the reaction was too strong. No other
topical treatments except for emollients were allowed during the trial. The face was excluded from
the analyses.
A crossover trial by Gambichler and colleagues386 compared UVA1 phototherapy with narrowband UVB
phototherapy each given three times a week for 6 weeks. The trial randomised 47 participants with
eczema diagnosed according to the Hanifin and Rajka8 criteria, with a SCORAD score of ≥ 20. For UVA1
treatment the dose was 50 J/cm2. For narrowband UVB treatment, the first dose was 70% of the minimal
erythema dose and this was increased by 10–20% per session up to a maximum of 1.2 J/cm2 for skin type
II or by 1.5 J/cm2 for skin type III or IV. Any prospective participants with an abnormal photosensitivity to
UVA1 were not included in the trial. Participants were allowed to use emollients and moisturisers during
the trial.
Assessment of risk of bias
Table 91 provides the risk-of-bias assessment for the new studies.
TABLE 91 Ultraviolet A compared with UVB treatments: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Gambichler 2009386 Low risk Unclear risk Low risk Only 28/47 participants were included
in the intention-to-treat analyses
Majoie 2009385 Unclear risk Unclear risk Unclear risk
Reynolds 2001384 Low risk Unclear risk Low risk
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Benefits
The trial by Reynolds and colleagues384 reported that 19 out of 21 participants in the UVB group had a
reduction in itch over the treatment period compared with 12 out of 19 in the UVA group. The number of
participants who improved in the visible light group was not reported, but it was stated that the UVA and
UVB groups had higher numbers of improvers than the visible light group. In total, 15 out of 21 in the
UVB group and 10 out of 19 in the UVA group had an improvement in sleep at the end of treatment.
Again, the number of improvers in the visible light group was not provided but the UVA and UVB groups
were reported to have higher proportions of improvers than this group. The total disease activity score
improved in the UVA group by a mean of 4.4 points (95% Cl –1.0 to 9.8) more than the visible light
group and in the UVB group by a mean of 9.4 points (95% Cl 3.6 to 15.2) more than the visible light
group. All three groups started with a similar mean baseline severity score (UVA group 32.3, UVB group
29.8, visible light group 30.8). The maximum severity score obtainable was 90. These data were
extrapolated from graphs.
In the trial by Majoie and colleagues385 the participant-assessed reduction in itch over 12 weeks was similar
for the two treatments. The medium-dose UVA1 group fell from 5.8 to 2.7 and the narrowband UVB
group fell from 5.9 to 2.3. In the between-group analysis it was reported that no significant difference was
found, but no data were provided. Eczema severity was recorded using the Leicester Sign Score.61 The
medium-dose UVA1 group fell from 19 to 10 and the narrowband UVB group fell from 18 to 9. In the
between-group analysis it was reported that no significant difference was found, but no data
were provided.
The trial by Gambichler and colleagues386 found no significant differences in the reduction in pruritus,
eczema severity measured using SASSAD and quality of life measured using Skindex-29. For pruritus,
the UVA1 group had a 16% SD± 61.8% reduction at the end of treatment whereas the narrowband UVB
group had a 25.2% SD± 30.5% reduction for treatment at the end of treatment (p= 0.5). Eczema severity
was reported as the mean relative reduction in SASSAD score after 6 weeks. The UVA1 group had
a 43.7% SD± 31.4% reduction at the end of treatment whereas the narrowband UVB group had a
39.4% SD± 24.1% reduction at the end of treatment (p= 0.5). Quality of life was also reported as the
mean relative reduction after 6 weeks. The UVA1 group had a 12.7% SD± 18.8% reduction at the end of
treatment whereas the narrowband UVB group had a 16.5% SD± 17.6% reduction at the end of
treatment (p= 0.1).
Harms
In the trial by Reynolds and colleagues384 two participants withdrew because of ‘burning’ (one in the
narrowband UVB group, one in the visible fluorescent light group) and four withdrew because of
‘exacerbation of eczema’ (one in the narrowband UVB group, two in the broadband UVA group and one
in the visible fluorescent light group). A further three participants withdrew because of ‘dislike of
treatment’ (two in the broadband UVA group and one in the visible fluorescent light group). The trial by
Majoie and colleagues385 did not report any data about adverse events. In the trial by Gambichler and
colleagues386 one participant in the UVA1 group and four in the narrowband UVB group developed
mild erythema.
Overall implications for research and practice
Both UVA and UVB phototherapy appear to reduce pruritus and the severity of eczema after a course of
treatment, although broadband UVA therapy did not appear to fare as well as narrowband UVB or UVA1
therapy. The length of time for which these benefits are sustained after the cessation of phototherapy has
not yet been addressed; as there does not seem to be much of a difference in the efficacy of UVA
compared with UVB, this is now a key research gap. Phototherapy is labour intensive for all involved and
some of the adverse effects such as heat loading can be difficult to cope with, especially for children. There
is a large degree of variability observed in treatment response, which is evident from the wide deviations in
severity score reductions in the trial by Gambichler and colleagues.386 Trials involving two different
phototherapy treatments are easier to blind than trials of phototherapy compared with other treatments.
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Ultraviolet A/B treatments compared with or in combination
with other active treatments
Studies
A trial by Valkova and Velkova387 compared phototherapy with UVA/UVB against phototherapy with
UVA/UVB combined with the topical corticosteroids fluticasone and hydrocortisone butyrate. Thirty-one
adults and children aged between 8 and 45 years with moderate to severe eczema were randomised and
underwent UV treatment five times a week, with one group also applying topical corticosteroids twice a
day, five times a week. The length of time that the study treatment was given was not reported.
A left/right within-person trial by Tzung and colleagues388 compared narrowband UVB alone against
narrowband UVB in combination with 1% pimecrolimus, twice daily for 6 weeks. The trial randomised
26 children aged 5–17 years to either half-body UVB and whole-body pimecrolimus or whole-body UVB
and half-body pimecrolimus. The first dose of UVB treatment was 70% of the minimal erythema dose and
then percentage-based increments up to a maximum of 1.5 J/cm2 were carried out.
A multicentre, two-arm trial by Heinlin and colleagues389 compared synchronous balneotherapy, in which
the participants were immersed in a bath containing dead sea salts at a concentration of 10% and
given UVB (311 nm) phototherapy, with UVB (311 nm) phototherapy only. In total, 180 adults with
dermatologist-diagnosed eczema were given treatment according to a dose escalation schedule for their
skin type. The bathing time for the synchronous balneotherapy increased in line with the schedule for the
phototherapy. Participants started with three to five sessions a week and underwent 35 sessions in total.
The trial by Granlund and colleagues390 is discussed in Chapter 11.
Assessment of risk of bias
Table 92 provides the risk-of-bias assessment for the new studies.
Benefits
In the trial by Valkova and Velkova387 no between-treatment comparisons were reported. There was a
large reduction in the severity of itch in the phototherapy and topical corticosteroid combination group,
from a mean± SD of 235.7± 16.9 to 78.6± 18.7 after treatment. In the phototherapy-only group the very
low score of 3± 13.6 increased to 5± 12.3 after treatment. Sleep loss decreased in the phototherapy and
topical corticosteroid combination group, from a mean of 50± 20.2 to 21.4± 11.4 after treatment. In the
phototherapy-only group the score decreased from 76± 23.5 to 11± 8 after treatment. Overall eczema
clinical severity decreased in the phototherapy and topical corticosteroid combination group, from
395.4± 35 to 36.9± 7.3 after treatment. In the phototherapy-only group the score was 360.4± 37.6 at
baseline and 37.9± 6.7 after treatment.
TABLE 92 Ultraviolet A/B compared with, or in combination with, other active treatments: risk of bias of the
included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Granlund 2001390 Unclear risk Unclear risk High risk
Heinlin 2011389 Unclear risk Low risk High risk
Tzung 2006388 Unclear risk Unclear risk Low risk Objective outcome assessors were
blinded; however, participants were not
Valkova 2004387 Unclear risk Unclear risk High risk
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In the trial by Tzung and colleagues388 the primary outcome of change in eczema severity was measured
using EASI scores. For combination treatment compared with pimecrolimus alone, there was no significant
difference in the reduction of severity from baseline (p= 0.084). This was also the case for combination
treatment compared with narrowband UVB treatment alone (p= 0.059). The combination treatment and
each of the treatments alone all reduced the baseline severity of eczema by around 50%. No absolute
values were given for severity in the trial report. All three treatments also reduced the severity of pruritus
by around 3 points. Again, no absolute values for pruritus were given.
The trial by Heinlin and colleagues389 reported quality of life, measured using the Sickness Impact Profile,
which was evaluated by the patient. There was no significant difference in mean quality of life between
the treatment groups at the end of treatment [synchronous balneotherapy 4.6 (SD 6.8) vs. phototherapy
only 4.0 (SD 5.5); p= 0.98]. Disease-specific quality of life was measured using the Freiburg Quality of Life
Index and it was reported that there was no significant difference between the groups at the end of
treatment. The participants assessed their global impression of treatment on a 6-point scale from ‘very
good to ‘very bad’ and the proportion of participants with a score of ‘good or ‘very good’ at the end of
treatment was statistically significantly different between the groups (synchronous balneotherapy 73.6%
vs. phototherapy only 55.4%; p= 0.002) and was also significantly different at 1 and 6 months after the
end of treatment. There was a statistically significant difference in the reduction from baseline in the
severity of eczema (primary outcome), measured using the SCORAD index, between the synchronous
balneotherapy group [61.8 (SD 14.1) to 25.6 (SD 22.0)] and the phototherapy-only group [61.5 (SD 12.4)
to 34.6 (22.3)] at the end of treatment (after 35 treatments) (p= 0.004).
Harms
The adverse events reported were erythema with skin tenderness, burning, skin xerosis, uncomfortable
heat load and intense sweating.387 All of these events except for skin xerosis were reported with a
frequency of ‘five or less’ but it was unclear whether this was ‘events’ or ‘participants affected’. Skin
xerosis was reported with a frequency of 10 for the phototherapy-only treatment group and five for the
combination treatment group.
In the trial by Tzung and colleagues,388 two participants in the whole-body narrowband UVB and half-body
pimecrolimus group had intractable generalised pruritus and tender erythema after the UVB treatment.
The trial by Heinlin and colleagues389 reported that 30 participants in the synchronous balneotherapy group
experienced 46 adverse events compared with 24 participants in the phototherapy group who experienced
31 adverse events. Eleven out of 46 events in the synchronous balneotherapy group were ‘definitely’ or
‘probably’ related to the trial treatment whereas 10 out of 31 events in the phototherapy group were
‘definitely’ or ‘probably’ related to the trial treatment. The most common events related to trial
treatment were erythema and light dermatoses. Eight of the adverse events were serious (synchronous
balneotherapy, n= 2; phototherapy only, n= 6), but none of these was classed as related to the trial
treatment. Eight participants withdrew before the end of the trial because of adverse events (synchronous
balneotherapy, n= 2; phototherapy only, n= 6).
Overall implications for research and practice
Although no formal comparative analyses were reported, it is obvious from the reduction in scores that
there was no difference between a combination of UVA/UVB and topical corticosteroids and UVA/UVB
alone. A huge disparity in baseline itch scores leads to questions about the method of randomisation
and allocation concealment and makes it impossible to interpret the impact of the treatments on itch
compared with each other. One small trial of balneotherapy combined with UVB phototherapy compared
with UVB phototherapy only gives some evidence of benefit from the addition of balneotherapy; however,
as there is no mention of a blinded severity of eczema outcome assessor for this trial, this evidence must
be treated with caution until appropriately blinded trials are carried out to confirm this beneficial effect.
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Full-spectrum light treatments
Studies
One trial by Byun and colleagues391 compared full-spectrum light (320–5000 nm) for eight irradiations
(twice a week for 4 weeks) plus emollient against emollient only twice a week for 4 consecutive weeks.
The 38 children randomised into the trial were all Korean with a SCORAD score of > 25 and skin type III or
IV. The children were not allowed to use any other treatments during the trial.
Assessment of risk of bias
Table 93 provides the risk-of-bias assessment for the new study.
Benefits
The participants assessed their own clinical improvement in the trial, with 75% of the full-spectrum
light group recording a ‘good’ or ‘excellent’ response on a 4-point scale compared with 50% of the
emollient-only control group. The severity of eczema was measured using the SCORAD index. The score
in the full-spectrum light group reduced from a mean of 47.87 at baseline to 30.76 at week 8. The
score in the control group reduced from a mean of 39.79 at baseline to 33.8 at week 8. Although a
significant reduction from baseline was reported in the full-spectrum light group, no between-group
analyses were reported.
Harms
No serious adverse events were reported. In the full-spectrum light group, 6 out of 20 participants
reported erythema, 6 out of 20 reported dryness, 4 out of 20 reported pruritus and 2 out of 20 reported
burning. Six out of 20 participants also reported a transient exacerbation of eczema in the first 2 weeks.
Overall implications for research and practice
This trial391 was reported as open. It is not clear whether the SCORAD assessor was blinded and the
baseline SCORAD scores were noticeably higher at baseline in the full-spectrum light group than in the
control group. This means that the results should be treated with caution. The trial appears to show a
reasonable improvement in eczema severity matched by the participants’ assessment of their own response
to treatment. With only a small number of participants and a narrow range of skin types and a common
heritage, much larger studies on mixed populations are needed before any recommendations about the
use of full-light phototherapy can be made.
Excimer laser (form of ultraviolet laser)
Studies
A within-person trial from the Netherlands by Brenninkmeijer and colleagues125 compared once-daily
clobetasol propionate (0.05%) against twice-weekly 200mW/cm excimer laser for 10 weeks. The trial
involved 13 participants with atopic eczema (diagnosed according to the millennium criteria392) and more
than four symmetrical prurigo nodules.
Assessment of risk of bias
Table 94 provides the risk-of-bias assessment for the new study.
TABLE 93 Full-spectrum light treatment: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Byun 2011391 Unclear risk Unclear risk High risk
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Benefits
A blinded physician assessment of individual signs of eczema found a statistically significant difference in
favour of excimer laser treatment at 14, 22 and 34 weeks after starting treatment, which in all cases was
after the end of the 10-week treatment period. There was a mean absolute decrease in the score over
34 weeks of 6 points on a 15-point scale in the excimer laser group and of 4.1 points in the clobetasol
propionate group. Pruritus, assessed on a VAS, showed a 63% improvement in the excimer laser group
and a 49% improvement in the clobetasol propionate group over the entire 34 weeks of the trial. The
difference between the pruritus scores was reported as non-significant for weeks 14, 22 or 34, with the
absolute values being only 1 point apart on a 10-point scale over this time period.
Harms
Excimer laser treatment resulted in a fairly high level of adverse events, although there were no reported
serious adverse events. Adverse events included four reports of a burning sensation, five reports of erythema,
two reports of vesicles and one report of blistering. All 10 participants analysed for the trial experienced
hyperpigmentation at the treatment sites. Two participants withdrew because of an exacerbation of eczema
that required systemic treatment. It is unclear which treatment group the patients withdrew from, although
the exacerbations were described as being unlikely to be related to the study treatment.
Overall implications for research and practice
This very small trial125 hints at the potential for using clobetasol propionate laser treatment for a relatively
short-term period to confer long-lasting beneficial effects compared with a moderate-potency topical
corticosteroid. However, the level of adverse events is a serious cause for concern.
Summary of phototherapy
l There were six trials of phototherapy treatment reported up to 2000 comparing different UVA or UVB
treatments and regimens. The trials were small and poorly reported but did provide some evidence of a
large treatment benefit.
l Twelve trials were published after 2000; all were small but they showed some weak evidence of a large
and rapid treatment benefit of phototherapy.
Ultraviolet B
l One very small trial, with a high risk of bias for blinding, did not provide any evidence of benefit for
UVB treatment with fixed doses guided by skin reflectance of red (660 nm) and green (555 nm)
wavelengths to calculate the highest dose not eliciting erythema compared with standard UVB
fixed-dose increments.
Ultraviolet A
l One small trial, with an overall unclear risk of bias, compared high-dose UVA1 with medium-dose or
low-dose UVA1, but failed to compare the treatment group results against each other.
l One small trial, with a mostly unclear risk of bias, provided evidence of benefit for PUVA compared
with UVA1 for length of remission and reduction in eczema severity.
TABLE 94 Excimer laser: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Brenninkmeijer 2010125 Low risk Unclear risk High risk Only 10/13 participants included
in the analysis
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Ultraviolet A compared with ultraviolet B
l One very small trial, with an overall unclear risk of bias, did not provide any evidence of benefit for
medium-dose UVA1 (350–400 nm) compared with narrowband UVB (311 nm).
l One small trial, with a mostly low risk of bias, compared narrowband UVB with broadband UVA or
visible light and failed to compare the treatment group results against each other.
l One small trial, with a mostly low risk of bias, did not provide any evidence of benefit for UVA1
compared with narrowband UVB.
Phototherapy in combination with other active treatments
l One small trial, with a high risk of bias for blinding, did not provide any evidence of benefit for
UVA/UVB combined with the topical corticosteroids fluticasone and hydrocortisone butyrate compared
with UVA/UVB treatment alone.
l One very small trial, with a high risk of bias for blinding, did not provide any evidence of benefit for
narrowband UVB alone compared with narrowband UVB in combination with 1% pimecrolimus.
l One moderately sized trial, with a mixed risk of bias, did not provide any evidence of benefit for
synchronous balneotherapy with UVB phototherapy compared with UVB phototherapy alone.
Phototherapy compared with other active treatments
l One small trial, with a high risk of bias for blinding, provided evidence of benefit for oral ciclosporin
(initial dose 4mg/kg/day) compared with combined UVA/UVB treatment.
Full-spectrum light therapy
l One small trial, with a high risk of bias for blinding, did not provide any evidence of benefit for
full-spectrum light therapy applied with emollients compared with emollient treatment alone.
Excimer laser (form of ultraviolet laser)
l One very small trial, with a mixed risk of bias, provided evidence of benefit for twice-weekly excimer
laser treatment for 10 weeks compared with once-daily clobetasol propionate (0.05%) treatment.
PHOTOTHERAPY TREATMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
Chapter 11 Systemic immunomodulatory agents
Background
Systemic immunomodulatory agents are third-line treatments considered when other interventions are not
adequately controlling the eczema.
Existing systematic reviews
The NICE guidelines for the management of atopic eczema41 include most of the treatments in this
chapter, apart from mepolizumab, omalizumab, immunotherapy and montelukast.
A systematic review with a search ending in August 2005, which covers all of the systemic
immunomodulatory agents included in the NICE guidelines,41 was published by Schmitt and colleagues393
in 2007. This review concluded that, because of the weight of evidence of effectiveness, ciclosporin should
be considered as the preferred option for third-line treatment of severe eczema. A systematic review by
Schram and colleagues,394 with a search ending in 2009, reviewed the off-label use of azathioprine,
including use for severe eczema. Two reviews93,395 examined trials of biological therapies and reviewed
their use for eczema and two reviews396,397 examined desensitisation treatments (systemic immunotherapy)
for eczema.
Scope of this chapter
This chapter covers the following systemic immunomodulatory agents:
l azathioprine (oral)
l ciclosporin (oral)
l methotrexate
l systemic corticosteroids:
¢ prednisolone
l mycophenolate mofetil
l montelukast
l systemic immunotherapy (desensitisation)
l biological therapies:
¢ mepolizumab
¢ omalizumab
l intravenous immunoglobulin
l pimecrolimus (oral).
Azathioprine
The systemic immunosuppressant azathioprine has been used to prevent rejection following organ
transplantation and to treat steroid-responsive diseases such as inflammatory bowel disease and vasculitis.
It is sometimes used as a topical steroid-sparing agent. Azathioprine is converted to a purine synthesis
inhibitor, which inhibits the production of lymphocytes, especially B and T cells. Thiopurine
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methyltransferase levels are checked before treatment to enable adjustment of the individual starting dose.
Azathioprine is now commonly used for cases of severe eczema for medium- to long-term control.
Studies
There were no trials involving azathioprine reported before 2000.
Three new trials have been published since 2000. A double-blind placebo-controlled crossover trial by
Berth-Jones and colleagues398 compared azathioprine against placebo in 37 adult participants with eczema
that seriously affected their quality of life, despite the daily use of topical corticosteroids. The treatments
were taken consecutively, with each treatment taken continuously for 3 months; the order of treatment
was randomly allocated. The use of topical corticosteroids was permitted during the trial, except for very
potent corticosteroids.
Another double-blind trial by Meggitt and colleagues399 allocated participants to groups using
minimisation. This trial compared azathioprine suspension given once a day for 12 weeks with a placebo
suspension using the same regimen. Sixty-three adults with moderate to severe eczema that had been
stable in the recent past were enrolled. The ratio of participants given azathioprine to participants given
placebo was 2 : 1 and therefore 42 participants were given azathioprine.
One small single-blind trial, reported by Schram and colleagues394 in 2011, compared azathioprine
(1.5–2.5mg) against methotrexate (10–22.5mg) for 12 weeks in 43 adult patients with severe eczema
who were unresponsive to or intolerant of ciclosporin. This trial is discussed in more detail later in this
chapter (see Ciclosporin).
Assessment of risk of bias
Table 95 provides the risk-of-bias assessment for the new studies.
Benefits
The trial by Berth-Jones and colleagues398 showed statistically significant improvements in eczema when
using azathioprine compared with placebo, measured using the SASSAD scale.59 For the participant-
assessed outcomes of itching, sleep disturbance and disruption of work/daytime activity, the difference in
mean improvement between azathioprine and placebo was statistically significant only for disruption of
work/daytime activity. There was no evidence of carry-over effects of taking azathioprine (analysis of
covariance= 0.8), despite the lack of a washout period between treatments.
In the trial by Meggitt and colleagues,399 the results for the primary outcome, change in severity of eczema
over 12 weeks, showed a 5.4-point (17%) difference [95% CI 1.4 to 9.3 (4.3% to 29%)] in favour of
azathioprine. This difference was less than the difference of 30% that the trial was powered to detect,
based on pilot studies. For participant-rated itch and sleep loss over 12 weeks there were only small
differences in scores, although the significance of these reductions is not clear. For quality of life there was
TABLE 95 Azathioprine: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Berth-Jones 2002398 Low risk Low risk Unclear risk Intention-to-treat population did not
include two participants who attended
only the baseline assessment
Meggitt 2006399 Low risk Low risk Low risk Intention-to-treat population did not
include participants who attended
only the baseline assessment
Schram 2011394 Low risk Low risk Low risk The study was underpowered to
provide evidence of equivalent efficacy
between groups
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a 3.5-point difference (95% CI 0.3 to 6.7) in favour of azathioprine, but it is very difficult to interpret the
significance of this reduction. The investigator- and participant-assessed severity scores showed significant
differences in favour of azathioprine, with the investigator assessment having the greatest significance.
The study by Schram and colleagues394 provided evidence of benefit of 12 weeks of treatment with both
methotrexate and azathioprine, but there was no significant difference in efficacy between the two
treatments (SCORAD 50, p= 0.76; at least mild IGA score, p= 0.74; mean IGA score, p= 0.2; mean PGA
score, p= 0.95; mean EASI score, p= 0.95; sleeplessness, p= 0.24; itch, p= 0.78).
Harms
In the trial by Berth-Jones and colleagues398 the most frequent adverse events were gastrointestinal
(nausea, vomiting, diarrhoea, abdominal pain, bloating and anorexia). Treatment with azathioprine
resulted in more adverse events, some serious enough to result in four withdrawals from treatment.
In comparison, there were no withdrawals in the placebo group. The study reported that treatment with
azathioprine resulted in transient mild neutropenia, lymphopenia and transient elevation of liver enzymes
in eight participants. Placebo treatment resulted in transient elevation of liver enzymes in two participants.
It was reported that one of these elevations of liver enzymes, near the end of the study, would have been
severe enough to require withdrawal; however, it was not clear which group this participant was in.
The trial by Meggitt and colleagues399 reported that the most frequent adverse event was nausea,
which mainly occurred in participants taking azathioprine (51% of this group) and resulted in seven
participants having their doses reduced and four withdrawals in the azathioprine group. Another two
participants withdrew from the azathioprine group because of hypersensitivity to the treatment.
One participant withdrew from the placebo group because of headaches and malaise.
Overall implications for research and practice
Two fairly high-quality trials398,399 comparing azathioprine with placebo in adults, with sufficient power to
detect a 25% improvement in SASSAD scores, have shown significant benefit in terms of the severity of
eczema and disruption of work/daytime activity. There is not yet any clear evidence of benefit for itching
and sleep disturbance, which may be of much more importance to some people with severe eczema when
weighed against the potential harms of this treatment. The treatment was only given for 3 months and
may not yet have reached its full therapeutic potential,399 which can be established only by conducting
trials over a longer period of time. There is insufficient evidence to deduce whether the benefit provided by
azathioprine is equivalent to that provided by methotrexate in adults, as there have not been any
non-inferiority or equivalence trials.
As yet, there appear to be no trials looking at the use of azathioprine in children with eczema. Given
that azathioprine treatment is increasingly used for children with severe eczema, it is important that
high-quality RCTs involving children are conducted. These future trials need to pay attention to the
azathioprine regimens currently being used in clinical practice to maximise the applicability of the results.
Ciclosporin
Ciclosporin (Neoral®; Novartis) is a systemic immunomodulator that is used to treat severe eczema. There
has been previous evidence from controlled trials that it is beneficial compared with placebo, in particular
for the relief of itching. Relapse can be very rapid after discontinuation of treatment.
Studies
Fifteen trials were reported before 200055 (see Appendix 3).
Eight new trials have been published since 2000.151,390,400–405
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A trial by Czech and colleagues400 included 106 adults with severe eczema and compared high
(300mg/day) and low (150mg/day) doses of oral ciclosporin, regardless of body weight.
Bemanian and colleagues401 compared 3 months of daily ciclosporin at doses of 4mg/kg against one
intravenous immunoglobulin infusion of 2 g/kg in 16 participants with severe eczema.
A trial by Granlund and colleagues,390 which included 72 adults with severe eczema, compared UVAB light
therapy against ciclosporin using cycles of treatment, with 2 weeks of topical treatment between each
cycle, for 1 year.
A small double-blind trial by Pacor and colleagues151 of 30 adolescents and adults compared a dose of
3mg/kg of oral ciclosporin daily with topical tacrolimus (0.1%) ointment applied twice a day for 42 days
using a double-dummy technique to ensure blinding.
One small, well-reported trial by Schmitt and colleagues402 included 38 adults with severe eczema and
compared a 2-week tapering dose of oral prednisolone with a constant daily dose of ciclosporin for
6 weeks. This mimics the treatment regimens frequently used in clinical practice. No other topical or
systemic treatments apart from emollient, prednicarbate (0.25%) and antihistamines (at the dose taken
before the study) were allowed.
A feasibility crossover trial by Kwon and colleagues,405 reported in 2013, included 10 patients aged
> 12 years and compared ciclosporin treatment with and without glucosamine supplementation.
Treatments were given once a day for 2 weeks followed by crossover to the other treatment for 2 weeks.
This 4-week cycle was continued for 6 months and there were no washout periods because of concern
about rebound exacerbation of eczema. The severity of eczema was assessed at the end of each 2-week
period of treatment.
A trial by El-Khalawany and colleagues404 compared methotrexate against ciclosporin for 12 weeks in
40 children aged > 8 years with severe eczema that had been unresponsive or poorly responsive to topical
therapy or phototherapy. Blinding procedures were not reported in this study. No dropouts were reported.
The trial by Haeck and colleagues403 compared mycophenolate mofetil with ciclosporin and is discussed
later in this chapter (see Mycophenolate mofetil). This trial found mycophenolate mofetil to be non-inferior
to ciclosporin.
Assessment of risk of bias
Table 96 provides the risk-of-bias assessment for the new studies.
Benefits
The trial by Czech and colleagues400 did not compare the different doses of ciclosporin investigated against
standard body weight-dependent dosing, was of short duration and involved only a short follow-up period
The authors concluded that there appears to be no difference between these treatment regimens;
however, without another comparator, such as standard topical treatment, the clinical relevance of this
trial is lost.
Four trials151,390,401,402 compared body weight-dependent doses of ciclosporin against other active
treatments. The trial by Bemanian and colleagues401 showed a significant improvement in the severity of
eczema according to SCORAD scores for ciclosporin compared with intravenous immunoglobulin by
day 30, which was sustained until the end of the study on day 90. Use of topical corticosteroids was allowed
to control flare-ups but no data were provided on the amount of corticosteroids used in each group.
The immunoglobulin was given only once compared with continuous treatment with ciclosporin and so it is
difficult to make a direct comparison; however, immunoglobulin is much more expensive than ciclosporin
and requires hospitalisation to administer.
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In the trial by Granlund and colleagues,390 the amount of time spent in remission (reduction in disease
activity assessed by SCORAD to ≤ 50% of the baseline) was significantly higher for the ciclosporin group
and the speed of reduction in eczema severity was faster. Overall, there was no difference in quality of life
and after the first complete treatment cycle (10 weeks) there was no significant difference in severity
between the treatments, pointing to a similar relapse rate. The trial set out to measure how much
emollient and topical corticosteroid was used, but these data were not reported.
In the trial by Pacor and colleagues,151 the assessments of itching, sleep loss and erythema by participants
showed a significant improvement with topical tacrolimus compared with ciclosporin between day 7 and
day 21; tacrolimus ointment was also significantly more effective in terms of eczema severity as assessed
by SCORAD scores between day 14 and day 35. These differences were not present at any other points in
the trial. The trial reported that there were no exacerbations of eczema during the 3-month follow-up.
The trial by Schmitt and colleagues402 assessed the number of participants in stable remission at the end of
treatment. Because of rebound/exacerbation of eczema, half (11/21) of the participants taking
prednisolone and six out of 17 of the participants taking ciclosporin dropped out before the study was
stopped prematurely. Significantly more of the participants achieved stable remission on ciclosporin. Both
treatments improved the severity of eczema but were not significantly different from each other at the end
the trial period or after a further 12 weeks. For those who responded to the treatments initially, 89% on
prednisolone relapsed and 45% on ciclosporin relapsed during the 12-week follow-up.
By combining the severity of eczema SCORAD scores for all 2-week periods on each treatment, the trial by
Kwon and colleagues405 reported that ciclosporin combined with glucosamine was significantly more
beneficial than ciclosporin alone from 1.5 months of treatment onwards.
In the trial by El-Khalawany and colleagues404 there was no statistically significant difference between
groups in the reduction in SCORAD score at 12 weeks (SCORAD mean absolute reduction was 26.2 in the
methotrexate group and 25.0 in the ciclosporin group; p= 0.93).
TABLE 96 Ciclosporin: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Bemanian 2005401 Unclear risk Unclear risk Unclear risk Very small sample size and exclusion criteria
not specified. Participants were hospitalised for
treatment. Blinding not reported and not likely
Czech 2000400 Low risk High risk Low risk
El-Khalawany 2013404 Low risk Unclear risk High risk Intention-to-treat population not used
Granlund 2001390 Unclear risk Unclear risk High risk
Haeck 2011403 Low risk Unclear risk Low risk All participants initially received a course of
ciclosporin at a higher dose than the trial
treatment
Kwon 2013405 Unclear risk Unclear risk Unclear risk Very small sample size. Intention-to-treat
analysis not described
Pacor 2004151 Unclear risk Unclear risk Unclear risk Trial not long enough to see the full potential
effect of ciclosporin
Schmitt 2010402 Low risk Low risk Low risk Study terminated early and so the number
analysed was underpowered (only 38 out of
the 66 needed)
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Harms
The trials published since 2000 have compared ciclosporin against different active agents. In each of these
trials, the number of people taking ciclosporin who reported adverse events was fairly high; however, the
rates were about the same for tacrolimus, UVAB phototherapy and intravenous immunoglobulin. It is
worth noting that there were more withdrawals because of treatment failure/exacerbation of eczema for
UVAB phototherapy and prednisolone. The treatment duration in these eight trials varied from 2 weeks to
1 year. For these time periods the levels of liver- and kidney-related adverse events reported appear to be
very low.
Overall implications for research and practice
The previous review55 provided good evidence that oral ciclosporin is of significant benefit compared with
placebo. It is reassuring that there have now been trials comparing ciclosporin with other active treatments
for eczema. These studies suggest that a short course of ciclosporin might be more effective than
intravenous immunoglobulin or oral prednisolone.401,402 For oral prednisolone treatment, there is evidence
that this lack of benefit results from serious eczema exacerbations when oral prednisolone has to be
stopped, rather than because it is less effective when being taken. There was some evidence that UVAB
phototherapy,390 or methotrexate,404 is not significantly more beneficial than a short course of ciclosporin.
Topical tacrolimus showed more favourable results than ciclosporin in one small, short-term study,151 but
this needs clarification from much larger methodologically robust trials. It is not possible to assess whether
or not ciclosporin combined with glucosamine is actually more beneficial than ciclosporin alone as the trial
demonstrating a beneficial effect was very small and of an unusual design.405 This raised doubts about
which treatment effect was being measured, the treatment just given or the treatment given in the
2 weeks before, because of a lag in the reduction of the SCORAD score.
Methotrexate
Methotrexate is a folic acid antagonist that targets several T-cell activities. It is a common drug that has
been used for decades in inflammatory rheumatic diseases and severe psoriasis.
Studies
No trials of methotrexate were reported before 2000.
Two new studies have been published since 2000. One small single-blind trial, reported by Schram and
colleagues394 in 2011, compared methotrexate with azathioprine for 12 weeks in 43 adult patients with
severe eczema that was unresponsive or intolerant to ciclosporin. The trial by El-Khalawany and
colleagues404 is discussed in the section on ciclosporin, earlier in this chapter.
Assessment of risk of bias
Table 97 provides the risk-of-bias assessment for the new studies.
TABLE 97 Methotrexate: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
El-Khalawany 2013404 Low risk Unclear risk High risk Intention-to-treat population not used
Schram 2011394 Low risk Low risk Low risk
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Benefits
In the trial by Schram and colleagues,394 both treatments improved eczema severity but were not
significantly different from each other at 12 weeks. The mean reduction in SCORAD score for methotrexate
was 22.7 points and for azathioprine was 22.2 points. The proportion of patients with a SCORAD score
reduction of ≥ 50% was 40.0% in the methotrexate group and 45.4% in the azathioprine group. There
were also no differences between the two groups at 12 weeks in patient-reported outcomes – itch
assessment using a VAS, POEM scale, quality-of-life scale – and in the use of concomitant steroids during
the study.
Harms
In the trial by Schram and colleagues,394 no serious adverse events were reported in either group. One
patient in the methotrexate group dropped out after 4 weeks because of nausea and fatigue and three
patients were withdrawn in the azathioprine group. Abnormalities in blood count were significantly more
frequent in the azathioprine group [n= 17 (77%) vs. n= 6 (30%); p= 0.002]. In the trial by El-Khalawany
and colleagues,404 common adverse effects in the methotrexate group included anaemia (30%), fatigue
(30%), abnormal liver function (25%), nausea and vomiting (20%) and glossitis with oral ulceration (20%).
In the ciclosporin group, common complications included fatigue (45%), leucopoenia (35%), headache
(25%), anaemia (20%) and flu-like symptoms (20%). None of the adverse events reported necessitated
discontinuing or decreasing the dose of the drug and all had resolved when followed up.
Overall implications for research and practice
These two trials are underpowered. Additionally, the study by El-Khalawany and colleagues404 had some
methodological weaknesses and used a dose that could well have been subtherapeutic. Consequently,
larger, clearly reported, clinically relevant studies are needed to properly compare the benefits of these
drugs in adults and children with severe eczema. Based on the findings in these two small trials, there is no
evidence that methotrexate is significantly more beneficial than azathioprine or ciclosporin. Adverse events
for methotrexate do not appear, from the current trial evidence, to be any less significant than those for
either azathioprine or ciclosporin, but long-term evidence for the safety of these treatments is lacking.
There is definitely a need for further trials to assess the efficacy and safety of methotrexate for the
treatment of eczema.
Prednisolone
Prednisolone is a systemic corticosteroid widely used to treat a variety of health conditions such as asthma,
pyoderma gangrenosum and inflammatory bowel disease. This treatment needs to be slowly tapered
when stopping.
Studies
One trial involving oral prednisolone was published before 200055 (see Appendix 3).
One small, well-reported trial by Schmitt and colleagues,402 published in 2010, included 38 adults with
severe eczema and compared a 2-week tapering dose of oral prednisolone with a constant daily dose of
ciclosporin for 6 weeks. This mimics the treatment regimens frequently used in clinical practice. The only
treatments permitted were emollients, prednicarbate (0.25%) and antihistamines at the dose taken before
the study. The trial looked at the number of participants in stable remission at the end of treatment.
Assessment of risk of bias
Table 98 provides the risk-of-bias assessment for the new study.
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Benefits
Significantly more of the participants on ciclosporin than on prednisolone achieved stable remission. Both
treatments improved eczema severity but were not significantly different from each other at the end of the
treatment period or after a further 12 weeks. For those who responded to the treatments initially, 89% on
prednisolone relapsed and 45% on ciclosporin relapsed during the 12-week follow-up.
Harms
This trial was stopped early because of the unexpectedly large number of participants who withdrew
because of exacerbation of their eczema (15/38 participants, two of whom needed to be hospitalised).
Most other adverse events noted in the study were mild; however, both groups included a few participants
who had reversible hypertension. No increases in creatinine levels were reported. Although standardisation
of the concomitant treatments makes analysis of the trial results easier, this is very unlikely to compare to a
normal clinical situation.
Overall implications for research and practice
Prednisolone cannot be used for long periods of time without a significant risk of side effects. The trial by
Schmitt and colleague402 seems to suggest that short courses also lead to high rates of eczema relapse,
some of which can be very severe (10/15 participants who relapsed were on prednisolone). As this
treatment was also not as effective as ciclosporin, and the trial was underpowered, these results should be
treated with caution. Whether or not prednisolone can be useful as an emergency rescue treatment on top
of other third-line treatments has yet to be investigated in a RCT, but based on the results of these two
trials the use of prednisolone for the treatment of eczema should be very carefully considered.
Mycophenolate mofetil
Mycophenolate mofetil is an immunosuppressant that works by preventing T cells and B cells dividing.
Studies
No trials of mycophenolate mofetil were reported before 2000.
One new trial was reported after 2000. This small industry-funded single-centre non-inferiority trial from
the Netherlands403 compared 1440mg/day of enteric-coated mycophenolate sodium against 3 mg/kg/day
of ciclosporin for 30 weeks. All participants were treated for a 6-week run-in period with 5mg/kg/day of
ciclosporin. The participants were also followed up for 12 weeks after the treatment stopped. Only the
assessing physician was blinded. Fifty adults with eczema, assessed according to the Hanifin and Rajka8
criteria, who were not responding adequately to potent topical corticosteroids were randomised.
Assessment of risk of bias
Table 99 provides the risk-of-bias assessment for the new study.
TABLE 98 Prednisolone: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Schmitt 2010402 Low risk Low risk Low risk Study terminated early and so the number analysed
was underpowered (only 38 out of the 66 required)
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Benefits
The participants did not report any significant differences in itch and sleep loss during the trial, but the
data were not reported for this outcome. The severity of eczema, measured using the SCORAD index after
10 weeks, was comparable in both study arms (difference 0.8, 95% CI –4.4 to 6.0) until the end of the
maintenance phase.
There were fewer participants with a high quality-of-life score in the mycophenolate mofetil group after
6 weeks of treatment, but there were no significant differences for the rest of the trial.
Harms
There were no serious adverse events reported for this trial. Hypertrichosis was reported for 62% of
the ciclosporin group, whereas fatigue (46%) and flu-like symptoms (34%) were reported for the
mycophenolate mofetil group. Anomalies in laboratory tests were recorded when they occurred more than
twice during the trial; of those reported, two had a notable difference in numbers affected in each
treatment group: magnesium decreased by 27% (n= 7) in the ciclosporin-only group and by 4% (n= 1) in
the mycophenolate mofetil group and blood pressure increased by 15% (n= 4) in the ciclosporin-only
group and 0% in the mycophenolate mofetil group. All laboratory abnormalities were reported to be
transient in both treatment groups.
Overall implications for research and practice
This trial provides some evidence of reasonable quality that, in an objective measurement of the severity of
eczema, mycophenolate sodium is not inferior to ciclosporin. As only the assessing physician was blinded
to treatment, the participants’ assessments of quality of life, itching and sleep loss must be treated with
some caution; however, they did not appear to show a significant difference between the two treatments.
It is important to bear in mind that all participants used ciclosporin first and the trial then compared the
two treatments as maintenance treatment. Consequently, this trial does not provide evidence about
the use of mycophenolate sodium for initial symptom reduction or long-term efficacy, The trial report
states that there is evidence that mycophenolate mofetil sustains improvements in eczema after the
treatment is stopped, but insufficient data for this were provided for independent verification of this claim.
Montelukast
Montelukast (Singulair®; Merck Sharp & Dohme) is a specific antagonist of cysteinyl-leukotriene receptor 1.
Chemicals produced by mast cells and eosinophils bind to this receptor to mediate responses associated
with inflammation. Montelukast is currently used to treat asthma and seasonal allergic rhinitis.
Studies
There were no trials involving montelukast published before 2000.
Six new trials have been published since 2000.251,406–410
TABLE 99 Mycophenolate mofetil: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Haeck 2011403 Low risk Unclear risk High risk All participants were treated for a 6-week run-in period
with a higher dose of ciclosporin than that used in the trial
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Montelukast compared with placebo
Four trials comparing montelukast with placebo have been reported.
The trial by Pei and colleagues406 in Hong Kong, China, compared a 5-mg once-a-day dose of montelukast
against a placebo (chewable ascorbic acid) taken daily for 4 weeks. Fifteen participants aged 6–16 years
were given the treatments in a crossover design: all participants were given one treatment in a randomised
order and then, after a 2-week break, were given the other treatment. All participants used 70% light
liquid paraffin as a soap substitute, aqueous cream as an emollient and clobetasone butyrate (0.05%)
cream twice daily during the study.
Three trials compared 10mg of montelukast daily against placebo in adults. Two of these studies407,408
looked at moderate to severe disease and both were supported by Merck Sharpe & Dohme, which markets
montelukast. Both trials compared 10mg per day of montelukast against placebo after a washout period
of 2 weeks in which all participants took only placebo. The trial by Veien and colleagues,408 which included
59 participants aged 16–70 years with moderate to severe eczema, did not allow any other topical or
systemic treatments during the study, which ran for 4 weeks of treatment. The trial by Friedmann and
colleagues407 gave treatment for 8 weeks.
The third trial409 was carried out in adults with mild to moderate eczema and used a crossover design to
compare 10mg daily of montelukast with placebo for 4 weeks. The eight participants were allowed class V
(potent) or weaker topical corticosteroids, emollients and antihistamines.
Montelukast compared with active treatments
Two trials compared montelukast with other active treatments.
An open, randomised parallel-group trial from Bangladesh by Rahman and colleagues410 compared
hydrocortisone (1%) and antihistamine with a 5-mg (participants aged ≤ 14 years) or a 10-mg once-a-day
dose of montelukast for 4 weeks in 31 participants aged ≥ 6 years.
Another randomised, single-blind trial by Capella and colleagues251 compared 10mg per day of
montelukast and placebo topical and tablet treatment against cetirizine, clarithromycin and topical
mometasone furoate (0.1%) or topical methylprednisolone aceponate (0.1%) in 32 adults with moderate
to severe eczema.
Assessment of risk of bias
Table 100 provides the risk-of-bias assessment for the new studies.
TABLE 100 Montelukast: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Capella 2001251 Unclear risk Unclear risk Unclear risk
Friedmann 2007407 Low risk Low risk Low risk
Pei 2001406 High risk High risk Unclear risk Baseline severity not comparable between groups;
more severe in the montelukast first group
Rahman 2006410 Unclear risk Unclear risk High risk
Veien 2005408 Unclear risk Unclear risk Unclear risk
Yanase 2001409 High risk High risk Low risk Only a 2-day washout between treatments.
Participants do not appear to have been blinded
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Benefits
Montelukast compared with placebo
In the trial by Pei and colleagues,406 for each group the greatest decrease in eczema severity using a score
of six eczema signs across eight areas of the body (maximum score of 144) was during the first treatment
phase [group A decreased by 22.9 points (IQR –35.6 to –18.7 points) on placebo and group B decreased
by 20.0 points (IQR –55.5 to –13.5 points) on montelukast], with a much smaller decrease in the second
treatment phase (p= 0.043). There were no significant differences in quality of life or extent of disease.
This trial included children who were already using a class II (moderate-potency) topical corticosteroid,
emollients and soap substitutes; however, their eczema was still not being adequately controlled. All
participants in the trial were instructed to use clobetasone butyrate twice daily during the trial and this
seems most likely to have been responsible for the changes in severity seen, potentially masking any
benefit from montelukast.
In the trial by Veien and colleagues,408 the severity of eczema was measured using a modified EASI score
(which included pruritus scores). No significant differences between the groups were found. The trial by
Friedmann and colleagues407 administered treatment for 8 weeks and measured the severity of eczema
using SASSAD scores in addition to participant- and clinician-assessed response to treatment, severity of
itching and severity of sleep loss, No significant differences were observed. Although the quantity of
topical corticosteroids used was reported, and does not appear to differ greatly between groups, the
report is difficult to interpret.
The results of the very small trial by Yanase and colleagues409 are difficult to interpret but appear to show
a significant difference in severity (ADASI) scores between treatments (p= 0.014). It is not clear for most of
the results whether between-group or within-group differences are being reported.
Montelukast compared with other active treatments
In the trial by Rahman and colleagues410 the severity of eczema was measured using SCORAD scores and
showed a significant difference between groups in favour of montelukast (p= 0.01). Not much detail
about the study design was reported, including whether any other treatments such as emollients were
permitted or whether the groups were comparable at baseline. This positive result should be treated with
caution as the trial was not blinded.
There were no significant differences between the treatments in the trial by Capella and colleagues251 in
terms of reducing the severity of eczema. Although reported as a single-blind trial, it was not clear who
was blinded. This trial is discussed in more detail in Chapter 7.
Harms
According to the available evidence, montelukast does not appear to result in any significant harms after
short-term use. One of the trial reports did not give details about whether there were any adverse
events.409 One trial stated that there were no withdrawals because of adverse events but did not give any
other safety data.406 Three trials reported either no adverse events or no adverse events related to the
study treatments.251,408,410 The trial by Friedmann and colleagues407 reported one serious adverse event of
septicaemia, at the end of the trial, in a participant in the montelukast group (who rapidly recovered).
There was also one withdrawal because of dizzy spells in a participant in the montelukast group. The
authors also stated that there had been other adverse events that were mild (respiratory tract infections,
headaches, flares of eczema, mild gastrointestinal disturbances) but that these occurred in both treatment
groups at comparable rates.
Overall implications for research and practice
There have now been a number of small RCTs comparing montelukast with placebo. Only two of these
trials can be given serious credit for their results, as the others all use concomitant medications in their
trials, required for ethical reasons, but often to a level that interferes with interpretation of any potential
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beneficial effects of montelukast. These trials, both of good methodological quality, fail to demonstrate a
beneficial effect of montelukast over placebo. Although much larger, longer-term studies are needed to
fully explore the question of whether montelukast is effective, it is unlikely that these will now be funded.
The two small trials comparing montelukast with active treatments were not performed in a
methodologically rigorous manner. The favourable result in the unblinded study by Rahman and
colleagues410 is not enough evidence to suggest that this treatment be considered in routine clinical practice.
Systemic immunotherapy (desensitisation)
Immunotherapy aims to desensitise the immune system to one or more specific allergens or to produce a
more general desensitisation to raised levels of IgE. Levels of sensitivity to house dust mite, as measured by
circulating IgE antibodies in the blood, skin-prick tests or atopy patch tests, are relatively high amongst
people with eczema, and there have been links made between sensitivity to house dust mite and eczema
severity, implying that such sensitivity may be playing a role in the disease.366 One treatment approach is
to reduce exposure to allergens such as house dust mite and another is to desensitise by deliberately
exposing people to small amounts of allergen until tolerance develops. Desensitisation using the allergen
to which they display sensitivity has been tried in selected patients to reduce the severity of eczema.
Studies
Three trials involving systemic immunotherapy were published before 200055 (see Appendix 3).
Four new studies have been published since 2000.411–414
A small double-blind trial by Silny and Czarnecka-Operacz411 compared specific immunotherapy using
house dust mite allergens (two common species) or grass pollen by injection with placebo (histamine
injections). Twenty participants who had sensitisation to grass or house dust mite as well as eczema, 10 in
each group, were treated for 1 year.
One small unblinded trial by Sanchez-Caraballo and Cardona-Villa,412 reported in 2012, compared specific
immunotherapy using subcutaneous house dust mite allergens once a month for 1 year plus standard
treatment (emollients, topical steroids, tacrolimus and oral steroids if needed) with standard treatment
alone in 65 children and adults with eczema and sensitisation to house dust mite allergens (two common
species). There were four dropouts in the control group and one in the experimental group.
A trial by Novak and colleagues,413 reported in 2012, compared specific immunotherapy using
subcutaneous house dust mite allergens every 6 weeks plus standard treatment (emollients, topical
steroids, pimecrolimus and oral steroids if needed) for 18 months with standard treatment alone in
168 adults with moderate to severe eczema and sensitisation to house dust mite allergens (two common
species). Participants were randomised 2 : 1 to immunotherapy plus standard treatment or standard
treatment alone. There were 37 dropouts in the experimental group (out of 112 participants) and
18 dropouts in the control group (out of 56 participants).
A blinded trial by Pajno and colleagues414 included 56 children aged from 5 to 16 years with chronic
eczema that had not spontaneously improved before 5 years of age and with a proven house dust mite
IgE-mediated sensitivity. The trial compared sublingual immunotherapy using a solution containing house
dust mite (allergens Der p1 and Der f1) against a placebo solution. The immunotherapy dose was gradually
titrated from 100 to 1000 and finally to 10,000 RAST units per ml and was given at the highest
concentration (five drops, three times a week) for 18 months. The severity of eczema, parent-assessed
overall symptoms of eczema, the amount of rescue medication used and any local or systemic adverse
events were recorded.
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Assessment of risk of bias
Table 101 provides the risk-of-bias assessment for the new studies.
Benefits
The trial by Silny and Czarnecka-Operacz411 reported a significant difference in eczema severity and extent
of skin inflammation between treatments in favour of specific immunotherapy. It is not clear whether any
other treatments for eczema were permitted during the trial.
The trial by Sanchez-Caraballo and Cardona-Villa412 reported a significant improvement in disease severity,
measured using the SCORAD index, in the experimental group compared with the control group after
6 months (p= 0.03), but the magnitude of benefit cannot be found in the reported data. An unvalidated
patient-reported subjective score was also used to assess disease severity in this study and there was a
significant difference in severity between treatments in favour of specific immunotherapy (p= 0.01).
Moreover, after 1 year of follow-up, a reduction in the use of topical steroids and tacrolimus was
presented in the experimental group compared with the control group (p= 0.02).
The trial by Novak and colleagues413 reported no significant differences between the treatment groups
in disease severity measured by SCORAD scores, quality of life measured by the DLQI or use of basic
medication during the trial. Post hoc analysis performed in the severe subgroup of patients (SCORAD
score of > 50 at baseline) found a statistically significant reduction in the median total SCORAD score over
time, with the immunotherapy plus standard care group having a 21% improvement compared with
standard treatment only (p= 0.02).
The trial by Panjo and colleagues414 showed no significant difference between the two groups for
participant-/carer-assessed severity of eczema over 18 months. The sublingual immunotherapy group
performed significantly better than the placebo group when the severity of eczema was assessed by
SCORAD scores, but only from 9 months onwards until the end of the trial at 18 months. At 9 months the
immunotherapy group had improved by an average of 12 SD± 3.8 points and the placebo group by an
average of 4 SD± 3.5 points (p= 0.0025); this difference only reduced slightly by 18 months. The sublingual
immunotherapy group used significantly less rescue medication than the placebo group over the trial period.
Patient with mild to moderate eczema (SCORAD score of < 40) gained the most benefit, with a significant
benefit of sublingual immunotherapy for eczema severity compared with placebo; participants with severe
eczema did not show a significant benefit of sublingual immunotherapy for any of the outcomes.
Harms
The trial by Silny and Czarnecka-Operacz411 reported that there were no clinically significant systemic
adverse events. Eight participants in the immunotherapy group and six participants in the placebo group
experienced worsening of skin inflammation that required mild topical corticosteroids.
TABLE 101 Systemic Immunotherapy: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Novak 2012413 Low risk Unclear risk Unclear risk
Pajno 2007414 Low risk Unclear risk Low risk Efficacy analyses using intention-to-treat
principles not carried out. Eight
participants withdrew during the trial
Sanchez-Caraballo 2012412 Unclear risk Unclear risk High risk The intention-to-treat population was
not used for analysis
Silny 2006411 Unclear risk Unclear risk Unclear risk The trial was very small and severity was
measured by the point index, which is
not as sensitive as other measures
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In the trial by Sanchez-Caraballo and Cardona-Villa,412 16 local immediate reactions were observed in 11
patients in the first 3 months of treatment, whereas no systemic reactions were recorded. It was unclear in
which groups these adverse events were observed.
In the trial by Novak and colleagues,413 local reactions of mild intensity were reported in 39% of
participants in the immunotherapy group and 35% in the placebo group.
In the trial by Pajno and colleagues,414 two participants experienced generalised itching and flares about
1 hour after being given sublingual immunotherapy, which needed treatment with intramuscular
chlorpheniramine and betamethasone. They were rechallenged three times and then excluded. Tiredness
was reported by six participants in the immunotherapy group and one participant in the placebo group.
One participant in the immunotherapy group reported headaches. There were local, delayed reactions in
the build-up of dosing for one participant, who experienced swelling of the mouth, lips and face, and a
further three participants experienced oral itching.
Overall implications for research and practice
Four trials reported after 2000 provide contradictory evidence. The largest did not find any benefit for the
addition of house dust mite-specific immunotherapy in sensitised adult patients, except in a post hoc
subgroup of only those with severe eczema.413 Two smaller trials in children contradict each other. In one
trial of sublingual immunotherapy treatment414 the results from 9 to 18 months do provide evidence of
benefit, but there is a lack of evidence of benefit over the entire 18 months. This trial also found no
treatment effect for those with severe eczema. The other trial in children did not find any evidence of
benefit.412 The smallest trial provided evidence of benefit for immunotherapy, but with only 20 participants
and a questionable placebo treatment (histamine) this does not add much weight to the evidence.411
The evidence base for this treatment is far from clear. A better picture of which severities of eczema may
benefit and whether there is a difference in effectiveness between adults and children is still needed. There
is some evidence that there is a steroid-sparing effect of immunotherapy but exactly why this occurs is
unclear. As immunotherapy appears to take a long time to show effectiveness, future trials should ideally
include longer durations of treatment and longer follow-up periods to investigate the full potential of
immunotherapy. A pragmatic trial should consider approaches to standardise concomitant medication for
eczema during the initial treatment phase, to avoid losing unacceptable numbers of participants because
of an initial lack of efficacy.
The adverse events reported here are similar to those observed in previous trials on desensitisation and
there are some individuals who cannot use immunotherapy because of serious reactions such as acute
exacerbation of eczema or allergic reactions. This is an important consideration and requires further
specific research using methodologies more appropriate to assessing harms.
Mepolizumab
Mepolizumab is a humanised monoclonal antibody to interleukin 5, which is a key cytokine in eosinophil
production in the bone marrow.
Studies
There were no trials involving mepolizumab published before 2000.
One new trial by Oldhoff and colleagues415 compared mepolizumab with placebo in 43 adults with eczema
who were experiencing a flare. The treatment was given in two single doses, 7 days apart. The only other
treatments allowed were non-medicated emollients, bath oils and hydrocortisone acetate (1%) for the
face. Those who had not responded by day 16 were allowed fluticasone propionate (0.05%) once daily.
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Assessment of risk of bias
Table 102 provides the risk-of-bias assessment for the new study.
Benefits
Of the 40 participants evaluated after 2 weeks, there were no significant differences between the
treatments according to the physician’s global assessment (p= 0.115), severity measured by SCORAD
scores (p= 0.293) and itching.
Harms
Adverse events were only very briefly discussed in the trial report. The report states that there were some
mild and transient adverse events in the mepolizumab group and that they did not differ from those seen
in the placebo group.
Overall implications for research and practice
This trial has failed to show any clinically relevant effects of mepolizumab. It is too early to conclude with
certainty that mepolizumab does not have any treatment effect, as this one trial was powered to detect
only large treatment effects over a short period. That said, mepolizumab is a very expensive treatment and
so it may be difficult to justify its use, even if future trials show a moderate short- or long-term benefit.
Omalizumab
The recombinant humanised monoclonal antibody (IgG1κ) omalizumab has been shown to lower
blood serum levels of free IgE. Omalizumab has shown efficacy and a good safety profile when tested in
allergic asthma, rhinitis and food allergy. It is also used in immunotherapy to help prevent type I
hypersensitivity reactions.
Studies
There were no trials involving omalizumab published before 2000.
One new trial has been published since 2000. This small mechanistic trial416 compared omalizumab
[0.016mg/kg/IgE (IU/ml) every 4 weeks] with placebo for 16 weeks in 20 participants aged 12–60 years.
Emollients, hydrocortisone acetate (1%) and diflucortolone valerate (0.1%) were all permitted.
Assessment of risk of bias
Table 103 provides the risk-of-bias assessment for the new study.
TABLE 102 Mepolizumab: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Oldhoff 2005415 Unclear risk Unclear risk Unclear risk The sample size was powered to detect only large
treatment effects. The treatment and follow-up
durations were short for the nature of eczema
TABLE 103 Omalizumab: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Heil 2010416 Unclear risk Unclear risk Low risk Only 20 participants and designed as a
mechanistic study; not clear whether it was
powered to detect a clinically relevant effect
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Benefits
No significant differences were found in the secondary outcomes of eczema severity measured using the
EASI scale, IGA score and investigator’s assessment of itch, but detailed data were not reported.
Harms
The trial reported a high level of adverse events; however, there were no serious adverse events or deaths
and no withdrawals because of adverse events. Fourteen participants reported 19 adverse events, with 10
of the participants being in the omalizumab group. The adverse events reported were diverse and included
vertigo, injection site reaction and migraine thought to be related to taking omalizumab.
Overall implications for research and practice
This very small trial416 that did not show any benefit of taking omalizumab and which reported a high level
of adverse events should be treated with caution. Much larger, longer-term, studies are needed before this
treatment can be considered for routine clinical practice.
Intravenous immunoglobulin
Treatment with intravenous immunoglobulin has immunomodulatory and anti-inflammatory properties and
has been shown to be effective for several immune-mediated conditions.
Studies
One trial involving intravenous immunoglobulin was published before 200055 (see Appendix 3).
Three RCTs401,417,418 of 2 g/kg intravenous infusions of immunoglobulin have been reported since 2000.
One fairly well-reported trial by Paul and colleagues417 in 10 adults compared immediate intravenous
immunoglobulin treatment for 2 days against standard care (emollients and topical corticosteroids).
The trial by Bemanian and colleagues401 compared oral ciclosporin against intravenous immunoglobulin
(2 g/kg over 4–8 hours) in 16 participants with severe eczema who were hospitalised for treatment.
Blinding was not reported, but as the ciclosporin was taken daily for 3 months it seems unlikely that
blinding could have taken place.
The industry-funded trial by Jee and colleagues418 compared 3 months of intravenous immunoglobulin
treatment given in monthly injections (2 g/kg per month) to hospitalised patients against a ‘placebo’ of
general topical moisturising lotion, 1% hydrocortisone cream and oral antihistamines for itching. The
intravenous immunoglobulin group could also use the same treatments as the placebo group and all
participants could also use an emollient ointment or steroid-free hydrophilic cream as an adjuvant
to treatment.
Assessment of risk of bias
Table 104 provides the risk-of-bias assessment for the new studies.
Benefits
In the trial by Paul and colleagues,417 the severity of eczema was measured using SCORAD scores and a
participant-assessed global disease measure at day 30, after which the standard care group received the
intravenous immunoglobulin treatment and the participants were assessed again at day 60. The study found
no significant difference in eczema severity between the two groups after 30 days (p= 0.4) and the
participant-assessed global disease measure was also not significantly different between groups, with little
change for the delayed treatment group and a slight improvement for the intravenous immunoglobulin group.
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The trial by Bemanian and colleagues401 reported a significant difference in eczema severity in favour of
ciclosporin (p= 0.005), which was evident by day 30. The severity of eczema did decrease in both groups
over the 90 days of the trial but the clinical significance of the trial is difficult to gauge as the improvement
may have resulted from the close monitoring and attention given in the trial.
The trial by Jee and colleagues418 reported no significant differences in participant assessments of itching
and sleep loss. A significant difference in favour of intravenous immunoglobulin treatment for change in
SCORAD score after 3 months of treatment and 3 months after treatment was stopped was reported.
Harms
The trials by Paul and colleagues417 and Bemanian and colleagues401 did not report any information about
serious adverse events for participants on intravenous immunoglobulin treatment. Adverse events of
hirsutism and herpetic keratoconjunctivitis occurred in one participant each taking ciclosporin.401 The trial
by Jee and colleagues418 reported that 5 out of 30 participants in the intravenous immunoglobulin group
withdrew because of adverse events including headache and nausea. Two out of 10 participants in the
placebo group withdrew for personal reasons.
Overall implications for research and practice
Intravenous immunoglobulin therapy is an expensive and resource-intensive treatment (because of the
need for secondary care resources) that to date does not have any good-quality evidence of benefit in
comparison to other systemic immunomodulatory agents. The trial by Jee and colleagues418 reported that
intravenous immunoglobulin is beneficial compared with a standard treatment regimen; however, baseline
eczema severity and atopy (assessed by total IgE level) were considerably higher in the intravenous
immunoglobulin group at baseline and the very small number of participants in the standard care group
raises serious concerns about the validity of these results. The participants in the trial did not report any
significant differences in sleep loss and itching. The use of this treatment for eczema in clinical practice
should be carefully considered until good-quality evidence of the benefits and harms becomes available.
TABLE 104 Intravenous immunoglobulin: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Bemanian 2005401 Unclear risk Unclear risk Unclear risk Very small sample size and exclusion criteria not
specified. Participants were hospitalised for
treatment. Blinding not reported and not likely
Jee 2011418 Unclear risk Unclear risk Unclear risk Baseline values for SCORAD and total IgE are
much higher in the intravenous immunoglobulin
group than in the placebo group
Paul 2002417 Low risk Low risk Low risk Very small sample size may not allow detection
of small differences. Previous use of systemic
treatments may have confounded the results
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Oral pimecrolimus
Studies
There were no trials of oral pimecrolimus reported before 2000.
One trial has been reported since 2000. This industry-funded multicentre trial by Wolff and colleagues419
compared three different doses of oral pimecrolimus (20mg, 40mg and 60mg) against a placebo given
twice daily as divided doses for 12 weeks. In total, 103 adults with moderate to very severe eczema were
randomised to one of four treatment groups. All participants were allowed to use emollients and 1%
hydrocortisone throughout the trial and for 7 days before the trial. There was a 12-week follow-up phase
after treatment during which the participants could use only standard eczema treatment.
Assessment of risk of bias
Table 105 provides the risk-of-bias assessment for the new study.
Benefits
A statistical comparison between treatment groups of the percentage of participants with a pruritus score
of ≤ 1 and the IGA score was not reported. The percentage of participants achieving ‘complete control’ (0)
or ‘good control’ (1) for the participant assessment of the response to treatment was significantly different
between the placebo group (27%) and the 60-mg pimecrolimus group (62%) after 6 weeks of treatment.
The severity of eczema, measured using EASI, was significantly different after 6 and 12 weeks of treatment
for the three pimecrolimus treatment groups combined compared with placebo (overall superiority using
analysis of covariance test: p= 0.042 at week 7, p= 0.263 at week 12). The 40-mg and 60-mg
pimecrolimus groups were also reported as being superior using the same test at week 7.
Harms
This trial reported that there were no differences in the overall incidence of adverse events between
treatment groups. Adverse events of nausea and feeling hot occurred and presented a dose–response
relationship with pimecrolimus. Two participants reported serious adverse events. One participant taking
60mg of pimecrolimus a day, who had a family history of type 1 and type 2 diabetes and a body mass
index of 33.3 kg/m2, had an elevated fasting blood glucose level. Another participant in the placebo group
had chest and abdominal pain, an abnormal electrocardiogram and sinus bradycardia.
Overall implications for research and practice
This trial of different doses of oral pimecrolimus compared with placebo did not provide much convincing
evidence that any dose < 60mg per day gave a meaningful clinical benefit on top of standard treatment
alone, taking into account the known risks of this treatment. The trial did follow up participants for
3 months after the treatment was stopped but did not present these results, which leaves the long-term
benefits and harms of oral pimecrolimus still unknown.
TABLE 105 Oral pimecrolimus: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Wolff 2005419 Low risk Low risk Low risk
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Summary of systemic immunomodulatory agents
Azathioprine
l There were no trials of azathioprine for eczema reported before 2000.
l Three trials were reported after 2000:
¢ Two small trials, with a mostly low risk of bias, found evidence of a large beneficial effect of
3 months of treatment with azathioprine compared with placebo in adults.
¢ One small trial, with an overall low risk of bias, did not provide any evidence of benefit of
azathioprine compared with methotrexate.
l Azathioprine treatment has a high burden of adverse events such as nausea, vomiting and diarrhoea,
which may limit its use. Serious adverse events such as elevated liver enzymes, neutropenia and
lymphopenia present a risk of harm from long-term use.
l There have not yet been any trials of azathioprine treatment in children with eczema.
Ciclosporin
l There were 10 trials of oral ciclosporin for eczema reported before 2000. These provided evidence of a
strong short-term beneficial effect of ciclosporin compared with placebo.
l Serious adverse effects, especially renal damage and hypertension, indicate that long-term use of
ciclosporin presents a significant risk of harm. Even for short-term treatment there is no evidence that
having strategic treatment interruptions are beneficial in decreasing the risk of adverse events.
l Three small and very small trials reported after 2000, with a mixed risk of bias, provided evidence of
significant benefit for oral ciclosporin (doses ranged from 2.7 to 4mg/kg per day) compared with
topical tacrolimus, intravenous immunoglobulin or phototherapy treatment.
l One trial reported in 2000, with a high risk of bias for allocation concealment, did not provide any
evidence of benefit for body weight-dependent dosing of ciclosporin compared with standard
ciclosporin treatment. This trial did not compare ciclosporin against another treatment comparator.
l One small trial reported in 2010, with an overall low risk of bias, provided evidence of benefit for
remission for ciclosporin compared with a 2-week tapering dose of oral prednisolone. This trial was
forced to close early because of the unexpectedly high number of relapses requiring hospitalisation
or withdrawal.
l One small trial reported in 2011, with a mostly low risk of bias, provided evidence of non-inferiority for
ciclosporin compared with mycophenolate mofetil.
l One very small trial reported in 2013, with an overall unclear risk of bias, did not provide evidence of
benefit for ciclosporin plus glucosamine compared with ciclosporin alone.
l One small trial reported in 2012, with a mixed risk of bias, did not provide any evidence of benefit for
ciclosporin compared with methotrexate.
Methotrexate
l There were no studies involving methotrexate before 2000.
l Two small trials were reported after 2000:
¢ One trial, with an overall low risk of bias, did not provide any evidence of benefit for azathioprine
compared with methotrexate.
¢ One trial, with a mixed risk of bias, did not provide any evidence of benefit for 12 weeks of
treatment with low-dose methotrexate compared with treatment with low-dose ciclosporin in
children with severe eczema.
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Prednisolone
l There were no trials involving oral prednisolone reported before 2000.
l One small trial reported in 2010, with an overall low risk of bias, involving a 2-week tapering course of
oral prednisolone treatment provided no evidence of benefit of prednisolone compared with ciclosporin
for 6 weeks. A higher proportion of participants using prednisolone relapsed during the 6-week
treatment phase and in the 12 weeks after this. The trial was forced to close early because of the
unexpectedly high number of relapses requiring hospitalisation or withdrawal.
Montelukast
l There were no trials involving montelukast for eczema reported before 2000.
l Four trials, two small and two very small, reported after 2000, with a mixed risk of bias, gave
conflicting evidence of benefit for montelukast compared with placebo.
l Two small trials reported in 2001 and 2007, with a mostly unclear risk of bias, gave conflicting results
for montelukast compared with a standard treatment regimen of topical corticosteroids, antihistamines
and antibiotics (for only one of the trials).
Systemic immunotherapy (desensitisation)
l One medium-sized trial in 2012 involving house dust mite desensitisation in sensitised adult patients
with eczema, with a mixed risk of bias, provided no evidence of benefit for specific
systemic immunotherapy.
l Two small trials in 2006 and 2012 involving house dust mite desensitisation in sensitised patients with
eczema, with a mixed risk of bias, provided evidence of benefit for specific systemic immunotherapy.
Mepolizumab
l There were no trials involving mepolizumab for eczema reported before 2000.
l One small trial in 2005, with an overall unclear risk of bias, did not find any evidence of benefit for
mepolizumab compared with placebo for clinically relevant outcomes.
Omalizumab
l There were no trials involving omalizumab for eczema reported before 2000.
l One small trial in 2010, with a mostly unclear risk of bias, did not provide any evidence of benefit for
omalizumab compared with placebo, considering the clinically relevant outcomes only.
Intravenous immunoglobulin
l One small trial reported before 2000, with an overall unclear risk of bias, provided evidence of benefit
for intravenous immunoglobulin compared with intravenous albumin.
l Two trials, reported in 2002 and 2011, provided conflicting evidence of benefit for intravenous
immunoglobulin compared with standard treatment (topical corticosteroid and emollients and oral
antihistamines in one of the trials). The largest and much longer-term trial, with an overall unclear risk
of bias, did not provide evidence of benefit for 3 months of treatment (2 mg/kg/month).
l One very small trial reported in 2005, with an overall unclear risk of bias, provided evidence of benefit
for ciclosporin compared with intravenous immunoglobulin treatment.
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Pimecrolimus (oral)
l There were no trials involving oral pimecrolimus reported before 2000.
l One trial in 2005 involving three different doses of pimecrolimus (20mg, 40mg or 60mg per day in
two divided doses) provided evidence of benefit for the highest dose of pimecrolimus (60mg)
compared with placebo after 7 weeks of treatment. However, development of this treatment was
halted because of concerns over carcinogenicity.420
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Chapter 12 Complementary therapies
Background
We define complementary therapies as a group of therapeutic and diagnostic disciplines that exist largely
outside the institutions where conventional health care is taught and provided. This chapter includes all
trials of interventions that met this definition at the time of writing the review.
Existing systematic reviews
A technology report94 accompanying the AAD guidelines covered hypnotherapy, Chinese herbal medicine,
homeopathy and evening primrose oil. The NICE guidelines41 covered homeopathy, massage, hypnotherapy
and aromatherapy. The SIGN guidelines42 covered homeopathy and acupuncture. A review of systemic
treatment for severe atopic eczema in 2007,393 a review of treatments for eczema to relieve pruritus in
201293 and a Cochrane review of Chinese herbal medicine for atopic eczema in 2013421 reviewed the trials
of Chinese herbal medicine. A review of complementary/alternative treatment in dermatology in 2002282
also assessed hypnotherapy. Three systematic reviews282,422,423 covered homeopathy.
Scope of this chapter
This chapter covers the following treatments:
l St John’s wort
l acupuncture
l acupressure
l hypnotherapy
l aromatherapy/massage
l Chinese herbal medicine
l homeopathy
l other herbal medicine
l Japanese traditional medicine
l Hwangryunhaedoktang
l balneotherapy
l progressive muscle relaxation.
St John’s wort (Hypericum) (topical)
St John’s wort is the common name given to a genus of herbs found in Europe. The plants are used to
create a herbal preparation now used in mainstream medicine in many European countries for treating
mild to moderate depression, but this use is not currently recommended by NICE.424 The exact mechanism
of action of St John’s wort is unclear. For topical treatment, the flavonoids and tannins may be possible
active components.
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Studies
No studies using topical St John’s wort for eczema were reported before 2000.
One study involving St John’s wort was reported after 2000. This small within-person study by Schempp
and colleagues425 compared St John’s wort (1.5%) (Hypericum perforatum L.) cream with a placebo cream
in 21 participants aged 12–59 years with ‘subacute’ eczema, defined as a SCORAD score of < 80. The
creams were applied twice daily for 4 weeks.
Assessment of risk of bias
Table 106 provides the risk-of-bias assessment for the new study.
Benefits
At the end of the trial period of 28 days the mean± SD change in eczema severity, as assessed using
objective SCORAD scores, was –5.4± 4.9 for the St John’s wort group compared with –2.3± 3.3 for the
placebo group.425 This was a statistically significant reduction for St John’s wort compared with placebo
(p= 0.022). This significant reduction in severity was also reported between the treatments at weeks 1 and
4. Participant-assessed skin tolerability and cosmetic acceptability were described as ‘good or excellent’ for
both treatments, but no further information was provided.
Harms
There were four acute episodes of eczema, which led to withdrawal from treatment for three participants
reported in this study.425 It was not reported whether these exacerbations of eczema were thought to be
related to both or one of the treatments. One of the three participants also developed contact eczema on
the area treated by the placebo, which was thought to be probably related to the vehicle cream. There
were no serious adverse events reported.
Overall implications for research and practice
The results of this one small pilot study425 are potentially encouraging; however, the lack of information
about allocation concealment and blinding and the lack of a formal sample size calculation means that the
results must be treated with caution. It is important that any future studies of St John’s wort compare it
against emollients and topical corticosteroids to enable a clearer judgement to be made on its potential
clinical usefulness.
TABLE 106 St John’s wort: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Schempp 2003425 Unclear risk Unclear risk Unclear risk The intention-to-treat analysis excluded three
participants who had used the treatment for
< 10 days or who did not have efficacy data.
Although the creams were colour matched, It was
unclear if other differences were controlled for
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Acupuncture
Studies
No trials involving acupuncture were reported before 2000.
One new trial involving acupuncture was reported after 2000. This observer-blinded single-centre
industry-funded trial by Pfab and colleagues426 compared acupuncture twice weekly for 33 days against a
control of a study examination visit only, with no acupuncture. The 10 participants who were randomised
had to have a history of eczema for > 10 years, a SCORAD score of > 20 and allergic rhinitis with
sensitisation to Phleum pratense and D. pteronyssinus.
Assessment of risk of bias
Table 107 provides the risk-of-bias assessment for the new study.
Benefits
The baseline itch intensity, measured on a VAS from 0 to 100, was markedly different between the
groups, with mean± SD itch intensity being 11± 7 in the non-acupuncture group and 55± 22 in the
acupuncture group. The change in itch intensity from baseline to day 15 and day 30 was not statistically
compared. There were no significant differences between the treatment groups in change in eczema
severity from baseline to 15 days or 30 days (change from baseline to 30 days: acupuncture group
–5.6± 17.6, non-acupuncture group 3.5± 3.4).
Harms
No adverse events were reported for this trial.
Overall implications for practice and research
This very small trial with very little methodological detail and a huge disparity in baseline pruritus scores
does not provide any evidence of benefit for acupuncture. Until a larger, methodologically rigorous trial is
conducted, the use of acupuncture for eczema remains unclear.
Acupressure
Studies
No trials involving acupressure were reported before 2000.
One new trial involving acupressure was reported after 2000. This single-centre trial compared acupressure
in addition to standard treatment against standard treatment only. The 15 adult participants, who had not
used acupressure or acupuncture in the previous year, were treated for 4 weeks. Those randomised to
acupressure were taught the technique and applied pressure to the large intestine point 11 using a 1.2-mm
titanium ‘acupellet’ for 3 minutes, three times a week.
TABLE 107 Acupuncture: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Pfab 2011426 Unclear risk Unclear risk High risk
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Assessment of risk of bias
Table 108 provides the risk-of-bias assessment for the new study.
Benefits
Compared with baseline, the reduction in pruritus (p= 0.04) and severity of eczema measured using the
IGA score (p= 0.03) and the lichenification score from the EASI measure (p= 0.03) was greater in the
acupressure group than in the standard treatment-only group. For itching, three out of seven participants
in the acupressure group did not change (0–25% change) and four out of seven improved (≥ 25%
improvement); in the control group five out of five participants in the control group did not change
(0–25% change). For eczema severity measured using IGA, two out of seven in the acupressure group did
not change and five out of seven improved (≥ –1 point); in the control group two out of five worsened
(≥+1 point), one out of five did not change and two out of five improved (≥ –1 point).
Harms
It was reported that there was no adverse events during the trial.
Overall implications for research and practice
As the authors of the trial point out, although this trial reported a statistically significant benefit for
acupressure compared with no acupressure, as there were so few patients and no ‘placebo’ such as sham
acupressure, a larger trial needs to be carried out to see whether this beneficial effect can be confirmed.
Until then, there is insufficient evidence of benefit for acupressure.
Hypnotherapy
Hypnotherapy and biofeedback used to develop relaxation techniques with or without mental imagery may
be beneficial in the management of atopic eczema to distract from the symptoms associated with the
itch–scratch cycle.
Studies
One trial involving hypnotherapy was reported before 200055 (see Appendix 3).
One new trial involving hypnotherapy was reported after 2000. This trial in Germany,428 which compared
12 sessions of hypnotherapy (1 hour in duration) with no hypnotherapy, included 33 adults diagnosed
with eczema by a dermatologist. The participants were assessed once a week, with the last assessment
1 week after the last treatment session.
TABLE 108 Acupressure: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Lee 2012427 Unclear risk Unclear risk High risk 3/15 participants were lost to follow-up
and were not included in the analyses
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Assessment of risk of bias
Table 109 provides the risk-of-bias assessment for the new study.
Benefits
The severity of eczema, measured by SCORAD scores, increased by 32% in the control group and
decreased by 40% in the hypnotherapy group from baseline to 1 week after the last hypnotherapy session
was given. The difference between the two treatments appears to have been analysed but the significance
was unclear as it appears to have been reported as p= 0.000. Eczema-related quality of life, measured
using the Marburg Atopic Dermatitis Questionnaire,349 showed a 26% improvement for the hypnotherapy
group, also reported as p= 0.000. The percentage change in quality of life for the control group was not
given; however, it was reported to be insignificant. Pruritus, scratch intensity and subjective skin condition,
all recorded by participants on a VAS, showed an improvement in the hypnotherapy group and a
worsening in the control group compared with baseline. The difference between the groups was highly
significant for all of these outcomes (p= 0.000).
Harms
No adverse events were reported for this trial.
Overall implications for practice and research
This trial of hypnotherapy shows a striking level of benefit for eczema; however, the results of this one trial
must be treated with caution, especially given the high risk of detection/information bias and other
concerns regarding possible selection and performance bias because of the poorly reported nature of the
study. It is unclear whether any attempt at blinding of the outcome assessors was made, but it would
seem almost impossible to blind the participants, who were recording the subjective outcomes. A group of
people with eczema who are not on any treatment at all is very unlikely to match reality, where nearly all
people with eczema are at a minimum at least using an emollient. It appears that the control group in this
trial did not use any treatment and not surprisingly deteriorated during the trial, making the difference
between the control group and those having hypnotherapy seem more significant than it is likely to be in a
normal clinical setting. Although it is unlikely that participants on a hypnotherapy trial could ever be
blinded to their treatment allocation, blinding of outcome assessors and the inclusion of a purely objective
outcome measure where possible will be essential in any future hypnotherapy trial. With two small trials
on hypnotherapy showing some positive indications of benefit, a large, pragmatic and methodologically
robust trial of hypnotherapy should now be conducted.
Aromatherapy/massage
It is possible that massage therapy may be beneficial in childhood eczema as a stress-reducing and
enjoyable interaction between parent and child. Massage may also increase peripheral circulation (which
may be defective in eczema) or may be a way of increasing compliance with topical treatments.
Studies
There were no RCTs of aromatherapy for eczema reported before the year 2000, although the abstract of
the one new trial reported below was mentioned in the previous review.55
TABLE 109 Hypnotherapy: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Senser 2004428 Unclear risk Unclear risk High risk
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Anderson and colleagues429 compared massage administered by the mother using essential oils in massage
oil against massage administered by the mother using massage oil without essential oils. All participants
bathed daily and essential oils were added to the bath only for the essential oils group. A therapist visited
the home of each participant once every week and performed 30 minutes of massage on the participant
and counselled the participant and the mother together. The trial consisted of 16 white children aged
3–7 years from middle-class backgrounds with professional working mothers, living as a family with their
natural father. The participants’ GP, therapist and mother all separately assessed the children’s general
improvement using an ordinal scale from 0 (no improvement) to 10 (considerable improvement) and the
mother assessed night-time and daytime disturbance using the same scale.
Assessment of risk of bias
Table 110 provides the risk-of-bias assessment for the new study.
Benefits
Parent-assessed improvement was not significantly different between the treatment groups. Mother-
assessed night-time and day-time disturbance also showed no significant difference in improvement
between the groups after 8 weeks of treatment. All of the above assessments showed a statistically
significant improvement within the treatment groups; however, there did not appear to be any statistically
or clinically significant differences between the treatment groups, although no other between-group
analyses were reported.
Harms
Adverse events were not reported for this trial. The possibility that patients may develop allergic contact
dermatitis to the aromatherapy constituents was mentioned.
Overall implications for research and practice
It is impossible to draw conclusions from this trial about the use of either aromatherapy oils or massage for
children with eczema. The addition of counselling and massage could have masked any potential beneficial
effects of the aromatherapy. Small numbers of a very select population of people with eczema were all
treated with massage therapy, with one group using aromatherapy in addition. It was also highly likely
that the assessors of all but one of the outcomes (parent and therapist) were aware of the group to which
the child was allocated. If there is serious interest in exploring further the possible benefits of massage in
eczema, a much larger and pragmatic trial of a more representative population is needed, which adds a
simple combined massage with aromatherapy oils regimen to standard care.
Chinese herbal medicine
Chinese herbal medicine forms part of a system that includes oral and/or topical Chinese herbs,
acupuncture, diet and exercise for both treatment and prophylaxis of disease. Medicinal plants of various
kinds can be taken orally, usually in combination with others as a decoction by boiling them in water and
drinking the ‘tea’ produced, or can be applied directly to the skin.
TABLE 110 Aromatherapy: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Anderson 2000429 Unclear risk Unclear risk High risk Although the participants were not told which group
they were in, it is likely that the essential oils’ aroma
would unblind many participants and possibly the GP
performing the blinded outcome assessments
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Prescriptions are individually determined based on an overall assessment of the patient including pulse,
appearance of the tongue and disease features, hence standardised formulae are not generally prepared.
Studies
Four studies were reported before 2000, which compared different Chinese herbal preparations against
placebo55 (see Appendix 3).
Six new trials have been published since 2000.262,430–434
Hon and colleagues430 compared a five-herb concoction (containing Flos lonicerae, Herba menthae, Cortex
moutan, Rhizoma attactylodis and Cortex phellodendri) against placebo given in capsules for 12 weeks.
The placebo capsules were assessed by an expert panel to ensure that they were indistinguishable from
the herbal capsules. Eighty-five children and young adults aged between 5 and 21 years with moderate to
severe eczema (SCORAD score of > 15) took three capsules twice a day.
Another industry-sponsored study, by Shapira and colleagues,431 compared a herbal preparation of Siberian
ginseng, Achillea millefolium and Lamium album against placebo, both taken orally three times a day for
2 weeks. The trial was conducted at community-based clinics and included 49 participants aged > 12 months
with moderate eczema, diagnosed using criteria closely resembling the UK Working Party criteria.9
Participants were allowed to use emollients and topical corticosteroids as long as they were using them
before entering the trial and they were not altered during the trial.
Shi and colleagues262 conducted an open trial of 47 participants from China, comparing modified Jiawei
Danggui Decection against no treatment. Both groups took 10mg of loratadine per day and used
hydrocortisone butyrate (0.1%) once a day for 4 weeks. The active treatment group were also treated with
250ml of Jiawei Danggui Decection, but the treatment regimen was not reported.
A trial carried out in Taiwan by Cheng and colleagues432 compared Xiao-Feng-San (a mixture of 13
different plant materials in granular form dispersed in warm water) against a placebo of caramel, lactose
and starch, which had a similar taste to the active treatment. One packet (the dose was dependent on
age) was taken three times a day for 8 weeks. The participants had eczema on > 20% of their body
surface area, were described as ‘refractory’ and had no active infection or exudation.
A pilot trial by Choi and colleagues433 in Korea compared 2.5 g of TJ-15, a traditional compound of
Chinese herbs containing Scutellaria baicalensis root, Gardenia jasminoides fruit, Coptis chinensis rhizome
and Phellodendron amurense, against a mixture of 1.25 g of TJ-15 and 1.25 g of TJ-17, containing Alisma
orientalis root tuber, Poria cocos mycelium, Atractylodes lancea rhizome, Cinnamomum cassia branch and
Polyporus umbellatus mycelium. Twenty-four participants (age not reported) with eczema diagnosed
according to the Hanifin and Rajka8 criteria and a ‘Dampness-Heat’ pattern, diagnosed by a Korean
traditional medicine specialist, were randomised. The dose was taken three times a day, 90 minutes after
a meal, for 4 weeks. All participants were given guidance on the application of non-steroidal emollients.
All participants were also given dietary and environmental recommendations.
In 2000 an open study by Henderson and colleagues,434 sponsored by the manufacturers, compared a
Chinese herbal preparation PSE101, which was made up as tea, against the same herbal preparation
(PSE222) taken as lacquered granules, to avoid the palatability problems associated with the herbal
preparation as a tea. As no other treatment was tested, such as a placebo or different active treatment,
this trial was not suitable for assessing the clinical efficacy of the herbal preparation. Interestingly, no
participant assessment of palatability appears to have been reported, although the trial authors conclude
that the granules are better tolerated. This trial is not discussed further.
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Assessment of risk of bias
Table 111 provides the risk-of-bias assessment for the new studies.
Benefits
In the trial by Hon and colleagues,430 the severity of eczema decreased in each group by around 10 points
after 12 weeks, with no significant difference between the herbal treatment and the placebo. Quality of
life, measured using the CDLQI, improved by > 30% in the herbal medicine group compared with hardly
any improvement in the placebo group over 12 weeks of treatment, which was a statistically significant
difference (p= 0.008). The decrease in the number of days using topical corticosteroid did not differ
significantly between groups; however, the amount of rescue medication (mometasone furoate) used by
the herbal medicine group was significantly less than that used by the placebo group after 12 weeks in the
80 participants primarily using mometasone furoate.
In the trial by Shapira and colleagues,431 patients in both treatment groups experienced a fall of around
15–20 points in eczema severity after 2 weeks of treatment, with no significant difference between the
groups. Subjective daytime pruritus and sleep loss, measured as part of SCORAD, also showed no significant
difference between the groups when the results were separated from the objective outcome measures.
In the trial by Shi and colleagues,262 56.0% (14/25) of participants in the treatment group had a ≥ 70%
improvement in SASSAD score compared with 22.7% (5/22) in the control group (p< 0.05). The trial
report mentions measuring ‘scratch’ using a VAS, but does not report the results.
Cheng and colleagues432 found significantly greater improvements from baseline in the mean clinical lesion
score in the group using Xiao-Feng-San compared with the group using placebo after 4, 8 and 12 weeks of
treatment [79.1 points (SD 5.7 points) vs. 13.5 points (SD 7.56 points) at 8 weeks]. Improvement from
baseline in pruritus, sleep and skin surface damage scores was significantly greater in the Xiao-Feng-San
group compared to the placebo group at 4, 8 and 12 weeks. Improvement from baseline in erythema score
was also significantly greater in the Xiao-Feng-San group than in the placebo group at 4 and 8 weeks.
The trial by Choi and colleagues433 did not compare Chinese herbs against other eczema treatments or
placebo and so the trial cannot provide any clinically relevant data on the benefits or harms of Chinese
herbal medicine treatment. There was no statistically significant difference between the groups in reduction
in eczema severity, measured using EASI and SCORAD. The magnitude of the reduction in eczema severity
using the SCORAD index was large (TJ-15 –24.9 SD± 13.7; TJ-15 and TJ-17 –27.2 SD± 8.9).
TABLE 111 Chinese herbal medicine: risk of bias of the included studies
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Cheng 2011432 Low risk Low risk Low risk
Choi 2012433 Low risk Unclear risk Unclear risk
Henderson 2000434 High risk High risk High risk
Hon 2007430 Low risk Low risk Unclear risk
Shapira 2005431 Unclear risk Unclear risk Unclear risk
Shi 2008262 Low risk High risk High risk
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Harms
None of the five trials262,430–433 documented any change in blood chemistry or renal function. One
participant had a transient elevation of aspartate aminotransferase, which returned to normal levels within
8 weeks after the treatment was stopped. Other adverse events that occurred significantly more in the
active treatment groups were diarrhoea and visits to the GP. It was not clearly reported whether the
adverse events were thought to be related to the study treatment.
Overall implications for research and practice
There is evidence of striking levels of benefit from modified Jiawei Danggui Decection, although as the
amount of hydrocortisone and loratadine used in each treatment group was not reported this result should
be treated with caution, particularly as the steps to reduce bias were so poorly described.262 No difference
in the effect on severity of eczema was found between the five-herb concoction (containing F. lonicerae,
H. menthae, C. moutan, R. attactylodis and C. phellodendri) and placebo.430 The trial reported an
improvement in quality of life only in the participants treated with the herbal concoction and there also
appeared to be a specific steroid-sparing effect for those using mometasone furoate. The effect on quality
of life deserves further scrutiny in trials of Chinese herbal medicine; however, the steroid-sparing effect
does not appear to have been a prespecified outcome. The Xiao-Feng-San treatment also had a beneficial
effect on the severity of eczema after 8 weeks of treatment, which was still apparent 4 weeks later.432
Siberian ginseng, A. millefolium and L. album did not show any beneficial effect over placebo.431 The trial
comparing TJ-15 against a TJ-15 and TJ-17 mixture did not provide any evidence that one was superior to
the other, but as both treatments seemed to provide a good level of eczema severity reduction it would be
useful to see these treatments tested against standard mainstream eczema treatments in larger trials.433
With a total of four positive trials of Chinese herbal medicines, further clearly reported multinational large
trials with blinded outcome assessments at the core, and which pay attention to subjective outcomes such
as quality of life, are advised. Quality control is a key issue in developing such interventions.
Homeopathy
Homeopathy involves diluting a substance repeatedly with alcohol or distilled water. These solutions are
used to ‘treat’ many conditions, including many chronic conditions such as eczema. NICE currently does
not recommend homeopathy for the treatment of any health condition [see www.nhs.uk/conditions/
homeopathy/pages/introduction.aspx (accessed 15 January 2016)].
Studies
One study involving homeopathy was reported before 200055 (see Appendix 3).
One new trial involving homeopathy was reported after 2000. This blinded trial from Germany,435 which
included 24 adults aged between 18 and 35 years with eczema covering at least 20% of their body,
compared individualised homeopathic treatment against placebo for 32 weeks. The participants could not
use other treatments (including corticosteroids and antihistamines) during the trial.
Assessment of risk of bias
Table 112 provides the risk-of-bias assessment for the new study.
TABLE 112 Homeopathy: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Siebenwirth 2009435 Unclear risk Unclear risk Unclear risk A large number of participants withdrew from the
trial (10/24) and it is not clear whether they were
included in the final analyses
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Benefits
No difference or only small differences between the groups in the change from baseline scores for eczema
severity were shown. This outcome was measured using Costa and colleagues’249 multiparameter atopic
dermatitis score and the ADASI and SCORAD scores. The Marburg Atopic Dermatitis Questionnaire,349 list of
complaints and the global assessment of treatment success by both the physician and the participants all
showed virtually no difference or only small differences between groups in the change from baseline scores.
Harms
The 14 adverse events recorded in nine participants were distributed fairly evenly between the groups and
included herpes simplex, cough and influenza, which all occurred in both groups.
Overall implications for research and practice
This trial of homeopathy for eczema is not large enough or methodologically rigorous enough to provide
any evidence about the benefits or harms of homeopathy for eczema.
Other herbal treatments
Studies
No studies involving other herbal treatments were reported before 2000.
One trial involving a herbal treatment was reported after 2000. Klövekorn and colleagues436 conducted a
placebo-controlled within-person trial in south Germany. A herbal topical cream available in Germany as
Ekzevowen derma®, in the UK as Linderma® and in the USA as Dermavex® (Weber & Weber GmbH & Co.)
was used as the treatment. The cream contained 5 g per 100 g of each of the alcohol-based extracts of
Mahonia aquifolium, Viola tricolour and Centella asiatica. All 88 adults used herbal cream on one side of
the body and placebo cream on the other, in a randomised order, twice daily on the areas affected by
eczema for 4 weeks. The trial was reported as double blind but it was not reported who was blinded.
The interventions were in identical tubes and were described as being similar in appearance.
Assessment of risk of bias
Table 113 provides the risk-of-bias assessment for the new study.
Benefits
No significant difference in reduction of eczema severity was found when the entire population was
analysed. A post hoc subgroup of 64 participants treated when the mean outside temperature was ≤ 10°C
did show a significant reduction in severity for the herbal cream group compared with the placebo cream
group (p= 0.019). There were no significant differences in participant-assessed pruritus and efficacy and
the improvements recorded were all quite modest.
Harms
There were 33 adverse events reported during this trial, none of which was serious. Of these, 31 were
reported as being not related to the study treatment and did not occur at the test sites. Two adverse
events, one in the treatment group and one in the vehicle cream group, occurred at the test sites and
required cessation of study treatment.
TABLE 113 Other herbal treatments: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Klövekorn 2007436 Low risk Low risk Unclear risk
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Overall implications for research and practice
This herbal cream does not show any indication of having any benefit over the vehicle cream alone for
both the objective and subjective outcomes. One post hoc subgroup analysis did show a significant benefit
when the cream was used when the outside temperature was ≤ 10°C; however, pragmatically, even if
this significant result was replicated in a trial designed to confirm this, a treatment that is effective only
over a certain temperature range is of very limited use in normal clinical practice.
Japanese traditional medicine
Studies
No studies involving Japanese traditional medicine were reported before 2000.
One new study involving Japanese traditional medicine was reported after 2000. This manufacturer-
sponsored trial by Kobayashi and colleagues437 compared a herbal tea, Hochu-ekki-to (containing 10
species of medicinal plants), against placebo for 24 weeks. Ninety-one participants with eczema according
to the Japanese Dermatological Association criteria26 and a delicate (Kikyo) constitution took the
interventions twice a week for 24 weeks.
Assessment of risk of bias
Table 114 provides the risk-of-bias assessment for the new study.
Benefits
A significant reduction in the amount of topical treatments used (steroids or tacrolimus), adjusted for
potency, was reported for the Hochu-ekki-to group compared with the placebo group. No significant
difference was found in the number of participants achieving a score of 0 on the skin severity scale.
However, there were significantly fewer participants taking Hochu-ekki-to (1/37, 3%) whose use of topical
corticosteroids increased by ≥ 50% by the end of treatment than those taking placebo (7/39, 18%).
Harms
The number of adverse events was noticeably higher in the Hochu-ekki-to group (13/40 participants and
33 events vs. 12/44 participants and 20 events). The adverse events were described as ‘moderate’ events
such as nausea and diarrhoea; however, the number of events per participant is not known but is likely to
have been more than one as the majority of participants suffered adverse events, particularly in the
Hochu-ekki-to group. Slight increases in laboratory tests were also reported, the most common of which was
for eosinophilia (three participants in the Hochu-ekki-to group and four participants in the placebo group).
Overall implications for research and practice
Despite the fact that treatment with Hochu-ekki-to was given for 24 weeks, the trial authors suspected that
a longer time period would be required for this treatment to become effective. No significant beneficial
effect was seen in comparison to placebo within this 24-week treatment period. However, Hochu-ekki-to
appears to show a significant steroid-sparing effect. This effect would need to be confirmed in a future trial
in which either other concomitant treatments were not allowed or, more likely, the amounts of other
concomitant treatments used were closely recorded. It is also unclear whether blinding was assured, as no
information about whether the placebo was distinguishable from the active treatment was given.
TABLE 114 Japanese traditional medicine: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Kobayashi 2010437 Unclear risk Unclear risk Unclear risk Not clear if the active herbal ‘tea’ could be
distinguished from the ‘placebo’ tea in any way
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Hwangryunhaedoktang
A protocol for a RCT by Kim and colleagues438 comparing Hwangryunhaedoktang (a traditional Korean
medicine that is licensed for use by the Korean Food and Drug administration) against placebo was
published in 2011 as an open access paper. The protocol is very detailed and the authors are to be
congratulated on putting such valuable information clearly in the public domain. We await the full trial
report with interest.
Balneotherapy
Studies
No studies involving balneotherapy for eczema were reported before 2000.
One new study involving balneotherapy was reported after 2000. This unblinded trial439 compared Comano
spa water (Trentino, Italy) balneotherapy against topical corticosteroid treatment for 2 weeks. It was not
clear whether, or how often, the corticosteroid treatment group bathed. Comano spa water, which
contains various microelements with calcium and magnesium, was heated to 36–37 °C and participants
bathed in this water for 20 minutes twice a day. The participants in the topical corticosteroid group used
either methylprednisolone aceponate (those aged < 2 years) or mometasone furoate (those aged > 2 years),
once daily for 2 weeks. The only other treatment allowed for all participants was emollient.
Assessment of risk of bias
Table 115 provides the risk-of-bias assessment for the new study.
Benefits
A statistically significant difference between treatments was observed for severity of eczema, measured
using the SCORAD index, with a bigger reduction for those using topical corticosteroids than for those
in the balneotherapy group after 2 weeks of treatment (mean± SD 46%± 7.71% vs. 26%± 9.4%;
p< 0.03). There were no significant differences between groups after 2 weeks of treatment for severity of
eczema measured using IGA and also for pruritus, participants’ global assessment and quality of life. There
was a statistically significant reduction in pruritus and the participants’ global assessment in favour of
balneotherapy 4 months after the end of treatment.
Harms
There were no major side effects reported for this study. The most common adverse event reported was a
mild erythema and burning sensation, which affected 23 out of 25 participants in the balneotherapy
group. None of these participants stopped or altered their treatment.
Overall implications for research and practice
It is unclear what component of Comano spa water is thought to have an effect on eczema. It is clear
from the trial that 2 weeks of balneotherapy is not as beneficial as 2 weeks of topical corticosteroid use in
reducing the severity of eczema. The severity of eczema data were not available 4 months after the end of
treatment, when itching and participants’ global assessment had significantly improved for those receiving
balneotherapy compared with those receiving topical corticosteroids. A further confounding factor is the
lack of clarity about the circumstances of the spa treatment, such as whether the participants were
resident at the spa during the treatment or not.
TABLE 115 Balneotherapy: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Farina 2011439 Low risk Unclear risk High risk
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Progressive muscle relaxation
Studies
No studies involving progressive muscle relaxation for eczema were reported before 2000.
One new study involving progressive muscle relaxation was reported after 2000. This trial by Bae and
colleagues440 compared the addition of a progressive muscle relaxation technique to standard treatment
with standard treatment alone. The 25 participants were aged between 12 and 40 years and had a
diagnosis of eczema according to the Hanifin and Rajka8 criteria and an EASI score of ≥ 10. One group of
participants used audio and visual progressive muscle relaxation programmes at home twice a day for
4 weeks under controlled heating and lighting conditions and without eating or drinking anything except
water and also used their standard treatments. The other group used only their standard eczema treatments.
It was recommended to the participants that they did not drink alcohol or caffeine-containing beverages.
Assessment of risk of bias
Table 116 provides the risk-of-bias assessment for the new study.
Benefits
The treatment groups were not statistically compared for any of the outcomes and so there was no
evidence about the relative benefits of progressive muscle relaxation. The improvement in the progressive
muscle relaxation group was significant compared with baseline for sleep loss and pruritus. It was stated
that this was not the case for the standard treatment only group, but the data are not shown. The
reduction in eczema severity, measured using EASI scores, was significant in both groups compared with
baseline, but from the graph provided it appears that there was no significant difference between the
treatments after 1 month of treatment.
Harms
No information about adverse events was reported.
Overall implications for research and practice
There are so few methodological details provided and little appropriate analysis of the results in this trial
that it is impossible to obtain any useful information about the potential benefits and harms of progressive
muscle relaxation.
Summary of complementary therapies
St John’s wort
l There were no trials involving topical St John’s wort for eczema reported up to 2000.
l One very small trial reported in 2003, with an overall unclear risk of bias, provided evidence of benefit
for treatment with St John’s wort compared with placebo.
TABLE 116 Progressive muscle relaxation: risk of bias of the included study
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Bae 2012440 Unclear risk Unclear risk Unclear risk
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Acupuncture
l There were no trials involving acupuncture for eczema reported up to 2000.
l One very small trial reported in 2011, with a high risk of bias for blinding, did not provide any evidence
of benefit for acupuncture compared with a study visit only. Participants all had both eczema and
allergic rhinitis.
Acupressure
l One small trial reported in 2012 provided no convincing evidence of benefit for acupressure and
standard treatment compared with standard treatment alone.
Hypnotherapy
l One small trial reported pre 2000, with a high risk of bias for blinding, provided evidence of benefit for
hypnotherapy compared with a placebo discussion about eczema without mentioning symptom control.
l One small trial reported in 2004, with a high risk of bias for blinding, provided evidence of benefit for
hypnotherapy compared with no hypnotherapy.
Aromatherapy/massage
l Only an abstract of the trial summarised below was reported before 2000.
l One very small trial reported in 2000, with a high risk of bias for blinding, did not provide any evidence
of benefit for massage treatment with aromatherapy oils compared with massage treatment without
aromatherapy oils.
Chinese herbal medicine
l Four trials of Chinese herbal medicine compared with placebo were reported up to 2000. All four trials
were small, with an overall unclear risk of bias. Only one of the four trials provided evidence of benefit
for a Chinese herbal medicine compared with placebo, yet all four tested very similar combinations
of herbs.
l Four small trials reported after 2000, with a mixed risk of bias, provided some evidence of benefit for
oral Chinese herbal medicine compared with placebo or no treatment.
l One small trial reported in 2000, with an overall high risk of bias, compared the same Chinese herbal
treatment taken as either lacquered granules or as a tea. This trial did not include a control group and
did not provide any clinically relevant evidence of benefit for this Chinese herbal medicine.
l One small trial reported in 2013, with a mostly unclear risk of bias, compared one Chinese herbal
medicine against the same medicine combined with another Chinese herbal medicine. This trial did not
include a control group and did not provide any clinically relevant evidence of benefit for these Chinese
herbal medicines.
Homeopathy
l One trial protocol was reported pre 2000 for a study comparing homeopathy with placebo.
A published full trial report has not been found for this trial protocol.
l One very small trial reported in 2009, with an overall unclear risk of bias, did not provide any evidence
of benefit for homeopathy compared with placebo.
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Other herbal treatments
l There were no trials involving other herbal treatments reported before 2000.
l One small trial reported in 2007, with a mostly low risk of bias, did not provide any evidence of benefit
for a herbal cream containing extracts of Mahonia aquifolium, Viola tricolour and Centella asiatica
compared with placebo, except when the outside temperature was ≤ 10°C, in a subgroup analysis that
was probably post hoc.
Japanese traditional medicine
l There were no trials involving Japanese traditional medicine reported before 2000.
l One small trial reported in 2010, with an overall unclear risk of bias, provided evidence of benefit for
Hochu-ekki-to (a combination of 10 different medicinal plants) compared with placebo.
Balneotherapy
l There were no trials involving balneotherapy before 2000.
l One small trial reported in 2013, with a mixed risk of bias, provided evidence of greater benefit for the
comparator (topical corticosteroid treatment) than for balneotherapy.
Progressive muscle relaxation
l There were no trials involving progressive muscle relaxation for eczema before 2000.
l One very small trial reported in 2012, with an overall unclear risk of bias, did not provide any evidence
of benefit for progressive muscle relaxation in addition to standard eczema treatment compared with
standard eczema treatment alone.
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Chapter 13 Other interventions not
covered elsewhere
Background
Novel interventions that have been used successfully for other chronic conditions are often tested for
efficacy in eczema in the hope of finding additional effective treatments. This chapter covers all trials using
interventions that do not fit neatly into the other treatment categories covered in this review.
Existing systematic reviews
There have been no systematic reviews covering any of the interventions discussed in this section.
Scope of this chapter
The treatments covered in this chapter are:
l autologous blood therapy
l tandospirone citrate
l oral naltrexone
l Polypodium leucotomos.
Autologous blood therapy
Autologous blood therapy involves taking a small amount of a patient’s own blood and reinjecting it.
Variations of the technique include adding other substances to the blood or concentrating a particular
component, such as platelets, before reinjection. This technique has been used for some joint conditions
such as tendinopathy. The aim of the procedure is to provide cellular and humoral mediators to
induce healing.
Studies
There were no trials involving autologous blood therapy reported before 2000.
Two new trials have been published since 2000. A trial by Kief441 was unable to provide evidence on
the efficacy of autologous blood therapy for eczema because it compared two ‘active’ interventions
(a modified method of autologous blood therapy against standard autologous blood therapy).
A placebo-controlled study by Pittler and colleagues442 included 31 adults with non-exudative eczema
defined using the Hanifin and Rajka8 criteria who were not using potent topical corticosteroids. Treatment
involved taking a participant’s blood and reinjecting it intramuscularly, with the procedure being
performed once a week for 4 weeks. The participants were allowed to continue using their standard
treatments during the trial. The outcome assessor was blinded by not being allowed in the room while the
treatment was being given. Participants were blinded by means of a bedsheet drape while the treatment
was being administered. Participants were assessed at 5 and 9 weeks after the start of the trial.
Assessment of risk of bias
Table 117 provides the risk-of-bias assessment for the new studies.
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Benefits
The trial by Kief441 reported no significant differences between autologous blood therapy and modified
autologous blood therapy. Both groups in the trial displayed significantly decreased eczema severity,
assessed by SCORAD scores, and an improvement in DLQI score.
Pittler and colleagues442 found that there was a significant decrease in eczema severity in the autologous
blood therapy group compared with the placebo group (saline injections) after 9 weeks, with a mean
difference in change in SASSAD scores from baseline between the groups of 13.5 points (95% Cl 6.6 to
20.4 points; p< 0.001). This significant difference was also present at 5 weeks, shortly after treatment had
ended. There were no significant differences between the groups in the participant-assessed outcomes of
DLQI, pruritus, skin appearance and sleep loss. The trial report stated that there were no clinically
significant results with regard to the use of other topical treatments, although no data were provided.
Harms
The trial by Kief441 reported that no adverse events occurred.
In the trial by Pittler and colleagues,442 6 out of 15 participants treated with autologous blood therapy
reported adverse events and 7 out of 15 participants treated with saline placebo reported adverse events.
One participant had bruising in the antecubital region and another had an itching sensation on the face.
All adverse events were reported as minor and transient.
Overall implications for research and practice
One small trial442 found evidence of a significant reduction in the severity of eczema after 9 weeks when
using autologous blood therapy for 4 weeks in addition to standard treatment compared with standard
treatment alone. This preliminary study suggests that a larger and longer-term trial that includes children
might be worthwhile. Particular attention should be paid to participant and assessor blinding and
measurement of concomitant treatments in such a study. Future research should also explore the apparent
lack of beneficial effect on quality of life, sleep loss, pruritus and other participant-assessed outcomes.
It will be important to focus on whether this intervention is practical and whether it is realistic only for
patients with severe disease. Another small trial441 compared two slightly different methods of autologous
blood therapy against each other but did not include a control group. Without a control group as a
reference, the results of this trial do not provide any clinically relevant evidence for autologous
blood therapy.
Tandospirone citrate
Tandospirone citrate is a potent selective partial 5-HT1A (serotonin) receptor agonist that binds to the
5-HT1A receptor, thereby activating it. It is marketed mainly in Japan and China, where it is used as an
antianxiety treatment and an antidepressant.
Studies
There were no trials reported before 2000.
TABLE 117 Autologous blood therapy: risk of bias of the included studies
Trial Sequence generation Allocation concealment Blinding Other potential sources of bias
Kief 2007441 Unclear risk Unclear risk Unclear risk
Pittler 2003442 Low risk Low risk Low risk
OTHER INTERVENTIONS NOT COVERED ELSEWHERE
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One new trial was reported after 2000. This small pilot trial in Japan443 compared tandospirone citrate
(10mg, three times a day) in addition to standard corticosteroid or antihistamine treatment against
standard corticosteroid or antihistamine treatment alone in 37 participants for 4 weeks.
Assessment of risk of bias
Table 118 provides the risk-of-bias assessment for the new study.
Benefits
No significant difference was seen in severity of eczema, loss of sleep and mental stress between those
treated with tandospirone citrate and those not treated with tandospirone citrate. A significant
improvement in participant-assessed mood state, recorded considering the previous 3 days, was seen for
the tandospirone group compared with the no treatment group. Data from the 37 participants were
compared against ‘normal’ data from imaginary healthy control subjects for this mood state outcome.
Harms
No information on adverse events was provided in the trial report.
Overall implications for research and practice
Although there is a possibility that this serotonin receptor agonist could be beneficial in the treatment of
eczema, this pilot trial has not provided much additional evidence.
Oral naltrexone
Naltrexone is an opiate receptor antagonist that is used to treat alcohol and drug dependence. As opiate
membrane receptors have been implicated in the brain’s processing of pruritus, this treatment has been
suggested as being potentially suitable for eczema.
Studies
There were no trials involving oral naltrexone reported before 2000.
One new trial has been reported since 2000. This trial by Malekzad and colleagues444 compared twice-daily
treatment with 25mg of oral naltrexone with placebo for 2 weeks. Thirty-eight adults aged 24–85 years,
who had to have pruritus associated with eczema, were randomised. All participants continued with their
other eczema medication during the trial.
Assessment of risk of bias
Table 119 provides the risk-of-bias assessment for the new study.
TABLE 118 Tandospirone citrate: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Kawana 2010443 Unclear risk Unclear risk Unclear risk
TABLE 119 Oral naltrexone: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Malekzad 2009444 Unclear risk Unclear risk Unclear risk Those who withdrew were not included in the
analysis – 3/18 in the naltrexone group and 2/20
in the placebo group
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Benefits
The participant assessment of pruritus, measured on a VAS, decreased from a mean ± SD of 8.11± 1.4 to
3.3± 1.6 in the naltrexone group and from 7.8± 1.6 to 5.6± 2.1 in the placebo group after 1 week of
treatment. This was a statistically significant difference (p< 0.005) using a Mann–Whitney test. The
pruritus decreased to a mean ± SD of 1.3± 1.4 in the naltrexone group and 4.5± 2.8 in the placebo group
after 2 weeks of treatment, which was also statistically significant.
Harms
Two participants in the naltrexone group experienced treatment-related adverse events, including sedation
and nausea; in the discussion of the report, dizziness, vomiting, headache and cramps are also reported.
One participant in the placebo group reported nausea. It was reported that there was no significant
difference in adverse events between the treatment groups; however, no formal statistical calculations
were reported. It was not reported whether any of the participants who experienced adverse events
withdrew from the trial.
Overall implications for research and practice
This trial gave some evidence of a significant, short-term reduction in pruritus. However, the trial included
a small number of participants and was methodologically unclear. Larger, methodologically clear and
robust trials will be needed before this benefit can be confirmed. The levels of adverse events in this trial
do not appear to be a cause for concern but, again, this trial was not large enough to detect serious
adverse events.
Polypodium leucotomos
Polypodium leucotomos is a fern found in tropical and subtropical parts of Central and South America,
where it has been used in traditional medicine. Laboratory studies have demonstrated that P. leucotomos
extracts have antioxidant and photoprotective properties.445
Studies
There were no trials involving P. leucotomos for eczema reported before 2000.
One new multicentre trial conducted in Spain compared capsules containing P. leucotomos extract
(Anapsos®, Especialidades Farmacéuticas Centrum S.A.) against placebo capsules in 105 children aged
2–17 years.446 The treatment dose was dependent on age (children aged < 6 years 240mg/day, 6–12 years
360mg/day, > 12 years 480mg/day) and the treatment was given daily for 6 months. All participants
could use a thin layer of methylprednisolone aceponate 0.1% in emulsion to treat flares, and dry skin was
treated with moisturising cream after a bath or shower. Participants who needed systemic therapy were
given deflazacort (0.25–1.5mg/kg/day). Pruritus was treated with desloratadine.
Assessment of risk of bias
Table 120 provides the risk-of-bias assessment for the new study.
TABLE 120 Polypodium leucotomos: risk of bias of the included study
Trial
Sequence
generation
Allocation
concealment Blinding Other potential sources of bias
Ramírez-Bosca 2012446 Unclear risk Unclear risk Unclear risk
OTHER INTERVENTIONS NOT COVERED ELSEWHERE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
212
Benefits
Topical corticosteroid use (percentage of days) was not significantly different between the groups,
although the statistical results were not reported. There were no significant differences in eczema severity,
measured using SCORAD and IGA, or time to first flare, with a median of 0.5 months in both groups.
There was a significant reduction in oral antihistamine use (median percentage of days) (P. leucotomos
group 4.5%, placebo group 13.6%; p= 0.038), but this was not a prespecified outcome for the trial.
Harms
There were 218 adverse events in the P. leucotomos group and 223 in the placebo group, most of which
were reportedly mild. There were 14 participants in the placebo group and seven participants in the
P. leucotomos group with moderate adverse events. One serious adverse event occurred in the placebo
group (diarrhoea with dehydration). One participant in the placebo group withdrew because of an adverse
event, but the severity was not documented nor whether it was related to trial treatment.
Overall implications for research and practice
This trial failed to demonstrate any benefit of taking a P. leucotomos extract compared with placebo for
severity of eczema or reduction in the use of topical corticosteroids. A significant reduction in the use of
antihistamines for those taking the P. leucotomos extract is slightly encouraging; however, this was not a
prespecified outcome and reduction in the use of antihistamines could have more than one cause.
A trial specifically assessing this treatment’s ability to reduce pruritus compared with other routinely used
treatments would be needed to assess its potential benefit.
Summary of interventions not covered elsewhere
Autologous blood therapy
l There were no trials involving autologous blood therapy reported up to 2000.
l Two small trials involving autologous blood therapy, with a mixed risk of bias, were reported after
2000. One of these trials provided evidence of benefit for 4 weeks of treatment compared with
placebo. The other trial compared two types of blood therapy (no control group) and did not provide
any evidence of benefit for one treatment compared with the other.
Tandospirone citrate
l There were no trials involving tandospirone citrate reported before 2000.
l One small trial reported in 2010, with an overall unclear risk of bias, found no significant benefits of
the addition of tandospirone citrate to standard treatment with topical corticosteroids and
antihistamines compared with standard treatment with topical corticosteroids and antihistamines alone.
Oral naltrexone
l There were no trials involving oral naltrexone reported before 2000.
l One small trial, with an overall unclear risk of bias, was reported in 2009 and provided evidence of
benefit for oral naltrexone treatment compared with placebo.
Polypodium leucotomos
l One moderately sized trial, reported in 2012, did not provide any evidence of benefit for P. leucotomos
compared with placebo.
DOI: 10.3310/pgfar04070 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 7
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nankervis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
213

Chapter 14 Discussion
This systematic review of eczema treatments sits within a programme of work on eczema and otherdermatoses. The review both complements and has helped to inform other research on eczema
treatment: prioritising unanswered research questions; the HOME initiative; and the GREAT database
(see the companion report447). The rapidly expanding and important area of primary eczema prevention
has been separately reviewed as part of the wider programme of work (see the companion report447).
Main findings
The body of evidence evaluating specific eczema treatments has grown considerably since the last review
published in 2000.55 Regrettably, many widely used treatments such as emollients or bandages still lack a
strong evidence base. Theoretically, one could argue that they are established treatments and so do not
require evaluation. Yet history suggests, through various examples (such as the universal use of
cryotherapy for plantar warts, which is no better than topical salicylic acid448), that simple widespread use
of a mode of therapy may be a weak defence for an evaluation bypass. This is not to suggest that
universal treatments such as emollients should be stopped or restricted on the basis of a lack of RCT
evidence, as this would limit patient choice and paradoxically favour the use of powerful treatments such
as ciclosporin that have been evaluated thoroughly by RCTs. Instead, the juxtaposition of widespread use
and limited evidence should prompt a renewed and critical interest in evaluating such treatments.
Box 1 sets out the authors’ opinion on the value of the evidence base for the interventions considered.
When interpreting Box 1, it is important to point out that our classification of treatment options into four
categories, such as ‘evidence of benefit to support’, is not the same as a positive recommendation for
widespread use or otherwise, as that is the remit of guideline developers. Box 1 is also not intended as a
substitute for scrutinising the original studies in the context of local guideline and policy development.
How has the evidence base changed since the review in 2000?
Interventions with reasonable established efficacy
Topical calcineurin inhibitors, educational interventions and azathioprine have entered the category of
reasonable evidence of benefit since the previous review in 2000.
Only a few trials were reported on topical calcineurin inhibitors up to 2000 as these drugs were newly
developed at the time. The number of trials on pimecrolimus and tacrolimus has grown to a combined
total of > 50 by the end of August 2013. As a significant number of these trials are large and of
reasonable duration and carry a fairly low risk of bias, it is clear that these treatments are of benefit
compared with placebo treatments (plain grease or cream base).
Educational interventions were tested in only one trial up to 2000. Since 2000, seven trials covering various
educational interventions have been performed. Although these have provided evidence of benefit, the
active component of these interventions is unclear.
Although azathioprine was in use for severe eczema before 2000, no RCTs regarding its use had been
published. The two trials published since the previous review have bolstered confidence that azathioprine
provides a significant benefit for adults with severe eczema compared with placebo, although there is still
no trial evidence for children or including comparisons with other active treatments such as maximum
topical therapy or other systemic treatments.
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BOX 1 Evidence base for treatments for eczemaa
Interventions with reasonable established efficacy
(Based on at least one good-quality RCT or a large body of evidence and a clinically useful finding. We defined
a ‘good-quality’ trial as well designed and well reported and with a magnitude of benefit deemed by the
authors to be clinically relevant and a ‘large body of evidence’ as enough trials with consistent evidence of a
clinically relevant benefit, despite some limitations in reporting.)
Topical treatments to treat eczema
l Topical corticosteroids more beneficial than vehicle.
l Topical tacrolimus more beneficial than mild-potency topical corticosteroids, mainly in children with
moderate to severe eczema.
l Tacrolimus more beneficial than moderate topical corticosteroids for moderate to severe facial eczema
in adults.
l Pimecrolimus more beneficial than vehicle, mainly in children with mild to moderate eczema.
l Tacrolimus more beneficial than pimecrolimus, in children and adults with eczema of all severities.
l Atopiclair emollient more beneficial than vehicle, in children and adults with mild to moderate eczema
Topical treatments to prevent flares (maintenance or ‘proactive’ treatment)
l Topical corticosteroids 2 days a week more beneficial than vehicle, mainly in adults and children with
moderate to severe eczema (all over).
l Tacrolimus 2 or 3 consecutive days a week more beneficial than vehicle, in children and adults with mild to
severe eczema.
l Topical pimecrolimus 2 or 3 consecutive days a week more beneficial than vehicle, mainly in children with
mild to severe eczema.
Ultraviolet light therapy
l Many forms of UV light therapy have been tested against each other and other active treatments and in
various combinations in mainly small trials. Trying to summarise the many comparisons that have been
carried out is difficult but, overall, light therapy appears to be effective, with the best evidence favouring
narrowband UVB.
Systemic treatments
l Ciclosporin more beneficial than placebo, mainly in adults with severe eczema.
l Azathioprine more beneficial than placebo, in adults with moderate to severe eczema.
Other interventions
l Educational interventions more beneficial then no education, mainly in children with moderate to
severe eczema.
Interventions for which RCT evidence suggests no clinically relevant benefit
(At least one good-quality RCT or several less well-reported RCTs that consistently failed to show a convincing
benefit for overall disease activity. We defined a ‘good-quality’ trial as well designed and well reported and
large enough to exclude a clinically useful benefit and ‘several less well-reported RCTs’ as several trials with no
evidence of benefit to give confidence in there being no clinically relevant benefit, despite less clear reporting.)
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Topical treatments to treat eczema
l Twice-daily vs. once-daily topical corticosteroids.
l Topical corticosteroids in combination with antibiotics for eczema that is not clinically infected.
l Other topical treatments: protease inhibitor SRD441 in adults with mild to moderate eczema; emollient
with furfuryl palmitate in children; cipamfylline cream in adults with eczema on the arms.
Systemic treatments
l M. vaccae vaccine, mainly in children with moderate to severe eczema
Other treatments
l Probiotics for treating eczema, mainly in children with unspecified disease severity
l Avoidance of enzyme washing powders, mainly in adults with mild to moderate eczema
l Ion-exchange water softening devices, in children with moderate to severe eczema
l Dietary supplements rich in linoleic acid (such as evening primrose oil, borage oil), mainly in adults and
children with eczema of unknown severity
Requires additional research evidence
(Insufficient or contradictory RCT evidence that does not fall into the other two categories. We acknowledge
that some RCTs may have been missed and some RCTs may not have been included as they did not fulfil our
inclusion criteria)
Topical treatments to treat eczema
l Emollients to reduce the severity of eczema, prevent flares and reduce the need for other
eczema treatments
l Topical corticosteroids in combination with antibiotics for eczema that is infected
l Wet wraps on top of topical corticosteroids
l Antiseptic bath additives
l Topical antifungals
l Other topical treatments such as WBI-1001 cream, topical coal tar, topical vitamin B12, V. filiformis
lysate cream
Systemic treatments
l Oral prednisolone
l Methotrexate
l Mycophenolate mofetil
l Immunotherapy (desensitisation)
l Biological therapies: omalizumab, mepolizumab
l Oral sedating and non-sedating antihistamines
l Other interventions: oral pimecrolimus, oral naltrexone, autologous blood therapy, tandospirone citrate,
full-spectrum light therapy, excimer laser
l Intravenous immunoglobulin
l Montelukast
BOX 1 Evidence base for treatments for eczemaa (continued)
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Additional trials of oral ciclosporin and topical corticosteroids have further strengthened the already
existing evidence of benefit for these treatments but, again, with comparisons mainly against placebo
treatment, which limits their clinical relevance.
Interventions with insufficient evidence to make recommendations
Since 2000, many novel dietary, non-pharmacological, complementary and other topical or systemic
interventions have been the subject of one or two very small or small trials. Mainly because of the lack
of detailed reporting, the risk of bias for these trials has been mostly unclear. This coupled with few
participants has generally resulted in insufficient evidence of benefit for these treatments. It is a pity that so
much effort has been wasted on producing one inconclusive small and poorly reported trial after another,
as some of the interventions tested could have been useful and have been discarded on the false belief
that clinically useful benefits have been ruled out.449
Most of the treatments highlighted in the previous review as having insufficient evidence, because of small
sample sizes and poor reporting, have regrettably not been the subject of further trials. Those treatments
for which additional trials have been published have not clarified whether or not the treatments are of
genuine clinical benefit. This is the case for antihistamines and dietary restrictions for established eczema,
which are still in routine use.
Interventions for which randomised controlled trial evidence does not
support a clinically useful benefit
Despite the general improvement in methodology and reporting of RCTs of eczema treatments since the
previous review, there have been very few trials published that provide convincing evidence of no benefit.
Proving that something is not beneficial is a difficult task when traditional frequentist approaches are used
to challenge a null hypothesis of no treatment effect, but it is possible to exclude a minimum level of
clinical benefit in studies that find no difference between treatments by the narrowness of the CI around
that treatment difference. Since 2000, topical antibiotic/steroid combinations compared with topical
corticosteroids alone for non-infected eczema, probiotics, evening primrose oil and borage oil have been
Other treatments
l Specialised clothing (silk or synthetic fibres with or without antibiotics)
l Environmental interventions: house dust mite reduction and desensitisation, staying in a different climate
l Different approaches to the organisation of care such as additional visits to the doctor or nurse-led clinics
l Support groups, e-health management
l Dietary interventions such as prebiotics, dietary restrictions and synbiotics
l Complementary therapies such as Chinese herbal treatment, hypnotherapy, massage therapy,
aromatherapy, acupuncture, acupressure, other herbal treatments
l Psychological therapies such as stress reduction techniques and biofeedback
l Balneotherapy (salt baths)
No identifiable RCT evidence
l Dilution of topical corticosteroids
l Impregnated bandages (zinc paste bandages)
l Routine patch testing
l Other bathing practices such as avoidance of soaps and frequency of bathing
a Treatments covered only in the previous systematic review55 are in italics.
BOX 1 Evidence base for treatments for eczemaa (continued)
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the subject of additional trials, which in the views of the authors have resulted in an evidence base that is
large and robust enough to amount to reasonable evidence of no benefit.
Interventions that previously did not have randomised controlled trial evidence
There are now far fewer treatments in use in the UK with no RCT evidence available. It is pleasing to find RCTs
of widely used treatments for severe eczema, such as oral azathioprine. Ion-exchange water softening devices
have been ruled out for treatment of eczema in one definitive RCT.364 Other interventions such as organisation of
care, specialised clothing and wet wrap bandages have now also been tested to some extent in RCTs, although
there is not yet enough evidence from these trials to be clear whether these interventions are of benefit or not.
Interventions with no randomised controlled trial evidence
One of the most pressing remaining evidence gaps is whether the routine use of allergy testing (including
patch testing, RAST, skin-prick tests and aeroallergen tests) followed by avoidance of allergens yielding
positive reactions results in improved eczema control. The universal advice of soap avoidance and
arguments regarding bathing frequency also require further critical scrutiny. It is salutary that these issues
are all found on the list of prioritised eczema treatment uncertainties from the recent Eczema Priority
Setting Partnership57 (see Table 121).
Coverage and clinical relevance
Since the previous review,55 there has been a slight increase in trials of non-pharmacological interventions
such as specialised clothing and education, non-steroidal topical preparations and complementary therapies.
Disappointingly, there are still too many placebo studies, which are largely uninformative for clinical practice.
It is also worthy to note the mismatch research conducted by investigators and pharmaceutical companies
against the most pressing questions summarised in the Eczema Priority Setting Partnership57 between
clinicians and patients, highlighted in Table 121.
TABLE 121 Top priorities for eczema research. Adapted from Batchelor et al. 201357
Group Uncertainty
Shared priorities What is the best and safest way of using topical steroids for eczema: frequency of application,
potency, length of time, alternating with other topical treatments and age limits for treatment?
What is the long-term safety of applying steroids to the skin for eczema?
What role might food allergy tests play in treating eczema?
Which emollient is the most effective and safe in treating eczema?
Patient and carer
priorities
What is the best psychological treatment for itching/scratching in eczema?
What is the best way for people with eczema to wash: frequency of washing, water
temperature, bath vs. shower?
What are the best and safest natural products to apply to the skin for eczema?
How much does avoidance of irritants and allergens help people with eczema?
What is the role of diet in treating eczema: exclusion diets and nutritional supplements?
Health-care professional
priorities
Which is most effective in the management of eczema: education programmes, GP care,
nurse-led care, dermatologist-led care or multidisciplinary care?
Which is safer and more effective for treating eczema: steroids or calcineurin inhibitors?
How effective are interventions to reduce skin infections in the management of eczema?
Which should be applied first when treating eczema, emollients or topical steroids?
What is the best and safest way of using drugs that suppress the immune system when
treating eczema?
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Difficult body sites
Sensitive areas of the body can be problematic to treat, as the skin is thin and the potential for treatments
such as topical corticosteroids to cause local side effects, such as skin thinning, is greater.
Despite the need for good evidence on treating sensitive sites, hardly any of the trials in this review evaluated
treatment of these areas specifically. Most trials of topical corticosteroids have used low-potency
hydrocortisone acetate for such areas instead of the treatment being tested. Typically, outcomes are measured
over the whole body, thereby giving no specific indication of the success or otherwise of treatment on
sensitive sites. One area to have been given specific attention is the head and neck, for which trials of
antifungal agents have not provided any convincing evidence of additional benefit for non-infected eczema.
Another study of eyelid dermatitis failed to show any clear benefit of topical tacrolimus over topical
corticosteroids. Trials of pimecrolimus have provided some evidence of benefit for the head and neck region
compared with placebo and topical corticosteroids.
Combinations of treatments
It is encouraging that there has been progress in testing treatments in addition to ‘standard care’ since
2000, which has made the analysis of the potential benefits and harms of a treatment much easier in the
context of routine clinical practice.
Validity and robustness of results
Missed studies
Although there is a possibility that a mainly electronic search of reference databases will miss certain RCTs
because of misclassification, the authors have attempted to mitigate this risk by searching both the main
bibliographic databases (MEDLINE and EMBASE) and several smaller, specialist databases (CINAHL, AMED
and LILACS).
Author bias
The blinding of the review authors to the authors of the trials was not practically possible and it is possible
that some bias has occurred in the narrative summary of results. The authors have used a standardised
approach using a tool for assessing risk of bias in addition to their own comments and a consistent
approach for separating the actual results from their interpretation.
External validity
The population of those with eczema in the trials published does not reflect the majority of the eczema
population, as most trials were conducted in secondary care. Most people with eczema never reach
secondary care and so would not have had the opportunity to be recruited into these trials. This raises
serious concerns about the external validity of the results of most eczema treatment trials for people seen
in primary care.
Quality of reporting
Study design issues
The quality of reporting was assessed using the Cochrane Collaboration risk-of-bias tool,58 with an
assessment of the risk of bias for the generation of the randomisation sequence, allocation concealment
and blinding undertaken. Whether an intention-to-treat analysis was used was also assessed. The original
review55 did not use the Cochrane Collaboration tool, but did make a very similar assessment of the quality
of reporting for the same criteria that have been shown to lead to biased estimates of treatment effects.450
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The trials in the original review55 were generally of very poor quality. The trials since 2000 are mixed, with
notable differences in the quality of reporting between the treatment categories. In particular, concealment
of the allocation sequence was often poorly reported and some trials confused blinding of outcome
assessment with allocation concealment, making it impossible to assess whether either had taken place to a
satisfactory level.
The use of validated scales for physician measurement of severity or composite measurement has risen
considerably since 2000. Named scales that have been used are also far more likely to be ones that have
been tested to some degree. There is still widespread heterogeneity in the choice of outcome measures,
rendering any form of meta-analysis very difficult and underscoring the need for core outcome sets for
eczema, as are being developed by the HOME initiative.64,65
There has been a modest improvement in the number of trials reporting participant-assessed outcomes
such as itching and sleep loss, but these were almost always secondary outcomes and the results were very
often presented with insufficient detail.
Studies still need to be longer
Although eczema typically lasts for several years or a lifetime, many eczema trials investigate short-term
treatments lasting from 1 to 12 weeks. There is an argument for short-term trials and that is to test the
speed of induction of remission – studies could arguably be of 1–2 weeks’ duration as most patients
or parents would like to see some evidence of benefit within 48–72 hours. But the short-term studies that
keep appearing are neither one thing or the other in that they attempt to claim efficacy based on changes
reported over a period of say 6 weeks – too long for assessing the induction of remission and too short for
assessing the duration of disease remission. Some improvement in trial duration has occurred in those trials
of the maintenance of remission (using topical corticosteroids and calcineurin inhibitors) lasting from
6 months to 1 year. Running a clinical trial is generally a costly and lengthy business, with 1–2 years of
set-up before the first participant is recruited, so it is understandable that the length of follow-up becomes
a critical cost driver when conducting trials in this area.
Inappropriate comparators
Several areas of eczema treatment research have now matured to a point where there is a very strong
body of evidence which shows that a treatment or a class of treatments is of more benefit for those with
eczema than a placebo or not giving the treatment. Unfortunately, it has been common over the past
14 years for more trials comparing a treatment or a class of treatments against placebo or no treatment to
be conducted, despite overwhelming evidence of efficacy from previous placebo- or vehicle-controlled
studies. The total number of vehicle-controlled studies for topical pimecrolimus, for example, now exceeds
15 and yet not a single comparative trial has been published at the time of writing this report that
compares this newer treatment to the most obvious and least expensive existing comparator, that is, mild
topical corticosteroids. One can appreciate the need for two or three pivotal efficacy studies testing new
treatments against placebo in different populations such as children and adults or different ethnic groups
who may respond differently, but > 15 trials is excessive and possibly unethical. It is possible that some
placebo trials are used as marketing tools so that sceptical clinicians become engaged with a new product.
It is therefore important that trial participants, funders and ethics committees scrutinise the need for
additional placebo- or vehicle-controlled studies in the context of existing evidence.
Separate publications from the same study
A number of authors presented the results of a single trial in multiple publications, each highlighting a
specific population (e.g. children) or outcomes. Although these publications can serve to make researchers
with specific interests more aware of trial evidence, they are potentially serious sources of bias, as many do
not mention that they make up part of a larger trial or they lack clarity and detail if they do. The review
authors had to scrutinise trial publications to be certain not to include the results of any trial
participants twice.
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Chapter 15 Summary and conclusions
Strengths and weaknesses of this review
This updated review has used a clear and robust method for identifying RCTs for inclusion, combined with
a wide set of inclusion criteria, minimising the potential for selection bias by the review authors. Trying to
answer similar questions for the 92 or so interventions used for the treatment of eczema would be
impossible in one short report. Therefore, we have taken an approach that is a hybrid between a scoping
review451 and a full systematic review, in the hope that this will spin off more detailed Cochrane reviews.
We cannot be sure that we have found all relevant RCTs despite our rigorous searches. Although we are
not aware of any unpublished RCTs, there is good evidence that a large proportion of research never gets
published, particularly negative studies.452 This means that our review is likely to depict a more positive
picture of the true body of evidence than truly exists. The references were filtered by only one author, in
consultation with another author in cases of uncertainty. This does not reach the gold standard of two or
more authors independently screening all references and could have led to some studies being missed. We
did not contact authors for missing data as this was not practical for so many trials within the time and
resources available. Such data, if forthcoming, would probably not have altered any of our narrative
conclusions considering that so many of our studies were RCTs of single interventions. No meta-analyses
were performed as very few of the included studies shared common outcomes or treatment comparisons.
Implications for health care
The strength of evidence supporting the various interventions has already been reported in the separate
chapters dealing with the diverse intervention groups. The strength of evidence in relation to those
interventions that are commonly used in the UK is summarised narratively in Box 1. This box refers to
evidence on the short-term control of eczema, except where mentioned. It is now up to guideline
developers such as NICE and SIGN to use the evidence summarised in this report to update their
treatment guidelines.41,42
Future research priorities
Primary research
Although not unique to eczema, perhaps the biggest priority for future research is to better understand
why researchers across the world continue to conduct small, poorly planned, unregistered and poorly
reported trials on people who have volunteered to participate in such studies. This is despite the presence
of overwhelming evidence on the value of ensuring that all trials are registered in the public domain before
recruitment starts and that all of the essential features of the completed studies are reported, so that
readers can make judgements about their quality and utility. International organisations such as the
International Society of Atopic Dermatitis, HOME, the Expert Resource Group of the American Academy of
Dermatology and the European Task Force on Atopic Dermatitis are all in a good position to encourage
better-quality trials.
In addition to understanding why researchers continue to undertake trials without consideration of the
existing evidence base and what mistakes to avoid, perhaps the largest gap for primary research exists in
conducting clinical trials in primary care, where most patients are seen in the UK.
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Priority areas for future primary research have already been highlighted by a priority-setting partnership
between health-care professionals and patients in the accompanying Programme Grant for Applied
Research report447 and are summarised in Table 121. Specific examples of new RCTs with accompanying
cost-effectiveness analyses that could be undertaken in line with the priorities from the priority-setting
partnership are outlined below:
1. evaluation of allergy tests followed by avoidance of allergens guided by such tests in high-risk and
unselected participants
2. evaluation relating to emollients, especially to gain a better understanding of which are beneficial and
which are potentially harmful203
3. evaluation of expensive ceramide-containing preparations compared with cheaper petrolatum-
based products
4. evaluation of whether daily or less frequent washing and avoidance of soap is really necessary for
people with eczema
5. evaluation of the optimum use of topical corticosteroids over longer periods, especially with a view to
documenting whether skin thinning and problems associated with systemic absorption, such as clinically
relevant adrenal gland suppression, really do exist with modern recommended usage patterns
6. evaluation of topical tacrolimus 0.1% compared with potent topical corticosteroids for flare prevention
in those with moderate to severe disease, especially if accompanied by a cost-effectiveness analysis420
7. comparison of topical pimecrolimus with low-potency corticosteroids for the prevention of flares in
people with mild eczema in the community
8. evaluation of educational interventions for health-care providers as well as patients
9. head-to-head comparisons of systemic treatment for severe eczema in children.
Most of these new RCT ideas should ideally be carried out in a primary care population as well as
secondary care.
Although this report deals strictly with the treatment of established disease, disease prevention should not
be overlooked for eczema as it remains a distinct possibility as elaborated on in our eczema prevention
work programme of our companion monograph447 (see chapter 1, eczema prevention work programme).
Secondary research
This scoping review attempts to provide a panoramic overview of primary and secondary research on
eczema treatment. It appears that expansion of secondary research for eczema is outstripping the
availability of RCT evidence in many areas of eczema treatment. Several Cochrane reviews of eczema
either have been completed or are in progress (Box 2), which will provide a more detailed and in-depth
analysis of specific interventions and which will be updated as new evidence becomes available. Some
other non-Cochrane reviews have been well reported and are mapped for further reference on the Centre
of Evidence Based Dermatology resource section [see www.nottingham.ac.uk/dermatology (accessed
6 November 2015)]. Overviews of existing single intervention systematic reviews, such as the one
conducted for eczema prevention,70 are also needed, as is the application of mixed-treatment comparisons
for understanding more about the crucial missing treatment comparisons that are needed to inform
clinical practice.
Methodological research
Is eczema more than one disease? Although the clinical definition of eczema is relatively well established, it
is possible that eczema represents a constellation of different diseases. These diseases may be differentiated
into an exophenotype (based on observable characteristics such as discoid pattern or associated asthma) or
their endotype (based on measurable underlying pathological and genetic mechanisms). In the future, these
endotypes may be identifiable using genetic biomarkers. Different exo- and endophenotypes may respond
differently to treatments and researchers are encouraged to explore such subtypes in planned subgroup
analyses where possible.
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Trial design
Progress in trial design is moving forward and has provided some novel methodologies that may merit use
for specific research questions in eczema treatment. Adaptive designs could well inform the early
assessment of new treatments and dose-finding studies. RCTs combined with observational studies could
lend themselves well to a condition that waxes and wanes so frequently over time. Cohort studies from
which multiple RCTs are conducted may provide a more holistic picture of how cumulative treatment
changes the course of a disease such as eczema. The use of routine databases and biobanks also provide
possibilities to conduct large pragmatic trials with the potential to stratify disease.
The greatest challenge is in the field of outcome measures, where significant progress has been made
through international consensus in identifying the core domains of symptoms, signs, quality of life and
long-term control that should be measured in all future RCTs of eczema.449 Instruments of sufficient truth,
discrimination and feasibility probably exist for all four domains with the exception of long-term control,
which requires a lot of further fundamental thought on the underlying concepts and how they are
best measured.
Methods to prioritise future research
The development of priority-setting partnerships is a methodology that is itself evolving, as is the use of
economic modelling to identify the expected health benefits of additional evidence in prioritising research.56
BOX 2 Cochrane reviews and protocols on eczema treatments
Published Cochrane reviews
l Chinese herbal medicine for atopic eczema.421
l Dietary exclusions for established atopic eczema.276
l Interventions to reduce Staphylococcus aureus in the management of atopic eczema.244
l Psychological and educational interventions for atopic eczema in children.453
l Oral evening primrose oil and borage oil for eczema.189
l Topical pimecrolimus for eczema.89
l Dietary supplements for established atopic eczema.278
l Probiotics for treating eczema.273
l Oral H1 antihistamines as monotherapy for eczema.454
Cochrane reviews in progress
l Topical tacrolimus for atopic dermatitis.455
l Specific allergen immunotherapy for the treatment of atopic eczema.456
l House dust mite reduction and avoidance measures for treating eczema.457
l Different strategies for using topical corticosteroids for established eczema.458
l Leukotriene receptor antagonists for atopic dermatitis (no published protocol to date).
l Complementary and alternative medicine treatments for atopic eczema.459
l Systemic immunosuppressive therapies in atopic eczema (no published protocol to date).
l Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema (no published protocol to date).
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Key points
l Randomised controlled trials of interventions for eczema have often not answered the questions of
most importance to patients and their carers.
l The lack of studies in primary care is still a major problem as the majority of people with eczema are
managed in primary care.
l Several treatments for eczema now have a sound evidence base.
l Perhaps the greatest benefit identified in this review is the use of twice-weekly anti-inflammatory
treatment to maintain disease remission.
l There are still major gaps in current knowledge about commonly used treatments such as emollients
and impregnated bandages.
l This updated review has identified many of the same methodological issues noted by the original
review in 2000,55 including the lack of trial registration, poor reporting according to Consolidated
Standards of Reporting Trials guidelines, inadequate sample size, trials of too short duration,
inappropriate analysis of within-group changes only and lack of patient-reported outcomes.
l All of these deficiencies can be easily overcome if investigators, sponsors, ethics committees, journals,
patients and funders are made aware of the existing evidence base described in this review and
commit to full trial registration and complete trial reporting.
l The creation of the GREAT database,68 an international database of all RCTs and systematic reviews of
eczema treatments freely in the public domain, should facilitate future trial prioritisation and systematic
reviews for the benefit of patients.
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2. factorial$.mp.
3. (crossover$ or cross-over$).mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer name]
7. (assign$ or allocat$).mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. exp Dermatitis, Atopic/
15. atopic dermatitis.mp.
16. atopic eczema.mp.
17. exp NEURODERMATITIS/
18. neurodermatitis.mp.
19. infantile eczema.mp.
20. childhood eczema.mp.
21. (besnier$ and prurigo).mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name]
22. eczema.mp. or exp Eczema/
23. 21 or 17 or 20 or 15 or 14 or 22 or 18 or 16 or 19
24. 23 and 13
EMBASE (Ovid) search string
1. random$.mp.
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3. crossover$.mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device
manufacturer, drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device
manufacturer, drug manufacturer name]
7. assign$.mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
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Appendix 2 Randomised controlled trials of
eczema treatments in abstract form only
Study Interventions
Gromert N, Axelsson I. Lactobacillus reuteri effect in atopic eczema in childhood.
European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual
Meeting, Budapest, Hungary. J Pediatr Gastroenterol Nutr 2009;48:E148–9
L. reuteri dietary supplementation,
placebo
Rossi AM, Ortonne JP, Guillet G, Dubertret L, Lahfa M, Griffiths C, et al. Efficacy
and safety comparison of desonide 0.05% lotion versus fluocortolone 0.5%
ointment in atopic dermatitis. Ann Dermatol Venereol 2002;129:1S420
Desonide lotion 0.05%,
fluocortolone ointment
Barba JF. Pimecrolimus cream 1% is effective, well tolerated and safe in
infants/children with atopic eczema of the face. J Eur Acad Dermatol Venereol
2003;17:182
Pimecrolimus 1%, vehicle
Sugai J, Kakurai M, Otsuki M, Nakagawa H. Combination therapy with 0.1%
tacrolimus ointment and cetirizine for facial atopic dermatitis. J Eur Acad Dermatol
Venereol 2003;17:17
Tacrolimus and cetirizine combined
Smith CH, Ormerod AD. Pimecrolimus cream 1% once-daily maintenance therapy
for the prevention of relapse in mild to moderate atopic dermatitis in adults. Br J
Dermatol 2005;153:37
Pimecrolimus 1%, vehicle
Thaci D, Hengge UR, Goertz HP, Rossi AB. Treatment effects of 1% pimecrolimus
ointment formulations in adult patients with atopic dermatitis. J Eur Acad Dermatol
Venereol 2005;19:218
Pimecrolimus ointment
(three different formulations –
X, Y and Z), vehicle
Del Rosso J, Bikowski J, Hawkes S, Sanglay L. A double-blind, randomized
comparative assessment of efficacy and skin tolerability in patients using either
a branded wash versus a soap-based cleanser. J Am Acad Dermatol
2006;54(Suppl. 3):AB64
Branded skin cleanser, soap-based
cleanser
Freeman S, Day R, Williams K, Liauw W. A new treatment for atopic dermatitis:
a randomized double-blind placebo-controlled study. J Am Acad Dermatol
2006;54(Suppl. 3):AB3
Auranofin (gold compound) and
mometasone ointment,
mometasone ointment, vehicle
Friedlander SF, Loss R, Schlessinger J, Potts A. A phase 3 double-blind, randomized,
vehicle-controlled study of desonide foam in pediatric and adolescent patients with
mild to moderate atopic dermatitis. J Am Acad Dermatol 2006;54(Suppl. 3):AB84
Desonide foam, vehicle foam
Hanifin J. A novel topical nuclear factor kappa-B decoy: results from a phase I/II trial
in atopic dermatitis. J Am Acad Dermatol 2006;54(Suppl. 3):AB4
Nuclear factor kappa-B decoy,
placebo
Hoey S, Catney D, Maguire S, Mckenna K. Fixed low dose versus increasing dose of
ultraviolet B-TL01 in the treatment of atopic eczema. Br J Dermatol 2006;155:121–2
UVB TL01 (standard increasing-dose
regimen), UVB TL01 (fixed-dose
regimen)
Laumann A, Lai S, Lucky A, Schlessinger J, Jarratt M, Jones T, et al. The efficacy and
safety of MimyX Cream in reducing the risk of relapse in atopic dermatitis. J Invest
Dermatol 2006;126:45
MimyX cream (contains palmitic
acid monoethanolamide and other
lipids) and emollient, emollient only
(control)
Mraz S, Miller B, Bucko A, Tschen E. A multicenter, double-blind, placebo-controlled
study of the effectiveness of kiwi fruit extract in adults with atopic dermatitis of
moderate severity. J Am Acad Dermatol 2006;54(Suppl. 3):AB3
Oral kiwi extract, placebo
Ramon G, Cambazard F. Evaluation of the corticosteroid-sparing effect of a new
emollient in 162 atopic infants. 4th European Association of Dermatology and
Venereology (EADV) Spring Symposium, Saariselka, Lapland, Finland, 2006.
Abstract P-009
Emollient milk containing Rhealba®
extracts (Pierre Fabre), no emollient
(control)
Beutner K, Jones T, Bucko A, Loss R. A randomized, double-blind, vehicle-controlled,
multi-center study to evaluate the safety and efficacy of topically applied AN0128
cream, 1% for the treatment of mild to moderate atopic dermatitis. J Am Acad
Dermatol 2007;56(2 Suppl. 2):AB72
AN0128 cream (Anacor), vehicle
cream
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Study Interventions
Eichenfield LF. A randomized, double-blind, placebo-controlled, parallel group study
of nanocrystalline silver (NPI 32101) cream in pediatric atopic dermatitis (AD). J Am
Acad Dermatol 2007;56(2 Suppl. 2):AB75
Nanocrystalline silver (NPI 32101,
Westaim Holdings Limited) cream
1%, nanocrystalline silver (NPI
32101) cream 2%, vehicle cream
Hanifin J, Hultsch T, Paller A, Eichenfield L. The demographic profile of a large
population of infants with atopic dermatitis: a longitudinal study on development of
asthma and allergies. J Am Acad Dermatol 2007;56(2 Suppl. 2):AB68
Pimecrolimus 1%, vehicle
Bautista LC, Mendoza A, Sumpaico M, Recto M, Castor M, De Leon J. The effects
of fish oil supplementation on serum levels of interleukin 10 and total
immunoglobulin E among pediatric patients with atopic dermatitis: a randomized
controlled single blind clinical trial. Ann Allergy Asthma Immunol 2010;105:A126
Fish oil, no treatment
Kaur M, Feldman S, Clark A, Inabinet R. Adherence to topical hydrocortisone
17-butyrate 0.1% using different vehicles in adults with atopic dermatitis. J Am
Acad Dermatol 2007;56(2 Suppl. 2):AB74
Topical hydrocortisone 17-butyrate
cream, topical hydrocortisone
17-butyrate ointment, topical
hydrocortisone 17-butyrate
lipocream
Kuznecovs I, Jegina K, Kuznecovs S. Atorvastatin and polyprenol effect on atopic
dermatitis: pathogenesis links in adult patients. Allergy 2010;65(Suppl. s92):75
Atorvastatin with polyprenol,
placebo
Melamed IR, Robinson L, Heffron M. The benefit of montelukast in atopic dermatitis
induced by food allergies. J Allergy Clin Immunol 2010;125(2 Suppl. 1):AB93
Montelukast, placebo
Rikken G, Gertner J. SUn13834 in the treatment of subjects with atopic dermatitis.
J Invest Dermatol 2010;130:S69
SUN13834 (chymase inhibitor)
(Asubio Pharma), placebo
Bishop M, Vukovic-Wysocki I, Qaqundah P, Poulin Y. A 5-year randomized
study to investigate the safety of pimecrolimus cream 1% in the treatment of
mild-to-moderate atopic dermatitis in infants: Clinical safety. J Am Acad Dermatol
2011;64(2 Suppl. 1):AB56
Pimecrolimus cream, topical
corticosteroid-based regimen
Bostoen J, Geusens B, Bracke S, Dekeyser S, Lambert J. Follow-up on the effect of a
patient educational programme: early results of a prospective randomized controlled
trial in psoriasis and atopic dermatitis. Br J Dermatol 2011;165:e34–5
Education, no education
Rubio-Gomis E, Martinez-Mir I, Morales-Olivas F,
Martorell-Aragones A, Palop-Larrea V, Bernalte-Sese A, et al. Randomized
controlled, double blind trial of topical twice weekly fluticasone propionate
maintenance treatment to reduced risk of relapse in mild or moderate atopic
dermatitis (AD) in children. Basic Clin Pharmacol Toxicol 2012;111:30–1
Fluticasone propionate, vehicle
Yuen NS, Ibrahim K, Begum S. Does order of application of emollient and topical
corticosteroids make a difference to severity in children with atopic eczema? Eur J
Pediatr Dermatol 2012;22:14–15
Topical corticosteroids followed by
emollients, emollients followed by
topical corticosteroids
Zane LT, Gogoleva T, Heerinckx FA, Jermano JA. Safety and efficacy of AN2728 and
AN2898 ointments in a phase 2a bilateral study of mild-to-moderate atopic
dermatitis. J Invest Dermatol 2012;132:S90
AN2728, AN2829 (Anacor
Pharmaceuticals)
Alex P, Payne A, Desai A, Centola M, Thomas S, Yesudas T. HAT-01, a novel herbal
preparation, is superior to corticosteroids and pimecrolimus for the treatment of
moderate to severe atopic dermatitis. J Am Acad Dermatol 2013;68(4 Suppl. 1):AB76
HAT-01 herbal preparation
(Haus Bioceuticals Inc.), placebo
Fukuie T, Matsumoto K, Narita M, Nomura I, Tokura Y, Ohya Y. Does proactive
management of atopic dermatitis affect sensitization or tolerance? A randomized
controlled study. Allergy 2013;68:37
Proactive treatment with topical
corticosteroids, reactive treatment
with topical corticosteroids
Lee KC, West D, Holbrook J, Kwasny M, Lio P. Novel use of a cooling pillow for
treatment of severe head and neck atopic dermatitis. J Am Acad Dermatol
2013;68(4 Suppl. 1):AB77
Chillow (a water-filled, naturally
cooling pillow) (Soothsoft Ltd),
participant’s normal pillow
Nunez C, Hogan D, Humphrey M, Zhang P, Lisante T, Doshi U. A colloidal oatmeal
OTC cream is as clinically effective as a prescription barrier repair cream for the
management of mild to moderate atopic dermatitis in African American children.
J Am Acad Dermatol 2013;68(4 Suppl. 1):AB73
Colloidal oatmeal cream (over the
counter), prescription barrier repair
cream
Beck LA, Thaci DH, Graham JD, Bieber NM, Rocklin T, Ming R, et al. Dupilumab
treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med
2014;371:130–9
Monoclonal antibody, placebo
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Appendix 3 Studies published before 200055
C lick on section headings to access the previous 2000 NIHR HTA report.55
Topical corticosteroids compared with placebo
Topical corticosteroids were compared with placebo in 13 trials published before 2000, which were
included in the original review. Most trial reports had a poor quality of reporting, with very little
methodological detail provided, and nearly all of the trials were of < 1 month’s duration. Most notably,
there were no RCTs looking at betamethasone 17-valerate compared with placebo, but this topical
corticosteroid is used as the standard comparator for new topical corticosteroids.
Topical corticosteroids compared with active treatments
(except topical immunomodulators)
Forty trials were reported before 2000; however, an overall summary of the evidence from these trials was
not provided at that time as the trials did not compare all of the possible contenders for the most effective
and safest topical corticosteroid. Most of the trials were described as being of poor quality and they also
tended to mix eczema participants with participants who had other conditions. Fluticasone propionate and
mometasone propionate given once daily were compared against ‘older’ agents given twice daily and
demonstrated reasonable equivalence. Many trials that introduced a ‘me-too’ product claimed equivalence
by erroneously assuming that no evidence of statistical difference is the same as evidence of equivalence.
Many trials compared topical corticosteroids, usually as the standard comparator, with other active
treatments. Most of the trials did not include a placebo comparator, making it difficult to gauge the level
of clinical effect. Several trials compared a topical corticosteroid with a combination of a topical
corticosteroid with another active treatment, usually a topical antimicrobial. None of these trials involving
combined treatment demonstrated any additional benefit over the topical corticosteroid alone.
Topical immunomodulatory agents
There were four trials of topical immunomodulatory treatment published before 2000.
Other topical treatments
One trial by Harper and colleagues comparing Oilatum against Oilatum Plus containing triclosan and
benzalkonium chloride antimicrobials was published in 1995. There was a difference in the change from
baseline scores of 9.0 in the Oilatum Plus group and 2.7 in the Oilatum group after 4 weeks of treatment.
The participant-rated scores did not show any significant differences.
Five other RCTs were reported before 2000. Two studies comparing the use of two different emollients –
Moisturel™ (Warner Chilcott) which is not available in the UK, and Eucerin™ (Beiersdorf AG), which is used
in addition to topical corticosteroids – found no significant difference between them. These two trials,
which were very short and poorly reported, did not show any significant difference between one
emollient and the other when used in the presence of a moderately potent topical corticosteroid. One
manufacturer-sponsored study used Cetaphil with corticosteroid compared with corticosteroid alone. This
study reported that regularly using emollient in addition to topical corticosteroid may result in small increases
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in treatment response. Two poorly reported trials on emollients containing urea showed some benefit over
vehicle and one study did not show any difference in benefit for different concentrations of urea.
Antimicrobials
One crossover trial by Lever and colleagues conducted in Scotland in 1988 compared topical mupirocin
ointment with placebo for 2 weeks. The participants were also able to use topical corticosteroids and
emollients. There was a significant decrease in eczema severity for mupirocin treatment compared with
placebo treatment for the first 2-week treatment period. There appears to have been a strong carry-over
effect from the treatment phase of this trial.
One crossover trial by Harper and colleagues and one parallel-group trial by Holland and colleagues, both
published in 1995, compared the bath emollient Oilatum against Oilatum Plus, which has 2% triclosan
added as well as another antiseptic (6% w/w benzalkonium chloride). Both trials had a trial period of
4 weeks. The change in severity scores for the two treatments were not compared and baseline scores
were not reported in the trial by Harper and colleagues. There was no statistically significant difference in
severity between the groups in the trial by Holland and colleagues. Both trials had low numbers of
participants and relatively high numbers of dropouts, who were not included in the analyses.
One parallel-group trial from Sweden by Broberg and Faergemann compared a treatment regimen of a
miconazole and hydrocortisone cream applied twice daily to the neck and use of ketoconazole shampoo
twice a week with a treatment regimen of a hydrocortisone cream and the shampoo base.
Antihistamines
Three trials of loratidine, all given as 10mg a day, were reported. Two trials compared loratidine against
placebo and one three-arm trial compared loratidine against hydroxyzine or placebo.
Two trials of ketotifen were published before 2000. One study in adults and one in children compared
ketotifen against placebo. The study in children administered treatment for 4 months and reported no
significant differences between the groups in redness of the skin, day itch, night itch or asthma symptoms,
as reported by parents. Fifteen out of the 42 children in the trial had eczema. In the adult trial, treatment
was administered for 3 months and a significant reduction in itch in both groups compared with baseline
on a scale of 1–3 was reported. This trial also measured itch, sleep loss, erythema, lichenification and
overall efficacy of treatment.
Five studies of cetirizine were reported before 2000, three of which compared cetirizine with placebo.
The largest of the placebo trials, which was relatively well reported, showed possible benefit from cetirizine
only at 40mg, four times the normal dose, and at the expense of some sedation. The other trials were
missing important pieces of methodological information making them difficult to interpret.
One multiple crossover trial compared chlorpheniramine and cemitidine against chlorpheniramine or
placebo in adolescents and adults administered each treatment for 3 weeks. This underpowered small trial
did not show any significant benefit of taking chlorpheniramine alone or in combination with cemitidine.
Four trials of doxepin were reported: two compared topical doxepin against placebo; one compared 2.5%
hydrocortisone plus 5% doxepin, 0.1% triamcinolone plus 5% doxepin, 2.5% hydrocortisone only and
0.1% triamcinolone only; and one compared 2.5% doxepin hydrochloride only and 2.5% doxepin
hydrochloride plus 0.025% triamcinolone acetonide. All four trials were sponsored by the manufacturer
and conducted by the same group of researchers. There was some evidence of a reduction of itch in the
first 24–48 hours for doxepin compared with vehicle but this became non-significant after 1 week. None
of the trials demonstrated a clinically useful benefit at time points > 1 week. The trials reported drowsiness
and stinging as adverse events, which led to differential dropouts.
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Ten small trials of topical chromoglycate, all compared with placebo and lasting between 4 and 12 weeks,
were conflicting. Most of the positive trials were from the same group of triallists and used a solution
rather than a semi-solid formulation.
Dietary interventions
Five trials on borage oil were published before 2000, of which four were small and one was large and well
reported. Two of the small trials suggested that there was an improvement in eczema with borage oil and
two did not. The large trial did not find any evidence of benefit, not even a suggestion. A post hoc analysis
of a subgroup of this large trial, with an unknown number of the most compliant participants and those
with blood test changes, showed some beneficial effect. As this analysis was post hoc and the reasons for
differences in compliance were not reported, this would need to be explored in a RCT with participants
who showed an increase in GLA metabolites.
A large independently funded trial that compared fish oil against placebo did not find any hint of a
difference between the groups. Two smaller studies showed a possible benefit of fish oils, with one of
these trials showing a very large magnitude of benefit.
Nine trials involving evening primrose oil were published before 2000. Two large well-reported studies
showed no evidence of benefit whereas the four moderately sized trials reported conflicting results, with
one trial providing evidence of no benefit and another providing evidence of a 10–20% benefit for some
outcome measures compared with placebo. Three small studies reported a benefit of taking evening
primrose oil orally for eczema.
Non-pharmacological interventions
Only one trial of an educational intervention was reported before 2000. This trial compared an additional
nurse education session on top of usual dermatologist care with usual care in 50 infants and young
children. A modest benefit was seen for the participants in the intervention group after 3 months. The trial
was not blinded, did not use intention-to-treat analyses and did not adjust for different baseline values;
therefore, the results should be treated with some caution.
Three small studies compared desensitisation using house dust mite extracts, one in oral suspension and
two as injections, with placebo. Two of the studies recruited participants with eczema who a had positive
skin-prick test to house dust mite allergen. Neither of these studies found any significant differences in
outcomes between the desensitisation group and the placebo group. However, this lack of association
could have been a result of the small sample sizes, a strong placebo effect from regular injections or the
use of house dust mite reduction measures in the control group.
Four trials on house dust mite reduction were reported, which gave varying results. None of the trials
reported the method of randomisation and whether allocation concealment took place. Two of the studies
found a significant beneficial effect of intensive high-filtration vacuuming, mattress encasings made of
GORE-TEX and acaricide spray on the severity of eczema in children. Another study of Japanese infants not
allergic to house dust mite using mattress and quilt encasings found that, in the control group, just over
twice as many developed serological evidence of sensitivity to house dust mites, but the study did not look
at the impact on severity of eczema. These trials were not pragmatic and were often very intensive. None
of the trials reported adverse events.
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Three trials involving specialised clothing were reported. The trial by Diepgen and colleagues assessed four
different materials of varying fibre roughness. Cotton was found to be significantly more comfortable than
the two heaviest, roughest fibres. A second trial by Diepgen and colleagues compared seven different
fabrics of varying fibre roughness, yarn roughness and fabric weave. Irritation was higher for warp knits
than for jersey knits but there was no difference between cotton and polyester of fine fibre construction.
Sweating was found to reduce comfort for all fabrics. The final study compared cellulose with gel nappies
for infants with atopic eczema. Napkin dermatitis was reduced in the group using nappies with absorbent
gel, but overall there was no difference in the severity of eczema.
Phototherapy
Before 2000, only six RCTs of phototherapy were reported. The only two trials of PUVA treatment could
not be included as it was unclear whether the participants had eczema in one of the trials and the
subgroup of eczema participants was inseparable in the results of the other trial. The trials were generally
small and left and right side of body comparisons were carried out without blinding. The beneficial effects
seen were large with a rapid onset and the lack of effect on the placebo side of the body seemed to point
to a lack of systemic effect. The trials found that mild skin redness and burning was a common side effect.
Information on the long-term risk of cancer was not available from the trials.
Systematic immunomodulatory agents
Twelve trials involving ciclosporin were reported before 2000, two trials of oral ciclosporin and 10 trials of
topical ciclosporin. There was good evidence that topical ciclosporin was of benefit compared with
placebo; however, the adverse events reported in these trials make it clear that it would not be justifiable
to use ciclosporin for long-term treatment.
One trial involving intravenous immunoglobulin was published before 2000 and showed some evidence of
benefit but this result would need to be confirmed with further research evidence.
Four trials involving systemic immunotherapy were published before 2000 [three of these trials are in the
non-pharmacological treatments chapter (p. 82)55 under house dust mite hyposensitisation].
One trial involving oral prednisolone was published before 2000.
Complementary therapies
Four RCTs were reported before 2000 comparing different Chinese herbal preparations against placebo,
all with similar methodologies. Only one of these studies showed a significant beneficial effect of the
herbal preparation.
One trial protocol reported before 2000 compared classical homeopathic treatment with placebo for
8 months, in which the homeopathic doctor was free to change remedies, dosages or potencies if
required. It appears that this protocol relates to the full trial report described in this updated review.
One trial comparing hypnotherapy with biofeedback or discussion only in children was reported before
2000. There was some reduction in surface damage and lichenification for hypnotherapy compared with
discussion only but no difference for hypnotherapy compared with biofeedback. There was no difference
in erythema reduction between all of the interventions.
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Appendix 4 Topical corticosteroids compared
with active treatments
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e
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(t
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e
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ra
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at
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n
to
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pe
ar
an
ce
of
a
ne
w
fla
re
(S
ec
on
da
ry
)
C
ha
ng
es
in
th
e
in
ci
de
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e
of
fla
re
s
(b
as
ed
on
m
ea
n
nu
m
be
r
of
fla
re
s
re
po
rt
ed
fo
r
th
e
2
m
on
th
s
be
fo
re
th
e
ba
se
lin
e
vi
si
t)
A
fla
re
w
as
de
fin
ed
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an
ex
ac
er
ba
tio
n
th
at
co
ul
d
be
qu
an
tif
ie
d,
fo
llo
w
in
g
ev
al
ua
tio
n
of
th
e
pa
tie
nt
’s
di
ar
y,
ph
ys
ic
al
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am
in
at
io
n
an
d
an
in
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rv
ie
w
w
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th
e
pa
tie
nt
or
tu
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r,
w
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A
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e
of
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4
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th
e
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e
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l
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s
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r
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le
as
t
3
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tr
ac
t
us
e
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d
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t
si
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e
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n
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D
)
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to
pi
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l
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rt
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ro
id
s
w
er
e
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:
PL
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p
11
%
(S
D
12
%
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o
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p
12
%
(S
D
11
%
).
Th
er
e
w
as
a
si
gn
ifi
ca
nt
re
du
ct
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n
fo
r
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al
hi
st
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in
e
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e
(m
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n
pe
rc
en
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PL
gr
ou
p
4.
5%
,
pl
ac
eb
o
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ou
p
13
.6
%
(p
=
0.
03
8)
.
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m
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es
w
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w
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e
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n
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ra
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n
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t
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.
St
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y
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d
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t
bl
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w
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t
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.
In
te
nt
io
n-
to
-t
re
at
an
al
ys
is
w
as
us
ed
as
w
el
la
s
pe
r-
pr
ot
oc
ol
an
al
ys
is
m
ax
.,
m
ax
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um
;
m
in
.,
m
in
im
um
;
PL
,
P.
le
uc
ot
om
os
;
PO
M
S,
Pr
of
ile
of
M
oo
d
St
at
es
.
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Appendix 19 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses 2009 checklist
Section/topic Number Checklist item Reported on page
Title
Title 1 Identify the report as a systematic review, meta-analysis or both Title page
Abstract
Structured
summary
2 Provide a structured summary including, as applicable,
background; objectives; data sources; study eligibility criteria,
participants and interventions; study appraisal and synthesis
methods; results; limitations; conclusions and implications of key
findings; systematic review registration number
v, vi
Introduction
Rationale 3 Describe the rationale for the review in the context of what is
already known
xxxix, 7
Objectives 4 Provide an explicit statement of questions being addressed with
reference to participants, interventions, comparisons, outcomes
and study design (PICOS)
8+ 9
Methods
Protocol and
registration
5 Indicate if a review protocol exists and if and where it can be
accessed (e.g. web address) and, if available, provide registration
information including registration number
Previous HTA
review, 11
Eligibility criteria 6 Specify study characteristics (e.g. PICOS, length of follow-up) and
report characteristics (e.g. years considered, language, publication
status) used as criteria for eligibility, giving rationale
11+ 12
Information
sources
7 Describe all information sources (e.g. databases with dates of
coverage, contact with study authors to identify additional studies)
in the search and date last searched
14+ 15
Search 8 Present full electronic search strategy for at least one database,
including any limits used, such that it could be repeated
Appendix 1
Study selection 9 State the process for selecting studies (i.e. screening, eligibility,
included in systematic review and, if applicable, included in the
meta-analysis)
15
Data collection
process
10 Describe method of data extraction from reports (e.g. piloted
forms, independently, in duplicate) and any processes for obtaining
and confirming data from investigators
16
Data items 11 List and define all variables for which data were sought (e.g. PICOS,
funding sources) and any assumptions and simplifications made
12–14
Risk of bias in
individual studies
12 Describe methods used for assessing risk of bias of individual
studies (including specification of whether this was carried out at
the study or outcome level) and how this information is to be used
in any data synthesis
16
Summary
measures
13 State the principal summary measures (e.g. risk ratio, difference in
means)
Not applicable
Synthesis of
results
14 Describe the methods of handling data and combining results of
studies, if carried out, including measures of consistency (e.g. I2)
for each meta-analysis
Not applicable
Risk of bias
across studies
15 Specify any assessment of risk of bias that may affect the
cumulative evidence (e.g. publication bias, selective reporting
within studies)
Not applicable
Additional
analyses
16 Describe methods of additional analyses (e.g. sensitivity or
subgroup analyses, meta-regression), if carried out, indicating
which were prespecified
Not applicable
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Section/topic Number Checklist item Reported on page
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility and
included in the review, with reasons for exclusions at each stage,
ideally with a flow diagram
22+ 23
Study
characteristics
18 For each study, present characteristics for which data were
extracted (e.g. study size, PICOS, follow-up period) and provide
the citations
Main body of report,
25–214
Risk of bias
within studies
19 Present data on risk of bias of each study and, if available, any
outcome-level assessment (see item 12)
Results of
individual studies
20 For all outcomes considered (benefits or harms), present, for each
study: (a) simple summary data for each intervention group,
(b) effect estimates and confidence intervals, ideally with a forest plot
Not applicable
Synthesis of
results
21 Present results of each meta-analysis carried out, including
confidence intervals and measures of consistency
Not applicable
Risk of bias
across studies
22 Present results of any assessment of risk of bias across studies
(see Item 15)
Not applicable
Additional
analysis
23 Give results of additional analyses, if carried out [e.g. sensitivity or
subgroup analyses, meta-regression (see Item 16)]
Not applicable
Discussion
Summary of
evidence
24 Summarise the main findings including the strength of evidence
for each main outcome; consider their relevance to key groups
(e.g. health-care providers, users and policy makers)
215–218
Limitations 25 Discuss limitations at study and outcome level (e.g. risk of bias)
and at review level (e.g. incomplete retrieval of identified research,
reporting bias)
220–223
Conclusions 26 Provide a general interpretation of the results in the context of
other evidence and implications for future research
219–222
Funding 223–225
Funding 27 Describe sources of funding for the systematic review and other
support (e.g. supply of data) and the role of funders for the
systematic review
iii
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